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Abstract 
 
The work described within this thesis relates to the development and identification of 
novel inhibitors of two recently identified chemotherapeutic targets.
i/i
  
 
Apurinic/Apyrimidinic Endonuclease 1 – (Ape1/Ref1)
i
 
The  base excision repair (BER)  pathway is a  vital eukaryotic  process that acts to 
recognise,  process and remove  damaged  DNA from the  genome.  A critical step in 
BER involves the  processing  of an apurinic/apyrimidinic (AP) site intermediate  by  
Ape1/Ref1.  Such  AP site intermediates are  generated  when  DNA  bases  undergo 
spontaneous damage, and as such are continuously and ubiquitously being generated. 
Therefore, through its innate function Ape1/Ref1 ofers direct protection to cels from 
the efects  of  DNA  damaging agents, including commonly employed 
chemotherapeutics. Interestingly,  Ape1/Ref1 is  over-expressed in  many cancers and 
this  particularity  has  been shown to corelate  with resistances to  both radio and 
chemotherapy regimens.  Considering this,  Ape1/Ref1  has emerged as a  potential 
chemotherapeutic target. The availability of robust X-ray crystal data alowed for the 
implementation  of a  grass roots computer-aided  drug  design (CADD) approach. 
Multiple inhibitor scafolds  were identified,  designed, synthesised and  biologicaly 
evaluated in vitro. Furthermore,  during this  project several  publications emerged 
detailing novel inhibitors of Ape1/Ref1, investigations into these reports are detailed 
within.       
 
Liver Receptor Homolog-1 (LRH-1)
i
 
Nuclear receptors (NRs) are ligand regulated transcription factors and  have  been 
described as  nearly ideal  drug targets  due to their three-dimensional structure.  NRs 
contain  vast  hydrophobic internal  pockets that bind to  hydrophobic,  drug-like 
molecules. In the  presence  of a  natural endogenous substrate, ligand-induced 
conformational changes modulate the recruitment of transcriptional regulators to gene 
promoters.  Liver receptor  homolog-1 is a  NR that  has recently been shown to 
modulate the estrogen response in  breast cancers through the regulation  of estrogen 
receptor-α (ERα) expression.  Resorcylic acid lactones (RALs)  were recently shown 
by  Baret et. al. to  be capable  of antagonising this receptor in the low  micromolar 
range.  Such action could  possibly translate to the  potential  blocking  of co-activator 
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recruitment and  ERα expression in vivo and therefore these compounds served as a 
start  point for a ligand  based  drug  discovery campaign.  Additional synthetic 
investigations and  biological  developments  upon these  RALs are  discussed and 
detailed within. 
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1.0 Introduction 
As the quest for longevity gains momentum in the modern world, cancer continues to 
provide a formidable stumbling  block. The condition shows  no remorse, afecting 
people of al demographics and represents a huge burden upon patients, families and 
societies. In  2005, cancer  was responsible for  7.6  milion  deaths  out  of a total  58 
milion worldwide. Based upon curent projections, cancer related deaths wil continue 
to rise with an estimated 9 milion deaths in 2015 and 11.4 milion in 2030.
1
 Cancer 
incidence rates have also risen since 1970; approximations indicate an increase of 20% 
in  males and  40% in females.  The reasons for such a  drastic rise have  been  hotly 
debated. A significant factor is a globaly aging population, which corelates to 60% of 
al cancer  diagnoses  being in those  over  65  years  of age.  Secondly, lifestyle choices 
are thought problematic, notably, the continued use of tobacco products, obesity, over 
exposure to ultraviolet light, alcohol abuse and decreased environmental air quality.  
 
Cancer is not a single disease, over 200 diferent variations exist each with a unique 
set  of causes, symptoms and treatment. Each  variation relies  upon a complex 
biochemical cascade to survive,  which in turn can  make  diagnosis, treatment and 
understanding an incredible chalenge. The most common phenotype  within the 
disease class is the presence of a malignant neoplasm. This is the result of neoplasia, 
the abnormal and uncontroled proliferation of cels. When a suficient accumulation 
of cels  occurs the tumour can impact  negatively  upon its local environment.  These 
impacts can  manifest themselves as  pain, alteration  of tissue shape and loss  of 
consciousness; it is at this point many cases are first investigated. Although diagnosis 
has improved, (cancer survival rates in the  UK  have  doubled in the last  40  years)
2
 
much work stil needs to be done to combat the disease. This is underlined in the fact 
that an estimated 10% of cancers are caused by predisposed genetic damage. In theory 
this implies that  90%  of al  other cancers could  possibly  be  preventable. Increased 
understanding  of the  disease triggers and  genetic  predispositions are  desperately 
required to improve patient prognosis and reduce incidence amongst al age groups. In 
striving to reach these goals the disease must be considered and analysed from it’s first 
principles.  
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1.1 – The Halmarks of Cancer 
	  
 
 
 
 
 
   
 
Figure 1: The Halmarks of Cancer.
3
 
 
 
Over the past 15 years there has been a drastic change in the way we look at cancer 
and more specificaly tumours, (Figure 1). From an abnormal growth that’s destruction 
depends  on survival  we  now appreciate tumours as complex  organs. Single cancer 
cels are the starting  point for theses  organs, they  underpin the  development  of 
tumours  using their support  network  of  oncogenic and tumour suppressor  mutations. 
The whole process from healthy to cancerous is however much more complex, and in 
2000  Hanahan and  Weinberg  defined the six halmarks  of cancer.
4
 The factors they 
discuss provide an organised framework for understanding the biology of cancer, and 
rationalise how cancer cels gain the necessary mechanics to become tumourigenic and 
malignant.   
 
Sustaining Proliferative Signaling 
 
Normal tissues carefuly control the rate at which cels replicate, grow and ultimately 
die. Growth promoting signals ensure that celular processes are maintained which in 
turn supports and provides the integrity of al systems and major organs. Cancer cels 
have the capability to escape this regulation in a number of ways. The major pathway 
involves sidestepping and hijacking the healthy growth promoting signals. Cancerous 
cels can synergisticaly  produce  novel  growth factors and express a complementary 
receptor, rendering the  normal  growth  pathway redundant.
5
 Secondly they can 
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stimulate neighbouring healthy cels to overproduce growth factor, which results in a 
celular environment suited to tumour survival and proliferation.
6
 
 
Evading Growth Suppressors 
 
After discovering and implementing methods to grow beyond the limits of the healthy 
cel cycle, cancer cels must also combat the celular mechanisms in place that guard 
against excessive  proliferation. Within  healthy tissue tumour suppressor  genes are 
expressed accordingly alowing cels to replicate, senesce or undergo programmed cel 
death.
7
 Cancer cels often have defects in the genes coding for these suppressors and 
are therefore free to grow uncontrolably.  
 
Resisting Cel Death 
 
Apoptosis is a regulated  mechanism  of cel  death refered to commonly as 
programmed cel  death.  The  process is advantageous throughout an  organism’s life 
cycle, reflected in that 50-70  bilion adult cels  die  daily via this  pathway.
8
 It is 
generaly accepted that apoptosis serves as a  natural  defence to spontaneous cancer 
development. Tumour cells can however circumvent apoptosis through the loss  of 
tumour suppressor  genes that act  upstream  of a  variety  of co-factors that are  vital in 
the apoptotic cascade.
9
 Furthermore, tumour cels can  up-regulate antiapoptotic 
proteins causing a signal imbalance that either slows  or fuly  prevents  programmed 
cel death.
10
 Considering both of these abilities, cancerous cels are unhindered in their 
progression to a more mature and dangerous state.  
 
Enabling Replicative Immortality 
 
It is of no great surprise that cancerous cells require huge turnover rates of replication 
to achieve the size and classification of a tumour state. There appears to be no limit on 
the cel cycle, which difers greatly to normal healthy tissue (60-70 divisions).
11
 It is 
becoming widely accepted that the degree to which cels can replicate corelates to the 
length of telomeric DNA protecting the ends of chromosomes. As cels pass through 
generations  of  division the telomeres are eroded to the  point  where the chromosome 
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becomes exposed and unprotected.
12
 This triggers a crisis phase that rapidly results in 
the cel entering the apoptotic  process. In cancerous cels  DNA telomerase is  over 
expressed, therefore as the cells continue to divide any telomeric erosion is reduced or 
stopped completely.  With such a  degree  of  genomic  protection, cancer cels  gain 
replicative immortality never entering a state of senescence or apoptosis. 
 
Inducing Angiogenesis 
 
Analogous to healthy tissue, cancerous cels require energy in the form  of  nutrients 
and oxygen, they also require the apparatus to absorb and flush waste products. Aside 
from early embryonic development, the production and growth of new blood vessels 
and smaler  vasculature is limited. In the adult state angiogenesis  only  occurs in 
response to trauma.
13
 Within cancer cels the high expression of vascular endothelial 
growth factor (VEGF) permits continued angiogenesis. Tumour endothelial cels may 
divide every 7-10 days compared to the normal cycle time of every 10 years.
14
 During 
the uncontroled growth of a tumour cels this process is rapid, alowing continued and 
supported  growth through the construction and invasion  of a  vast  number capilaries 
that plug into the central circulatory system.  
 
Activating Invasion and Metastasis  
 
Until recently, the exact processes responsible for the spread of cancer throughout the 
body  were poorly  understood. Generaly as the  neoplasia increases in size the 
probability that cancerous cels  pass into adjacent  blood and lymphatic  vessels also 
increases.  More  woryingly the smalest  of tumours can reach  distant  parts  of the 
body. In cancerous tissue, it has been found that the expression of cadherin proteins is 
greatly reduced.
15
 These  proteins are responsible for cel-cel adhesion, and lacking 
this ‘celular glue’ it is possible for cels to pass from the epithelial sheets where they 
are generaly isolated, into healthy tissue. These combined events alow for transport 
of cancerous material throughout the body, initialy forming smal colonies that with 
time can develop into larger metastasised tumours.  
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1.2 – Therapeutic Targeting  
 
As a result  of the  general scientific acceptance into research revolved around the 
aforementioned  halmarks, the  development  of therapeutics to target cancer  has 
become  broader and  more focused. It is  of  note that  many  novel experimental 
therapeutics have  been  designed to target specific  biochemical  pathways that are 
involved with,  or are crucial to a  process  within a  given  halmark capability. It is 
thought that such specific targeting may alow for the disruption of cancer cel survival 
and also enhance the eficacy  of  known chemotherapeutic agents. Outlined  below 
(Figure 2) are the areas that are curently being targeted and the associated 
biochemical target. Such  defined targets provide an atractive specificity towards 
cancer treatment that to date has been relatively absent. Selective drugging of one or 
more targets should alow for a reduction in of target efects and lower toxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Targeting the associated biochemical pathways associated with each halmark.
3
 
 
These approaches appear to be revolutionary but initial observations suggest they may 
be problematical in their application. Cancers within a patient population may display 
diferent  genotypes and as such treatments  have to  be considered carefuly. In line 
with this the FDA has considered that targeted therapies cannot be issued to a patient 
without prior diagnostic testing for the required genotype.
16
 As such this is driving the 
emerging field of pharmacogenomics making the realisation of personalised medicine 
ever closer. Conversely, the ideal underlying physical makeup of a suitable drug target 
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has  been  broadly  defined; as a  macromolecule that is crucial to the  malignant 
phenotype but is not expressed significantly in vital organs and tissues.
17
 Furthermore, 
chemical inactivation of the target should lead to direct regression and destruction of 
the malignancy process. This definition summarises the therapeutic window between 
healthy and cancerous tissue that future research is trying to exploit. 
1.3. – Targeted Anticancer Therapies – Smal Molecules  
 
It is  widely accepted that the first targeted therapy  was the  development  of anti-
estrogen agents for  patients with  breast cancer that over-expressed the estrogen 
receptor (ER) protein.
18
 Tamoxifen (1), identified in the early  1960’s and trialed in 
1971 is the most successful of al these agents in treating ERα-positive breast cancers. 
Tamoxifen  has  now  been  prescribed to  milions  of  patients  globaly, in turn saving 
thousands  of lives. When tamoxifen  was first  prescribed, the impact  of  biology  on 
cancer drug development was minimal; the vast numbers of therapies were selected on 
the  basis  of their ability to limit cel  division in vitro or found serendipitously.  The 
subsequent  decades (1980’s – 2000’s) lay  witness to the advent  of  genetic 
manipulation and the  birth  of  modern  molecular  biology. It was this  biochemical 
revolution that alowed for the contemplation of rational drug design, and molecularly 
targeted therapies, examples shown in (Figure 3). 
 
 
 
 
 
 
 
 
 
Figure 3: Targeted smal molecule anticancer agents. 
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Imatinib Mesylate (Gleevec)  
 
In 2001 the FDA granted a fast track approval of Imatinib 2) for patients with with a 
bcr/abl positive translocation in chronic  myelogenous leukemia (CML). It  was 
discovered that the translocation coded for an active protein kinase, which possessed 
the ability to transform cels in vivo and in vitro. Imatinib is an ATP binding selective 
inhibitor  of the bcr/abl kinase and as such accesses a therapeutic  window  between 
tumour cels and  normal cels  whose abl activity is under  healthy regulation. 
Treatment with Imatinib has been shown to cause complete hematologic and cytogenic 
remission in the early phases of CML. 
19
 
 
Sunitinib & Sorafenib 
 
In the last 10 years the development of antiangiogenic agents has been considered an 
important approach in the treatment  of cancer. It was thought that cuting  of the 
vascular network supplying the tumour should lead to celular starvation and hypoxia, 
resulting in destruction and  dissolution.
20
 Sunitinib (3) (Pfizer) and  Sorafenib (4) 
(Bayer) are smal molecules that target multiple receptor tyrosine kinases (RTK’s). Of 
these, the predominant target is the vascular endothelial growth factor (VEGF) kinase, 
which is  over-expressed in  kidney, liver and  gastrointestinal cancers. 
21
 Inhibition  of 
this  growth factor reduces tumour  vasculisation, which in turn leads to reduced cel 
proliferation and cel  death. Indeed, the  major  drawback  of these treatments is that 
when administered alone their eficacy is  poor and  no tumour reduction is  noted. 
When  used in combination  with a cytotoxic chemotherapeutic agent the  patient 
prognosis  has  been shown to increase  mildly (3-4  months)
21
 indicating a paliative 
benefit but by no means a cure.  
 
The pipeline  of targeted therapies is growing, and this  wil continue as the 
understanding  of cancer  biology increases. In the  globalised fight against cancer the 
biggest chalenge is considered to  be the tailoring of the corect treatment to an 
individual  patient, instead  of finding the  best treatment for the average  patient. This 
task, coupled with frequent relapses, acquired drug resistance and the economic cost to 
develop these agents is formidable. It is therefore poignant that these discoveries and 
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observations indicate the need for huge investment in research and development into 
genomics and ‘novel’ targets and furthermore underpins the importance and 
efectiveness of curently employed more traditional chemotherapeutics.   
1.4. – Classical Chemotherapeutics 
 
In the early  1900’s the  German chemist  Paul  Ehrlich first  used the term 
‘chemotherapy’, defining it as the use of chemicals to treat disease. Ehrlich postulated 
the ‘magic bulet concept’: Chemical agents that can selectively target an appropriate 
pathogen leaving healthy tissue untouched. This idea was the result of his early work 
in elucidating  diferential staining  of tissues  with a  variety  of chemical  dyes and 
anilines.
22
 These results  gave the first insight into the  possibility  of obtaining 
selectivity in vivo. In the modern era a more recognisable definition of chemotherapy 
is, the treatment of cancer with anti-neoplastic drugs. The first early cancer treatments 
predated the elucidation  of the structure  of  DNA and  were somewhat a fortuitous 
discovery. The first DNA alkylators were discovered as a result of chemical warfare in 
WWI.  Nitrogen  mustards (5) caused lymphoid and  myeloid suppression in  humans 
and it was this observation that alowed for the later translation of these agents into an 
efective chemotherapeutic for non-Hodgkin’s lymphoma.
23
 
 
After  1953 the structural aspects  of the  DNA  duplex could  be  used informatively to 
guide  novel therapeutics. Notably, 5-Fluorouracil (6) and  Temozolide (7), were 
designed as nucleobase analogues that could alkylate
24
 and disrupt DNA replication 
leading to apoptosis (Figure 4) . 
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Figure 4: DNA interacting/damaging chemotherapeutic agents 
 
 
Further understanding and appreciation of the mode of alkylation led to the discovery 
of Bleomycin (9), a glycopeptide antibiotic that induces single strand breaks (SSB’s)
25
 
in the  DNA  backbone. Further focus  on the  disruption  of  DNA synthesis and 
replication led to the  discovery and application  of  Topotecan (10) and  Doxorubicin 
(12).  Both compounds  were  derived from  natural  products,  whose  mode  of action 
relies  on their  planarity and ability to intercalate into the  DNA  backbone afecting 
transcription. Furthermore cis-platin and oxaliplatin act in binding and crosslinking the 
DNA  duplex
26
 resulting in ineficient transcription and  hence apoptosis.  The final 
chemotherapeutic example is  Paclitaxel (11),  which  has the ability to stabilise 
microtubule formation.  During cel replication the  mitotic spindle assembles, and its 
breakdown leads to the segregation of chromosomes and progression of the cel cycle. 
Paclitaxel  gives an  unprecedented level  of stability to the  microtubules  preventing 
their separation hence stopping downstream events, leading to cel cycle arest and cel 
death, structures above (Figure 4)
27
 
 
The aforementioned treatments summarise several classes  of cytotoxic agents that 
have been developed over the last 80 years. Even with the discovery and elucidation of 
the structure  of  DNA these agents  were  developed  during an era  where the level  of 
biological information about the  disease state  was low.  Yet to the  present  day they 
remain the mainstay for combating the majority of cancers, administered singularly or 
in combination with one another. The specificity of these agents however is poor and 
their of target efects wel documented.
28
 It would therefore be advantageous to lower 
these  of target efects  without afecting the eficacy  of the agents. In short this 
requires a lower dosage of chemotherapeutic agent and raises the question of how to 
maintain  potency.  Paclitaxel excluded, al treatments (Figure 4) directly target  DNA 
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synthesis and replication, and when suficiently disrupted apoptosis is triggered. 
Problems with this  mode  of  drug action do exist, as the  human  genome  has the 
biochemical machinery to process and repair damaged DNA thus negating some of the 
therapeutic afect  of the drug.  Marying the approaches  of ‘classical chemotherapy’ 
and ‘targeted therapy’ may alow for the  development  of adjuvant treatments  using 
novel inhibitors  of  DNA repair  pathways alongside agents targeting  DNA synthesis 
and replication. Such a complementary atack may alow for increased drug eficacy, 
lower side efects (atributed to reduced  dosage) and an  overal expansion  of the 
curent therapeutic window.  
1.5 – DNA Damage  
 
DNA  damage can  be broadly defined as a  physical abnormality  within the  primary 
structure of a DNA duplex and can be characterised by a chemical alteration upon a 
single  nucleobase.  Such damage can  be recognised  by a  variety  of proteins and 
repaired through several pathways, outlined in (Figure 6).
29
 Damage of this type can 
be considered superficial and is not to  be confused  with a  mutation,  which 
encompasses a total change in the DNA base sequence within the duplex. Mutations 
therefore cannot be detected before transcription as the DNA strand is not chemicaly 
damaged, just rearanged rendering them more  dangerous.  Although chemical DNA 
damage and DNA sequence mutation are clearly  diferent  problems they are 
corelated. Suficient accumulation of unrepaired damaged DNA is often a source of 
mutation and as such repair is of utmost importance to maintain genomic integrity.
29a
 
1.6. – Sources and Types of DNA Damage  
 
The sources of DNA damage can be divided into two distinct groups, endogenous and 
exogenous.  Sources  of endogenous  damage are fewer and are limited to reactive 
oxygen species (ROS),  generated  by reactive  metabolites and aberant DNA 
replication erors.
30
 In al aerobic cels the  production  of  hydrogen  peroxide and 
superoxide  occurs  under  normal conditions.  These  metabolites can  breakdown to 
hydroxyl radicals that atack purine bases, shown below (Figure 5). 
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Figure 5: Endogenous oxidative damage of nucleobases 
 
 
The  DNA bases (13a) can undergo rapid  oxidation in the  presence  of  ROS to (13b) 
and such lesions cause redundancy in the DNA sequence. Aberant replication erors 
on the other hand, lead to the mismatching of complementary base pairs, meaning that 
the hydrogen bond network in the DNA duplex is distorted and therefore unable to be 
transcribed. Lesions in  DNA that  obstruct replication and transcription are  often 
associated with apoptosis and celular senescence, two processes that when incorectly 
triggered contribute to  diseases  of aging.
31
 The sources  of exogenous  DNA  damage 
are far  greater than their endogenous relatives. The overal impact  upon  DNA is 
however similar. The main exogenous damaging agents are summarised below. 
 
• Ultraviolet light (200-400 nM). 
• Ionising radiation (x-rays and gamma rays). 
• Alkylating agents (Nitrogen Mustards, 5-Fluorouracil, MMS, Temozolide). 
• DNA intercalating agents (Topotecan, Bleomycin). 
• Mutagenic plant toxins. 
 
Analogous to the  outcome of endogenous  DNA  damage, the aforementioned 
exogenous sources also lead to a  plethora  of DNA lesions.  Though the sources  of 
exogenous  damage are  greater and  more  dangerous, endogenous  metabolic  products 
cause the vast majority of DNA damage. Due to the intrinsic nature of DNA damage, 
nature  has evolved an arsenal  of repair  pathways that can selectivity recognise and 
process a variety of modes of damage; (Figure 6) below, gives a brief overview of the 
four main modalities. 
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Figure 6: DNA damage, repair mechanisms
a
 and consequences
b 32
 
 
Of the four highlighted repair  pathways,  base excision repair (BER) is the  primary 
DNA repair  pathway that corects lesions resulting from  oxidative, alkylation, 
deamination and  depurination/depyrimidination  damage.
29a
 It is considered to  be the 
‘workhorse’  pathway  due to the level  of complexity entailed  within the  process and 
the  degree to  which the  pathway constantly operates.
33
 Nucleotide excision repair 
(NER) is a closely related  process that  operates almost exclusively  upon lesions 
generated  by  ultraviolet light whereas  BER  deals  with  damage  mostly from 
endogenous sources. 
33
 Recombining and end joining systems  deal  with  damage 
resulting from  double strand  breaks (DSB’s).  Homologous recombination 
predominantly operates during the S and G
2 
phases of the cel cycle, and end joining 
during G
1
. 
34
 
 
Chemotherapeutic agents have the propensity to damage genomic integrity, via direct 
interaction/reaction with celular and nuclear DNA. Considering this, proteins that act 
within the  base excision repair  machinery have  been identified as  novel 
chemotherapeutic targets.  Consequently, a  deep understanding and analysis  of the 
BER pathway and its constituent makeup is vital before drug discovery campaigns can 
be launched. 
 
 
replication downstream of the blocking injury. The resulting gap is
filed in by recombinational replication, using the newly synthesized
complementary str das a template nd ignoring the orginal
lesion-containing one (Fig. 2, folow lower strand). Yeast proteins
implicated in this process, such as the Ubc13/Mms2 complex, are
conserved al the way to mammals. Thus, this largely unexplored 
system undoubtedly exists in humans and may be important in 
carcinogenesis.The endpoint ofbo  ofthese path ysis that dam-
age persists and — when unrepaired — wil cause similar problems in
subsequent rounds of replication. This is particularly relevant for
damage that is not eficiently recognized by any mammalian repair
process, such as cyclobutane pyrimidine dimers. 
Doubl-strand DNA breaks (DSBs) induced by X-rays, chmicals
or during replication of single-strand breaks (SSBs) and presumably
during repair of interstrand crosslinks are particularly relevant for
the recombination machinery. Cels with specialized DNA recombi-
nation activities, such as B- and T-cels, may be very sensitive to DSBs
when they are rearanging their immunoglobin or T-cel-ecptor
genes. This explains the frequent involvement of these genetic loci in
oncogenc trnslocations in leukaemia and lymphomas nd the 
preferential induction of these cancers by ionizing irradiation. DSBs
also pose problems during mitosis, as intact chromosomes are a 
perequisite for proper chromosome segregation during cel 
division. Thus, these lesions frequently induce various sorts of 
chromosomal aberrations, including aneuploidy, deletions (loss of
heterozygosity) and chromosomal translocations — events which
are al intimately associated with carcinogenesis. 
The cel-cycle machinery somehow senses genome injury and
arrests at specific checkpoints in G1, S, G2 and M to alow repair of
lesions befre thy are converted into permanent mutations
(reviewed in ref. 11). Lesion detection may occur by blocked 
transcription, replication or specialized sensors. When damage is too
sgnificant, a cel may optfor he ultimate mo e of rescue byinitiating
apoptosis at the expense of a whole cel (see review by Evan and 
Vousden, pages 342–348).
DNA damage repair systems 
In view of the plthoraof types of lesons,no single repairpocss can
cope with al kinds of damage. Instead, evolution has moulded a
tapestry of sophisticated, interwoven DNA repair systems that as a
whole cover most (but not al) of the insults inflicted on a cel’s vital
genetic information. Inherited defects in any of these pathways in
generalpredisposes to malignancy (Table 1).Becaue heproblem of
DNA damage has existed ab initio, DNA repair systems must have
arisen early in evolution. This explains why al known repair 
pathways are highly conserved (usualy across the pro/eukaryotic
evolutionary border). At least four main, partly overlapping damage
repair pathwaysoperate in ammals —nucleotide-exciso  repair
(NER), base-excision repair (BER), homologous recombination and
end joining
12,13
. The division of tasks btween them can be roughly
defined as folows (see also Fig. 1a). 
NER deals with the wide class of helix-distorting lesions that
interfere with base pairing and generaly obstruct transcription and
normal replication. Smal chemical alterations of bases are targeted
by BER. These lesions may or may not impede transcription and
replication, although they frequently miscode. BER is therefore par-
ticularly relevant for preventing mutagenesis. Most NER lesions arise
from exogenous sources (except for some oxidative lesions), whereas
BER is mostly, but not exclusively, concerned with damage of
endogenousorigin. Lesions for these two repair processes afeconly
insightreview articles
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2.0. – Base Excision Repair (BER) 
 
Tomas Lindahl first discovered the BER pathway around 40 years ago.
35
 At the time 
he  was searching for enzymatic activity that could facilitate the  processing  of  uracil 
present in  DNA.  He successfuly found the required activity in Escherichia coli, a 
discovery that spawned the elucidation  of  uracil-DNA  glycosylase and the catalytic 
steps present within the BER cascade. 
 
As  previously  mentioned in (1.6), DNA is subject to constant  damage in the sub-
celular environment and as such nature has evolved several mechanisms to cope and 
process this damage. Compared with other repair mechanisms, BER has the ability to 
fix an aray of damaged bases upon a DNA duplex in a cel and therefore limits the 
chances  of  mutation and transcription  of  undesired  DNA. In  his  1972 study  Lindahl 
extrapolated that within the mammalian cel environment ca. ~ 12,000 purines undergo 
spontaneous depurination per genome, per cel generation (20 h). This underlines the 
necessity for the BER pathway and its importance in maintaining the primary structure 
of genomic DNA. 
2.1. – The Core BER Pathway 
 
The core base excision repair pathway requires the function of four distinct proteins. 
36
 
Briefly these  proteins include a specific  DNA  glycosylase, an  AP-endonuclease, a 
DNA polymerase and a DNA ligase. These proteins function to recognise and remove 
a  damaged  DNA  base, replace it  with the coresponding undamaged  base and reseal 
the DNA backbone, pathway outlined in (Figure 7).
36
 
 
DNA Glycosylases 
 
DNA  glycosylases facilitate the induction  of  BER – A distinct  glycosylase  wil first 
recognise the identity of and specific damage to a DNA base. Folowing recognition 
the  glycosylase catalyses the cleavage  of the N-glycosidic  bond between the target 
base and  deoxyribose.  This efectively removes the  damaged  base  generating an 
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apurinic  or apyrimidinic (AP site), (15) that ‘flips’  out  of the  DNA  duplex  primary 
structure exposing itself to the subsequent enzyme in the cascade. 
 
Apyrimidinic/Apurinic (AP) Endonucleases  
 
The generated AP site is the recognition point for AP endonucleases. These proteins 
heavily chelate the DNA duplex and cleave the DNA sugar-phosphate backbone at a 
position 5’ to the AP site via a hydrolytic mechanism (Figure 7). This action generates 
a single strand break that further acts to prime DNA repair synthesis.
37
 The resulting 
single strand  break structure contains a  3’  hydroxyl  group and  5’  phosphate at the 
cleavage site that alows the cascade to proliferate, structure (16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Simplified overview of the core process of BER 
 
DNA Polymerases 
 
Matsumoto and  Kim subsequently discovered that  DNA  polymerase-β (Polβ) could 
facilitate the release of the 5’ deoxyribophosphate (dRP) from the processed AP site 
(16). 
38
 Polβ of the Xth family of polymerases is also responsible for DNA synthesis 
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during  BER. It therefore  has a  dual role in  BER through initial removal  of dRP and 
then filing  of the  one-nucleotide  gap  modulated by its  normal  DNA  polymerase 
activity. Polβ is a remarkable enzyme in that during the gap-filing synthesis, it must 
incorporate the corect  nucleotide to  preserve  Watson-Crick  base  pairing and restore 
genomic integrity in the absence of a proof-reading mechanism.
39
 
 
DNA Ligase 
 
With the  desired  undamaged  nucleotide replaced in the  DNA strand,  BER  pathways 
terminate via the ligation  of the  3’ terminus  of the  new  nucleotide into the  parent 
DNA. In  BER, DNA replication and recombination,  DNA ligase  generaly catalyses 
the formation of  phosphodiester  bonds at  SSB’s  between the  proximal  5’  phosphate 
and  3’  hydroxyl in the  DNA  duplex (16 to 17). In  BER the specific ligase IIα 
performs the final ligation step.
39
  
 
2.2. – Differential Modes of Base Excision Repair 
 
Building onto the core BER pathway that generaly operates in al cases, the cel can 
select whether to employ a ‘short’ or ‘long’ patch repair system, see (Figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Short (left) and long (right) patch BER. Specific E.coli and mammalian proteins 
seen in shaded elipses and boxes respectively. 
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Outlined in  detail above, are  both repair  pathways  which  detail an extra level  of 
complexity into the core  BER  pathway.
40
 In  mammalian cels two  pathways for the 
processing of AP sites generated spontaneously or via the action of DNA glycosylases 
have been described. 
 
Short Patch Repair 
 
Firstly,  DNA  glycosylases recognise and remove the  damaged  base. An AP 
endonuclease hydrolyses the phosphodiester backbone immediately 5' to the AP site, 
generating  5'-sugar-phosphate and  3'-OH as it  nicks the  DNA.
41
 Cleavage  of the  5'-
sugar-phosphate by a  deoxyribophosphodiesterase (dRpase)  generates the required 
single  nucleotide  gap that is then filed  by a  DNA  polymerase and sealed  by  DNA 
ligase.
36
 In  mammalian cels  DNA  polymerase-β (Polβ) is the  major  polymerase for 
this pathway. Interestingly, Polβ also shows intrinsic dRPase activity, and can cleave 
the  5'-sugar-phosphate residue itself  before processing the single  nucleotide  gap.
42
 
After the generation of the DNA nick, the actions of Polβ and DNA ligases I/II are 
mediated by the x-ray repair cross-complementing protein (XRCC1).
36
 XRCC1 is one 
of the first proteins recruited to the DNA nick, where it functions as a scafold protein. 
It has no enzymatic activity itself but key interactions with Polβ and DNA ligases I/II 
alow for the termination and success of the short patch BER pathway, (Figure 8).
43
 
 
Long Patch Repair  
 
The short-patch repair pathway appears to be the most active for the processing of AP 
sites, though an alternative ‘long  patch’ mode has  been identified.
44
 This sequence 
initiates  when the  DNA  damage requires the replacement  of  2  or  more  nucleotides 
(limited to 10 bases). Analogously to short patch BER, the AP sites are processed by 
an  AP endonuclease generating the aforementioned 5'-sugar-phosphate and  3'-OH 
termini. At this  point, unlike the short  patch  process the  5’sugar-phosphate is  not 
removed and instead the 3'-OH undergoes  homologation through the addition  of 
several  nucleotides, facilitated  by  DNA  Polβ, δ and ε.  These  polymerases are 
supported  by the  proliferating  nuclear cel antigen (PCNA),  which clamps the 
damaged DNA and binds DNA polymerases, alowing them to process the nick.
45
 The 
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processing factor  PCNA also stimulates the activity  of flap endonuclease  1 (FEN1). 
This endonuclease is required because during the homologation of the 3’-OH end, the 
5’-sugar-phosphate is  displaced as a single stranded flap. The flap structure is 
processed and excised by  FEN1 and the  pathway is terminated  via DNA ligation, 
mediated by XRCC1, outlined above (Figure 8).
46
   
 
Defects in Base Excision Repair 
 
The importance  of  BER  has  been  underlined through several in vitro and in vivo 
experiments. Complete knockout of a central BER protein in mice, (Polβ, Ape1/Ref1, 
XRCC1, FEN1 or a DNA ligase I/II) resulted in embryonic lethality. This observation 
highlighted the absolute requirement for the  BER  pathway in healthy  mammalian 
development.
47
 Consequently,  knockout  of  one  DNA  glycosylase  often  produces  no 
lethal phenotype. This finding was somewhat surprising given the mutagenic danger of 
accumulated unrepaired bases. It however, has been rationalised that the overlapping 
substrate specificity between  multiple  glycosylases alows repair  via an analogous 
protein.
48
 
 
The spontaneous  mutation rate in somatic cels cannot account for al  mutations 
present in human cancers. A popular model for cancer initiation revolves around the 
onset of a ‘mutator phenotype’. With BER providing a major DNA repair service, any 
such  defect in the  process could cause a  mutation and  predisposition to cancer.  To 
date, relatively few BER defects have been shown to cause cancer, though this may be 
a consequence in the  dificulties associated  with detecting causal links.
39
 Though a 
direct link has been identified between colorectal cancer and mutations in the MuTYH 
glycosylase.  The presence of this  mutation reduced the repair  of  8-oxoG:A 
mismatches which led to  G:T translations. These  mutations  ultimately propagated 
downstream with carcinogenic efect.
49
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2.3. – Clinical-Translational Advances – Targeting BER 
 
Alkylating and intercalating agents, and ionising radiation al cause specific  DNA 
lesions, that require  processing  by  BER,  highlighted in sections (1.6 and 2.0). The 
eficacy  of the classical chemotherapeutic agents (outlined in 1.5), relies upon their 
ability to cause lesions in DNA that the BER pathway aims to remove. The outcome of 
this atritional relationship is that  BER  processing leads to reduced  drug-related 
cytotoxicity. Such a reduction in eficacy is hard to counteract  due to the innate 
toxicity and side efects associated  with chemotherapy.  Simply increasing  dosage is 
not a good solution, given the obvious threat to the patient combined with the likely 
up-regulation of DNA repair that would negate the higher drug loading. 
 
Research into the BER  machinery  has elucidated an aray  of specific  proteins that 
function in a concerted, cooperative manner at the molecular level.
50
 It is accepted that 
the curent level of understanding may alow for the design of novel cancer treatments 
that target a  discrete  perturbation  within the  DNA repair  pathway. We therefore ask 
the  question,  wil inhibition  of a single  protein in the  BER  pathway  disrupt  DNA 
repair at a level suficient enough to increase the eficacy of curent chemotherapeutic 
agents? 
 
2.4. – Targeting Proteins Involved in BER; Poly ADP Ribose 
Polymerase 1 (PARP-1) 
 
PARP-1 is a nuclear celular protein that operates within the BER pathway. Its main 
role is to detect and signal the SSB generated by the activity of AP endonucleases, to 
DNA polymerases.  PARP-1 activation  occurs in  direct response to chemical, 
metabolic and radiation induced  SSBs. The  protein  displays remarkable afinity for 
SSB in  DNA and is  postulated to  bind  processed  AP sites  before any  other repair 
protein. Upon binding to a SSB, an alosteric shift activates PARP-1, which catalyses 
the synthesis  of  poly(ADP)ribose (PAR) chains.  These chains act as the signal for 
downstream  BER  proteins, (Polβ,  XRCC1 and  DNA ligases) which finish the  DNA 
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repair.
51
 PARP-1 is  overexpressed in a  plethora  of  human cancers and as a result 
chemical inhibition  of the  protein  has  been considered. It  was initialy thought that 
inhibition  of this BER  protein should alow for an increased eficacy  of 
chemotherapeutic agents and ionising radiation, through an accumulation  of 
unrepaired SSBs. Indeed, PARP-1 knockout mice were shown to be hypersensitive to 
alkylating agents and ionising radiation.
51
 This certainly provided some  proof  of 
concept, however in vivo PARP-1 inhibition is likely to be functionaly compensated 
for by another form of DNA repair, homologous recombination, highlighted in (Figure 
6). 
 
The application of PARP-1 inhibitors across al cancer variants may be limited, though 
clinical application is being sought in breast, ovarian and prostrate cancers that possess 
a  germline BRCA gene  mutation. The  process  of  homologous recombination is 
controled  by BRCA1 and BRCA2. When these  genes are  defective in tumour cels, 
DNA repair is solely reliant  upon  PARP-1 to recognise  SSB.  As such, inhibition  of 
PARP1 in tumour cels  with  deficient BRCA1/2 could alow for an increase in 
sensitivity towards alkylating agents and ionising radiation. Initial in vitro studies 
probing this strategy  have  been translated into a clinical application.  Curent trials 
have shown significant tumour reduction accompanied  with  mild side efects  when 
compared to control patients.  
 
Early  work in expanding the therapeutic  window  of classical chemotherapeutics is 
promising, and gives confidence that exploiting the intricate BER molecular pathways 
is  viable. Inhibition  of  PARP-1 is a flagship approach, though  with the  observed 
atrition (homologous recombination) targeting  upstream BER proteins  may  be  more 
advantageous. Considering this, our atention became focused upon AP-endonuclease 
1 (Ape1/Ref1), the details of which are disclosed in the folowing sections.  
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2.5. – Apurinic/Apyrimidinic (AP) Endonuclease 1 (Ape1/Ref1) 
 
Apurinic/Apyriminidic (AP) endonuclease  1 is a  magnesium  dependant  phosphatase 
containing 318 amino acids (35.5 kDa). It is a globular α/β protein consisting of two 
domains, a tight  nuclease  domain and a flexible,  disordered  N-terminal region.
37, 52
 
Each domain is made up of six-stranded β-sheets surounded by α helices. The protein 
is  packed into a four layered α/β sandwich that resembles  DNase I and exonuclease 
II.
53
 The  protein is  multifunctional, exhibiting  3’  phosphodiesterase,  RnaseH and 
weak 3’ phosphatase activity, however the functional significance of these properties 
is stil relatively unknown. The protein displays subcelular localisation in the nucleus, 
is expressed  ubiquitously and functions as the  major  mammalian endonuclease 
responsible for the excision and removal of abasic sites within DNA.
54
 
 
 
 
 
 
 
 
 
Figure 9: Abasic site formation: (A) DNA glycosylase mediated removal of 7oxoAdenine (B) 
Spontaneous depurination; Chemical forms of abasic site, (20 – 22) 
 
Curent biochemical predictions have postulated that Ape1/Ref-1 is responsible for 95 
percent  of abasic site cleavage  within the  human  genome (mediated  by the  BER 
pathway). Abasic site generation through spontaneous depurination is approximated to 
occur spontaneously  12,000 times  per  mammalian  genome, per cel equivalent ca. 
every  20  h, depicted above (Figure 9).
55
 Additional  AP site formation also occurs 
constantly through the previously mentioned modes, see (2.0). 
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2.6. – Protein Structure 
 
Ape1/Ref1 displays remarkable recognition for abasic sites. The exact reason for such 
profound recognition is stil unclear.  Employing x-ray crystalography, site directed 
mutagenesis and  using substrate analogs  has  not yet elucidated a single conclusion. 
Indeed, co-crystalisation of abasic DNA with Ape1/Ref-1, shown below (Figure 10) 
has revealed the binding mode in operation.
37
 Ape1/Ref-1 inserts loops into the abasic 
DNA  major and  minor  grooves  binding a ‘flipped  out’ AP site into a  hydrophobic 
pocket. The protein then cleaves the DNA sugar-phosphate backbone at a position 5’ 
to the AP site via a hydrolytic mechanism. This generates a single strand break that in 
turn acts to  prime  DNA repair synthesis. The  positively charged  Ape1/Ref1  DNA 
binding face interacts  with the abasic  DNA substrate  over a  vast area.  The  protein 
buries  1600 Å
2
 of  DNA solvent accessible surface into a cleft running across its 
structure (Figure 10).
37
  
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Abasic DNA/Ape1/Ref1 co-crystal structure. Front view (left) and side view (right), 
pdb code (1DEW), images produced with Pymol.
56
 
 
The protein substrate interface is centred upon the flipped out nucleotide, below (green 
Figure 11) and its flanking  phosphates,  which contribute  500 Å
2 
to the total  buried 
DNA surface.
37
 Ape1/Ref1 electrostaticaly orientates its rigid DNA binding face and 
wraps around  both the  major and  minor  grooves forming a  highly stable, short-lived 
complex.
37
 In forming the  protein-substrate complex, the  protein shows litle 
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flexibility (rmsd ~ 0.7 Å between Cα atoms of free protein and DNA bound protein).
52
 
The DNA however is severely kinked by 35° and the helical axis deviated by 5 Å. The 
binding and twisting of the DNA substrate across the protein cleft alows for optimal 
positioning of the abasic residue into the active site. This positioning places the target 
phosphate  bond into a  highly coordinated  hydrophilic environment,  priming the 
backbone hydrolysis mechanism.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: ‘Naked abasic DNA’ from co-crystal structure (1DEW). ‘Flipped out’ abasic site 
extrahelicaly visible (green).  
2.7 – Abasic Site Cleavage Mechanism – The Single Strand Break  
 
Much  debate  has ensued regarding the  precise residues responsible for activation, 
stabilisation and positioning of the phosphate linkage prior to its hydrolysis. It is now 
widely regarded that  one  of two  possible residues (Asp210,  His309) are responsible 
for the  deprotonation  of a  proximal  water  molecule.
57
 This event generates a 
hydroxide nucleophile that atacks the phosphorous oxygen double bond, subsequently 
hydrolyzing the phosphate-sugar backbone. Elucidating which residues were vital for 
cleavage  was conducted through  genetic  mutations  within the active site and also 
through  pH titrations.  Site  directed  mutagenesis studies  of  Asp210 and  His309 
indicated that both residues play an essential role in the incision reaction, but they do 
not stabilise binding of the DNA substrate.
58
 Considering its proximity to the scissile 
phosphate  bond it is conceivable that  His309 is acting as the  Lewis  base,  detailed 
below (Figure 12). In the postulated mechanistic cycle the sugar phosphate backbone 
is stabilised and  positioned  by active site residues  Asn174 and  Asp210.  His309 then 
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deprotonates a proximal  water  molecule that initiates the cleavage cycle. The 
hydroxide atacks the  phosphate  bond forming trigonal  bi-pyrimidial intermediate 
(24).  Colapse  of the resulting transition state  occurs forming the cleavage  products 
and an SSB in the DNA backbone. 
 
 
 
Figure 12: Postulated cleavage mechanism, His309 acting as the Lewis base.
57b
 
Metal dependency of the protein has also been widely investigated. Multiple theories 
have  been suggested that  questioned the site  of  metal  occupancy and also its 
stoichometry. Early  work  hinted at the  presence  of two cations  based  upon crystal 
structures  using  Pb
2+
 and  Mn
2+
 surogates.
59
 Claims as to  possible locations  of the 
metal were based upon dual occupancy of two sites and single occupancy of each site. 
It is now widely accepted from crystallographic evidence and solid-state 
25
Mg-NMR 
spectroscopy that a single Mg
2+
 atom is present.
60
 The cation occupies a site between 
residues  Asp70,  Glu96,  Asn212 and co-crystalised  water  molecules. The  metals 
localisation has solidified the hypothesis that it has dual roles in catalysis and abasic 
substrate stabilisation. Research into the  metal  dependency  of the system led to the 
postulation that  Asp210 could also act as the  Lewis  base in the cleavage cycle, 
detailed below (Figure 13). 
 
 
 
 
 
 
Figure 13: Postulated cleavage mechanism, Asp210 acting as the Lewis base.
57a
 
In this  postulation, the scissile phosphorous  oxygen  double  bond is stabilised  by the 
neighbouring  Asn212.  The  phosphate sugar  backbone is further stabilised through 
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interactions  with  Asn174,  His309 and coordination to the  metal. The active Asp210 
reside then deprotonates a proximal water molecule initiating the cleavage cycle. 
 
The  outlined studies supported  by crystalographic  data  defined a smal catalytic 
region  within the  macromolecular  protein structure. Identification  of this region 
alowed further analysis of residues proximal to this site. These studies built a model 
of the ‘catalytic domain’, which represented a possible drug target. 
2.8. – Protein Structure II - The Catalytic Domain 
 
Although Ape1/Ref1 binds abasic DNA over a vast surface area, seen in (Figure 10) 
the catalytic cleavage site is relatively smal. Figures (14 and 15) are crystal structures 
of the protein with resolutions of 1.8 and 2.5 Å respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Key active site residues (yelow) and Mg cation (pink) taken from 
P.S. Freemont (unpublished data).
61
 
 
Figure 14 details an unpublished crystal structure  of  Ape1/Ref1. The  most striking 
feature in this crystal is the  presence  of  Mg
2+ 
(pink sphere). This crystal structure 
unequivocaly confirms the location  of a single Mg
2+
 cation within the catalytic 
domain.  Structuraly the active site  has two  distinct regions  both  with  very  distinct 
characteristics.  The  western  hydrophobic region contains residues,  Asn174,  Arg177, 
Phe266 and Trp280. This region is responsible for π-stacking against the hydrophobic 
face of extrahelical AP-sites. The flexible Arg177 residue plays an important dual role 
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in H-bonding to the target DNA phosphate backbone and forming π-cation interactions 
with adjacent DNA  bases.  The eastern catalytic region is  of opposite electrostatic 
nature, containing the hydrophilic residues Asn212, His309, Asp70, Glu96 and Ala74. 
These residues are responsible for the chelation of the metal cation, orientation of the 
target 5’ phosphate and its hydrolysis. 
The second crystal structure shown  below (Figure 15) was taken from the co-
crystalised Ape1/Ref1/DNA structure, (pdb. code 1DEW).
37
 The DNA substrate and 
Mg
2+
 metal  have  been removed for clarity.  This DNA  bound structure is nearly 
identical to (Figure 14) apart from the flexible Arg177 residue is shown to be pointing 
down, eclipsing Trp280. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Key active site residues (yelow) taken from 1DEW 
(DNA removed for clarity). 
 
In (Figure 14) Arg177  points  out like an arm into the solvent space, ilustrating its 
importance for recognising and inserting into the incoming  DNA substrate. 
Conversely, in (Figure 15) the Arg177 is in a locked conformation alowing eficient 
anchoring  of the  DNA into the cleavage site.  Site  directed  mutagenesis  has  given 
strong support as to which residues are vital for endonuclease activity. Firstly, Glu96 
has  been shown to  play a  key role in  positioning the  Mg
2+
 co-factor in the catalytic 
site. An E96A mutation caused a significant decrease in the catalytic turnover of the 
enzyme. Furthermore, mutations in Try171 and Asp210 caused a 5000 and 25000 fold 
decrease in catalysis respectively. The exact function of the aforementioned residues is 
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stil unknown, but evidence suggests Asp210 acts as a proton donor and that Try171 
bonds intramoleculary with Glu96 stabalising the active site.  
 
In summation,  mutations that negatively impact  upon catalytic activity are  Glu96, 
Try171, Asp210 and His309; those afecting DNA-protein binding kinetics are Asp70, 
Asn212,  His  283 and  His308.  The  quantitative  observations  gained in enzyme 
catalysis and the structural  knowledge  gained from  x-ray crystalography forged a 
solid foundation for starting a smal  molecule inhibitor campaign from a  design 
perspective. In moving forward, it was vital to ascertain the importance of Ape1/Ref1 
within the development of cancer. Several groups have deduced its viability as a novel 
chemotherapeutic target and  have also  highlighted some  prognostic  value associated 
with this.  
2.9 – Ape1/Ref1 as a Chemotherapeutic Target 
 
As  previously  discussed, chemotherapeutic agents are employed target cancer cels 
and act by causing DNA lesions. Such genomic damage blocks cel replication leading 
to a  decrease in  proliferation and cel  death.  The sub-celular localization and 
omnipresence of DNA repair proteins does however cause a great deal of atrition with 
these treatments. In the interest  of improving cancer treatments and  moving towards 
‘targeted therapies’, researchers  have identified  Ape1/Ref1 as a  possible adjuvant 
chemotherapeutic target. Given the issues seen in the early stage targeting of PARP-1 
(2.4), it is thought that targeting  upstream  BER  proteins like  Ape1/Ref1, may  be a 
more fruitful approach.  The  general  premise folows that inhibiting  DNA repair 
activity  within tumour cels should  make them  more susceptible to classical  DNA 
damaging chemotherapeutic agents.  
 
DNA repair and the BER pathways are fundamental to the maintenance of the genome 
and the continued  healthy function  of cels.  This  point is  underlined  by the fact that 
RNAi directed against Ape1/Ref1 (in the absence of a DNA damaging agent) resulted 
in  decreased cel  proliferation, an increase in unprocessed AP sites and increased 
levels  of apoptosis.
62
 Such efects are  highly  desirable in a tumour cel environment 
and  provide a strong  basis for further  development.  Translating these findings into a 
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proof-of-concept study, researchers  demonstrated that a reduction in the intracelular 
levels of Ape1/Ref1 sensitised medulablastoma cels to the chemotherapeutic agents - 
carmustine,  bleomycin,  TMZ and  gemcitabine.
63
 These results  provided the first 
definitive  biochemical evidence that  Ape1/Ref1 characterised a  novel adjuvant 
chemotherapeutic target.  Furthermore, later studies  demonstrated that RNAi 
knockdown  of  Ape1/Ref1 in  ovarian cancer cels caused a  decrease in cel 
proliferation in vitro and severely inhibited the growth of ovarian tumour xenografts.
64
 
 
Curiously it  has also  been shown that Ape1/Ref1 is  over-expressed in  many  human 
cancers and subsequently  may  have some prognostic relevance.  The  over-expression 
patern is characteristic in lung,  breast,  bone, cervical,  head and  neck cancers, and it 
has also  been shown to corelate  with resistance to  both radio and chemotherapy 
regimens.
65
 Considering the increased and  uncontroled rate  of cel  proliferation in 
cancer cels, it has been postulated that the increased expression may be a result of an 
increase in spontaneous endogenous DNA damage during the cel cycle. As such, the 
over-expression of Ape1/Ref1 acts to compensate this and facilitates the propagation 
of carcinogenic material.  
 
The discoveries and paterns outlined by the literature have validated that Ape1/Ref1 
is a  worthwhile chemotherapeutic target.  While the  genetic tools employed in 
molecular  biology are ideal to  both elucidate and  understand the function and 
mechanics of a protein, RNAi knockdown clearly cannot translate clinicaly. Inhibition 
of  Ape1/Ref1  by a smal  molecule is therefore regarded as an  utmost  priority in the 
search for increasing the eficacy  of curent chemotherapeutics. In theory, efective 
inhibition of Ape1/Ref1 should reduce tumour growth and limit the known side efects 
of curent treatments, (as reduced dosage could in principle deliver the same level of 
efficacy). Furthermore, reduced dosage could slow the rate at which chemotherapeutic 
resistance  develops.  Any combination  of factors discussed would  be  beneficial and 
could provide a novel weapon in the anti-cancer arsenal. 
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2.10 – Project Objectives 
 
Over the last  decade researchers  have identified the role  of  Ape1/Ref1 in cancer. 
Having  gained solid  pre-clinical evidence in the corelation  between  protein 
expression and tumour cel survival,  Ape1/Ref1  became a  novel chemotherapeutic 
target. 
 
The aim of this  project  was to identify,  design and  develop a  novel smal  molecule 
inhibitor  of  Ape/Ref1.  At the inception  of this  project  only  one inhibitor  had  been 
described in the literature. In 2005 Hickson and co-workers
66
 employed a fluorescence 
based high-throughput assay to search a chemical library of 5000 compounds. In doing 
so they disclosed 7-nitroindole-2-carboxylic acid (29) as their lead compound with an 
associated IC
50 
value
 
of 3 µM, structure shown below (Figure 16). 
 
 
 
 
 
Figure 16: Structure of disclosed ‘inhibitor’ 7-nitroindole-2-carboxylic acid 
 
Unfortunately since its  publication several  groups failed to confirm this finding and 
(29) was considered to  be a false  positive.
67
 Considering this,  we ignored structure 
(29) and started a  grass roots  drug  discovery campaign.  High-throughput 
computational screening and rational  drug  design  was enabled  by the  wealth  of 
crystalographic  data available for  Ape1/Ref1 and served as a starting  point in  our 
approach.  
 
During this  project several  publications emerged that  detailed  novel inhibitors  of 
Ape1/Ref1. We selectively analysed and experimentaly probed these reports and used 
these findings to further guide our drug discovery eforts.  
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2.1.0. – Results and Discussion 
2.1.0 – General Aspects of Drug Design  
 
A  drug  molecule can  be readily  defined as, ‘a substance that  possesses  one  or  more 
functional groups positioned in three dimensional space on a structural framework that 
holds a  defined  geometrical aray, enabling the  molecule to  bind specificaly to a 
targeted biological macromolecule, a receptor’. As a result the drug’s structure should 
permit a  desired  beneficial  biological response, that  precludes  binding to  other 
untargeted receptors.
68
 
 
Puting it simply, al  drugs are  molecules,  but  most  molecules are  not  drugs.  This 
definition has led to the term ‘drug-like molecule’ (DLM): A structure that possesses 
the chemical and  physical  properties that  wil enable it to maintain its structural 
integrity and elicit a  biological effect in vivo. These  properties were famously 
characterised by Christopher Lipinski and serve as an efective tool in drug discovery 
today;  A  drug  molecule should  have a  molecular  weight less than  500, a logP  value 
less than  5, fewer than  5  hydrogen  bond  donors, and less than  10  hydrogen  bond 
acceptors.
69
 Lipinski’s rules are not absolute and should be considered as guidelines. 
Several drug curently marketed molecules namely Taxol, do not abide by these rules 
yet display remarkable eficacy as therapeutic agents. The overal properties of a novel 
drug  molecule cannot  be  100% accurately  mapped  prior to  biological evaluation, 
though consideration of these guidelines is thought to reduce the chances of atrition in 
late stage drug development. They therefore serve as a template from which a drug can 
begin to be carved.  
 
Since the  dawn  of  humankind,  people  have searched for remedies to combat a  vast 
aray of conditions. These treatments were often inefective and somewhat brutal for 
the patient to endure. Fast forwarding to the modern age, drug discovery is fueled by 
the science  of rational  drug  design, defined as, ‘a  method  whereby a  disease is 
understood at a  molecular level such that the  biological  macromolecules involved in 
the  disease  process have  been identified,  purified, characterised and  have  had their 
three-dimensional structure elucidated’.
68
 The most poignant feature of the definition 
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is that in solving the three-dimensional structure it is possible to design a smal DLM 
to target a biologicaly relevant active site. Roughly twenty years ago it was postulated 
that the combined afinity of a smal molecule for a biological target is a function of its 
constituent fragments. Using this idea the science of drug design entered a new realm, 
moving from the serendipitous drug discoveries of the 1900’s to specificaly designed 
DLM’s. 
2.1.1. – Computer Aided Drug Design 
	  
Computer-Aided-Drug-Design (CADD) details the employment  of computer-aided 
techniques to design, search and optimise potential bioactive drugs as putative drugs.
68
 
In the year 2000 a review of the drug design literature (J. Med. Chem. & J. Am. Chem. 
Soc.), found that  43%  of  published  papers included computational chemistry 
techniques in their eforts at identifying and analysing potential drug candidates.
68
 The 
advances in protein X-ray crystalography coupled with the birth of the computer age 
have alowed for the development of a vast aray of computational programs. Today, 
computational assistance  permeates al levels  of  drug  discovery and throughout 
industry teams  of computational chemists  work alongside synthesis and  ADMET 
teams in  designing  novel  drug  molecules.  This  working relationship  has led to the 
development of software accessible to al varieties of chemist, in turn has broadened 
understanding and innovation in the field.
70
 
The three major methods of drug discovery supported by computational advances are 
defined as: ‘structure  based  drug  discovery’ (SBDD), ‘ligand  based  drug  discovery’ 
(LBDD) and ‘fragment  based  drug  discovery’ (FBDD).  SBDD is  wholy  dependent 
upon structural information  of the target. With an  X-ray structure  of a  protein 
available, it is  possible to identify the active site and therefore  build a structure that 
could bind efectively, taking into consideration the chemical and electrostatic makeup 
of the receptor environment.  LBDD centres upon a  known ligand that  binds to the 
biological target of interest. Whether the ligand is a natural substrate e.g. dopamine or 
a synthetic entity, both can be used to derive a pharmacophore that can be built upon 
and  drive eforts to increase  potency  or reduce  undesirable side efects and 
metabolism. FBDD  disassembles lead  drug structures into smaler  pieces  or even 
discrete functional groups. Such simplification of the molecular entity has been used 
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to alow for easier computational assessment of the functionalities important for high 
afinity binding.
71
 This approach has greatly benefited from the development of high 
throughput x-ray crystalography and is curently regarded as an invaluable approach 
in drug design.  
2.1.2. – High Throughput Virtual Screening (HTVS)  
	  
The advantages of ‘high throughput’ techniques in drug discovery are overwhelming. 
Consider a  200,000 compound library requiring  biological assessment. If an assay 
could process 5 compounds per day, it would take 110 years to assess the ful library. 
Utilising modern robotics, it is conceivable that 200,000 compounds could be assessed 
in a mater of weeks. Although this is clearly an incredible improvement in eficiency, 
the cost to the  pharmaceutical industry to  operate such an assay is  great. Applying 
computational techniques to such a library could alow for the elimination  of 
compounds predicted to bind poorly, without the need for in vitro assessment.  
When  presented  with a  biological target lacking any  known inhibitor in silico 
modeling ofers a convenient method of ‘narowing’ the initial search. Large chemical 
databases either commercialy  or  publicly available can  be  used to assess  predicted 
eficacies  of a  vast  number  of ligands > 1  milion in a short  period  of time. Crude 
computational screening is  often  described as a subjective approach and that the 
natural interactions between a protein and ligand can never truly be predicted.
72
 In part 
this  may  be true,  but the computational screen alows for the identification  of 
favourable ligand shape and size against the proteins binding pocket. Key electrostatic 
and  hydrophobic interactions are also readily identifiable and such approaches  have 
been known to reveal initial leads on multiple occasions.
73
 
Due to the  wealth  of crystalographic  data available for  Ape1/Ref-1 and the lack  of 
any known inhibitor a computational approach was initialy employed. 
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2.1.3. – Application of Computer Aided Drug Design 
	  
 
Computational  Aided  Drug  Design (CADD)  was conducted at  Emory  University, 
Atlanta,  GA. USA. The  glide (grid-based ligand  docking  with energetics)
74
 
(Schrodinger  2007,  LLC)  program  was  used for al in silico analysis.  Glide  uses a 
selection  of filters to assess several locations  of the ligand that  wil favourably  dock 
(map) into the active site space.  The shape and  physiochemical  properties  of the 
receptor are  mapped against the ligand, this generates the  most favourable ligand 
‘pose’ that coresponds to the pre-defined properties of the receptor.
74
 The pose is an 
approximate quantification  of ligand  position,  orientation, core conformation and 
possible rotameric states.
74-75
 A glidescore is then generated, tabulated and ranked for 
each source ligand. The score is a parameterisation of al properties discussed above, 
and can  be considered as a  balance  between the inherent afinity the ligand  displays 
towards the active site and the conformation the ligand  must adopt to  maintain a 
favourable  overlap.  Negative  values ranging below -5.0 are considered to  be 
favourable  docking scores, and should  be further analysed. With a  promising 
glidescore in  hand, a second calculation  must  be  performed that  deals  with the 
predicted energetics of binding.  
The mmGBSA score employs molecular mechanics, and the generalised Born model 
and solvent accessibility  method to elicit free energies from structural information, 
which circumvents the computational complexity  of free energy simulations.
75
 The 
approach has been described as a reliable method for calculating the bimolecular free 
energies (ΔG) associated  with a given protein-ligand interaction.  Again  negative 
values indicate a favourable  binding interaction (ΔG  = ΔH - TΔS) hence the  more 
negative a  value the  beter the  hypothesised  binding.  To  be judged as a ‘hit’ a fine 
balance  between the  glidescore, feasibility  of the  pose and mmGBSA value must  be 
found. 
Computational modeling was conducted using a four step iterative approach due to the 
large  number  of ligands that underwent screening. Several virtual chemical libraries 
were screened (see computational appendix A1)  using the order  of methods outlined 
below. 
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High-throughput  Virtual  Screening (HTVS): The  HTVS  method is suitable for 
screening a vast quantity  of compounds in relatively litle time.  The  method screens 
and obtains docking scores that are ‘quite accurate’. The principle idea of a HTVS is 
to reduce a large  number  of ligands that are hard to  process into a smaler  number 
upon which a more accurate study can be conducted. Typicaly in a library containing 
100,000 structures the top  1000 (most  negative)  docking scores  were taken forward 
discarding the other 99,000 as less favourable.  
Standard  Precision  Screen (SP): With the top  1000  HTVS  hits in  hand a  more 
accurate screen namely SP is conducted. SP is described as a ‘forgiving’ function that 
wil allow structures to  dock even if  one significant  property  of  binding is 
unfavourable.
74
 Again a docking score is obtained and typicaly the top 250 hits from 
the SP analysis are taken forward for the next level of study.  
Extra  Precision  Screen (XP): The  250 top  hits from  SP are finaly screened in the 
most accurate of docking modes, extra precision. Severe penalisation is employed to 
ligand poses and interactions that  violate established thermodynamic and entropic 
laws.
74
 A common example is that polar side chains  must  be exposed to solvent  or 
taking part in hydrogen bonding. The screen is employed in atempt to minimise the 
percentage  of ‘false  positives’ observed.  The ligands are then tabulated according to 
docking score for selection and visualisation of the best possible structures. 
mmGBSA (ΔG  Binding): Typicaly the  best  hits from the  XP screen are then 
subjected to analysis by mmGBSA. It is also a worthwhile consideration to conduct an 
mmGBSA calculation on the top 250 hits from the SP study (as mentioned previously 
the identification  of a  good inhibitor in silico wil  be a  balance  between a  good 
docking score and  good  MMGBSA score).  This  methodology  was applied in an 
atempt to minimise the loss of ‘false negative’ results during earlier screening as the 
corelation between docking score and MMGBSA is not always strong. 
The  numerical  output  obtained from such a study should  not  be taken alone as the 
overiding factor in ‘lead’ computational ligand identification. Classical approaches to 
drug discovery are very relevant when a scafold or pharmacophore is identified. Key 
residues within and in close proximity to the active site can be targeted by predicted 
favourable interactions with the ligand. Atempting to match hydrophobic overlap and 
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π-stacking interactions alongside targeting specific  hydrogen  bond  donors and 
acceptors can lead to eficient ligand  design.  The  key  balance  between al  of these 
factors can ofer an increased probability of lead identification.	  
2.1.4. – Virtual Analysis of Chemical Databases  
	  
Molecular modeling simulations were caried out using the Maestro-software package 
from Schrödinger Inc, including Maestro 7.5.112, Glide 4.0, MacroModel 9.1, Prime, 
and  QikProp  v2.5. The  unpublished crystal structure  of  Ape1/Ref-1
61
 (resolution  1.8 
angstroms) was  used as the in silico receptor target (the selected active site residues 
that defined the docking centroid can be found in the computational appendix A1). 
Prior to  molecular  modeling the  protein  was  prepared accordingly.  Al  water 
molecules were removed, Mg
2+
 was left untreated, polar hydrogens remained, al bond 
orders  were assigned,  minimisation  was conducted to a RMSD of 0.3 angstroms. 
His309  was  manualy  protonated and flipped  out, reassigned to  HIP309. Al ligands 
contained in chemical libraries  were  prepared  using LigPrep v2.3 (Schrödinger) that 
generates possible protonated/deprotonated states between pH 7.0 -/+ 2.0 using default 
ioniser setings.  Possible tautomeric structures  were  generated and al specified 
chiralities retained. A combination of al these parameters achieves the lowest energy 
conformations  of the ligand,  which form the  most accurate  prediction  of the 
conformation the  molecule adopts in H
2
O solvated conditions, (for further  details  of 
specifics associated with CADD please see the computational appendix). 
Emory  University,  Atlanta,  GA.  USA, provided the relevant ‘drug-like’ compound 
libraries that  were purchased  or  obtained free  of charge from commercial suppliers. 
Computational drug  design was conducted  using the four step iterative approach, as 
outlined in section (2.1.3).  Approximately  1,000,000 ligands  were assessed in silico. 
Analysis  of al numerical data and  hypothesised  binding  modes produced 46 
structuraly varied compounds that were considered as potential leads and selected for 
in vitro evaluation, structures and associated data shown below (Table 1). 
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Entry Compound Glidescore mmGBSA ΔG Structure Entry Compound Glidescore mmGBSA ΔG Structure
1 30 -8.47 -1.91 19 48 -5.36 -25.04
2 31 -8.23 -2.1 20 49 -4.83 -2.02
3 32 -8.22 -3.78 21 50 -3.61 -29.22
4 33 -8.12 -4.58 22 51 -8.92 -13.15
5 34 -8.09 -8.93 23 52 -8.55 -9.28
6 35 -7.78 -1.49 24 53 -8.43 -7.12
7 36 -7.58 -4.63 25 54 -8.18 -11.39
8 37 -7.55 -4.54 26 55 -7.81 -11.24
9 38 -7.53 -38.74 27 56 -7.55 -13.68
10 39 -7.44 -6.5 28 57 -7.53 -18.19
11 40 -7.27 -12.5 29 58 -7.52 -11.05
12 41 -6.96 -12.36 30 59 -7.13 -12.12
13 42 -6.81 -6.28 31 60 -7.04 -11.94
14 43 -6.48 -23.4 32 61 -7.03 -9.6
15 44 -6.4 -4.38 33 62 -7.02 -13.12
16 45 -6.15 -10.93 34 63 -7.59 -6.74
17 46 -5.71 -28.4 35 64 -7.55 -10.27
18 47 -5.53 -8.45 36 65 -6.66 -7.58
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Table 1: Top 46 ranked in silico ligands. Compound 75 top mmGBSA hit. 
 
Of the 46 compounds retrieved, the top 30 were sourced commercialy. Unfortunately 
highlighted compound (75) (Table 1) was not commercialy available, though given its 
structural simplicity we rationalised that it should be readily accessible with minimal 
synthetic efort. At such an early stage we had no insight into how the in silico ligands 
would  behave in vitro.  We therefore  decided to  make several analogues  of 
sulphonamide (75) in atempt to gain a quick foothold in the active site. Moreover, this 
decision  was  based  upon the  observation that sulphonamide (75) had the  most 
favourable calculated ΔG mmGBSA (-32.0 kJ  mol
-1
) and was therefore the  most 
rational and synthetic starting point.  
3.0. – Synthesis of the Sulphonamide Series  
 
Access to sulphonamide scafold 76 was initialy pursued folowing the retrosynthetic 
analysis outlined in (Scheme 1). 
 
 
 
 
 
 
 
Scheme 1: Retrosynthetic analysis of sulphonamide scafold 76. 
Entry Compound Glidescore mmGBSA ΔG Structure Entry Compound Glidescore mmGBSA ΔG Structure
37 66 -6.59 1.44 42 71 -6.92 1.48
38 67 -3.62 -9.28 43 72 -6.84 2.3
39 68 -9.16 -4.83 44 73 -6.84 1.3
40 69 -8.61 -5.8 45 74 -6.09 -2
41 70 -7.26 -4.64 46 75 -6.15 !32.1
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It was thought that fuly elaborated core 76 could be realised folowing a simple five 
step synthetic sequence.  Alkylation  of  phenol 76 folowing removal  of the  benzyl-
protecting group alows access to the ful sulphonamide core from ether 77.  The 
protected core  was available from sulphonyl chloride 78 and aniline  derivative 79. 
Protected sulphonyl chloride 78 was thought to be accessible through  protection and 
chlorosulphonation of commercialy available phenol 80. 
 
In moving forward,  protection and chlorosulphonation  of  phenol 80 proved 
problematic. The high level of acidity displayed by chlorosulphonic acid prevented the 
use  of commonly employed and easily removed  phenolic  protecting  groups. 
Chlorosulphonation eforts upon the MOM, TBS and TIPS protected phenols al led to 
a complex mixture of products. Benzylation of 80 was not suitable, due to competing 
chlorosulphonation upon both aromatic rings. We finaly circumvented the protecting 
group issue through starting the synthesis with sodium salt 81 (Scheme 2).  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2: Initial forward synthesis of sulphonamide scafold 87. 
 
Phenolic  protection  of sodium salt 81 provided the  desired  benzyl ether 82 in  good 
yield.  Folowing this, sulphonyl chloride 83 was formed  upon treatment of 82 with 
thionyl chloride, and the sulphonamide was accessed via nucleophilic chloride 
displacement with aniline.  Deprotection  of the  benzyl ether employing classical 
hydrogenation conditions gave free phenol 85, in excelent yield over the three steps. 
Atempts to access the final elaborated core 87 through alkyation of the phenol were 
unsuccessful.  We were somewhat surprised  by this  observation, though rationalised 
that the p-sulphonamide could  be  hampering the reaction  by reducing the relative 
nucleophilicity  of the  phenol through its electron  withdrawing capabilities. 
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Furthermore, even though the reactivity  of the sulphonamide  nitrogen should  be 
negated, we were wary that a mixture of products could be obtained. At this point we 
became aware that an obvious solution had been overlooked.  
 
Protection of the phenol moiety with the desired side chain 86 could alow for an acid 
stable chlorosulphonation substrate and removed any  possibility  of alkylation at 
nitrogen. Phenol was therefore alkylated with methyl bromoacetate, obtaining ester 89 
in excelent yield, (Scheme 3).  
 
 
 
 
 
 
 
 
 
 
Scheme 3: Successful synthesis of sulphonamide analogues. 
 
 
With ester 89 in  hand, chlorosulphonation  proceeded smoothly  giving the  desired p-
sulphonyl chloride 90 as a single regioisomer. Intermediate 90 was then elaborated to 
the  desired sulphonamide scafold  with seven diferent anilines, structures shown 
below in (Table 2). 
 
 
 
Table 2: Synthesised sulphonamide esters/acids and associated yields. 
 
The anilines each contained  diferent  hydrophobic functionalities, as computational 
studies indicated the  possibility for such  variance in the aromatic.  Computational 
assessment of scafold 75 further indicated that the carboxylic acid functionality may 
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provide additionaly favourable  protein-ligand interactions.  Considering this,  we 
decided to store smal quantities of esters (91-97) for biological testing, bulk material 
of al synthesised esters  was taken forward and saponified to access the  desired 
carboxylic acid containing sulphonamides (98-104), (Table 2).  With the top  30 
purchased in silico hits and  14 synthesised sulphonamide analogues in  hand  we 
conducted our first round of biological assessment.     
3.1. – Biological Testing of Computationaly Identified Compounds 
3.2. – Assay Overview 
 
Our colaborators at Imperial Colege developed the biological assay, (specifics found 
in biological appendix B1). The general mechanics of this assay are analogous to those 
first  described  by  Madhusudan and co-workers in  2005.
66
 The assay is fluorescence 
(FRET) based, using a  hairpin  DNA  duplex that contains an engineered abasic site. 
The oligonucleotide was purchased from EuroGentec (Liege, Belgium) with sequence 
writen  5’ to  3’ – (GAC-TAA-5AA-TGA-CTG-CGG-TTA-CGC-AGT-CAT-TGT-
TAG-TC6-99T),  where  5 coresponds to the engineered abasic site (tetrahydrofuran 
residue) and  T coresponds to the  TAMRA fluorophore. A schematic  of the 
fundamental assay mechanics is outlined in below (Figure 17). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Schematic of the biological assay. F denotes TAMRA fluorophore and X denotes BHQ-II.  
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The engineered oligonucleotide structure 105 contains the abasic site (blue) and is dual 
tagged  with a  TAMRA-(F) BHQ-I-(X)  pair, that are located  upon adjacent sugar 
phosphate backbones. In the presence of Ape1/Ref1 the abasic site is recognised and 
processed by the protein. When site processing occurs at the abasic position from the 
5’ end, the TAMRA fluorophore containing oligonucleotide sequence dissociates from 
its complement  by thermal  melting.  As a result, the  proximal  quenching efect 
provided  by the  BHQ-I (black  hole quencher)
76
 complement is lost, and a 
fluorescence  output  occurs, via (108).  As such  Ape1/Ref1 catalytic activity can  be 
measured indirectly by the observed increase in fluorescence over time. Importantly, it 
has  been  previously  demonstrated that the abasic cleavage  product (TAMRA-
oligonucleotide) fuly  dissociates from the complementary  oligonucleotide at  37 °C 
and therefore should represent an accurate picture of Ape1/Ref1 endonuclease activity. 
Furthermore, the ful  oligonucleotide is  protected from  non-specific exonuclease 
activity at the opposite end by a resistant β-hairpin loop. A three-dimensional crystal 
representation of the engineered abasic substrate is shown below (Figure 18). 
 
 
 
 
 
 
 
 
 
 
Figure 18: Crystal structure of a THF containing abasic DNA substrate mimic. 
3.3. – Quantifying Protein Inhibition 
 
The relative activity of a smal molecule inhibitor was assessed at al times compared 
to a control  wel.  Simply, a  wel  was charged  with  bufer,  protein and inhibitor and 
incubated for  5  minutes at  30 °C, the abasic substrate  was then added.  The 
fluorescence  output  was  measured  directly  upon addition  of the abasic substrate, see 
(biological  appendix B1).  Under control conditions (DMSO  only) the  onset  of 
fluorescence output occured almost instantaneously and measurements were typicaly 
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taken every 3 seconds for a duration of 5 minutes. The relative activity of compounds 
versus control was deduced from the linear portion of the reaction, where abasic site 
cleavage operates under steady state kinetics. Significant retardation in rate (gradient 
of  graph)  was therefore indicative  of inhibition. (Graphs 1 and 2)  below, detail the 
normal  graphical representation  of the rate  of abasic site cleavage, under control 
conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 1: Fluorescence output under control conditions 50 µM DMSO only). 
 
Graph 1 details two control reactions taken over a 500 second time course. The data 
show the rapid  onset  of the cleavage reaction, demonstrated  by the steep initial 
fluorescence  output from time zero.  As  previously  mentioned the  protein  displays 
linear kinetics to t ~ 170 seconds, where the fluorescence signal begins to tail of and 
saturate.  Considering the irelevance  of  data  beyond this time  point  we calculated 
relative inhibition (relative rate) from the time window shown below (Graph 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 2: Linear rate section taken from graph 1. 
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At the 0 – 120-second time cross-section of (Graph 2) it is evident to the naked eye 
that the reaction rate is linear. Closer inspection indicates that the R
2 
values corelate 
with this, (0.99). Throughout this report inhibitors are either  graphed folowing the 
same format as graph 2 or displayed in bar format where the relative rate is taken from 
the  gradient (m)  of the linear  portion  of the reaction. It is noteworthy that the assay 
was deemed to  be incredibly robust, ilustrated  by the reproducibility  of the control 
measurements above (Graph 1). 
3.4. – Biological Assessment I  
 
First round biological evaluation of compounds shown in (Tables 1 and 2) highlighted 
three compounds of interest. They displayed consistent, reproducible inhibitory 
activity against Ape1/Ref1 in the low micromolar range, shown below (Graph 3 @ [50 
µM] inhibitor), structures given in (Figure 19). 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 3: Top compounds from (Table 1) tested in vitro. Inhibition ploted as relative rate, 
concentration of inhibitors = 50 µM.  
 
 
 
 
 
 
 
 
Figure 19: Chemical structures of the three active compounds (first number indicates compound ID), 
(second number indicates corresponding graph key). 
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Unfortunately the 14 synthesised sulphonamides from (Table 2) were inactive, despite 
their leading calculated ΔG mmGBSA values. Graph 3 displays the active compounds 
31, 45, and 34 and curiously (Figure 19) shown above, highlights the close structural 
similarity  between the two most active compounds 31 and 34.  We  were somewhat 
fortuitous at this  point as their structural  overlap  had  gone  previously  unnoticed and 
one compound  would  have  been eliminated from testing  had this  not  occured.  The 
fact that these two compounds represented our top hits coupled with their superior in 
silico scoring  values (relative to 45) and their structural similarity  made them an 
obvious choice for further development. Inhibitor titration experiments confirmed that 
both compounds 31 and 34 had IC
50
 values in the region of 10-15 µM, which provided 
us with a solid base level for improvement.  
3.5. –Predicted Binding Poses of Lead Compounds 31 and 34 
 
 
 
 
 
 
 
 
 
 
Figure 20: Low energy binding poses of lead thiazoles 31 and 34. Key active site 
residues shown (yelow), Mg
2+
 (purple). 
 
The two lead compounds  both possessed a central  2,4 substituted thiazole aromatic 
core. They also both contained a 2,4-dihydroxybenzene motif at C4 and difered only 
slightly in their makeup at C2. The more active analogue 31 was substituted through 
C2 to a  2-amino-4-methyl  pyridine aromatic,  whereas analogue 34 contained a  3,4-
dimethylaniline ring in the same  position. The  docking images above (Figure 20) 
detail the initialy calculated low energy  binding  poses  of  both analogues into the 
Ape1/Ref1 crystal structure.  Curiously, analogues 31 and 34 displayed radicaly 
different binding poses along the horizontal axis (flipped 180°), though clearly in vitro 
activity was retained. We  postulated in  both cases that the  2,4-dihydroxybenzene 
moieties could form hydrogen bonds with active site residues, (31 with Asn212 and 34 
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with Glu40 and Val278). The binding stabilisation gained from such H-bonding could 
then facilitate stronger  hydrophobic interactions  between the ligands aromatic side-
chains and protein residues Phe266 and Try280. Furthermore, if the in silico data was 
accurate VDW interactions were also possible with Leu282 and Ala273. From an SAR 
ligand  optimisation  perspective the  poses in (Figure 20) did  not supply  us with an 
obvious site for  modification.  Further analysis  of the  hypothesised  binding  poses 
revealed that in al  probability a vast area  of the active site  was  not ligand  bound, 
shown  below (Figure 21). This rationalisation  was  deemed logical  due to the 
comparative  mismatch in size  between the  protein  DNA  binding cleft and the active 
compounds.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Overlay of thiazoles 31 and 34 docked into binding site. Vast space unoccupied  
at northeast extremity of ligands, Mg
2+ 
(purple). 
 
Taking into consideration the hypothesised binding modes, the apparent importance of 
hydroxyl functionality and the  unoccupied  binding space  within the active site  we 
developed a dual approach towards the design of a 2,4-substituted thiazole series.  
 
3.6. – Synthesis of the 2,4-Substituted Thiazole Series 
Retrosynthetic Analysis 
 
The most eficient and plausible synthetic strategy to obtain a library of 2,4-substitued 
thiazoles was through application of the Hantzsch thiazole synthesis,
77
 (Scheme 4). 
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Scheme 4: Retrosynthetic analysis of the thiazole scafold. 
 
The key  disconnection in this approach was the  Hantzsch thiazole condensation that 
traced back to a  generic thiourea (113) and α-bromoketone (114). The  ketone was 
readily accessible from a Freidel Crafts reaction between dimethoxybenzene 115 and 
bromoacetyl bromide. 
3.7. – Synthesis of Thioureas 
 
To  obtain the fuly elaborated thiazole structures, the coresponding thioureas  were 
synthesised by the route outlined below (Scheme 5). 
 
 
 
 
Scheme 5: General thiourea synthesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Synthesised thioureas and associated yields. 
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The synthesis  began  with the  union  of  benzoyl chloride 116 and ammonium 
isothiocyanate, forming 117 in  quantitative  yield. Nucleophilic atack  by a choice 
amine at the  most reactive carbon  provided the  protected thiourea 118.  Final  basic 
hydrolysis of the thioamide bond gave the desired thioureas (120 – 133) (Table 3), in 
moderate to  good  yield,  over the three steps. We successfuly synthesised a  diverse 
range of thioureas paying close atention to the position and type of substitution upon 
the aromatic. Thioureas (130 – 133) were selected to examine if the binding site could 
tolerate larger side chains. It is worth noting that carboxylic acid containing thiourea 
133 was synthesised by slightly diferent means, shown below (Scheme 6).
78
 
 
 
 
 
Scheme 6: Synthesis of thiourea 133. 
3.8. – Synthesis of Thiazoles 
 
With the thioureas in hand we turned our atention to the synthesis of α-bromoketones 
114 and 138, shown below (Scheme 7). Starting from 1,3-dimethoxybenzene 115 we 
employed an  AlCl
3 
mediated  Friedel Crafts acylation reaction with  bromoacetyl 
bromide obtaining 114 as a single regioisomer, in excelent yield. The methoxy groups 
were removed upon treatment with BBr
3 
though 10 eq. were required for conversion to 
132.  Lesser  quantities  of  Lewis acid (4 eq.) alowed access to the  mono-methylated 
aromatic ketone 139 (Scheme 7) both were obtained in moderate yield. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 7: Synthesis of α-bromoketones and general thiazole syntheses (A-C). 
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Having accessed three  diferent α-bromoketones  we  were confident that  we could 
synthesise a  wide range  of thiazoles and  gain an insight into the structure activity 
profile  of this ligand class. The fuly elaborated thiazole structures  were synthesised 
via a Hantszch condensation  of the  doubly  nucleophilic thioureas  onto the  doubly 
electrophilic α-bromoketones, a general reaction  overview shown above in (Scheme 
7). For further clarity the thiazoles were synthesised according to method A, B or C, 
(Scheme 7).  This  becomes apparent from the  methylation  patern seen  upon the 
hydroxylated aromatic.  Firstly, (Table 4)  below, highlights al  of the  hydroxylated 
thiazoles synthesised by methods B/C and their associated yields.   
 
 
 
CA – Denotes commercialy available thiourea. Entry 12 obtained through the use of 2-bromoacetophenone. 
Table 4: Synthesised hydroxylated thiazoles, (initial ‘resynthesized’ hits highlighted in green). 
 
 
Entry Compound TU Thiazole Structure Yield (%) Entry Compound TU Thiazole Structure Yield (%) 
1 31-S 121 61 13 153 CA 46
2 34-S 122 65 14 154 CA 81
3 143 CA 74 15 155 129 61
4 144 CA 74 16 156 130 67
5 145 120 51 17 157 131 39
6 146 CA 73 18 158 132 25
7 147 CA 42 19 159 CA 57
8 148 CA 36 20 160 133 63
9 149 CA 78 21 161 CA 28
10 150 121 72 22 162 CA 44
11 151 CA 90 23 163 126 53
12 152 121 87 24 164 CA 64
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Pleasingly, the thiazoles synthesised by methods B/C were al obtained in moderate to 
good  yield (Table 4).  Entries (1 and  2)  highlight the re-synthesised lead compounds 
31-S and 34-S.  Their re-synthesis  was sought, as the initial commercialy sourced 
material  had  not  been subjected to ful chemical characterisation. It  was therefore 
prudent to retest the synthetic equivalents to eliminate the  possibility  of any  non-
specific inhibition from unknown impurities. 
 
In  moving away from the initial leads, we had synthesised a  narow range  of 
analogues making very smal alterations to compounds 31 and 34, hoping that potency 
could  be increased through  homologations or via functional  group inter-conversions. 
The chemistry outlined in previously (Scheme 7) could be used to access al but one of 
the target analogues. This analogue (168) was the 4-trifluoromethyl variant of lead 31. 
We highlighted this compound as an interesting variant, postulating that substitution of 
4-CH
3 
for  4-CF
3
 may increase  potency  with respect to forming non-polar  VDW 
interactions within the active site. The synthesis of 168 was relatively straightforward 
(Scheme 8) from the familiar α-bromoketone 114.  The synthesis  began with a 
classical  Hantszch condensation  between 114 and thiourea to  generate  2-
aminothiazole 165 in  good  yield.  Secondly, a  Buchwald-Hartwig coupling  between 
amine 165 and 2-chloropyridine 166 provided the coresponding arylated thiazole 167. 
Final methyl deprotection under standard conditions gave the target analogue 168 with 
relative ease, (Scheme 8).  
 
 
 
 
 
 
 
 
 
 
 
Scheme 8: Buchwald-Hartwig synthesis of 4-trifluoromethylpyridyl analogue 168. 
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computational  modeling  of analogues 31 and 34 was somewhat ambiguous,  we 
rationalised that one or both of the hydroxyl groups may be critical for activity. This 
hypothesis was generated on the basis that the active site has two distinct regions, one 
of a  hydrophobic  nature and the  other  hydrophilic. The later formed key  hydrogen 
bonds  during the  phosphate cleavage event. Based  on these ideas  we synthesised a 
narower range of methylated thiazole analogues (Table 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CA – Denotes commercialy available thiourea. 
Table 5: Synthesised methoxy protected thiazoles, (lead analogues red) and 
mono-methylated analogue 184 (yelow). 
 
Employing the previously  discussed synthetic  protocol,  method  B (Scheme 7)  we 
synthesised 16 methylated thiazole analogues. As with the hydroxylated aromatics we 
only  varied the right  hand functionality slightly throughout the ligand class.  Notably 
the mono and bis-methylated leads were included and are highlighted above (red and 
yelow, Table 5). 
 
 
 
 
 
Entry Compound TU Thiazole Structure Yield (%) Entry Compound TU Thiazole Structure Yield (%) 
1 169 120 82 9 177 126 71
2 170 121 75 10 178 127 59
3 171 122 73 11 179 CA 73
4 172 CA 61 12 180 124 48
5 173 CA 45 13 181 CA 48
6 174 CA 58 14 182 CA 41
7 175 CA 82 15 183 CA 74
8 176 125 64 16 184 122 59
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3.9. – Biological Assessment of 2
nd
 Generation Thiazole Series 
 
Having synthesised a diverse range of 2,4-substituted thiazoles we submited them for 
biological assessment. In accordance  with the initial  biological  work (Graph 3) the 
inhibitors  were first tested at a concentration  of  50 µM (any compounds  displaying 
inhibitory activity  would then  be assessed  more closely  over a wel defined 
concentration range). 
 
Methylated Thiazole Derivatives 
 
Firstly, we analysed the methylated derivatives contained within (Table 5). Graph 4 
highlights the results we obtained. 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 4: Biological evaluation of methylated thiazoles (Table 5), inhibitors at 50 µM. 
 
The results from these compounds  were easily interpretable,  methylation  of  one  or 
both aromatic  hydroxyl  groups eliminated biological activity.  The fluorescent 
phenotypes in (Graph 4) were al indicative  of  normal  protein function,  with  no 
pronounced inhibition by any compound. Although negative this result was somewhat 
encouraging and  gave added confidence to  our in silico docking  model, that the 
hydroxyl groups were forming hydrogen bonds within the active site.  
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Hydroxylated Thiazole Derivatives 
 
We  were satisfied  with the results  provided  by the  methylated thiazoles and so 
switched our atention to the more interesting hydroxylated thiazoles. We assessed the 
biological activity  of the hydroxylated thiazoles contained  within (Table 4), results 
detailed in (Graphs 5 and 6) below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 5: Biological evaluation of hydroxylated thiazoles (table 2), inhibitors at 50 µM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 6: Biological evaluation of hydroxylated thiazoles (table 2) inhibitors at 50 µM. 
 
 
The results obtained in the second round of biological assessment of the initial thiazole 
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analogues contained the 2,4-dihydroxybenzene motif at C4 and a substituted phenyl or 
2-pyridyl aromatic ring at C2. These results tentatively indicated that substituent size 
at  C2  was critical for activity, and that larger  or  homologated aromatics could  not 
interact with the protein as efectively. Interestingly, deletion of the methyl group from 
lead 31 resulted in a total loss  of activity (analogue 145), switching the  4-
methylpyridyl in (31) to 4-methylphenyl in (161) also caused a total loss in activity, 
(Scheme 9). 
 
 
 
 
 
 
 
Scheme 9: Active (blue) and inactive (red) close structural relations of lead analogue 31. 
 
Conversely,  movement  of the  methyl  group to the  3  position alowed for some 
retention in activity (analogue 144), and switching methyl for trifluoromethyl caused a 
similar afect.  Moreover, lead 31 was stil the  most active compound, (Graph 5). 
Woryingly  when  we compared the second (Graph 5) and first round (Graph 3) 
biological results there was an apparent disparity in the activities of lead compounds 
31 and 34. 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 3R: Initial biological testing results of most potent commercial thiazoles, 
(inhibitor concentration 50 µM), tween absent from bufer.  
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The relative rate  plot  of (Graph 3)  has  been  depicted above and relabeled as (Graph 
3R). The fluorescence trace shown above (Graph 3R) shows the activity displayed by 
lead compounds 31 and 34 in the first round of biological assessment. Comparison of 
the fluorescence outputs in (Graphs 3R and 5) underlines the lack of reproducibility of 
our results. Considering these observations, we became aware that our lead compound 
class might be problematic, and that our assay was reliable. 
3.10 – Non-Specific Aggregation of Drug-like Molecules 
 
In  2002,  McGovern and co-workers  published a report investigating biological false 
positives that translate from virtual screening that into  high-throughout in vitro 
screening.  They list the common  mechanisms  by  which certain compounds appear 
active  when in truth the converse applies.  The authors supplied fifteen  detailed case 
studies  upon  diverse chemical structures that show  promiscuous activity in vitro.
79
 
Modulated  by the action  of non-specific aggregation. In relation to  our study,  one 
report in the  publication  detailed aggregation  problems, which were atributed to a 
structure closely related to our lead compounds 31 and 34, shown below (Figure 22).  
 
 
 
 
 
 
 
 
 
 
 
.  
 
 
 
Figure 22: Non-specific aggregator 185 and our most potent analogues. 
 
 
In the  year  2000, the  2,4-substituted,  hydroxylated thiazole 185 (Figure 22)  was 
identified in vitro as an inhibitor  of  DNA  gyrase.
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that this compound displayed low  micromolar range activity against a  variety  of 
proteins, and dynamic light scatering studies (DLS) revealed that the likely mode of 
inhibition was mediated through the formation of aggregates in solution.
79
 Moreover, 
the authors  demonstrated that the IC
50 
of compound 185 increased  9-fold after 
prolonged incubation  with the  protein target β-lactamase,  whereas the IC
50
 of a  wel 
studied competitive inhibitor did not change.
81
  
 
Considering these revelations we treated al of the biological testing results with some 
caution.  To further examine  whether  or  not a false  positive  was  being  observed  we 
decided to reassess the lead compounds.  
 
Reassessment of Lead Compounds 31/31-S – 34/34S 
 
The commercialy  obtained lead thiazoles and their re-synthesised counterparts  were 
reassessed for  biological activity against  Ape1/Ref1, the results are shown  below 
(Graphs 7i/i). 
 
 
 
 
 
 
 
 
 
 
Graphs 7i – 7i: Retesting of most active synthesised compounds at 25 µM. Graph 7i (right) includes 
commercial hits from round I, lead thiazole 31 shown at 25 and 50 µM, (tween present in bufer). 
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thiazoles, however the SAR is relatively flat and no dose dependent activity is present, 
(31 and 31-S).  Moreover, the initial activity  displayed  by  both 31 and 34 was not 
reproduced.  The results  of the  McGovern  publication coupled  with  our inconsistent 
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partialy assess this assumption the assays  were conducted in the  presence  of 
Tween20. This substance is a detergent commonly added into bufer media to stabilise 
BSA, it also acts to  disrupt the formation  of aggregates.
82
 The initial assay was 
conducted  without  Tween20 (Graph 3)  when the lead compounds  demonstrated the 
highest  potency, (IC
50 
- 10-15 µM).  Al subsequent  biological assessment  was 
conducted in the presence of Tween20 (Graphs 4 – 7i) and the observed potency of 
leads 31 and 34 decreased. These findings were not definitive but did lend support to 
the argument that this compound class was aggregating in vitro.   
 
Dynamic Light Scattering (DLS) - Studies 
 
In an atempt to  gain further evidence to support  our aggregation theories,  our 
biological colaborators conducted a DLS experiment with lead compound 31, and the 
results are shown below (Figure 23).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Rayleigh scatering data of lead thiazole 31-S. 
 
The data  presented above (Figure 23) indicated significant scatering  of light at 
concentrations  of (31) above  40 µM.  These  observations could only  be the result  of 
particle formation in the  bufer  media and therefore lended further support to the 
suspected aggregation of (31).  
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Conclusions  
 
Considering al  of the  data  presented and the ireproducibility  of the initial activity 
measurements  we  were forced to  question the  validity  of the  2,4-substituted thiazole 
scafold as a  potential  basis for further  development.  We  had  no computational 
rationale to explain the results and the lack of reproducible dose dependent data of 31 
damaged our confidence. Taking our DLS results and the structural similarity between 
31 and 185 we were forced to abandon the thiazole pharmacophore. This decision was 
compounded by the fact that an aggregate based mechanism of inhibition was the only 
plausible  way to explain the near flat structure activity relationship shown  by al 
compounds. 
 
The  decision to stop  working  on the thiazole scafold  was  made easier  by a sudden 
surge in literature activity, detailing a range of novel inhibitors of Ape1/Ref1. We used 
these  publications as a  platform for further investigation and  novel compound 
development. The results of these studies are wil be disclosed in the next chapter. 
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CHAPTER 2 – Analysis of Published Inhibitors 
4.1. – Overview  
 
The results  obtained from the  biological assessment  of the thiazole compound class 
were  disheartening. Though at this time, several  groups  disclosed a range  of  diverse 
chemical entities shown to inhibit Ape1/Ref1 within their biological assays, structures 
shown below (Figure 24). 
 
 
 
 
 
 
 
 
 
Figure 24: Published inhibitors of Ape1/Ref1.
67, 82
 
 
Although the molecules outlined are structuraly diverse, a common theme was found 
in al literature reports. The authors of al communications underlined the importance 
of  having a  negatively ionisable functionality  within the inhibitor.  These comments 
arose as al  publications reported inhibitors that contained at least  one carboxylate 
functional group,  highlighted in (Figure 23). Furthermore, they commented  on large 
observed overlaps in computational results that predictably highlighted carboxylates as 
possible inhibitors of Ape1/Ref1. These observations likely stemmed from the ability 
of carboxylic acids to either bind magnesium directly, or occupy the same area as the 
cation through  binding to the  hydrophilic amino acids  present  within the catalytic 
region.  
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Sieple’s Inhibitors 
 
Lauren  Sieple and co-workers
67a
 described a range  of arylstibonic acids and aryl  di-
carboxylic acids the best of which are displayed (186) and (187) (Figure 24). Firstly, 
the arylstibonic acid demonstrated remarkable  potency and the authors  believed that 
this  was a  direct result  of the  pentavalent antimony acting as a  phosphate  mimic. 
Secondly, the dicarboxylates were loosely predicted to be interacting within the same 
domain,  with added enzyme-substrate complex stability  gained through  hydrophobic 
binding  of the  napthyl rings to  Phe266  or  Trp280.  These compounds  were also 
examined in specificity studies to assess  whether  or  not they  were intercalating into 
the fluorescent  DNA substrate, which could result in a  non-specific  phenotype. 
Ethidium  bromide competition assays confirmed that the  observed inhibition  was a 
direct result of a protein-ligand interaction and that no non-specific DNA intercalation 
was  occuring.  Although these results  were al encouraging, the  use  of antimony 
within a  drug compound is  highly  undesirable  due to the  obvious toxicity issues. 
Furthermore, the authors could  not reproduce the in vitro activity in vivo citing 
bioavailability as a limiting factor.  
 
Wilson’s Inhibitors 
 
David  Wilson and co-workers
82
 disclosed another set  of  novel  Ape1/Ref1 inhibitors 
identified from a  quantitative  high-throughput screen.
83
 The authors  purchased the 
commercialy available  LOPAC
1280 
(Library  of  Pharmacologicaly  Active 
Compounds)
84
 compound series and conducted a speculative  biological assessment. 
Twelve compounds were characterised by complete concentration-response inhibitory 
curves, possessing IC
50
 values in the sub-micromolar region. Specificity testing upon 
these compounds alowed the authors to  discard  half as  non-specific aggregators  or 
DNA intercalators. Further testing highlighted 6-OH-DL-DOPA (188) and Myricetin 
(189) as the  most interesting lead compounds  both  of  which  displayed excelent 
potency in vitro (Figure 24). Furthermore, the authors disclosed CADD studies upon 
the most potent compound 188, revealing plausible binding within the active site. As 
with Sieple’s analogue (187), CADD studies predicted that the carboxylic acid would 
bind to magnesium or Glu96 in the hydrophilic region. The phenyl ring could π-stack 
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with  Phe266 and  Trp280  positioning the  4-hydroxy  group to form a  hydrogen  bond 
with either  Asn229  or  Ala230 and the  primary amine to  Asn212. Interestingly, the 
computational studies indicated that the  C6  hydroxyl  group  was  unimportant for 
binding, hence activity.   Such studies  upon  Myricetin  were  deemed futile  by the 
authors and by our own observations. Myricetin has a rigid structure containing eight 
oxygen atoms al  of  which could participate in  hydrogen  bonding. Considering this, 
the  degree  of  possible  binding  modes retrieved  by the algorithms  were  vast, 
nonsensical and lacking any shape complementarity conflicts.     
 
Neamati’s Inhibitors 
 
Nouri  Neamati and co-workers
67b
 published another set  of compounds al  of  which 
showed  potency in the low  micromolar range.  Of the compounds  published, the 
pyrole  based  dicarboxylates (N1/2) (Figure 24)  displayed the  best activity.  These 
compounds were identified from a CADD campaign and the results indicated that the 
carboxylates  were again  binding  within the  hydrophilic catalytic region  or  possibly 
directly to magnesium. Furthermore, the central pyrole core was positioned neatly to 
interact with Phe266 and Trp280 via hydrophobic contact.  
 
After a thorough assessment of the aforementioned publications we carefuly decided 
how to proceed. The Sieple and Wilson publications ofered sub-micromolar scafolds 
for  development and importantly  both  had identified their inhibitors  using 
fluorescence-based assays that were nearly identical to ours. The Neamati publication 
ofered arguably  more drug-like molecules though their associated IC
50 
values were 
less atractive. The assay utilised was also slightly diferent to the one employed by us. 
In the interests  of an accurate comparison  we  decided to first investigate the  Wilson 
publication.  
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4.1.1 – Analysis of David Wilson’s Ape1/Ref1 Inhibitors 
 
The lead compounds  disclosed  within the Wilson  publication  were  both  naturaly 
occuring and luckily there were many commercialy available structural analogues of 
similar chemical  makeup.  This  was an atractive start  point as  we envisaged rapid 
structure activity relationship studies.  Firstly, we  decided to compare the two lead 
compounds, looking for functional group and structural overlap (Figure 25). 
 
 
 
 
 
   
 
 
Figure 25: Structural comparison of lead Wilson structures.  
 
Crude analysis  of  both structures revealed a  great  deal  of structural similarity. 
Considering the  observed activity and the  hypothesised  binding  mode  of 188 in the 
Wilson publication, we postulated that ring A in 189 may be less important for binding 
than ring  B and far less important than ring  C.  Rings  C  both contain a 3,4-
dihydroxylated  benzene motif, and interestingly  myricetin  has  no  hydroxyl at  C6. It 
was postulated that the C6 hydroxyl in dopamine derivative 188 was unimportant for 
binding. The structural overlap may also suggest that the hydroxyl group in 189 (ring 
C/C5) is  not  needed for activity.  The amino acid  present in 188 and the α-hydroxy 
enone in 189 may also act in a similar manner, binding either to the magnesium cation 
or the surounding  hydrophilic residues.  Taking these similarities into consideration 
we  were  keen to synthesise ring constrained ‘hybrids’  of analogue 188, in  order to 
analyse if the C rings were possibly interacting with the same protein residues. 
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Attempted Synthesis of Ring Constrained Dopamine Analogues 
 
From lead  dopamine  derivative 188,  we  postulated that the six and seven-membered 
ring constrained analogues 190 and 191 would be interesting ‘hybrid’ analogues. 
 
 
 
 
Figure 26: Ring constrained analogues of 6-OH-DL-Dopamine. 
 
Building  upon the ideas  mentioned above,  we  were also keen to remove the  C6 
hydroxyl from 188 to assess  whether it  was important for inhibition and also reduce 
the  oxidative susceptibility  of the ring. Compound 191, shown in (Scheme 26) was 
available in one step from a commercialy available amino acid. Considering this, we 
decided to concentrate our eforts on the  more chalenging synthesis  of seven-
membered ring analogue 190. Our first synthetic approach was inspired by the work of 
Gibson and co-workers who employed several intramolecular endo-Heck cyclisations 
to furnish 7,8 and 9-membered ring constrained analogues of phenylalanine (Scheme 
27).
85
  
 
 
 
Scheme 10: Gibson’s synthesis of conformationaly constrained phenylalanine analogues. 
The reaction outlined in (Scheme 10) was chosen as the key bond forming reaction in 
our proposed retrosynthesis of analogue 190, details of which folow.  
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4.1.2 – Retrosynthetic Analysis of Compound 190 
	  
The  Heck  precursor 196 was available in several simple steps and a reductive 
amination  upon aldehyde 197 was  deemed the  best approach to  provide the  desired 
target substrate 196. The aldehyde was available in two steps from the commercialy 
available ethyl alcohol 198, (Scheme 11).  
 
 
 
 
Scheme 11: Retrosynthetic approach towards analogue 190. 
In  moving forward, the synthesis  of  Heck  precursor 196 is  outlined  below, (Scheme 
12). 
 
 
 
 
 
 
 
Scheme 12: Synthesis of Heck precursor and atempted Heck reaction to access 190. 
Activation of iodine with silver triflate led to the regioselective iodination of alcohol 
198 in excelent  yield.
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 The alcohol  was then  oxidised via a  Swern  oxidation to 
aldehyde 197
87
 that  was  directly subjected to a reductive amination  with  DL-serine 
benzyl ester obtaining alcohol 200 in excelent yield over the two steps. Protection of 
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the secondary amine as the coresponding tert-butyl carbamate and tosylation  of the 
primary alcohol in the presence of excess Et
3
N alowed for smooth elimination of the 
tosylate accessing key alkene 196 in good yield.
85
 With the Heck precursor in hand we 
employed the Gibson Heck cyclisation conditions (solvent was switched to DMF due 
to the insolubility of 196 in THF). After prolonged heating no product was formed and 
instead we observed major side product 201. This product was fuly characterised and 
upon consultation  of the literature  we found  no such  observation in the  Gibson 
publication.  We  postulate that the  decreased electrophilicity  of the  Ar-I  bond in  our 
system, results in a much slower oxidative insertion of the paladium species into this 
bond. Therefore instead, the paladium inserts more rapidly into the alylic ester via an 
n
3 
type mechanism, in turn extracting this moiety from the molecule. At this point the 
paladium can transfer the alylic ester  onto the  phenyl ring via and intermolecular 
Heck pathway.  
Although  we envisaged issues  with the Heck reaction  we  had  not anticipated this 
alternate  mode of reactivity.  We considered increasing the electron  density at 
paladium through the use of more electron rich ligands, though such an approach was 
unlikely to circumvent the reactivity issue and instead accelerate the  observed side 
reaction. At this point we decided to utilise a diferent ring forming reaction to access 
the target compound 195. 
Ishibashi’s Radical Cyclisation Approach 
Hiroyuki Ishibashi and co-workers reported the folowing  observations  when 
conducting radical cyclisations upon similar systems (Scheme 13).
88
 
 
 
 
 
 
Scheme 13: Ishibashi’s 7-endo selective aryl radical cyclisations onto enamides. 
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Upon examining their results the authors postulated that  within their system the 
position  of the carbonyl in the enamide  was  vital to control  product selectivity. 
Moreover, the size  of the  R  group  upon the terminal  olefin  was  deemed to  have a 
further impact  upon the  observed  product  distribution.  The  7-endo selectivity  we 
required was high when R
1 
increased with size, (
t
Bu > Et > Me > H), however no other 
substituents  were reported. We  believed that the  CO
2
Bn in  our system should  give 
excelent  7-endo selectivity if the additional carbonyl  group  was  not  problematic 
(Scheme 13). Indeed submiting carbamate 196 to Ishibashi’s conditions led to the 
desired radical cyclisation  product 195 in excelent  yield and no trace  of the  6-exo 
product could be detected in the crude 
1
H NMR spectrum (Scheme 14). 
 
 
 
 
Scheme 14: Successful intramolecular 7-endo cyclisation.  
With compound 196 in hand al that remained was global deprotection, though due to 
the  orthogonality  of the  protecting  groups this required three steps.  The tert-
butoxycarbonyl  group  was first removed  upon exposure to  TFA forming salt 206 in 
excelent yield. The compound was fuly characterised at this stage as carbamate 196 
was rotameric and  decomposed  during  variable temperature  NMR experiments.  The 
Lewis acid mediated deprotection to 207 appeared to proceed smoothly as observed by 
TLC.  However isolation,  purification and characterisation  of 207 proved incredibly 
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and the solution  was saturated  with  gaseous  HCl according to the  known literature 
procedure.
89
 Repeated atempts to access 191 using these conditions failed and every 
reaction yielded an insoluble yelow solid, shown (Scheme 15).  
 
 
Scheme 15: Atempted synthesis of 6 membered ring analogue 191. 
At this point we decided to abandon cyclic analogues 190 and 191. It was clear that 
their  physical  properties  were sub-optimal and further analogue development  would 
present significant synthetic  dificulties. Before further  work  was envisaged,  we 
decided to assess the biological activity of myricetin under our assay conditions. 
 
4.1.3 – Biological Assessment of Myricetin  
	  
Before further compound  design  was considered,  we  decided to test  Myricetin (320 
nM IC
50 
Wilson)
82
 in  our  biological assay. It is  noteworthy that  our assay closely 
paraleled  Wilson’s and  more exact  details can  be found within the (biological 
appendix B1).  We examined the inhibitory activity  of  Myricetin (189) and its close 
structural relatives Quercetin (210) and Kaempferol (211) (Figure 27, Graphs 8 and 9). 
 
 
 
Figure 27: Myricetin 189 and close structural analogues of the flavanol family. 
The  naturaly  occuring analogues  of  Myricetin (Figure 27)  were included in the 
biological assessment  with the aim to elucidate some early  SAR  paterns, inhibitory 
data is shown below, (Graphs 8 and 9). 
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Graph 8: Biological evaluation at 50 µM inhibitor, 100 nM substrate, IC bufer @ 30 °C. 
 
 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Graph 9: Biological evaluation at 25 µM inhibitor, 100 nM substrate, IC bufer @ 30 °C. 
 
Graphs 8 and 9 indicate the activity of these analogues at concentrations of 50 µM and 
25 µM respectively. As indicated by the fluorescence outputs, we obtained values that 
did  not corelate to  Wilson’s findings. In fact repeated  measurements at  50 µM 
[inhibitor] indicated that at  best  Myricein and  Kaempferol  had IC
50
 values  of 
approximately 25 µM.  These results  were confusing and  multiple assay repetition 
returned the same numerical figures.  
	  
These disparities waranted further investigations into the conditions employed in both 
biological assays. The results of which are discussed in the folowing section.  
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Evaluation of Biological Assessment’s 
 
The vast disparity in biological results forced us to investigate if Wilson’s data were 
the result  of a false  positive  or if  our assay  was compromised.  David  Wilson  kindly 
donated his materials (Ape1/Ref1 protein and the abasic DNA substrate) used within 
his studies at the  NIH,  Bethesda,  Maryland,  USA.  To ascertain the reason for such 
pronounced  diferences in the  measured IC
50 
values a series  of cross assays  were 
conducted. In order to limit the number of possible variables we initialy concentrated 
upon switching proteins and abasic DNA substrates.  
 
Protein Analysis 
 
Structural investigations into the Ape1/Ref1 protein have shown that the first 42 amino 
acids are disordered while the remainder have a globular fold.
37, 52, 90
 Blast homology 
searching  has revealed that the  protein  C-terminus is  highly conserved,  while the  N-
terminus (first  ~40 residues) is  not. It is  noteworthy that the conservation  of the  N-
terminal domain within mammals is high (>90%) but near absent in other organisms.
91
 
Data on the human Ape1/Ref1 protein has clearly indicated that the protein N-terminal 
domain (first  ~35 amino acids) is responsible for interacting  with  other co-factors 
including  XRCC1,
92
 CSB
93
 and  NPM-1.
94
 These  data  have  been  used to  underline a 
common operating theme for this protein: broadly that the presence of an unstructured 
N-terminus alows for the mediation  of a range  of  protein-protein interactions.
91
 
Conversely, the  N-terminal  domain contributes  nothing to the  processing  of abasic 
sites whose cleavage is dependent wholy upon the C-terminus (amino acids 65-318).
95
 
This fact is  underpinned  by the existence  of the  human  Ape1/Ref1  protein in a 
truncated form (NΔ33Ape1) in  which the  N-terminal  domain is  missing.  These two 
proteins  hApe1/Ref (ful length) and (NΔ33Ape1) share a conserved  C-terminus and 
display near identical kinetic turnover of the engineered abasic site present within our 
assay substrate (J.  Silhan  unpublished results).
96
 Considering this  data the  proteins 
should  be  directly comparable from an inhibitor screen  perspective and therefore 
employing either in an in vitro assay is scientificaly viable. The Imperial Colege (IC) 
assays employed the  NΔ33Ape1 truncated  protein  due to its  perceived enhanced 
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stability against its ful-length relation.  David  Wilson and co-workers  used the ful-
length hApe1/Ref1 in their biological assessment that identified myricetin and 6-OH-
DL-DOPA as  potent inhibitors  of the  protein.  Although this  was thought to  be a 
negligible factor, cross  biological assessment  was required to assess any  potential 
diferences in activity between to two proteins. 
 
Composition of Abasic DNA Substrates  
 
The abasic substrates  used  by IC (see B1) and  Wilson  were  very similar in 
composition and both were designed upon the same idea of mimicking abasic DNA, 
substrate composition shown below (Figure 28). 
 
	  
	  
5’ to 3’ – TAMRA TC-ACC-FTC-GTA-CGA-CTC (Wilson)	  
	  
5’ to 3’ – GAC-TAA-5AA-TGA-CTG-CGG-TTA-CGC-AGT-CAT-TGT-TAG-
TC6-99-TAMRA (Imperial)	  
	  
Figure 28: Substrate composition in both assays, abasic site (red). 
	  
Both duplexes comprised a string of nucleotides containing a THF abasic site mimic 
and a  TAMRA-BHQ-I fluorescence  quench system.  As  previously  mentioned, the 
THF residue mimics the lesion obtained after nucleotide incision by DNA glycosylase 
and  presents  Ape1/Ref1  with a site for  processing.  Upon cleavage  of the 
phosphodiester  backbone at this site the  TAMRA/BHQI  FRET system  becomes 
separated  generating a  measurable fluorescence  output. At IC we employed a  38mer 
oligonucleotide  protected at the  C-terminus  by a loop.  The loop is specificaly 
engineered and included to  protect the substrate from any  non-specific  Ape1/Ref1 
exonuclease activity.
97
 This activity could result from a  non-specific increase  of 
fluorescence and therefore the loop serves to  protect against false  negatives.  Wilson 
and co-workers employed a straight chain 17mer oligonucleotide without a protecting 
loop. In the context  of  our assay comparison this is  unimportant though it is 
noteworthy that their system might be vulnerable to false negatives.  
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The  bufer  media employed  by IC and  David  Wilson  were similar (biological 
appendix B1) and for comparative  purposes the  Wilson  bufer  was  used  within  our 
cross biological studies. 
 
4.1.4 – Cross Biological Assessment of Myricetin 
 
We first sought to switch our substrate and bufer conditions with those outlined in the 
Wilson  publication  keeping the truncated  protein constant. The results are shown 
below (Graph 10). 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Graph 10: Biological evaluation of Myricetin. Wilson’s conditions, Wilson’s substrate and IC 
truncated NΔ33Ape1 protein @ 30 °C. 
	  
The data shown in (Graph 10) highlight a total lack of myricetin activity against the 
truncated  protein in the range  of  100 – 1000  nM.  These  data support  our initial 
biological evaluation (Graphs 8 and 9) and suggest that substrate composition and 
bufer makeup do not afect the inhibition profile of myricetin against Ape1/Ref1. 
 
The second cross assay again employed  Wilson’s substrate and  bufer  however  we 
switched the truncated  NΔ33Ape1/Ref1 for the ful-length  hApe1/Ref1  protein. 
Remarkably the data shown below in (Graph 11) completely difered with al of our 
previous studies and the observed inhibition of abasic site cleavage showed corelation 
with Wilson’s published figures (IC
50 
320 nM).
82
 The relative rate of cleavage has also 
been displayed (Graph 12). 
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Graph 11: Biological evaluation of Myricetin. Wilson’s conditions, Wilson’s substrate and Wilson’s 
ful length hApe1/Ref1 protein @ 30 °C. 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Graph 12: Biological evaluation of Myricetin. Wilson’s conditions, Wilson’s substrate and Wilson’s 
ful length hApe1/Ref1 protein @ 30 °C	  
	  
	  
 
4.1.5 – Conclusions – Myricetin Binds in the N-Terminal Domain 
 
A  direct  measurement  of the IC
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value  of  myricetin  was  not sought. We were 
confident that  our cross assay  data corelated  with the  published  values (50% 
inhibition  > at  500  nM).  These  data therefore indicated that  myricetin efectively 
inhibits ful-length  hApe1/Ref1  but  does inhibit the truncated  homolog 
NΔ33Ape1/Ref1. As previously mentioned the C-terminus is wel conserved between 
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the proteins and is responsible for abasic site cleavage. The truncated protein operates 
normaly in the presence of myricetin (Graph 10), which suggests that this compound 
is  not  binding  within the active catalytic  C-terminal site.  The ful-length  protein 
contains the same active catalytic site but the data suggest that the N-terminal domain 
is somehow  modulating the inhibitory activity  of  myricetin (Graph 11).  Crude 
observations of the data indicate that the basis for inhibition of ful-length hApe1/Ref1 
by myricetin lies within the N-terminal domain. Unfortunately, we can only speculate 
that  myricetin causes an alosteric shift in  protein conformation  which, induces 
inhibition  of abasic site cleavage through spatial  deviation  of  key substrate  binding 
residues. 
 
Although this was an interesting result we were disappointed that the compound was 
not  binding  within the active site.  The  N-terminal  domain region  has  yet to  be 
crystalised and therefore its absolute three-dimensional structure is  unknown. 
Furthermore, from a compound  design and  development  perspective  we  had  no 
information about how proceed and therefore decided to quickly test a close structural 
relation of myricetin, taxifolin (212) (Graph 13). 
 
 
  
 
 
	  
	  
	  
	  
	  
	  
	  
	  
Graph 13: Biological evaluation of Taxifolin. Wilson’s conditions, Wilson’s substrate and Wilson’s 
ful length hApe1/Ref1 protein @ 30 °C. 
	  
	  
From the results shown above (Graph 13) it was clear that Taxifolin (212) was inactive 
against  hApe1/Ref1, in the range  between  100  nM and  1000  nM.  We  were 
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diminished  biological activity,  which indicated  no  obvious route for scafold 
development of of the Myricetin core.  
 
The validations that myricetin as an hApe1/Ref1 inhibitor prompted us to investigate 
the inhibitory profile of the other more potent compound 6-OH-DL-DOPA 188. 
 
4.1.6 – Attempted de novo Synthesis of 6-OH-DL-DOPA 
 
After an examination of the literature  we  discovered that there  was  no reported 
synthesis  of 188. Commercial sources  were available though the  material  was 
incredibly expensive (Sigma Aldrich, 10 mg/£250), we therefore envisaged a de novo 
synthesis outlined by the retrosynthesis shown below (Scheme 16). 
	  
	  
	  
	  
	  
	  
	  
Scheme 16: Retrosynthetic approach to 6-OH-DL-DOPA 188. 
	  
	  
The key bond forming reaction in this approach was an electrophilic azidation reaction 
upon ester 214 that could be accessed from commercialy available aldehyde 215 with 
minimal synthetic efort.  The electrophilic azidation reaction  was first  developed  by 
David  Evans and required the  pre-synthesis  of the electrophilic azide source 219, 
outlined below (Scheme 17). 
	  
	  
	  
	  
	  
	  
	  
	  
Scheme 17: Evans’ electrophilic azidation protocol and synthesis of azidation 
reagent 219.
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Evans reported the synthesis  of 217 using  his azidation  protocol. Oxazolidinone 216 
was  deprotonated at low temperature  with  LDA  or  KHMDS to form the required 
enolate that was subsequently trapped rapidly with electrophile 219 at low temperature 
forming the α-azido product 217 upon acidic workup in excelent yield, shown above 
(Scheme 17). 
	  
	  
	  
Scheme 18: Synthesis of precursor 214. 
	  
We  were  hopeful that this reaction could  be applied to  our system and therefore 
synthesised the ester  precursor (214), shown above (Scheme 18).  Treatment  of 
aldehyde 215 with malonic acid (220) under basic conditions gave the decarboxylated 
Knoevenagel product 221 in excelent yield.
99
 A simple two-step alkene reduction and 
benzylation provided the desired ester precursor 214 in good yield. With 214 in hand 
we employed the literature conditions to our substrate, detailed below (Scheme 19). 
	  
	  
	  
	  
	  
 
 
Scheme 19: Failed electrophilic azidation atempt.
99
 
 
Treatment  of  benzyl ester 214 with a fresh solution  of  KHMDS at low temperature 
failed to yield the α-azido ester 213 upon quenching with azidation reagent 219, and 
both starting  materials  were recovered  upon  workup.  The  generation  of the enolate 
under these conditions did not appear to be problematic but in line with the literature 
we switched the  base to  LDA.  Again the same result  was  obtained and  product 213 
was not detected. This distinct lack of reactivity was puzzling and we can only suggest 
that steric  hindrance  may  be impeding the reaction.
98
 Faced  with a severe reactivity 
issue we sought another route to 188, again from precursor 215. We were inspired by 
the intramolecular  Horner-Wadsworth-Emmons (HWE) reaction employed  by  Miler 
and co-workers, the reaction is outlined below in (Scheme 20).
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Scheme 20: Miler’s Intramolecular Horner-Wadsworth-Emmons reaction in the synthesis  
of 3-(Hydroxymethyl)carbacephalosporin.
100
 
	  
During the synthesis of 3-(Hydroxymethyl)carbacephalosporin the authors conducted 
a  HWE reaction as the  key  bond forming reaction.  Phosphonate (223) was 
deprotonated using NaH and the resulting carbanion smoothly added into the ketone. 
The final elimination step generated the desired alkene and six-membered ring in 
(224) in excelent yield. 
 
We rationalised that this reaction should be amenable to our substrate aldehyde (215) 
and encouragingly the azido and amino  phosphonates 225/226 were commercialy 
available. Our atempted HWE is detailed below (Scheme 21). 
	  
	  
	  
	  
	  
	  
	  
Scheme 21: Atempted Horner-Wadsworth-Emmons synthesis of alkene 227. 
 
Unfortunately  both  our atempted  HWE reactions  between aldehyde 215 and 
phosphonates 225 and 226 failed. Exposure of azido phosphonate 225 to NaH resulted 
in  decomposition  of the starting  material and  we swiftly  moved to its the  Cbz 
protected counterpart.  After  prolonged reaction times  under the  published conditions 
no  product  was  detected, increasing the temperature from  25 to  80 °C also had  no 
afect. In al cases aldehyde 215 was recovered and again we were puzzled by the lack 
of reactivity.  As  with the atempted azidation (Scheme 19)  we rationalised that the 
deprotonation  of the  nucleophile, in this case  phosphonates (225/226) was  not the 
problem and that our lack of reactivity was being determined by another factor.  
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The  problems faced in the synthesis  of 188 prompted  us to reconsider  our 
investigation into the  possible  utility and further functionalisation  of this 
pharmacophore. We postulated that its poly-hydroxylated core would be vulnerable to 
rapid  metabolic  degradation and also  questioned the  bench stability  of such a 
molecule. As a testament to this wory atempts to obtain a pure commercial sample of 
6-OH-DL-DOPA always failed. 
 
Conclusions 
 
In investigating the Wilson publication we successfuly validated our biological assay. 
More importantly,  we  discovered that  Myricetin  does not interact  with the active 
catalytic region of Ape1/Ref1. Interestingly, we discovered a previously unknown and 
unprecedented mode of inhibition atributed to the interaction of myricetin with the N-
terminal  domain  of ful-length  hApe1/Ref1.  Our results indicate that this smal 
molecule causes either an alosteric shift distorting key functional site residues, or that 
the flexible N-terminal domain shifts into the active DNA binding cleft. 
 
Although these observations were encouraging, we had no desire in pursuing inhibitor 
structures  based  upon  myricetin  or  6-OH-DL-DOPA.  The  N-terminal  domain  of 
Ape1/Ref1  has  many  biological functions, and is associated  with  multiple  biological 
co-factors in vivo.
65b
 Targeting such a region could produce an aray of unwanted of 
target efects.  Furthermore, in the absence  of structural information  we saw  no 
possible way to begin an accurate drug design efort.  
 
Furthermore,  we discovered that  myricetin  displays a  broad range  of  beneficial and 
potentialy harmful pharmacological efects.
101
 The authors of these studies speculate 
that this range of activity stems from metabolites of the compound and not the parent 
structure (189).  Taking these  observations into account  we  deemed that further 
investigation into myricetin was totaly unwaranted. 	  
	  
Considering this, we decided to analyse Neamati’s published inhibitors, the structures 
of which were previously outlined in (Figure 24). Further details of these studies can 
be found in the next section.  
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5.0. – Analysis of Neamati’s Inhibitors 
 
Nouri  Neamati and co-workers  published a report entitled, ‘Pharmacophore  Guided 
Discovery  of  Smal-Molecule  Human  Apurinic/Apyrimidinic  Endonuclease  1 
Inhibitors’. This publication detailed the first computational approach in the search for 
novel inhibitors  of  Ape1/Ref1.  Analogous to  our study, the authors  docked a 
searchable  multi-conformer  database  of ligands into a  predefined three-dimensional 
grid of the active site.
67b
 
 
Our computational approach was based upon a 15 Å three-dimensional box generated 
around a centroid of co-ordinates provided by selecting critical interacting active site 
residues. Neamati et al., constructed four individual three-dimensional pharmacophore 
models  based  upon interactions  between the  protein and abasic  DNA fragment, 
depicted in the crystal structure pdb. (1DEW). The interactions of the protein with the 
abasic substrate were elucidated and divided into three pharmacophoric components: 
hydrogen bond acceptor (A), hydrophobic/VDW (H) and negatively ionisable (NI). A 
combination  of these features alowed the construction  of four ful  pharmacophore 
models that represent the catalytic site of the protein.  
 
The authors sourced a commercialy available  database  of  365000 smal  drug-like 
molecules and  docked them into their four  pharmacophore  models  using the  GOLD 
software package.
102
 Compounds with good computational scoring outputs in multiple 
pharmacophore  models  were assessed  more closely.  Consequently  158 compounds 
were shown to  have favourable  docking scores in three  diferent  pharmacophore 
models. The authors then selected 80 compounds for in vitro assessment based upon a 
pharmacophore fit  value,  mapping  patern,  binding  orientation and  predicted 
interactions with key active site residues. The paper reported an aray of compounds 
with IC
50
 values  <  50 µM against  Ape1/Ref1.  Among these structuraly  diverse 
molecules a class  of  di-carboxylic acids  demonstrated the  highest  potency and 
moreover, good computational overlap with the co-crystallised abasic DNA substrate, 
shown  below (Table 6 and  Figure 28).  The  most  potent and selective inhibitors 
contained two carboxylate functional groups thought to mimic the arangement of the 
3’ and 5’ deoxyribose phosphate groups upon the abasic DNA (Figure 28). 
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a
Compounds found  using H1NI2  pharmacophore (1  hydrophobic interacting  moiety and  2  potentialy  negatively 
ionisable groups at physiological pH). 
 
Table 6: Most potent compounds retrieved by the H1NI2 phamacophore model (N1/N2) and 
synthesised active analogues (N22/N23). 
 
The  overal  Ape1/Ref1 inhibition  profile suggested that although two  negative 
ionisable groups are preferable, their intramolecular proximity and substitution upon a 
central hydrophobic core is also of paramount importance. The computational docking 
image highlights this below (Figure 28). 
 
 
 
 
 
 
 
 
 
Figure 28: (A) Docking image of N1 into 1DEW. (B) Overlap of N1 with co-crystalised 
DNA in 1DEW (phosphorous in orange). (N1) Chemical structure of N1. 
 
From the authors computational model the N-methyl carboxylic acid (N1) could form 
a  hydrogen  bond  with  Arg177 and the  C5  pyrole substituent could form  multiple 
Compound ID Structure IC50 (µM)
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N23 9 ± 1
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enzymes, HIV-1 integrase also requires a divalent metal cation
for catalysis. Importantly, this structuraly diverse set of
molecules we have identiﬁed are selective APE1 inhibitors
and are suitable as lead molecules to establish quantitative
structure-activity relationship models for further development
of clinicaly relevant APE1 inhibitors.
Results and Discussion
Design and Generation of Pharmacophore Models.APE1
uses a wel-deﬁned positively charged surface to selectively
recognize the ﬂipped-out abasic DNA fragment, which binds
within a unique binding pocket on the botom of the DNA
binding region of APE1.
36
Charge interactions, several strong
H-bonding interactions, and shape complementarity are observed
between prominent amino acid residues of APE1 and abasic
fragment of the abasic DNA (Figure 1). An unusual interaction
between the APE1 amino acid residue Arg177, which inserts
through the major groove of abasic DNA and the negatively
charged 3!-phosphate of the abasic fragment indicate unique
functionality for this enzyme. A hydrophobic pocket surounded
by amino acid residues Phe253, Trp280, and Ile282, selectively
recognizes and binds to the abasic deoxyribose sugar moiety
and prohibits binding of DNA bases and racemized -anomer
abasic sites. The negatively charged 5!-phosphate is involved
in a number of strong charge and H-bonding interactions with
APE1 amino acid residues Asn174, Asn212, His309, and the
Mn
2+
metal ion (Figure 1).
Given the importance and uniqueness of these interactions
for APE1 in recognizing and incising abasic DNA sites, we
transformed the prominent ones into a set of 3D pharmacophore
models using the abasic fragment as a template. These phar-
macophore models represent the chemical and electrostatic
environment of speciﬁc APE1 interactions with the abasic DNA
fragment (Figures 2-3). The co-crystal structures used to
Figure 6. (A) Compound1mapped onto pharmacophore H1NI2. There is a good agreement between chemical features of compound1and
pharmacophoric features of H1NI2. (B) The predicted bound conformation of compound1inside the abasic DNA binding site of APE1. The blue
surface represents abasic DNA binding regon of APE1. Compound1s shown s astick (gree) model. Compound1interactions with promnent
amino acid residues of APE1 are shown as dashed-lines. There is a strong agreement between mapped pharmacophoric features of compound1and
its interactions with prominent amino acid residues of PE1active site. C) The predicted boud conformation of compound1is supeimposed
onto the bound orientation of abasic unit in the cocrystal structure of APE1-abasic DNA complex (PDB: 1DEW).
Table 2.APE1 Inhibitory Activity of Analogues of Compounds1and2
24 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 1 Zawahir et al.
A B N1
	   93	  
potential hydrogen bonds with His309, Asn212 and Asn174. Additionaly, the central 
pyrole scafold could occupy the  hydrophobic cavity and the chlorophenyl  moiety 
could participate in π-cation  binding to  Arg177.  To test the feasibility  of the 
computational result (A) the authors synthesised compounds N22 and N23 structures 
shown above (Table 6).  These compounds  were nearly identical to N1 and N2 
difering only in the para phenyl substituent. Alteration of this one characteristic was 
thought to  be  unimportant, as the computational  binding  pose suggests it contributes 
litle to the  binding eficacy.  Switching para chloro to para fluoro  or para methyl 
phenyl indeed resulted in a slight decrease in activity (~ 5 µM to ~10 µM), which gave 
added confidence to the predicted binding pose. With some reassurance in the binding 
pose and the reported activity, we saw an opportunity to make several analogues of N1 
in atempt to further increase potency. 
5.1. – Synthesis of Neamati Analogue N1  
Retrosynthetic Analysis 
 
The initial retrosynthetic approach towards N1 is shown below, (Scheme 22). We were 
keen to folow this route instead  of a traditional  pyrole synthesis so that the  mono-
acid could also be intercepted from the same synthetic sequence. It was thought that 
the easily accessible N-protected pyrole 232 would be a good synthetic starting point.   
 
 
 
 
 
 
 
 
 
Scheme 22: Initial retrosynthetic approach towards N1 
 
 
Therefore, the boronic acid 231 could be obtained through a Pd catalysed borylation, 
or a lithium  halogen exchange folowed  by a trimethyl  borate  quench and acidic 
hydrolysis. With the boronic acid in hand, biaryl 230 could be accessed via a Suzuki 
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coupling with the required aryl halide. Alkene 229 could be obtained utilising a C-H 
activation  protocol and then  hydrogenated to the aliphatic employing  Crabtree’s 
catalyst. The reduction was highlighted as the key synthetic transformation, due to the 
inherent instability of pyroles in reductive environments. Folowing reduction, the N1 
synthesis can be completed through deprotection, N-alkylation with bromoethylacetate 
and saponification.  The  mono-carboxylate could also  be accessed  via N-deprotection 
and saponification without the alkylation step on nitrogen. 
 
Towards the Synthesis of N1 – Synthesis I 
 
The borylation of halo-pyrole 232 was not sought due to the commercial availability 
and relative cost of boronic acid 233. In moving forward, the synthesis began with a 
Suzuki coupling  between 233 and  4-chloroiodobenzene (234),  which  gave the  2-
substituted pyrole 230 in excelent yield, shown below (Scheme 23). 
 
 
 
 
 
Scheme 23: Synthesis of 2,5-disubstituted pyrrole 235. 
Folowing the first  Pd catalysed transformation, a second  one  was employed taking 
advantage  of a recent  C-H activation  protocol  published from the  Gaunt laboratory 
(Scheme 23).
103
 Treatment of pyrole 230 with Pd(OAc)
2
 and ethyl acrylate in acidic 
media  under an atmosphere  of  O
2 
to (facilitate re-oxidation  of the catalyst) gave the 
desired C5 regioisomeric  product 235 in  good  yield.  We envisaged that reduction  of 
the double bond might be problematic due to the tendency of pyroles to decompose 
under  H
2
/Pd conditions.  The  Fürstner  group  however recently  demonstrated a 
reduction on a similar system using H
2
 and Crabtree’s catalyst giving us confidence in 
our approach.
104
   
Unfortunately, subjection  of  our substrate (235) to these conditions resulted in  no 
conversion to product (236), shown below (Scheme 24). 
 
N
Boc
(HO)
2
B
I
Cl
N
Boc
Cl
N
Boc
Cl
CO
2
Et
Pd(OAc)
2
Na
2
CO
3
Acetone/H
2
O
1/1 rt 1 h
+
Pd(OAc)
2
AcOH:Dioxane
O
2 
baloon 35 °C
60%
CO
2
Et
98%
233 234 230 235
:H
2
O (3:9:1)
	   95	  
 
 
 
Scheme 24: Atempted Iridium mediated chemoselective reduction of alkene 235 
Changing the catalyst to  Pt/C  made litle diference and starting  material  was stil 
present after prolonged reaction times and elevated pressures. We finaly atempted to 
reduce the  double bond selectively using classical  Pd/C conditions, hoping that  with 
careful  monitoring the  product could  be  obtained.  Unfortunately these conditions 
resulted in the complete  decomposition  of  pyrole 235 after  2  h at ambient 
temperature. At this point we rationalised that a more classical pyrole synthesis would 
be viable, and that if necessary, the mono-acid could be synthesised at a later date. 
 
Towards the Synthesis of N1 – Synthesis II 
 
Our second approach folowed the classical Hantszch pyrole synthesis, whereby the 
key intermediate ß-diketo-ester 241 could  be rapidly obtained in two steps, shown 
below (Scheme 25)
105
. 
 
 
 
 
Scheme 25: Successful synthesis of Neamati analogue N1 
Treatment of commercialy available 4-chloroacetophenone 238 and furfuryl aldehyde 
with NaOMe in MeOH gave the desired Aldol condensation product 240 in excelent 
yield.
106
 Subjection of 240 to concentrated aqueous HCl in EtOH gave rise to cleavage 
of the furan ring, instaling the  desired  ketone and ester in  one step, albeit in  poor 
yield.  Exposure  of diketone 241 to  glycine ethyl ester and catalytic acid at elevated 
temperature gave the desired pyrole in a poor though typical yield for such a double 
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dehydration.
107
 A smal  quantity  of the  di-ester  was stored for  biological evaluation 
and the  bulk  material  was saponified to the  di-acid.  The  desired compound N1 was 
therefore obtained over four steps and the observed analytical data matched perfectly 
with that reported in the literature.
67b
 
The importance of the di-acid in N1 was underlined by many as being of paramount 
importance for activity in vitro.
66, 82
 The aforementioned (Figure 28) details the 
computational  proximity  of  both carboxylic acids to  key active site residues. 
Considering this, we thought it prudent to further probe this postulated binding mode 
through the synthesis  of an N1 analogue  possessing a  C5  methyl carboxylic acid in 
place  of its ethyl carboxylic acid. If  pose A was corect, (Figure 28) the result  of 
shortening this carbon chain should have a drastic impact on compound potency. Such 
an  observation  would alow for  greater confidence in  pose A and that could further 
functionalisation and elaboration of the curent lead di-carboxylic N1. 
5.1.2 – Synthesis of N1.1  
	  
Analogous to the synthesis  of N1, the  pyrole could  be accessed from a classical 
Hanztch pyrole condensation using the one carbon shortened ß-diketo-ester 246 and 
glycine (Scheme 26). 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 26: Synthesis of N1.1 
 
Synthesis of the ß-diketo-ester 246 began from the commercialy available propionic 
acid 243, which was activated via conversion to the acyl imidazole 244. Addition of 
the preformed dianion of ethyl hydrogen malonate alowed for a smooth Claisen type 
addition/decarboxylation that  gave the  desired ß-diketo-ester 246 in an moderate 
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yield.
108
 Exposure  of 246 to  glycine and catalytic acid at elevated temperature 
folowed  by saponification in  basic  media  gave the  desired shorter carbon chain 
pyrole N.1.1 in moderate yield over two steps. Having synthesised analogues N1 and 
N1.1 with relative ease  we  decided to  quickly  probe this  pharmacophore a litle 
further. With the commercial availability of interesting amino acids and the ß-diketo-
ester 241 in hand, it was decided that a smal library of analogues containing the di-
acid motif should be synthesised. (Table 7) highlights the general synthetic approach 
and details the compounds synthesised. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
Indicates yields over two steps, purified by column chromatography 
 
Table 7: Smal N1 library, based upon a LBDD approach 
The compounds  outlined above (Table 7) were synthesised  on a speculative ligand 
based drug design hypothesis. We assumed that binding pose detailed in (Figure 28) 
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was corect.  Therefore, both carboxylic acids  were retained  due to their inherent 
importance.  The pyrole core  was also left intact  under the assumption that its 
substitution  patern and  overal three-dimensional structure  positions the sidechains 
optimaly  within the active site.  The remaining site for introducing  variability  was 
therefore  upon the alpha carbon  of the  methyl carboxylic acid.  The  binding  pose in 
(Figure 28) seems to alow for substitution at this  position,  with the  possibility  of 
gaining extra  hydrophobic  overlap  with  Phe266,  Trp280 and  Leu282  or further π-
cation interactions  with  Arg177. Considering this,  we  used serine and a  variety  of 
chiral and racemic aromatic amino acids to test  our  hypothesis. In synthesising al 
analogues, the  observed  yields were reproducibly  poor  ~  15%.  The reasons for this 
were two-fold in that the double dehydration to form the pyrole core is known to be 
low  yielding
105
 and that  during  purification  of the  di-acids  product  was lost  during 
workup and column chromatography. 
 
5.1.3 – Design of Pyrrolidine Analogue 256 
 
In synthesising the parent compound N1, the short chain analogue N1.1 and the more 
highly functionalised analogues (250 – 254), it  became apparent that  one final 
assessment had to be made.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Co-crystal structure 1DEW. Simplified abasic DNA structure (green) and (pink). 
Hydrophobic region Phe266, Trp280 and Leu282 (red), Arg177 (yelow) and polar 
region His309, Asn212, Asn174 (blue). 
 
Detailed above, (Figure 29) shows a simplified image of the co-crystal structure pdb. 
(1DEW) of Ape1/Ref1 and abasic DNA. The highlighted abasic deoxyribose residue 
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(pink) flanked  by two  phosphates (orange) indicates the flipped  out region  of  DNA 
that is the recognition  point for  Ape1/Ref1 to initiate  DNA repair. It is this short 
sequence  of DNA that  Neamati and co-workers  believe N1 and its analogues are 
mimicking. This may be a valid hypothesis however we were curious that the pyrole 
di-carboxylic acid N1 could instead  bind in a similar  mode  mimicking the abasic 
substrate via the adjacent nucleotide residue (pink Figure 30). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Co-crystal structure 1DEW. Colour coded as figure 31. Pink nucleotide 
highlights the region of substrate N1 could also mimic.  
 
In analysing the DNA substrate in this region it is worth noting that nucleotide is of 
course  2,5-substituted.  At  C1 it  possesses an aromatic sp2-sp3  nitrogen-carbon  bond 
and the phosphate is elongated of C4. Therefore you could postulate that N1 mimics 
this structure through its 2,5-substitution patern. It too possesses an aromatic sp2-sp2 
carbon-carbon bond that could form a π-cation interaction with Arg177. Furthermore, 
its ethyl carboxylic acid elongates  of  C5 analogous to the  phosphate in the  natural 
substrate.  The function  of the N-methyl carboxylic acid is less certain,  but its 
proximity to Arg177 may alow for the formation of a hydrogen bond as seen above in 
(Figure 30). 
 
The analysis  discussed in the  previous  paragraph alowed  us to suggest an 
improvement to the structure of N1. Neamati and co-workers suggest that the aromatic 
pyrole core ‘buries’ itself into the  hydrophobic cavity.  This  binding rational is  not 
possible in  our  hypothesised  model and therefore  we  postulated another function. 
Instead, the pyrole acts as a planar ribose mimic, alowing for favourable position of 
the aromatic and carboxylates  only.  As such,  we  postulated that the  positioning  of 
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these residues may be improved if the pyrole was instead a saturated cis-substituted 
pyrolidine, of type (256), structural similarities displayed below, (Figure 31). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: Similiarity between the chemical structures of the abasic DNA subsection, N1 and 255/256. 
 
This structure  now  has the exact stereochemical relationship  between the two 
sidechains as seen in the  natural substrate 255.  Furthermore, incorporation  of this 
feature into N1 may increase  potency and alow for further compound  design  based 
upon homologation at C3 and C4. We therefore sought a synthetic route to realise this 
goal and test our hypothesis alongside the other chemical entities.  
 
5.1.4. – Synthesis of Pyrrolidine Analogue 256 
Retrosynthetic Analysis 
 
Our retrosynthetic analysis towards 256 is  highlighted  below, (Scheme 27). We 
decided that di-acid 256 could be obtained from alkene 259 folowing hydrogenation, 
N-alkylation and a  double saponification.  The alkene could  be accessed through a 
Swern oxidation/Witig olefination of alcohol 260, which in turn could be accessed via 
an acid catalysed intramolecular cyclisation and stereoselective imine reduction  of 
ketone 261.  The  open chain  phenyl  ketone could  be readily synthesised  utilising a 
Grignard addition into the protected L-pyroglutamic acid derivative 262.  
 
 
  
 
O
N
O
N
O
H
2
N
O P O
O
OH
Cl
N
OH
O
O
OH
256
N1
Cl
N
OH
O
O
OH
255
257 258
	   101	  
 
 
 
 
 
 
 
 
 
 
 
Scheme 27: Retrosynthetic analysis of pyrrolidine analogue 256. 
 
 
Our retrosynthetic analysis of target structure 256 led to the choice of L-pyroglutamic 
acid as an  obvious starting chiron. Its structure contained one required  predefined 
stereocentre at C5 from which the other at C2 could be infered in our strategy. This 
key factor coupled  with commercial availability and economic  viability  made 263 a 
perfect starting point for our synthesis, highlighted below (Scheme 28). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 28: Successful synthesis of 256. 
 
In  moving forward, the synthesis  began  with a two-step sequence starting from  L-
pyroglutamic acid (263) that quickly provided protected carbamate (262). A carefuly 
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controled addition of pre-formed Grignard 264 then folowed which provided phenyl 
ketone 265 in  good  yield.
109
 The tert-butoxycarbonyl  protecting  group  was removed 
upon exposure to  TFA and the resulting amino  ketone  underwent an acid catalysed 
intramolecular cyclisation to form intermediate Schif base 266. With 266 in hand we 
atempted the key step under classical hydrogenation conditions (Pd/C/H
2
). Formation 
of the  desired syn-diastereomer  was  predicted, folowing selective  delivery  of 
hydrogen to the rear face of the molecule, facilitated by the stereocentre at C2. Initial 
eforts to hydrogenate over Pd/C were unsuccessful leading to a complex mixture of 
products. It  was  postulated that open chain  products  may  be forming  due to the ful 
hydrogenolysis at the  C2 benzylic position in structure 266.  Atempts to reduce the 
imine  with  mild borohydrides (NaBH(OAc)
3
)  was  met  with limited success and  no 
diastereoselectivity. We  were finaly able to circumvent this issue via the  use  of 
platinum  on carbon,
109
 which resulted in excelent conversion to the  desired syn-
pyrolidine  product 267 as a single  diastereomer confirmed  by  NOe studies, 
(iradiating at 4.21 ppm, enhancement observed at 3.96 ppm). The amine was then re-
protected as a carbamate and the ester  was reduced to the alcohol  under standard 
conditions. Protected alcohol 269 was then subjected to a “one pot” Swern oxidation 
Witig olefination protocol providing alkene 270 in excelent yield, over the two steps. 
Hydrogenation of the alkene and acidic cleavage of the tert-butoxycarbonyl gave free 
amine 271 that  was alkylated  with ethyl  bromoacetate to  give  diester 272.  Basic 
hydrolysis to the  di-acid  mediated  by aqueous  LiOH  gave the  desired  product in an 
moderate yield after isolation.  
In summation, pyrolidine di-acid 256 was obtained in 9% overal yield in 13 steps. In 
moving forward, we wanted to assess the biological activity of analogues discussed in 
this section. The details of which are disclosed below. 
 
5.1.5 – Biological Evaluation of N1 and Associated Analogues 
We first analysed the  biological assay conditions employed by  Neamati and co-
workers.  The  overal  biochemical  basis for assessing inhibition  of  Ape1/Ref1 
paraleled  our approach,  however their  methods  of activity  detection  did  difer.  The 
authors employed a synthetic  oligonucleotide,  whose top strand composition read 
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(5’ATTTCACCGGTACG(F)TCTAGAATCCG  3’)  where  F  denotes the engineered 
tetrahydrofuran abasic site  mimic.
67b
 Unlike  our fluorescence tagged  oligonucleotide 
(see B1) they labeled their 5’ end with 
32
P. This labeling diferential was not thought 
to afect the enzyme kinetics but a diferent phenotype is produced, which has to be 
analysed via diferent method. Experimentaly, Neamati and co-workers pre-incubated 
Ape1/Ref1  with a  potential inhibitor at  30 °C for  10  minutes. The 
32
P labeled 
oligonucleotide  was then added, and incubation continued for a further  10  minutes. 
Folowing this, the reaction  was  quenched, an aliquot  of the  media electrophoresed 
and the resulting gel analysed using a PhosphorImager cassete. This assay therefore 
alowed for the  determination  of the amount  of  oligonucleotide  processed  by 
Ape1/Ref1  upon  visualisation  of 
32
P  products, further  details found in (biological 
appendix B1). 
Considering the aforementioned,  we were confident that  our assay  was scientificaly 
comparable and  possibly even more robust, alowing a real time image  of substrate 
cleavage. The only other remaining variable between the two setups appeared to be the 
bufer compositions.   We therefore set about cross biological assessment  using  both 
the IC bufer and the bufer used by Neamati and co-workers.  
 
 
 
 
 
 
 
Graph 14: Biological evaluation at 50 µM inhibitor, 100 nM substrate, IC bufer @ 30 °C. 
 
In moving forward, (Graph 14) above, details biological assessment of the discussed 
compounds at a concentration of 50 µM in IC bufer at 30 °C. The compounds were 
pre-incubated in  protein and  bufer for  10  minutes  prior to the addition  of substrate 
0"
50000"
100000"
150000"
200000"
250000"
0" 20" 40" 60" 80" 100" 120" 140" 160" 180"
r
F
U
!
Time (s)!
Control"
Control"
N1"
N1.1"
250"
251"
252"
253"
254"
256"
	   104	  
and thus  measurement  of activity.  As clearly indicated  by (Graph 14) none  of the 
synthesised compounds showed any activity at  50 µM.  This  observation  was 
unexpected as Neamati’s lead compound N1 was reported to have an IC
50
 value of 4 
µM, (such activity  would be represented by a flat line (m  ~  0) at an inhibitor 
concentration of 50 µM). In our measurements al curves are comparable to the control 
wel. In the interests  of fair  biological assessment  we  performed an identical assay 
altering  one  parameter, switching the IC bufer for  Neamati’s  bufer, shown  below 
(Graphs 15 and 16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 15: Biological evaluation at 50 µM inhibitor, 100 nM substrate, 
Neamati bufer conditions. 
 
At a glance (Graph 15) seems to indicate that al compounds are biologicaly active at 
50 µM. The striking feature however, is that under the control conditions no cleavage 
of the abasic substrate is occuring, evident from the total lack of fluorescence output. 
We repeated the measurement several times double-checking al  parameters, these 
actions unfortunately resulted in a similar  graphical  output.  Somewhat  bemused  by 
these findings  we spiked the control  wel with  10x the amount  of  Ape1/Ref1, the 
results are shown below (Graph 16).  
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Graph 16: Biological evaluation at 50 µM inhibitor, 100 nM substrate, Neamati bufer conditions, 
protein spiked into wel containing 778. 
 
The observation detailed above (Graph 16) confirmed our suspicions that the protein 
was clearly unstable or inactive under Neamati’s bufer conditions. Spiking the control 
wel with 10x protein gave a huge increase in fluorescence at t = 10 seconds, after this 
period the level of fluorescence stayed constant. The observation that fluorescence was 
constantly  high is a reflection  of the cumulative recording  of fluorescence  output  by 
the detector. The fact that the fluorescence ‘jumped’ indicated initial abasic cleavage 
activity in the wel, the folowing immediate ‘flatline’ confirmed protein inactivity.  
 
Conclusions  
 
These results discussed in the last section indicate that  not  only is the  pyrole  di-
carboxylic acid N1 not active in the IC  bufer conditions it is also  not active in the 
publication’s conditions.  Neamati et. al., did  not conduct a fluorescence  based assay 
like our study, instead a similar protocol was performed using gel electrophoresis. At 
present we are confident that our assay is of high accuracy and can only speculate that 
the authors  were  observing a false  positive in their results. In analysing the 
composition  of  both  bufers  we cannot scientificaly suggest  what is causing such a 
discrepancy in protein stability. As a result, we abandoned looking at the pyrole di-
carboxylic acids. Although we had observed a second negative result, we were happy 
to  have  disproved a literature report.  Furthermore,  during these studies  we  had 
designed and successfuly synthesised syn-pyrolidine 256. Moreover,  we  were 
inspired  by the initial  CADD studies  of the  pyrolidine analogue,  particularly in the 
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2,5-syn substitution  patern across the core.  This  provided a catalyst for looking at 
higher  order  pyrolidines incorporating  more  diverse active site  directed chemical 
functionality, in the search for a novel Ape1/Ref1 inhibitor. The details of these eforts 
are disclosed in the next chapter. 
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CHAPTER 3  
Design and Synthesis of Pyrrolidine based DNA Substrate Mimics 
6.0. – Overview  
 
The last two chapters summarised the  discovery  of a  highly conserved secondary 
binding site within the N-terminal domain of Ape1/Ref1. Furthermore, we discovered 
that inhibitors  disclosed  by  Neamati and co-workers were in fact inactive and are 
instead most  probably the result  of a false  positive in their  biological assay. 
Considering that our design and synthetic eforts up to this point had yielded litle in 
the way of an active compound, we decided that a novel approach was necessary. 
 
Structuraly, Ape1/Ref1 lacks a classical three-dimensional binding pocket. Instead the 
protein  displays a  vast  binding cleft that forms  multiple interactions  with its target 
DNA substrate.  This large  protein surface-substrate interaction is  best  viewed in the 
co-crystal structure below (Figure 32). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Abasic DNA – Protein co-crystal structure. DNA (orange) wraps over a vast surface area 
positioning the abasic site into the active site for processing.
110
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In order to compete with the DNA substrate we rationalised that we needed to design a 
scafold that could potentialy mimic the region of DNA that binds transiently within 
the cleavage domain. In realising this, we were confident that such compounds were 
unlikely to exist in commercialy available ‘drug-like’ libraries and therefore a de novo 
design approach  was required.  This chapter entails  our synthetic eforts to  design 
scafolds and fragments that both mimic the shape  of the abasic  DNA substrate and 
also contain electronicaly relevant functionality that encourage  binding within the 
catalytic region.  
6.1. – General Design Approach  
 
In order to generate the best possible overlap between the abasic DNA substrate and 
our  novel analogues, we chose to concentrate  on the region  of  DNA that  directly 
interacts with the active site, shown below (Figure 33). Extending focus past this point 
was deemed impossible based on computational studies alone and at this stage a proof 
of concept was the ultimate goal. 
 
 
 
 
 
 
 
 
Figure 33: Natural DNA substrate for Ape1/Ref1 (275), dissected into functional 
regions of importance for substrate recognition and subsequent analogue design. 
 
The functionalities we wished to mimic are highlighted in blue, black and red, shown 
above in (Figure 33). Generaly, the makeup of the binding cleft requires an inhibitor 
to  possess  more  hydrophobic character towards the  blue  nucleotide and  more 
hydrophilic character towards the  phosphodiester cleavage  domain (red). It is 
noteworthy, that the  western  green  nucleotide is  positioned  outside  of the phosphate 
cleavage site, and therefore has been included only for clarity.  
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Building  on the syn-pyroldine idea, first  postulated in  Chapter 2 we  decided that a 
2,5-substituted  pyrolidine  or  2,6-substituted  piperidine  would serve as an excelent 
mimic for the western nucleotide (blue). Importantly, these mimics are substituted at 
the same carbon atoms (relative to abasic  DNA) and the stereochemistry at these 
carbons is conserved  between structures.  The blue  nucleotide  blue in (Figure 33) 
arbitrarily contains an adenine  base, though in vivo the identity  of this residue is 
independent  on  Ape1/Ref1 activity as the  protein  binds al abasic  DNA through 
recognition  of the flipped  out abasic site (red)  only.  The  DNA  base  upon this 
nucleotide provides a key stabilising interaction through π-cation binding to Arg177. 
The Arg177 residue is known to be vital for inserting into the DNA backbone when 
the  binding  of abasic  DNA  occurs and therefore represents an interesting target. 
Furthermore, arginine residues in general are known to make significant contributions 
to the binding energy of protein-substrate complexes binding in a co-planar fashion.
111
 
Considering this, we postulated that any interuption of the normal binding at Arg177 
might lead to reduced  DNA  binding eficiency or even a complete loss  of  binding. 
Indeed, it has been shown that a site directed mutagenesis of Arg177 to Ala177 caused 
a severe  decrease in the  binding eficacy  of  Ape1/Ref1 to abasic  DNA.
112
 We 
therefore decided that a large aromatic at C2 in (273/274) (Figure 33) may alow for 
eficient π-cation binding to Arg177 and could therefore serve as a handle to anchor 
other ligand functionality into the hydrophilic region of the active site.  
 
Extending from the  blue  nucleotide are two  phosphate linkages that flank the abasic 
site, shown in (black and red Figure 33). The later red 5’ phosphate situated upon the 
abasic ribose is the target for cleavage and therefore  was suited to  bioisosteric 
replacement  only.  The former  phosphate  was also identified as a possible target for 
this treatment, however and more importantly  we required a linker to connect the 
anchoring π-cation  binder to  more  hydrophilic functionality.  Computational analyses 
identified that a sulphonamide  was the  best choice to  potentiate the  geometry  of the 
natural substrate backbone, normaly provided by a phosphate, shown in (black Figure 
33). 
 
The abasic ribose (red) constituted the  greatest chalenge for  designing  mimics.  We 
decided simply that bioisosteric replacement of the phosphate by a phosphonate might 
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provide an inhibitory efect through the laters inability to be cleaved via hydrolysis. 
Furthermore,  unpublished experimental  data from the  Freemont laboratory identified 
the tendency of Ape1/Ref1 to co-crystalise with glycerol, (when present in the bufer 
composition).
61
 The glycerol was shown to lie in the cleavage site, forming hydrogen 
bonds to  key  phosphate stabilising residues  Asn174,  Asn212 and  His309, see (2.6). 
Atempting to  benefit from this  observation  we  designed and synthesised analogues 
containing a glycerol equivalent and a hydroxylated abasic ribose mimic, see (6.10). 
6.2. – Targeting Arginine 177 
Towards the Synthesis of the Pyrrolidine and Piperidine Cores 
 
Retrosynthetic Analysis 
 
Analogous to the design outlined Chapter 2, we envisaged that the syn-2,5-substituted 
pyrolidine scafold (276), could provide us with a core, from which our DNA based 
substrate  mimics could  be elaborated.  Considering this, a  modified retrosynthetic 
analysis is highlighted below, (Scheme 29). 
 
 
 
 
 
 
 
Scheme 29: Retrosynthetic analysis of pyrrolidine scafold. 
 
Our fuly elaborated structure could be obtained folowing the alkylation of sulphonyl 
halide 277, which in turn could be accessed via the sulphonylation of alcohol 278. The 
alcohol can  be traced  back to carboxylic acid 279 that could  be  obtained through a 
Suzuki coupling  between enol triflate 280 and a  boronic acid  of choice.  The triflate 
can  be accessed through trapping the coresponding enolate  of the  previously 
synthesised protected L-pyroglutamic acid derivative. 
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6.3. – Towards the Synthesis of Triflate 280 
 
The retrosynthetic approach outlined above (Scheme 29) was  particularly appealing 
due to the generic utility of triflate 280, that in principle could be coupled to a series of 
diverse aromatic  boronic acids, selected to target  Arg177. The synthesis started  with 
the previously utilised protection of commercialy available L-pyroglutamic acid. With 
the  protected lactam in  hand we atempted to  generate the lithium enolate in the 
presence  of  TMEDA and thus trap the  oxyanion  with a triflate source, provided by 
Comins reagent.
113
 Careful  manipulations  of temperature, concentration and  base al 
aforded a mixture of products, of which only a trace amount coresponded to the enol 
triflate, (triplet at ~  5.2  ppm 
1
H  NMR).
114
 These observations difered with the 
reported literature and instead the alternative benzyl lactam (284) was synthesised, 
shown below (Scheme 30). 
 
 
 
 
 
 
 
Scheme 30: A: Atempted synthesis of enol triflate 281 and alternative lactam 284: B: Literature 
formation of enol triflate 286 and its use in a Suzuki coupling. 
115
 
The reason for this  was two-fold. Firstly, the  presence  of the ester in 262 may have 
been a concern for side reactions and secondly epimerisation at C2 could occur. The 
synthesis  was straightforward and  began  with an esterification  of chiral acid 261. A 
LiBH
4
 reduction folowed generating lactam alcohol 283 in excelent yield. A two-step 
protection  of the lactam  nitrogen and  primary alcohol  gave the alternative lactam in 
excelent yield. Further eforts to access the coresponding enol triflate 289 were then 
sought from this synthon, shown below (Scheme 31). 
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Scheme 31: Synthesis of enol phosphate 290 and atempted Suzuki couplings. 
 
Our synthetic eforts  began  by exposing lactam 284 to the  previously  described 
conditions,  outlined above in (Scheme 31).  Based on 
1
H  NMR analysis enol triflate 
289 appeared to form  with an improved  yield, compared to ester 262,  discussed in 
(Scheme 30).  Disappointingly, compound 289 was  not stable to silica  gel 
chromatography. Furthermore, the compound was unstable at room temperature, and it 
decomposed after 12 hours at ambient temperature. The innate instability of compound 
289 was  puzzling, since the coresponding tosyl lactam 286 had been previously 
described in the literature, shown in (Scheme 30B) The tosyl species 285 was 
converted into its enol triflate 286 that  was suitably stable to  be used  directly in a 
Suzuki coupling yielding 288, albeit in modest yield.
115
 
Conversely,  our required enol triflate 289 decomposed at room temperature and we 
therefore postulated that a subsequent Suzuki or Buchwald-Hartwig reaction had litle 
chance  of success (due to thermal  decomposition  of the triflate species prior to 
catalytic turnover at  paladium). Due to the  obvious  mismatch in stability and 
reactivity, we sought a  more stable coupling  partner in  phosphate 290, shown above 
(Scheme 31).
115
 
In moving forward, to access phosphate 290, protected lactam 262 was deprotonated 
with LiHMDS at low temperature. The presence of TMEDA and phosphoryl chloride 
then facilitated the enolate trapping through O-acylation.  This reaction  proved to  be 
much cleaner than the triflate, quench  probably  due to the enhanced stability  of the 
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product.  Though, to  our  dismay, this  product also displayed sub-optimal stability. 
Despite this, we atempted to synthesise both the boronate ester 292 and  Suzuki 
product 291, shown above (Scheme 31). Unfortunately, in  both cases the reactions 
were unsuccessful and decomposition of 290 was observed. 
We rationalised that the stability of the targeted O-acylated enols was a limiting factor 
within the chemistry.  As  discussed, this synthetic approach  would  have alowed for 
easy  derivatisation,  however an alternative route was conceived.  The pyrolidine 
moiety was stil our target ribose mimic, but due to the problems encountered at the 
early stage of the synthesis,  we  postulated that a six-membered ring  variant  would 
serve as a suitable model study to develop the overal scafold chemistry. 
6.3.1. – Towards the Synthesis of Piperidine Triflate 301 
	  
Considering the aforementioned, an alternative six-membered ring scafold  was 
targeted,  maintaining al features  of the  pyrolidine retrosynthetic design. However 
firstly, the six-membered lactam 297 had to  be synthesised, shown  below (Scheme 
32). 
 
 
 
 
 
 
 
Scheme 32: Successful synthesis of 6-membered ring enol triflate 301. 
 
Starting from lysine hydrochloride 293 we ultilised a four step literature procedure to 
access lactam 297, (Scheme 32).
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acid 295.  Methylene  oxidation, employing  RuO
4
 generated in situ provided the 
cyclisation  precursor 296 in excelent  yield, on  multigram scale.
116
 Deprotection and 
intramolecular cyclisation in neat TFA at reflux occured in good yield providing the 
stereochemicaly  pure lactam ester 297.  The ester  was then selectively reduced  with 
NaBH
4
/EtOH to  gain the lactam alcohol 298. Notably, the ester reduction  had to be 
employed  prior to carbamate  protection  of lactam 297.  Formation  of the carbamate 
before the reduction step resulted in a total lack of chemoselectively due to the relative 
increased electropositivity of the lactam carbonyl. 
 
 
 
 
 
 
Scheme 33: Successful Suzuki coupling and atempted linker incorporation. 
With the amino alcohol in  hand, diferential  protection  was sought  due to  potential 
problems highlighted in the pyrolidine syntheses. Protection of the alcohol as the tri-
isopropylsilyl ether and t-butoxycarbonyl protection  of the lactam  nitrogen  gave the 
triflate precursor 300 in excelent  yield. Deprotonation of 300 by LiHMDS  was 
employed as before, however low  yields  were  observed. Switching to  LDA in the 
presence of TMEDA and Comins reagent alowed the O-acylation to take place 
smoothly and in excelent  yield, providing stable enol triflate 301, shown above 
(Scheme 32). Unlike its 5 membered ring counterpart (289), this compound was very 
stable and could be stored and purified  using conventional chromatographic 
techniques. The enol triflate (301) was then subjected to a  Suzuki coupling  with 2-
napthylboronic acid at  60 °C.  Pleasingly, this reaction  was successful,  providing 
desired product 302 in good yield, shown above (Scheme 33). Subsequent reduction of 
the alkene  gave product (303) as a  2:1  mixture  of inseparable  diastereoisomers in a 
moderate yield.  
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Although the enol triflate was a beter substrate for the Suzuki chemistry, the lack of 
complete diasteroselectivity in the reduction was very problematic. We had envisaged 
that the reduction should have occured with complete diastereomeric control, as seen 
in the synthesis  of N1.  Considering this,  we continued the synthesis and  obtained 
alcohol 304 through TBAF mediated deprotection of the silyl ether. With the alcohol 
in hand we hoped to further the model study by incorporating the sulphonyl bromide 
linker 308, (Scheme 33). The bromomethanesulphonyl chloride linker was synthesised 
ultilising a two-step literature  procedure, shown in (Scheme 33).
117
 The linker (308) 
was then reacted  with alcohol 304 in the  presence  of  base, though  no  product  was 
obtained and instead deprotection of carbamate was noted. The failure of the reaction 
was atributed to the presence of trace HCl in the starting material, from the previous 
chlorination step  with  PCl
5
.  Repeated  distilation  of linker 308 was conducted to 
remove HCl, though after several atempts the elaborated structure (305) was  not 
obtained.  
Given the  problems encountered  with  our approach to  both the  5-membered and  6-
membered ring scafolds we decided that a new strategy was required. The synthetic 
approach towards the  6-membered ring core 305 had to  be terminated  due to the 
detrimental failure  of the  hydrogenation to  yield the single  desired syn-
diastereoisomer.  The  5-membered ring synthesis  was staled at an early stage  due to 
the inherent instability of our enol triflate and enol phosphate coupling partners (289 
and (290). In retrospect, the  predominant reason for employing this synthesis  was 
based  upon the atractive  nature  of a common coupling intermediate that could 
derivatised  quickly and eficiently to  obtain a range  of fragments targeting  Arg177. 
Having  made litle headway into realising this approach,  we  decided to switch  our 
atention back to the previously optimised synthetic sequence from Chapter 2. 
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6.4. – Application of the Previously Optimised Route 
	  
Considering the  outcomes from the  previous section,  we  decided to apply the  more 
transformation intensive synthesis  of 256 to  our  desired scafold 309, shown  below 
(Scheme 34). 
 
 
 
 
 
 
Scheme 34: Summarised successful synthesis of 256 and proposed application of this 
strategy to access pyrrolidine based mimic scafold 309. 
 
We successfuly synthesised the single syn-diastereoisomer 256 as an analogue  of 
Neamati’s compounds in (5.1.3).  Having  developed and  optimised this route  we 
decided to exploit it further through incepting intermediate 267 and elaborating it to 
the target pyrolidine (309). 
 
Application of this chemistry to the new scafold required the predefined selection of 
an aromatic  unit at  C2. As this functionality  was  previously introduced through a 
Grignard addition and therefore would not be able to be derivatised at a later stage.  
 
 
 
 
 
 
 
Figure 34: Natural abasic DNA lesion 310. Postulated pyrrolidine mimic scafold 309 (aromatics 
targeting Arg177 seen in red). Strongest aromatic arginine π-cation binders (311 –313) (red). 
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6.5. – Towards the Synthesis of the Pyrrolidine Core – Synthesis I 
 
In 2005, Crowley and co-workers discussed the prevalence and importance of arginine 
residues upon the surface of proteins.
111
 In doing so, they computationaly modeled a 
series of aromatic motifs against arginine, assessing the stabilisation gained through π-
cation  binding  between the two functionalities. In their report, they  highlighted 
napthyl, phenol and indole aromatics as the best binders in silico, shown above (Figure 
34). Considering this observation, we decided that an anisole aromatic sidechain was 
the best C2 substituent choice, (employment of the free phenol aromatic would require 
protecting  group chemistry that at this  discovery stage was  deemed an  unnecessary 
complication). Highlighted below, (Scheme 35) is the successful synthesis of the syn-
2,5-substituted pyrolidine scafold (324).  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 35: Successful synthesis of 2,5-substituted scafold 324. 
 
In  moving forward, a two-step sequence starting from  L-pyroglutamic acid quickly 
provided protected carbamate 262, (synthesis previously shown 5.1.3). Commercialy 
available  4-methoxyphenylmagnesium  bromide  was then added at low temperature 
obtaining  ketone 314 via a  nucleophilic addition, ring  opening reaction.
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resulting amino ketone underwent an acid catalysed intramolecular cyclisation to form 
intermediate Schif base 315. With 315 in hand we employed the previously optimised 
hydrogenation conditions, utilising platinum  on carbon.  After  36  h, the  desired syn-
diastereomer 316 was obtained in excelent yield, again confirmed by NOe studies. It 
is  noteworthy that  on larger scales, increasing the  pressure to  30  Tor significantly 
lowered the reaction time and catalyst loading, providing a comparable  yield.
109
 The 
amine was then converted to the coresponding carbamate and the ester reduced with 
LiBH
4 
to  provide alcohol 318 in  good  yield.  At this stage it  was  decided  not to 
homologate through oxygen but instead convert the alcohol to the previously modeled 
more robust amine 321.  Tosylation  of the  primary alcohol folowed  by  S
N
2 
displacement  with sodium azide and subsequent  hydrogenation  gave the  desired 
primary amine 321 in excelent  yield, over the three steps.  Unlike the  previous 
synthesis, we purchased the sulphonyl linker 322 rationalising that HCl contamination 
should  be  minimal.  Reaction  of chloromethanesulphonyl chloride  with amine 322 in 
the presence of excess pyridine gave the target sulphonamide in a pleasing yield. We 
were woried that the free N-H may impede nucleophilic substitution of the α-chloride 
and therefore protected it as the coresponding carbamate 324 (Scheme 35). With the 
core scafold in  hand  we atempted to  derivatise through  displacement  of the α-
chloride substituent, conditions shown below (Table 8).  
 
 
 
 
 
 
 
 
 
 
Table 8: Atempts to displace α-chloride and homologate to analogues of general structure 325-g. 
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We atempted to  displace the chloride (324) with a range  of  nitrogen and  oxygen 
nucleophiles that  were representative  of required further functionalisation. 
Unfortunately, heating 324 in the presence of a nitrogen nucleophile and base gave no 
conversion to  product (entry 1). Increasing the temperature and addition  of  NaI also 
aforded the same result. We switched our atention to using a stronger base (entry 3) 
again no product was obtained. Further examination of the literature revealed the use 
of the soft  Lewis acid  AgOTf in similar transformations.
118
 We therefore employed 
these conditions with our nitrogen nucleophile (entry 4) and the literature nucleophile 
(entry 5).  After  prolonged  periods  of sonication (~24  h) no  product formed and al 
starting materials remained. These results were worying and we rationalised that the 
electrophile  was inherently  unreactive to such a  nucleophilic atack.  Finaly, we 
employed a primary alcohol as the nucleophile (entries 6 and 7) and NaH/KH as the 
base respectively. Predictably, after prolonged reaction times no product was formed 
and the starting  materials  were recovered intact.  Considering the  distinct lack  of 
reactivity, we decided to alter the structure of electrophile 324. We rationalised that a 
one-carbon  homologation to  vinyl sulphone 328 should  yield a  much  more reactive 
electrophile, alowing nucleophilic atack to  occur thorough a  pseudo  Michael type 
addition (Scheme 36). 
 
 
 
 
 
 
 
 
 
 
Scheme 36: Optimised synthesis of vinyl sulphone 328. 
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electrophile  may  be sensitive to  base and therefore employed  Et
3
N as a  weaker 
alternative (Scheme 36/B).  Treatment  of amine 321 with  5.0 eq,  of  Et
3
N  gave the 
desired product 327 albeit in poor yield.
119
 The low yield was thought to be resulting 
from the instability  of the electrophile in  basic  media.  The  process  was therefore 
optimised (Scheme 36/C).  This alowed the initial formation  of sulphonamide 327i 
upon exposure to 1 eq. of Et
3
N and secondly formation of vinyl sulphone 327 after the 
addition of excess base. With the desired electrophile in hand, we again protected the 
sulphonamide nitrogen as the coresponding carbamate 328 in excelent yield (Scheme 
36). Having  obtained the  desired electrophilic scafold in  25%  over  12 steps, we 
turned  our atention to the  development  of  other  C2 aromatic variants,  designed to 
target Arg177 through the previously discussed modes (6.2). 
 
6.6. – Synthesis of a C2 Bi-Aryl Containing Fragment 
 
The successful synthesis of vinyl sulphone 328 enabled us to design more analogues to 
target  Arg177  within the active site.  We conducted computational studies  upon  C2 
biaryl fragment 329 (Figure 35). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: Low energy binding pose of C2 biaryl pyrroldine 329. Actual docking pose (left), overlay 
with complexed DNA protein crystal 1DE9 (right). Active site residues (yelow) 
Mg
2+ 
(pink), electrostatic surface of Arg177 shown (yelow). 
N
H
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The left-hand image (Figure 35) ilustrates the low energy  binding  pose  of  biaryl 
analogue 329 (-4.90  XP-glide, -11.75 ΔG mmGBSA).  The  docking  pose  was 
encouraging, showing eficient  hydrophobic  overlap  with  Arg177 and an 
intermolecular  proximity to  Asn212 akin to  possible  hydrogen bond formation, 
stabilising the ligand deep in the active region. The right-hand image is an overlay of 
the abasic  DNA  bound co-crystal structure (1DE9).  Upon  binding the  DNA the 
flexible  Arg177 repositions itself into the  DNA  major  groove.  Assuming this 
flexibility could also  be triggered  by smal  molecule 329, the  docking  overlay 
highlighted an increase in surface overlap and potential π-cation binding between the 
two functionalities.  Although it  was  very  dificult to computationaly  model such 
interactions we were intrigued by the results and set about synthesising 329 using the 
previously optimised synthesis of 328, details of which are shown below (Scheme 37). 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 37: Synthesis of biaryl analogue 329. 
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first  methylated and then a lithium  halogen exchange  TMS-Cl  quench  gave 
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precursor.
120
 Atempts to form  phenyl  ketone 334 via Grignard addition  under the 
previously optimised conditions failed. We were somewhat surprised by this outcome 
and instead performed a lithium halogen exchange upon bromide 331 and utilised the 
resulting biaryl lithium as our nucleophile. Addition of the biaryl lithium to protected 
lactam 262, successfuly accessed  phenyl  ketone 334 in moderate yield. The tert-
butoxycarbonyl  protecting  group  was removed  upon exposure to  TFA and the 
resulting amino  ketone  underwent an acid catalysed intramolecular cyclisation.  The 
intermediate imine  was then  directly subjected to the  optimised  hydrogenation 
conditions  over  platinum, to aford the  desired syn-diastereoisomer in a good  yield, 
over the two steps.  Exposure  of ester 335 to  LiBH
4 
alowed for smooth reduction to 
the target alcohol fragment 329. 
 
6.7. – Synthesis of a C2 Napthyl Containing Fragment 
 
In line  with the previously  highlighted published  data, (Figure 34) we  were  keen to 
synthesise a C2 napthyl analogue to target Arg177. We again assessed the plausibility 
of this scafold as a potential inhibitor in silico, data shown below (Figure 36). 
 
 
 
 
 
  
 
 
 
 
Figure 36: Low energy binding pose of C2 napthyl pyrroldine 336. Actual docking pose (left), overlay 
with complexed DNA protein crystal 1DE9 (right). Active site residues (yelow) 
Mg
2+ 
(pink), electrostatic surface of Arg177 shown (yelow). 
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The left-hand image (Figure 36) ilustrates the low energy  binding  pose  of  napthyl 
analogue 336 (-6.80 XP-glide, 2.14 ΔG mmGBSA). In comparison to biaryl fragment 
329, these figures indicated a  beter induced fit for the  napthyl ligand, though the 
binding energetics  were somewhat less favourable.  We  were  unperturbed  by these 
calculations  due to the radicaly  diferent  binding  pose shown  by the napthyl ligand. 
Unlike biaryl 329 the postulated binding pose of the C2 napthyl indicated ineficient 
targeting of Arg177. The low energy binding pose (Figure 36) ilustrates no interaction 
with Arg177 but instead π-stacking against Phe266 and edge to face VDW interaction 
with Typ280. Furthermore, the pose indicates a possible H-bond to Asn229 or Asn226 
and in the right-hand  overlay image this  H-bond could also form  with  Arg177. 
Moreover, it seemed that if the  pose in (Figure 36) was corect, we could target the 
Mg
2+ 
cation and surounding  hydrophilic amino acids could  be targeted through 
substitution at carbons  4 and  6  upon the aromatic ring.  Analogous to the  previously 
described syntheses we set about constructing the napthyl analogue, details of which 
are shown below (Scheme 38). 
 
 
 
 
 
 
 
 
 
 
 
Scheme 38: Synthesis of napthyl analogue 336. 
 
Considering the success  of the  other syntheses, we envisaged the same synthetic 
approach to 336.  The commercialy available  1-iodonapthalene  underwent lithium 
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After  prolonged reaction times  napthyl  ketone 338 was  not  observed, and traces  of 
what appeared to be lactam 339 were detected via 
1
H NMR. We rationalised that the 
reaction was unsuccessful due to steric congestion from the nucleophile, and that any 
further investigation into this transformation  was  unwaranted.  We therefore  decided 
to change the electrophile to an aldehyde (342) so that it was both more reactive and 
less stericaly encumbered.  Aldehyde 342 was literature  known and accessible in  3 
steps from (S)-glutamic acid.
121
 The ester (340) was quickly transformed into aldehyde 
342 via formation  of the  di-carbamate and chemoselective  DIBAL reduction  of the 
terminal ester, by virtue of its relative steric accessibility. With aldehyde 342 in hand 
we assessed its  utility as an electrophile, and  pleasingly  upon addition  of  1-napthyl 
Grignard  we  obtained racemic alcohol 343 in excelent  yield.  Oxidation  of the 
benzylic alcohol was facilitated  by  PCC and  provided the coresponding  napthyl 
ketone in moderate yield.  Having  obtained the napthyl  ketone (338) we could  now 
revert  back to the  previously  optimised chemistry.  Exposure of the dicarbamate to 
TFA alowed smooth deprotection of both tert-butoxycarbonyl protecting groups and 
the resulting amino  ketone  underwent an acid catalysed intramolecular cyclisation. 
The intermediate imine  was then  directly subjected to the  optimised  hydrogenation 
conditions  over  platinum, to aford the  desired syn-diastereoisomer (345) with a 
slightly  disappointing  yield  over the two steps.  Reduction  of ester 345 using  LiBH
4 
gave the desired napthyl alcohol target (336). 
 
Having synthesised the two  modeled fragments (329) and (336) we  decided to turn 
our atention back to the larger substrate mimics based upon the central vinyl sulphone 
core (328), details of which are highlighted in below. 
6.8 – Towards the Synthesis of Larger DNA Substrate Based Mimics 
 
Having designed and synthesised smaler fragments, we wished to further our eforts 
and target  both the  hydrophobic region and the  phosphate cleavage region. 
Computational studies previously highlighted that vinyl sulphone 328 was an excelent 
scafold for further  development.  At this  point  we  needed to identify suitable 
functionality to link onto the sulphone, so that the hydrophilic region could be suitably 
targeted. A summation of our computational work is ilustrated in (Figure 37) below. 
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Figure 37: Identified potential hydrophilic binding groups 
from CADD studies. 
 
The four sidechains  highlighted in red  were selected from a range  of  hydrophilic 
entities. Trihydroxy fragment 347 was designed to mimic both the abasic ribose within 
the natural substrate and to form potential H-bonds with Asp70, Lys98, Asn174, and 
Asp210, as  wel as chelate the  magnesium cation.  Trihydroxy amine 348 was also 
implemented to  H-bond  with the aforementioned residues and  potentialy  mimic the 
binding  mode  displayed  by  glycerol (Freemont lab  unpublished results).
61
 
Phosphonate sidechain 349 was included to mimic the target phosphate group within 
the  natural substrate (346) and considering  Sieple’s  work (4.1)  proved an atractive 
target.  The final  piperidine sidechain 350 displayed a range  of alternative  binding 
modes into a northern cleft of the active region. This aray of feasible and interesting 
computational  binding  modes could  not  be  overlooked and  due to the amines 
commercial availability the compound was easily accessible.  
6.9. – Synthesis of a Glycerol Containing Mimic 
 
The idea  of incorporating trihydroxy  motif 348 into the larger scafold  was twofold. 
Firstly, the close  proximity  of the three alcohols  provides a  hydrophilic chelation 
sphere  potentialy capable  of  binding either  Mg
2+ 
or the residues that suround the 
cation.  Although  H-bonds alone  ofer litle towards  binding energy, the anchoring 
efect  may stabilise the  molecules conformation, alowing stronger  hydrophobic 
interactions to  be realised  more easily.  Secondly, sidechain 348 is structuraly 
analogous to glycerol, a molecule that has been showed on multiple occasions to co-
crystalise  out  of the  bufer  with  Ape1/Ref1 (Freemont lab  unpublished results) into 
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this  hydrophilic  protein region.  We  modeled several  hydroxyl  motifs  upon scafold 
328 and the best result is shown below (Figure 38). 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
Figure 38: Postulated CADD binding interactions of 351. Low energy binding pose of trihydroxy 
glycerol mimic 351. Actual docking pose (left), overlay with complexed DNA protein crystal 1DE9 
(right). Active site residues (yelow) Mg
2+ 
(pink), electrostatic surface of Arg177 shown (yelow). 
 
The left-hand image (Figure 38)  details the low energy  binding  pose  of trihydroxy 
analogue 351 (-6.05  XP-glide,  44.14 ΔG mmGBSA).  Although the  Gibbs  binding 
energy appeared unfavourable, the figure is misleading owing to the size of molecule 
351. The computational algorithm heavily punishes molecules with a large number of 
rotatable bonds. This is due to the hypothesised entropic loss, the system endures upon 
protein ligand binding. On the other hand, the glidescore proved encouraging and the 
larger non-planar compound appeared to fuly occupy the active site, a characteristic 
thought important and  not  yet seen in computational  work to this  point.  From an 
interaction  perspective, the compound showed  multiple  points  of  potential contact, 
highlighted  by the structure in (Figure 38),  notably  Mg
2+
 chelation and edge to face 
overlap between the C2 4-methoxylphenyl and Trp280. 
 
With the synthesis of scafold 328 completed we required syntheticaly useful amounts 
of trihydroxy amine 348. The initial idea behind using this amine was conceived from 
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previous usage of the sidechain within the Baret group. Sidechain 348 was used as a 
southern fragment  upon the selective and  potent cyclin-dependent  kinase (CDK) 
inhibitor BS-194.
122
 This compound displayed good ADMET properties and high oral 
bioavailability and although this  was  not a  primary concern at this stage, its 
incorporation was atractive. High stocks of this side chain were available within the 
Baret group and a summary of the synthesis is shown below (Scheme 39).  
 
 
 
 
 
Scheme 39: Barret group synthesis of protected  
BS-194 sidechain 355 
 
The protected amine (355) was accessed in seven steps starting from commercialy 
available (-)-diethyl tartrate 352. Treatment  of 352 with thionyl chloride and  Et
3
N 
gave cyclic sulphite 353 that was opened with sodium azide.
123
 The ethyl esters were 
then reduced with lithium borohydride (generated in situ) giving triol 354 in 64% yield 
over three steps.  Protection  of the  hydroxyl  groups  with the  observed functionalities 
and reduction of the azide gave target the amine (355) shown above (Scheme 39).  
 
 
 
 
 
 
Scheme 40: Completion of trihydroxy analogue 351. 
 
In  moving forward,  vinyl sulphone 328 and amine 355 were  heated to reflux in iso-
propyl alcohol, which  provided coupled  product 356 in excelent  yield.
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 Treatment 
of 356 with 4N HCl facilitated the removal of al protecting groups and provided the 
desired triol 355 in a moderate yield, (atributed to the water solubility  of the 
compound and loss  of  material  during chromatographic  purification).  The successful 
synthesis of 351 alowed us to pursue the synthesis of the hydroxylated ribose ‘mimic’ 
357, discussed in the next section. 
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6.10. – Towards the Synthesis of a Ribose Containing Mimic 
 
Folowing the  hypothesis  outlined in (6.2)  we searched for a  hydroxylated ribose 
fragment that could  potentialy form a  H-bond anchor  network  within the catalytic 
region, or mimic the abasic ribose present within the natural DNA substrate. Similarily 
to compound 351, the  most favourable elaborated ligand (357) from the  CADD 
assessment is shown (Figure 39).  
 
 
 
 
 
  
 
 
 
 
 
 
Figure 39: Low energy binding pose of ribose mimic 357. Actual docking pose (left), overlay with 
complexed DNA protein crystal 1DE9 (right). Active site residues (yelow) 
Mg
2+ 
(pink), electrostatic surface of Arg177 and Trp280 shown (yelow). 
 
The left-hand image (Figure 39)  details the low energy  binding  pose  of  dihydroxy 
ribose analogue 357 (-5.08 XP-glide, 15.42 ΔG mmGBSA). The calculated energetics 
of  binding were considerably  more favourable than trihydroxy analogue 351 which 
may have been a reflection  of the similiarity  between 357 and the  natural substrate. 
The  di-hydroxyribose  moiety appears to efectively  occupy the  phosphate cleavage 
region, chelating the  magnesium cation and also forcing  one sulphonamide  oxygen 
into a position proximal to forming H-bonds with Glu96 and Asp70. Interestingly, the 
overlay image (right) indicates that if Arg177 was to flex into the protein, excelent π-
cation overlap could occur with the phenyl ring. Furthermore, the internuclear distance 
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between Phe266 and ligand could alow for π-stacking or VDW overlap between the 
two  parties.  Considering this, we set about synthesising alcohol 347 from a  known 
literature protocol (Scheme 41).  
 
 
 
 
 
Scheme 41: Schomakers synthesis of functionalised THF rings.
125
 
 
The Payne rearangement
126
 has been demonstrated by both Sharpless
127
 and Ganem
128
 
to be an efective means of favouring selective C1 atack of 2,3-epoxy alcohols (359). 
The Payne rearangement of 358 led to the formation of the more stericaly accessible 
terminal epoxide 359. Using this notion, Schomaker and co-workers opened the 2,3-
epoxy alcohol 359 with trimethoxysulphoxonium iodide, afording intermediate 360 in 
excelent yield with exquisite regiochemical control. Folowing this, intermediate 360 
closed spontaneously via an intramolecular 5-exo-tet cyclisation accessing a range of 
substituted THF rings with the general structure of 361, shown above (Scheme 41).
125
 
Furthermore, the reactions  were conducted at [0.02]M to  minimise any competing 
intermolecular  processes and encouragingly there  was  no evidence  of  oxetane 
formation via the  plausible 4-exo-tet ring closure.  Keen to access sidechain 347, we 
employed the literature synthesis starting from the commercialy available enantiopure 
alcohol 362, shown below (Scheme 42).  
 
 
 
 
 
 
 
Scheme 42: Synthesis of protected sidechain 366. 
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Protected alcohol 362 was submited to a one pot Swern oxidation/Witig olefination 
protocol that yielded a mixture of cis/trans esters in excelent yield. Inseparable at this 
stage, the material was taken forward and reduced directly to alylic alcohols (E)-364 
and (Z)-364 in good yield. The isomeric alcohols were then subjected to a Sharpless 
asymmetric epoxidation with only the trans-alcohol able to react.
129
 Epoxide 365 was 
obtained in excelent yield as a single  diastereoisomer observed in the 
1
H and 
13
C
 
spectra. Notably, the unreacted cis-alylic alcohol (E)-364 was separated at this point. 
With epoxy-alcohol 365 in  hand, only the  key  bond forming reactions remained.  As 
outlined in the literature, treatment  of 365 with  NaHMDS efected the  Payne 
rearangement to the aforementioned  2,3-epoxy alcohol, which  was subsequently 
opened at  C1  with  with trimethoxysulphoxonium iodide. The intermediate  diol then 
underwent a  5-exo-tet ring closure afording  desired alcohol 366 in excelent  yield. 
Having completed the synthesis  of sidechain 366 we sought to couple it  with  vinyl 
sulphone 328, reaction shown below (Scheme 43).
130
 
 
 
 
 
Scheme 43: First atempted synthesis of analogue 367. 
Alcohol 366 was pretreated with KH at -20 °C for approximately 30 minutes and then 
vinyl sulfone 328 was added. Analysis via TLC indicated rapid consumption of both 
reagents, though upon workup and purification only traces of trans-esterified product 
368 and unidentified decomposition products were obtained. We were very surprised 
by this result  given the strong literature  precedent for this  bond forming reaction, 
highlighted below (Scheme 44). 
 
 
Scheme 44: Literature precedent for nucleophilic atack of alcohol 366 into vinyl sulphone 328.
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The reaction outlined (Scheme 44) displayed unparaleled similarity with our system. 
The nucleophile (369) is a secondary alcohol as is the ribose mimic 366, furthermore 
the  vinyl sulphone electrophile 328 is somewhat less reactive than sulphone 370 by 
virtue  of the  dimethyl substituted  nitrogen versus our carbamate (328). Considering 
these comparisons, we were confident that with some optimisation we would be able 
to obtain elaborated target compound 367, conditions outlined in (Table 9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9: Screened conditions in atempting to synthesise 367. 
 
Firstly, we employed NaH and KH and increased the reaction temperature in line with 
the published procedure,
130
 (entries 1 and 2). Unfortunately under these conditions our 
substrates  were  unreactive and  no  product  was  obtained.  We rationalised that the 
reactivity  of  vinyl sulphone 328 was  unquestionable and that  our  problems  were 
stemming from the alcohol.  We therefore atempted to increase the reactivity  of the 
oxygen anion  by solvating the  potassium counterion  with  18-crown-6 and further 
increasing the reaction temperature (entry 3), again no product was detected. Our final 
atempts (entries  4 and  5) employed  phase transfer conditions
131
 and refluxing 
temperatures, to  our  dismay  product 367 was  not formed.  Reasons as to  why this 
Entry Nucleophile Base Additive Solvent Temp °C Yield
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reaction was problematic were unclear and we can only postulate that the steric bulk 
present at the α-carbon impeded the reaction. Although we have no solid proof for this 
hypothesis, a crude  observation  of Schemes 43 and 44 ofer litle  other explanation. 
We  were  disappointed  with  our failure to  obtain compound 367 and  due to time 
constraints decided we not to pursue another synthetic route.  
6.11. – Bioisosteric Replacement I: Synthesis of Phosphonate 376 
 
Incorporation  of the  phosphonate functionality into  potential and curent  drug 
candidates is  wel  documented in the literature.  Common examples include reverse 
transcriptases,  often  used in the treatment  of serious  viral infections (e.g.  Cidofovir, 
Adefovir and  Tenofovir).
132
 Phosphonates can efectively  mimic the  naturaly 
occuring  phosphate functionality  binding via a similar  manner,  however the 
phosphonate is stable to hydrolytic cleavage as the C-P bond is of superior strength.
133
 
Considering that  Ape1/Ref1 cleaves the  phosphodiester  backbone, we  hypothesised 
that incorporating a phosphonate into the scafold was a logical move. We conducted 
CADD studies  upon several amino  phosphonate sidechains  varying the length  of the 
aliphatic portion, the optimal structure is shown below (Figure 40). 
 
 
 
 
 
 
  
 
 
 
 
Figure 40: Low energy binding pose of phosphonate analogue 371. Actual docking pose (left), overlay 
with complexed DNA protein crystal 1DE9 (right). Active site residues (yelow) 
Mg
2+ 
(pink), electrostatic surface of Arg177 (yelow). 
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We  discovered that the lowest energy  pose required a  C3 amino  phosphonate that 
alowed eficient targeting  of  both the  hydrophilic cleavage and the  hydrophobic 
regions, detailed in (Figure 40). Compound 371 was our best design (-5.05 XP-glide, 
8.73 ΔG mmGBSA)  of al  modeled structures.  The low energy  binding  pose 
demonstrated fantastic π-stacking with  Phe266 and edge to face  VDW interactions 
with  Trp280.  Furthermore, these strong intermolecular interactions  provided a 
hypothesised orientation alowing potential chelation of magenesium by the C3 amino 
phosphonate (Figure 40). 
 
Syntheticaly, the C3 phosphonate sidechain 374 could be obtained in two steps from 
the commercialy available phthalimide 372, shown below (Scheme 45). 
 
 
 
 
Scheme 45: Synthesis of amino phosphonate sidechain 374. 
 
In  moving forward, a Michaelis-Arbuzov reaction in  neat triethyl  phosphite gave 
protected  phosphonate 373 in excelent  yield.
134
 Standard  deprotection  of the amine 
using  hydrazine in  EtOH
135
 gave the  pure amino  phosphonate (374),  which required 
minimal purification. The amine  was then  directly coupled to  vinyl sulphone 328, 
outlined below (Scheme 46). 
 
 
 
 
 
 
 
 
 
Scheme 46: Synthesis of phosphonate analogue 376. 
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The elaborated scafold 376 was  obtained in excelent  yield.  We first sought 
deprotection of the phosphonate esters and carbamate under the known trimethylsilyl 
iodide protocol,
136
 unfortunately a complex mixture of products was obtained. Instead, 
we employed concentrated aqueous HCl and  gratifyingly after  prolonged reflux, we 
obtained the  desired  phosphonate  product, albeit as a (4:1)  mixture  of 
demethylated/methylated core, shown above (Scheme 46). This result was acceptable 
considering our docking calculations and that al other vital functionalities were intact. 
 
Having completed the synthesis of several computationaly designed larger molecules 
and fragments targeting the  hydrophobic region, we  were  keen to  widen  our 
parameters.  We envisaged the synthesis  of some fragments targeting the  hydrophilic 
magnesium binding residues. Taking inspiration from the bioisosteric replacement of 
phosphate, we searched for other functionalities capable of performing the same role.   
 
6.12 – Bioisosteric Replacement II: Synthesis of Sulphur Hydantoin 
Fragment 377 and Carboxylic Acid 378 
 
The  majority  of compounds detailed in the literature as  potential  phosphatase 
inhibitors  generaly fal into two classes.  Commonly, compounds containing two 
carboxylate  groups are  often employed as  phosphatase inhibitors, as the two formal 
negative charges can  mimic those  upon the  phosphate functionality at  physiological 
pH.
137
 The other class incorporates the non-hydrolysable phosphonates (see Figure 42) 
or  difluoro  phosphonates. Although  both approaches  have  yielded some success, the 
curent focus  has shifted towards the  development  of  novel  more  bioavailable 
heterocycles as  phosphate isosteres. In  2004, Miknis and co-workers
137
 built  on the 
work of Groutas
138
 and demonstrated sulphur hydantoins as novel phosphate isosteres 
with improved bioavailability over their phosphorous-based counterparts.  
 
The synthesised phosphonate 376 displayed a poor solubility profile and without any 
other knowledge of Ape1/Ref1 inhibitors, the sulphur hydantoin 377 proved to be an 
interesting lead, shown  below.  Considering al  other ‘larger’  molecules  had  been 
constructed upon the vinyl sulphone scafold core, we decided that the hydantoin was 
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suited to a smaler fragment scafold. The idea was that coupling of the hydantoin to 
scafold 328 may  not  give an accurate reflection  of the functionalities eficacy.  We 
decided not to abandon the core scafold 328 altogether and instead conducted CADD 
studies  upon less complex  pyrolidine cores,  which led  us to compound 377, shown 
below (Figure 41).  
 
 
 
 
 
   
 
 
 
 
 
 
 
Figure 41: Low energy binding pose of hydantoin analogue 377. Actual docking pose (left), overlay 
with complexed DNA protein crystal 1DE9 (right). Active site residues (yelow) 
Mg
2+ 
(pink), electrostatic surface of Arg177 (yelow). 
 
The  CADD scoring functions  obtained for  hydantoin 377 were average (-3.02  XP-
glide,  36.33 ΔG  mmGBSA).  We  were  undetered  by this, as the lack  of aromatic 
functionality  was  undoubtedly responsible for these figures.  The fragment showed 
encouraging occupation  of the catalytic region and could  potentialy  pick  up 
interactions with magnesium, Asn212 and Phe266, highlighted in (Figure 41). 
 
In moving forward, we employed the literature synthesis of the hydantoin functionality 
shown  below (Scheme 47).
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 A three-step  protection  of commercialy available 
proline 378 gave ester 380 in excelent  yield.  Borohydride reduction  of the ester 
folowed  by a  Swern  oxidation  gave the  desired aldehyde 382 in excelent  yield. 
Reductive amination of the aldehyde with glycine ethyl ester gave key amine 383. The 
amine  was then converted to sulphonamide 384 upon exposure to sulphamoyl 
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chloride,  which  was  prepared folowing the  known literature  procedure.
139
 Upon 
exposure to  NaOMe the sulphonamide amine 384 underwent an intramolecular 
cyclisation to form  protected sulphur  hydantoin 385.  A final two-step  deprotection 
aforded the desired fragment 377 in 16% over ten steps.  
 
 
 
 
 
 
 
 
 
 
Scheme 47: Synthesis of sulphur hydantoin analogue 377. 
 
After exploring the sulphur  hydantoin fragment 377 as a  possible  phosphate  mimic, 
we were urged to examine the more traditional difluoro-phosphonate isostere 386 and 
for comparative purposes the difluoro carboxylic acid 387, shown below (Figure 42).  
 
 
 
 
 
Figure 42: Sulphur hydantoin analogue 377 and more traditional phosphate  
isostere targets 386 and 387. 
 
CADD studies  predictably  polarised these smal hydrophilic fragments towards the 
catalytic region,  with  both the  phosphonate and carboxylate interacting  with the 
magnesium cation, shown below (Figure 43). The low energy poses of both fragments 
gave encouraging  glidescores (-6.36  XP-glide,  25.31 ΔG mmGBSA – carboxylate 
387) and (-6.03  XP-glide,  23.01 ΔG mmGBSA – phosphonate 386). The  Gibbs 
binding energetics were again poor due to reasons outlined previously with hydantoin 
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377.  From a functional  group  perspective, the added  presence  of an alcohol in both 
compounds ofered the possibility of a H-bond to either His309 or Asp210, which may 
account for the slightly beter glidescore. The geminal di-fluoro substituent present in 
both structures seems to ofer litle in terms of binding, though their presence is vital 
for  bringing the  pKa  value  of the  phosphonate  OH closer to that  of the  natural 
phosphate substrate.
140
   
 
 
 
 
  
 
 
 
 
 
Figure 43: Low energy binding poses of carboxylic acid 387 (right) and fluoro-phosphonate 386 (left). 
Active site residues (yelow), Mg
2+ 
(pink), electrostatic surface of Arg177 (yelow). 
 
With the computational studies complete,  we set about the synthesis  of the  di-
fluorocarboxylate 387, shown below (Scheme 48). 
 
 
 
 
 
 
 
 
 
Scheme 48: Synthesis of di-fluorocarboxylate analogue 386. 
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With protected proline 378 in hand, we first sought protection of the C4 alcohol as the 
MOM ether under standard conditions, shown above (Scheme 48). The ester was then 
reduced to alcohol 389 and a  Swern  oxidation  gave aldehyde 390 in excelent  yield. 
Aldehyde 390 was then subjected to a  Reformatsky reaction  with ethyl 
bromodifluoroacetate and activated  Zn in  THF/Ether.
141
 This  key  bond forming 
reaction proceeded as described in the literature afording a diastereomeric mixture of 
β-hydroxy-esters (392) in a 3:1 ratio.
141b
 The absolute stereochemistry of the products 
was  not  unambiguously assigned  but instead infered from the application  of the 
Felkin-Ahn  models for  1,2-asymmetric induction.
142
 Furthermore  our  predictions 
aligned with the observations in a near identical literature reaction.
141b, 142b
 The major 
product (392), was discarded as CADD studies indicated that it was less desirable than 
the minor diastereomer. Moving forward, the β-hydroxy-ester 392 was first saponified 
and then the acid labile  protecting  groups were removed  upon exposure to  HCl, 
yielding the target di-fluoro acid 387, albeit in moderate yield, shown above (Scheme 
48). 
6.13. – Towards the Synthesis of Di-fluorophosphonate 386 
 
In  204,  Arnaud  Gautier and co-workers reported  on the facile synthesis  of α,α-
difluorophosphonates  mediated  by the radical addition  of phosphorous into geminal 
di-fluoroalkenes (394), synthesis shown below (Scheme 49). 
 
 
 
 
Scheme 49: Gautier’s eficient synthesis of α,α-difluorophosphonate 396.
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We were intrigued by this reaction as it gave rapid access to the desired scafold 386 
and avoided the formation  of the  previously  problematic  phosphonate ester 373. 
Furthermore, with aldehyde 390 in  hand, we could  potentialy realise  our target 
molecule in three steps.  Gautier synthesised the  geminal  difluoroalkenes from either 
the coresponding aldehyde  or  ketone  using the  procedure  outlined  by  Wheaton.
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the  Corey  Fuchs alkyne synthesis.
145
 Treatment  of  dibromodifluoromethane  with 
triphenylphosphine  generated a  difluoro  ylide that could react  with aldehydes and 
ketones, directly accessing the difluoro alkene, producing triphenylphosphine oxide as 
the  byproduct.  We therefore applied these conditions to aldehyde 390, though 
unfortunately after prolonged reaction times no alkene was formed (Scheme 50).  
 
 
 
 
 
Scheme 50: Atempted syntheses of gem-difluoroalkene 390.
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Repetition  of literature  procedures resulted were  met  with no success and it  was 
initialy thought that the volatility of the fluorocarbon might be problematic (b.p. 22-
23 °C)
146
 Rigorous application  of temperature control and cold finger traps stil 
resulted in no conversion to alkene 397. 
 
At this stage  we  decided  not to  pursue  phosphonate analogue 386.  We already  had 
obtained the larger C3 phosphonate for biological testing, and concluded that further 
eforts to access 386 were unnecessary due to time constraints. 
 
  
6.14. – Towards Targeting the North-Eastern Binding Region 
 
Having synthesised  nearly al target compounds,  only one remained.  As  previously 
highlighted, piperidine sidechain 350 was identified from a speculative CADD study. 
However, the piperidine sidechain displayed the ability to form a range of potentialy 
favourable interactions  with the  previously  untargeted  northeastern  binding cleft 
(above the active catalytic cleavage residues).  The lowest energy  binding  pose  of 
compound 399 is displayed below (Figure 44). 
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Figure 44: Low energy binding pose of north-eastern targeting analogue 399. Actual docking pose 
(left), overlay with complexed DNA protein crystal 1DE9 (right). Active site residues (yelow) 
Mg
2+ 
(pink), electrostatic surface of Arg177 (yelow). 
 
Compound 399 was designed  with a sidechain to interact  with the  protein surface 
northeast  of the catalytic  domain.  The  pose retrieved, shown above (Figure 44) 
displayed an excelent scoring function fit (-6.56  XP-glide). However the calculated 
binding energy was somewhat disappointing (39.7 ΔG mmGBSA). The magnitude of 
the later value was again a direct consequence of the ligands flexibility, though this 
was thought to  be  minimised through the incorporation  of the N,N disubstituted 
piperidine ring. The CADD studies of compound (399) showed a great deal of overlap 
with the previously discussed analogues. Inclusion of the piperidine sidechain alowed 
for the potential formation of a H-bond to Arg181 and hydrophobic overlap with the 
previously  untargeted  Trp128.  Furthermore, this  hydrophobic  homologation stil 
alowed for some anchoring  within the catalytic region through  H-bonding  between 
the sulphonamide oxygen and the residues responsible for magnesium binding. 
 
The aforementioned amine (350) was commercialy available and therefore the 
synthesis of analogue 399 was straightforward. We employed the same conditions as 
before and coupled secondary amine 350 with  vinyl sulphone 28 in excelent  yield. 
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obtained the  desired compound in excelent yield, synthesis  highlighted  below 
(Scheme 51). 
 
 
 
 
 
 
 
 
Scheme 51: Synthesis of analogue 399. 
 
Upon completion of the synthesis of compound 399 we directed our atention towards 
the  biological assessment  of al compounds  detailed  within this chapter.  Details  of 
which can be found in the next section.  
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6.15. – Biological Assessment of DNA Substrate Mimics, Alcohol 
Fragments and Bioisosteres 
 
Upon completing the synthesis of the analogues and fragments, shown below (Figure 
45), and (Graph 17) we submited them for biological assessment against our truncated 
Ape1/Ref1 protein.  
 
 
 
 
 
 
 
 
 
 
 
Figure 45: Compounds submited for biological assessment.  
 
 
 
 
 
 
 
 
 
 
 
Graph 17: Biological evaluation of hypothesised mimic structures in (Figure 45) inhibitors at 50 µM. 
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377, 387) were tested at 100 µM, and again no activity was found. We were obviously 
disappointed  with this result  having  vested time in efort in the  CADD analysis and 
synthesis.  Furthermore,  we truly  believed that this compound class represented a 
promising approach, however the biology suggested otherwise.  
 
Conclusion 
 
This chapter outlines our work towards developing a totaly novel class of Ape1/Ref1 
inhibitors. Unlike the previous work described in this thesis, we atempted to modulate 
the  proteins function through the design of drug-like  molecules that  mimicked the 
abasic DNA substrate structure. This was achieved through the synthesis of a syn-2,5-
substituted  pyrolidine core, substituted  with an aray  of  diferent functionalities 
designed to  match the electrostatic receptor environment.  Unfortunately, the 
compounds  we synthesised  were inactive (Graph 17)  which  means  we  have to 
question  our  design approach. The lack in ability  of the larger  molecules (351, 371, 
399) to  bind strongly  may  be atributed to their rotational  degrees of freedom,  but 
without further investigation, such hypotheses are hard to prove. Moreover, we were 
especialy  disappointed  with the lack  of activity shown  by analogues (329 and 336), 
whom  both  displayed fantastic  overlap  with  Arg177 in the  previously  mentioned 
docking studies.  
 
Considering  our findings in this chapter, a  whole  new  design approach  may  be 
required to access potent inhibitors of Ape1/Ref1. Unfortunately, given the size of the 
task at hand, this wil probably require a high-throughput in vitro screen. Although our 
campaign yielded litle in the way of a novel inhibitor, we were pleased to be able to 
test our hypotheses, that we believed had a solid foundation.  
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6.16. – Ape1/Ref1 – Project Conclusions 
 
Our studies towards the design and development of novel inhibitors of Ape1/Ref1 can 
be broken down into four distinct phases, each of which wil be summarised below. 
 
HTVS 
Our initial eforts  were centred around a  high-throughput  virtual screen  of  potential 
drug-like molecules against a crystal structure of Ape1/Ref1. These studies generated 
46 in silico leads of which 30 were purchased. Furthermore, an interesting compound 
class emerged in the form  of the sulphonamides (91-104),  which  were synthesised 
with relative ease. Initial  biological assessment  highlighted two lead compounds  of 
interest, both of which shared common structural features, (2,4-substituted thiazoles). 
SAR work around these leads and subsequent  biological studies indicated that the 
activity  of these compounds  was  probably  modulated through  non-specific 
aggregation.  A structural comparison against  known literature aggregator 185 and 
DLS experiments  provided some evidence to support  our claims.  At such an early 
stage we took the decision to abandon the compound class. 
 
Wilson’s Inhibitors 
We analysed the  Wilson  publication in  detail and atempted to synthesise ring 
constrained  hybrids  of  his lead compound 188. Unfortunately, although the target 
structure  was realised, removal  of the  protecting  groups lead to a compound  with a 
sub-optimal solubility  profile. In atempting to repeat  Wilson’s assay,  we found that 
his ‘hits’  were  not active  under  our conditions.  Considering this,  we contacted  Dr. 
Wilson,  who  kindly supplied  his  materials.  Through conducting a series  of cross 
biological assays we discovered that myricetin was binding in the N-terminal domain 
of the  protein and  not  within the active site, (as  previously thought  by  Wilson).  We 
relayed  our findings to the author  who  was  grateful for  our  observation.  Continued 
work on this compound class was not sought due to the nature of the inhibition mode, 
and also the broad promiscuity shown by myricetin. In retrospect, we believe that this 
was the corect decision as Dr. Wilson has recently published a new study rubbishing 
myricetin 189 and 6-OH-DL-DOPA 188. Instead, his report detailed a high-throughput 
in vitro screen  of  350000  drug-like  molecules, against  Ape1/Ref1 (using the assay’s 
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previously  discussed).
147
 Of this large compound library the authors report  one lead 
compound,  which  displayed an IC
50 
– 3.3 µM, against  Ape1/Ref1, structure shown 
(Figure 46). 
 
 
 
 
 
Figure 46: David Wilson’s latest lead compound. 
 
Considering the resources  used  within this  publication, it is  no surprise that  one 
compound  was  highlighted.  Although its activity is low  micromolar,  we believe that 
the scafold could be further developed. This publication underlined the dificulties in 
inhibiting  Ape1/Ref1, and  we suggest that ligand-protein co-crystalisation studies 
may be the key to further compound design and development. 
 
 
Neamati’s Inhibitors 
We synthesised and tested the lead structures  disclosed  within the  Neamati 
publication. Unfortunately, these compounds appeared to be inactive in our assay and 
also we found that Ape1/Ref1 was unstable in Neamati’s bufer, likely causing a false 
positive.  Atempts to share  our findings  with the author failed, and  no subsequent 
publications have been disclosed from his laboratory.   
 
 
Abasic Substrate Mimics 
We designed and highlighted a series of larger compounds that were thought to be able 
to mimic the natural abasic DNA substrate, that Ape1/Ref1 processes. The design was 
centred upon a syn-2,5-substituted pyrolidine core, aims to target Arg177 via π-cation 
binding interactions. Furthermore, we included a range of hydrophilic binding groups 
searching for ligand stabilization with the active catalytic region. Unfortunately, these 
approaches failed and al compounds synthesised  were  deemed inactive. In  moving 
forward, we believe that Ape1/Ref1 may not be an ideal drug target. The protein does 
have a smal indentation, (where abasic site processing occurs) but the local residues 
are al  very  hydrophilic and located  upon the  protein surface.  Considering this, they 
HN
S
NH
O
N
S
Compound 52 3.3 µM IC50
	   146	  
are likely to be always water exposed in vivo making them incredibly tough to target. 
Furthermore, the  protein  binds  DNA  over a  vast surface area, although  only a smal 
portion enters the active cleavage region, intermolecular stabilisation occurs through a 
huge  number  of  DNA-protein surface-surface interactions, which is  hard to combat 
with such a smal  molecule.  As  previously  mentioned,  x-ray crystalography  may 
prove to be the best future approach in targeting Ape1/Ref1. We believe using smal 
fragments as a  way to  build a  more sizeable inhibitor,  may also  provide the  best 
results. 
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SYNTHETIC STUDIES  TOWARDS  NOVEL INHIBITORS  OF 
LRH-1 
1.0. - Introduction 
 
Breast cancer is the second  most common cancer  worldwide after lung cancer  with 
many  of the later cases  being avoidable. It is also the fifth  most common cause  of 
cancer  mortality, and the leading cause  globaly  of cancer  deaths in  women.
148
 The 
global burden of breast cancer is thought to exceed al other cancers and curent trends 
indicate that the number of diagnosed cases is increasing.
149
 As with many cancers, the 
observed increase in incidence  may in  part  be  due to increased  understanding and 
detection of the disease. Globaly over 1.1 milion women are diagnosed with breast 
cancer each year, which in turn leads to over 410,000 deaths annualy.
150
 Despite such 
grim figures the  overal rate  of  breast cancer  mortality is faling in the  developing 
world. In the United States for example the five-year survival rate for localised breast 
cancer  has increased from  80% in the  1950’s to  98% today,  5 and  10  year  post 
treatment survival rates  have also risen.
151
 The  overal increase in these figures  has 
been atributed to  many factors, including increased awareness,  mobile screening 
vehicles, improvements in mammography and more eficacious drug therapies. More 
precisely the eficacy of the classical chemotherapeutics highlighted in (1.6) is being 
boosted  by the development  of targeted adjuvant therapies  particularly the anti-
estrogens.  
 
 
Estrogens & Breast Cancer  
 
The major estrogens produced by women are estrone (1), estradiol (2), and estriol (3), 
shown below (Figure 1). 
 
 
 
 
Figure 1: Chemical structure of the most common estrogens 
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Estrone and estriol are synthesised either in the liver, from estradiol, or in peripheral 
tissues, from androgens such as androstenedione.  Estradiol  on the  other  hand, is the 
major secretory product of the ovary.
68
 Broadly, estrogens are produced in the ovaries 
when they  become stimulated  by the folicle-stimulating  hormone (FSH).  Estrogens 
are steroid hormones and their expression levels have been shown to corelate with the 
development and  maintenance  of the female reproductive  organs,  metabolism,  bone 
density, cardiovascular protection and pregnancy.
68, 152
 The action of estrogens in vivo 
is  primarily  modulated  by two estrogen receptors (ERs),  ERα and  ERβ. These 
receptors are  members  of the  nuclear receptor (NR) superfamily  of ligand-activated 
transcription factors,
153
 who function to regulate the expression of estrogen-responsive 
genes upon binding estrogen.
154
   
 
The human adult mammary gland consists of a branching glandular ductal system of 
15-25 lobe structures localised in a fat  pad.  Maturation  of the  glands  occurs  most 
rapidly  during  puberty and relies  upon  high levels  of estrogen and  progesterone 
produced  by the  ovaries.  These  observations  were supported  by evidence from  gene 
knockout studies in mice, which indicated that mammary gland development was ERα 
dependant.
155
 Moreover, estrogens are  vital in  maintaining the  ducts and  promote 
dynamic changes that  occur  during the  menstrual cycle and  pregnancy.
156
 Estrogen 
clearly  plays a  positive critical role in a  variety  of  biophysical  pathways, though its 
over-expression has been corelated to the onset and proliferation of breast cancer.
157
 
 
Precisely how estrogens afect breast cancer risk is stil debated and the outcome may 
be  dependent  upon the timing and  duration  of exposure to estrogen.  Commonly, 
estrogens are considered to act either as  promoters (factors that stimulate 
proliferation/survival  of existing cancer cels)  or as initiators (factors that lead to 
carcinogenesis).
158
 Evidence that estrogens are tumour promoters is wel documented 
both experimentaly and in the clinic. The continued growth of several human breast 
cancer cel lines in vitro and in vivo was found to be estrogen dependent.
159
 Evidence 
that estrogens are responsible for carcinogenesis is  widely controversial.  The  most 
famous study  described  how estrogens could induce renal cancer in  Syrian 
hamsters.
160
 The quantitative links between initiated carcinogenesis and breast cancer 
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development in humans is curently a hotbed of research activity, and corelations are 
stil yet to be found.  
 
The relationship between breast cancer and ovarian function was first identified in the 
late  19
th
 century  when it  was  demonstrated that an  ovariectomy led to remission  of 
metastatic  breast cancers in  pre-menopausal  women.
161
 The  vast  majority  of  breast 
cancers originate in the terminal duct lobular unit, where they progress through three 
distinct  phases; initial  hyper-proliferation,  precancerous and  ultimately an invasive 
carcinoma.  Up to  80%  of al  breast cancers are characterised as invasive  ductal 
carcinomas and 5-15% as invasive lobular carcinomas.
162
 The growth of the majority 
of these primary breast cancer tumours (70-80%) is estrogen regulated. This has been 
elucidated in comparing the  ERα expression levels  between  healthy and cancerous 
breast tissue. In  healthy  mammary epithelial cels  only  15-25%  of the  population 
express  ERα.  Conversely in  breast cancer tumour cels  75% express  ERα, and at 
significantly higher levels.
163
 These findings infer an unknown destructive alteration in 
ERα function in cancerous tissue. In summation,  over-expression  of  ERα in  breast 
cancer leads to an increased local concentration  of estrogen that in turn fuels the 
growth and  proliferation  of tumourigenic  material.  As such, the  design  of anti-
estrogenic agents could  provide an adjuvant treatment for  patients  displaying  ERα 
positive breast cancers.  
	  
 
Nuclear Receptors, Structure & Mechanics 
 
Nuclear receptors (NRs) are one of the largest families of transcription factors with 48 
individual members identified in the human genome.
153
 Many become activated upon 
binding and responding to certain steroids and signaling  molecules such as thyroid 
hormones and retinoids.  Conversely  distinct subsets  of  NRs  within the extended 
superfamily exist as ‘orphan receptors’ lacking a natural endogenous ligand.
164
 
 
	  
	  
	  
	  
Figure 2: Generalised structure of nuclear receptors
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FXR is an obligate partner of the 9-cis-retinoic acid
receptor (RXR). The FXR/RXR heterodimer binds DNA
sequences composed of two inverted repeats (IR) separated
by one nucleotide, IR-1, and can be activated by ligands for
both receptors (BAs and/or 9-cis-retinoic acid). Upon ligand
binding, FXR undergoes conformational changes to release
corepressors such as NCor (nuclear co-repressor) and recruit
coactivators such as SRC-1 (steroid receptor coactivator-1),
PRMT-1 (protein arginine(R) methyl transferase-1), CARM-
1 (coactivator-associated arginine(R) methyltransferase-1),
PGC-1a(peroxisome-proliferator-receptor (PPAR)-gcoacti-
vator-1a) and DRIP-205 (vitamin-D-receptor-interacting
protein-205) (Figure 1)[12,13]. The mechanism(s) that
regulate recruitment of these coactivators by FXR ligands
and the relevance of these molecules to the regulation of
speciﬁc genes by FXR ligands is stil unknown.
FXR in BA homeostasis
Chenodeoxycholic acid (CDCA) and cholic acid (CA) are two
primary BAs that are the most potent endogenous ligands
for FXR[5–7]. BAs are synthesized from cholesterol in the
liver by a pathway consisting of a cascade of 15 reactions
[14]. The main BA biosynthetic pathway (classical or neu-
tral) is initiated by 7a-hydroxylase cytochrome P-450
Figure 1. Molecular structure of FXR(a)General structure of a nuclear receptor. A typical nuclear receptor is composed of several functional domains. The variable NH2-
terminal region (A/B) contains the ligand-independent AF-1 transactivation domain. The conserved DNA-binding domain (DBD), or region C, is responsible for the
recognition of specific DNA sequences. A variable linker region (D) connects the DBD to the conserved E region that contains the ligand-binding domain (LBD) as wel as the
dimerization surface and the ligand-dependent AF-2 within the C-terminal portion of the LBD.(b)Schematic representation of the exon–intron organization of FXRagene
and relative protein isoforms. Distinct FXRaisoforms are generated by alternative promoter usage (arrows) and splicing (linked exons). FXRa1 and FXRa3 have an insertion
of four amino acids (MYTG) in the hinge-domain region; this insertion is generated by the alternative splicing of the 12 bp at the 3
0
end of exon 5.(c)Coactivator and
corepressor complexes are involved in FXR activation and repression, respectively. In the absence of ligand, the FXR heterodimer is associated withcorepressor complexes,
which recruit histone-deacetylase activities. Deacetylation of histone tails leads to chromatin compactation and transcriptional repression. Receptor activation causes the
release of the corepressor complex and the AF-2-dependent recruitment of a coactivator complex that contains at least a p160 coactivator (such as SRC-1). These proteins
possess histone-acetyltransferase activity that alows chromatin decompactation and gene activation. Multiple protein–protein interactions exist among the FXR and other
coactivators such as PRMT-1 (protein arginine(R) methyl transferase-1) and CARM-1 (coactivator-associated arginine methyltransferase-1), which induce histone
methylation, and PGC-1a(ppar-gamma coactivator-1a) and DRIP-205 (vitamin-D-receptor-interacting protein-205).
Review
TRENDS in Molecular Medicine Vol.13 No.7 299
www.sciencedirect.com
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As shown in figure above (Figure 2)  nearly al  NRs contain two  wel-defined 
structural  domains: a  DNA  binding  domain (DBD) and a ligand-binding  domain 
(LBD). Activation functions 1 and 2 (AF-1/AF-2) are responsible for the recruitment 
of transcriptional activators.
166
 Bridging the  DBD and  LBD is the  hinge region that 
alows for flexibility in the overal macrostructure. From a drug design perspective, the 
LBD represents an intriguing target as its  general  physical  makeup consists  of an 
inherently  hydrophobic cavity sheltered  within several α-helices.
164
 Under  normal 
physiological control the complementary ligand  wil  bind to the  LBD  of the  NR 
causing an alosteric conformational shift,  which in turn activates co-factor 
recruitment and  gene expression.  Blocking such action through the  design and 
implementation of potent antagonists should facilitate a conformational change within 
the  NR that  disrupts co-factor  binding,  which  directly impacts  upon  downstream 
processes.  Such an afect could result in a total shutdown  of  gene expression and 
therefore retard the key functions of the NR, shown below (Figure 3). 
 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
 
Figure 3: Alternate conformations of NRs upon ligand binding: a. RXR b. ERα c. PPARα. (helix 12 
shown in red)
164
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the LBD causes alosteric changesthat appear
on the receptor surface at the crucial sites of
receptor-coregulator interactions. The selec-
tivity of the NRs for speciﬁc target-speciﬁc
DNA response elements is mainly encoded by
the DBDs, their DNA recognition helices, and
the paterns of homo- and heterodimerization
between NRs (12, 18). DNA response elements
ultimately localize the physiological responses
to ligands into a precise genetic program that is
both temporaly and spatialy controled.
NR LBD structures typicaly contain nearly
12αhelices that are arranged around a central
hydrophobic pocket, with helices 3, 7, and 10
providing amino acid residues that shape the
pocket (2, 19, 20). The sizes of these ligand
pockets can range from nearly zero in volume
(ﬁled with the receptor’s own hydrophobic side
chains) to larger than 1500
˚
A
3
(19). Neverthe-
less, the most interesting ﬁnding over recent
years has been that pocket shapes and sizes are
highly inducible, both in size and in receptivity
to molecules that are unrelated to endogenous
ligands. The C-terminal-most helical segment,
helix 12 (H12), is the major architectural feature
associated with AF-2 function and can undergo
dramatic shifts in position in response to the
molecule in the pocket (2, 21). Otherαhelices
in the LBDs also shift in positions in subtle but
stil meaningful ways that can impact receptor
activation.
As shown inFigure 1, the ligand can be-
have as a switch for coactivator and corepressor
binding (2). The transcriptional coactivators in-
clude more than 200 proteins at this time, with
diferent cel and tissue distributions and enor-
mously varied functions (16, 17, 22–24). The
coregulators bind to NRs typicaly using one
or more LXXLL motifs within their polypep-
tides and associate with H12 via a charge clamp
that supports this motif’s binding as a shortα
helix to the surface of the LBD. Operationaly,
an agonist can be viewed as a molecule that
enhances the interactions of LBDs with one
or more coactivator LXXLL motifs and there-
fore leads to transcriptional activation in a cel-
based assay. By contrast, antagonists position
H12 to physicaly compete with and block the
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Figure 1
(a) The 12-helical canonical fold of nuclear receptor (NR) ligand-binding
domais (LBDs) andtheconformtional changesin retinoid Xreceptor (RXR)
associated with ligand binding and ceptor activation. The unliganded
RXR-LBD changes its protein conformation, including helix 12 (H12) (shown
inred) positioning upon binding to an agonist (SR11237). The ligand-activated
receptor uses H12, as wel as additional features in H3 and H4, to promote the
binding of short helical LXXLL (where L is leucine and X is any residue)
elements from coactivator protein (shown inpurple) (21). (b) H12 geometry and
activation function-2 (AF-2) function is ligand dependent. NR agonists, such as
the natural ligand 17β-estradiol (E2) in the estrogen receptor (ER), cause a
conformation in the LBD, particularly in H12 (red), which supports the
formation of a binding surface for the helical NR-box module of the
coactivators. Antagonists such as raloxifene, through the extension group on
the C-ring of their ligand, induce alternate conformations in the LBD in which
H12 is displaced away from its agonist conformation where it normaly supports
NR-box binding. Instead, H12 moves into that site of coactivator motif, using
its own helical LXXML sequence to mimic the interactions normaly made by
the LXXLL motifs (41, 42). (c) The ligand-mediated exchange of coactivators
and corepressors on NRs. The peroxisome proliferator–activated receptorα
(PPARα) binding to coactivator versus corepressor segments can be governed
by speciﬁc ligands. Whereas agonist ligands such as GW731 recruit coactivator
NR-box elements from coactivators (SRC-1, shown inpurple) to PPARαLBD
(PDB ID 2P54), some antagonist ligands, such as GW6471, prevent the AF-2
helix (H12, shown inred) from assuming the active conformation, resulting in a
larger crevice that can accommodate a corepressor (SMRT, shown inblue)
segment with the LXXXIXXXL motif (25).
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(a) The 12-lical canonil fld ofnuclear re pto (NR) ligand-binding
domais (LBD) and thecnformatinal chages  retinoid X recepto(RX)
associated wh ligandbnding a  receptor activation. The unliganded
RXR-LBD changes its protein cnformatin, includ g helx 12 (H12)shown
inred) positioning upo bindig to a agnist(SR11237). The ligand-activated
recepto uses H12, as wel additional features in H3ad H4, topromte the
binding of short helicalLXXL (where L is lucne and Xis anyreidue)
elements from coactivator proein (shown inpurple) (21). (b) H12 geometry and
activation function-2 (AF)function is lgaddependent. NR agonists, such a
the nauralligand17β-estradiol (E2) intheestrogn ecepto (ER),cause a
cnformatin in heLBD,particully in H12 (red),whichsupport the
formatin of a binding surfacefo thhelicalNR-box module f th
coactivators. Antagoniss such a raloxifene, through the extension groupon
the C-ringof their ligand,nducealternate coformatins in theLBD in which
H12 is displaced away from its agonit c formatin whereit nomaly support
NR-box binding. Instead, H12 movesinto that site ofcoactivator moif,using
its own helicalLXXM sequenc to mimicthe nteractons normaly made by
the LXXL motifs(41, 42). (c)The ligand-mediated exchange of coactivators
and corepressors on NRs. The peroxisome prlifratr–acivated receptoα
(PPARα) binding to coacivator versuscoepressor sgments can begoverned
by speciﬁc ligands. Whereas agonitligands such a GW731 recruitcoactvator
NR-box elements from coactivators (SRC-1, showninpurple) to PPARαLBD
(PDB ID 2P54),some antagonis ligands, such a GW6471, prevent the AF-2
helix (H12,showninred) from assuing the activconformatin, resulting in a
larger crevicethat an commodate a corpressor (SMRT, showninblue)
segment with he LXXXIXXXL motif (25).
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More specificaly the  NR  LBDs  generaly consist  of  12α helices that suround the 
aforementioned  hydrophobic cavity.  The  volume  of these cavities  varies  greatly, 
ranging from 1500 Å
3 
to zero, (when the receptor’s side chains occupy them).
167
 The 
C-terminus  of the  LBD contains the  omnipresent  helix  12 (H12) and the location  of 
this helix is directly related to the function of the adjacent AF-2 region. Often when a 
ligand  binds into the  LBD it results in a  drastic shift in the  position  of  H12, either 
causing receptor activation (agonist)  or receptor inactivation (antagonist).
168
 These 
synergistic efects are a  direct result  of ligand  binding and the alosteric result is 
translated to the receptor surface,  where the crucial receptor-coregulator interactions 
occur.
169
 These  observations are  outlined in (Figure 3) where  diferential crystal 
structures of three NRs display the relative location of H12 (red) upon ligand binding. 
Such  precise  biochemical  understanding  of  NR  operation, led to the  development  of 
anti-estrogenic agents to combat breast cancer.  
	  
	  
Drugging the Estrogen Receptors ERα/ERβ 
 
Estrogen  was first identified in the  1920’s,
157, 170
 it took a further  40  years  until the 
ERα was identified and a further  35  years  until the existence  of  ERβ was 
confirmed.
171
 The  purification and subsequent cloning  of  ERα highlighted sequence 
similarities between ERα and the glucocorticoid receptor, which in turn helped define 
the  previously  mentioned  NR superfamily. It is therefore  no surprise that estrogen 
receptors  ERα and  ERβ are categorised  within the  NR family.  They are ligand-
activated transcription factors that control the expression of estrogen-responsive genes 
upon binding estrogen,
154
 and their structures are highlighted below (Figure 4). 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure 4: Structures of ERα and ERβ
163
; Percentage homology and the location of amino acid 
positions for the diferent domains are displayed. 
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promoter (70) and identiﬁed a cel type–speciﬁc
enhancer downstream of the coding region
in the cyclin D1 gene (71), which brings into
question the in vivo importance of the indirect
recruitment of ERαto these gene promoters.
Importantly, regions of ERαbinding are
frequently rich in binding sites for other tran-
scription factors. In particular, FoxA1 binding
sites are present near almost half of al ERα
binding sites. ERαbinding appears to be de-
pendent on the presence of FoxA1 at these
sites, an observation that prompted FoxA1 to
be named a “pioneer” factor (70). FoxA1 ex-
pression is strongly associated with ERαex-
pression in breast tumors (72), indicative of its
importance for estrogen-regulated BC growth.
Similar roles in coregulation of estrogen-
responsive gene expression have been proposed
for GATA-3, whose expression is also strongly
associated with ERαexpression in BC.
Estrogen binding promotes the recruitment
of ERαto gene promoters, to regulate gene
expression through the recruitment of tran-
scriptional coregulator complexes, resulting in
extensive histone modiﬁcation and chromatin
remodeling. More than 300 potential NR
coregulators have been reported to date (73).
Clear roles in mediating gene regulation are
conﬁned to a relatively smal number of these
coregulators, although the large numbers of
potential coregulators ofer a convenient, but
as yet unproven, mechanism for tissue-selective
NR function in vivo. For a few model genes, in
particular the estrogen-regulated pS2 (TFF1)
gene, mechanisms of coregulator recruitment
and associated chromatin remodeling and his-
tone modiﬁcation have been recently analyzed
in ﬁne detail, largely with the aid of ChIP assays.
These studies show that ERαand RNA poly-
merase II (PolII) are recruited and dissociate
from these gene promoters in a cyclical manner,
with a periodicity of 40–60 min, accompanied
by cyclical changes in the association and
dissociation of SWI/SNF (SWItch/Sucrose
NonFermentable) ATP-dependent chromatin
remodeling complexes, histone acetyltrans-
ferases, and histone methyltransferases. Nu-
cleosome rephasing and histone methylation
a
b c
ERα
ERβ
27% 97% 60%
AF-1
1 185 250 312 546 595
1 149 214 264 497 530
DBD LBD/AF-2
CoR CoA
Unliganded ER
CoR CoA
Estrogen-bound ER
d e
CoR CoA
Tamoxifen-bound ER
Tissue-specic gene
repression/activation
CoR CoA
TK
receptors
Estrogen/antiestrogen/ER
in endocrine-resistant
breast cancer cels
Figure 3
Estrogen receptors and mechanisms of coregulator recruitment by selective
estrogen receptor modulators (SERMs). (a) Schematic structures of human
estrogen receptors ERαand ERβare shown together with positions of the
DNA binding domains (DBDs) and ligand binding domains (LBDs). The
N-terminal region encodes transcription activation function AF-1 and the LBD
includes AF-2. The percentage homology between ERαand ERβin AF-1,
DBD, and LBD is indicated. The numbers above and below the ERαand ERβ
schematics show the amino acid positions for the diferent domains. (b–d)
Model for ER action at responsive gene promoters. The unliganded ER recruits
unproductively transcriptional coactivators (CoA) and corepressors (CoR), with
no stimulation of gene expression. The estrogen-bound receptor recruits
coactivators that facilitate gene expression, with the antiestrogen-bound ER
recruiting coactivators and corepressors in a tissue-selective manner. (e)The
relative expression and/or activities of CoA and CoR may regulate response and
resistance to antiestrogens, with their activities and ER recruitment being
inﬂuenced by phosphorylation mediated by cel surface receptor signaling.
www.annualreviews.org
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The ER LBD is the workhorse of the nuclear receptor in terms of its function in ligand 
binding, receptor  dimerisation and transcriptional activation.  The  percentage 
homology in the  LBD  between the two isoforms is  60%,  which suggests that 
preferential targeting  with  diferent ligands  may  be  possible.  Structural studies  have 
revealed how the binding of estrogen and anti-estrogenic agents to the LBD modulate 
the structural morphology of the NR.
172
 Upon binding estrogen, helices 3,4,5 and 12 
undergo a conformational change that both forms and exposes a hydrophobic groove. 
This feature is located near the protein surface and provides a signal for the sequence 
specific recognition  of transcriptional co-activators,  whose  binding alows the 
expression  of adjacent  genes.  Conversely  upon  binding an estrogen antagonist the 
conformational change  within the  LBD  positions  H12  over the co-activator  groove. 
The location of H12 therefore shields the previously exposed hydrophobic face of the 
LBD  preventing co-factor  binding and recognition, transcriptional activation and 
ultimately gene expression.  
 
Estrogen Antagonists (Anti-estrogens) 
 
The concept of estrogen antagonists dates back to the 1930’s and was realised by the 
identification of non-steroidal anti-estrogens. These early agents often displayed acute 
toxicity in the  CNS,  which limited their further  development and application.
163
 The 
development  of antagonistic agents to target the  ERs and thus  block the  unwanted 
transcription, such as in breast cancer, was paramount and it was thought they could 
provide a  powerful chemotherapeutic adjuvant.  Anti-estrogens  primarily act  by 
competing  with estrogens for the  binding to the  ER and constitute the  most  widely 
prescribed endocrine agents for the treatment and management of ER-positive breast 
cancers. The first compounds were discovered in the 1950s initialy as fertility drugs 
but their eficacy in some  breast cancer  patients soon  became the  priority for 
investigation.
173
 Significant  drug research and  development reduced the toxicity 
associated with earlier agents and led to the discovery of Tamoxifen.
174
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Tamoxifen 
 
Tamoxifen, a non-steroidal triphenylethylene anti-estrogenic agent, was first disclosed 
by TCI pharmaceuticals in the 1970’s and is stil a leading adjuvant therapy for ER-
positive  breast cancer.
175
 Tamoxifen elicits its  pharmacological efect  by  directly 
competing with estrogens in binding to the LBD of ERs, shown below (Scheme 1). 
 
 
	  
 
	  
	  
Scheme 1: Tamoxifen (4), 4-Hydroxy Tamoxifen (5), 17β-estradiol (2) and their 
associated relative ER binding afinities.
175-176
 
	  
	  
Tamoxifen itself  displays  poor afinity for the  LBD  of the  ERs.  Fortunately  upon 
administration the structure is metabolised to its phenolic counterpart, which displays 
a  much  higher afinity for the  LBD compared to  both the  parent and the natural 
estrogen (17β-estradiol 2) (Scheme 1). Such an increased afinity for the ER leads to 
eficient antagonism of the receptor and in turn blocks the normal efects of estrogen. 
Physicaly this inhibits the  growth  of  ERα-positive and estrogen sensitive breast 
cancer cels.
177
 The success of the drug is underlined by its administration to milions 
of patients and subsequent saving of approximately 0.5 milion lives. Statistical studies 
have shown that five years of constant tamoxifen treatment reduces annual recurence 
rate  by  50% and  overal  breast cancer  mortality  by  over  30%.  Notably, at  periods 
greater than five  years, the  beneficial efects appear to  diminish and are replaced  by 
detrimental side efects including, endometrial cancer,  ovarian cysts and 
thromboembolism related deaths.
178
  
	  
Although the  development  of estrogen antagonists is evidently  beneficial there are 
inherent  problems associated in targeting these receptors.  As  previously  noted the 
action of estrogen throughout the body is dependent upon the healthy functioning of 
ERs. Expression of estrogen alone does not confer a physiological response, it is the 
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estrogen  binding to the  NR that facilitates  downstream activity.  Considering this, 
although  ER inhibition efectively combats  breast cancer, the ful  body shutdown  of 
ERs is less than ideal, as shown  by  Tamoxifen’s  of target efects.  These concerns 
gave  drug  designers a sharper focus and led to the  description  of ‘selective estrogen 
receptor modulators’ SERMs
179
. 
1.1. – Selective Estrogen Receptor Modulators (SERMs) 
 
Estrogenic compounds can display a range of biological activity: 
 
• Ful agonist  
• Ful antagonist 
• Mixed agonist/antagonist  
 
SERMs  make  up the later class  of compounds that selectively target the estrogen 
receptor. The vital characteristic that distinguishes these substances from pure receptor 
agonists and antagonists is that their action appears to  difer in  various tissue types, 
thereby granting the possibility to selectively inhibit or stimulate estrogen-like activity 
as  desired.  The ideal  SERM  would show antagonistic efects in tissue  where the 
efects  of estrogen are  potentialy  dangerous, (breast, endometrium, liver) and 
agonistic activity  where estrogenic action is  beneficial (bone,  brain, cardiovascular 
system).
179
 
 
Tamoxifen is widely regarded as a SERM although this characteristic was fortuitous. 
It  displays  beneficial antagonism (in  breast cancer) and  partial agonism it skeletal 
tissue which maintains bone density.
180
 This compound also displays partial estrogenic 
activity in the  uterus and is associated  with the increased incidence  of endometrial 
hyperplasia and cancer that  presents in  patients  prescribed to long term tamoxifen 
treatment  programs.
181
 The ability  of  SERMs to act  oppositely throughout  diferent 
tissues is thought to  be  dependent  on two factors:  Firstly, the sub-celular 
concentrations of co-activator/co-repressor proteins in various cel types and secondly, 
the conformation the  protein adopts  upon ligand  binding, which  determines  how 
strongly the  drug/receptor complex can recruit co-activators/co-repressors.  These 
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factors  have  provided a  window  of  opportunity for researchers to further  design and 
exploit estrogen antagonists  with an  unprecedented level  of selectively. In  principle 
such compounds could provide the desired pharmacological efect with no side efects. 
This sentiment echoes the previously discussed ‘targeted therapies’ and could provide 
a  much improved adjuvant therapy against  breast cancer.  Unfortunately the 
biochemical mechanisms associated with estrogen action are complex and stil require 
improved  understanding to alow eficient formulation  of a ‘pure’  SERM.   The 
complexity  of the task at  hand coupled  with  observed  biological resistance to 
tamoxifen
182
 highlights the  need for the identification  of  novel targets that alow for 
greater selectivity. In the last  decade researchers  have shown that liver receptor 
homolog-1 (LRH-1) regulates the  ER expression in  breast cancer cels,  which 
potentialy provides a new therapeutic target.
182-183
 
 
1.2. – LRH-1 Structure & Function 
 
Liver receptor  homolog-1 (LRH-1) is a  monomeric  nuclear receptor.  As  with  ER it 
belongs to the nuclear receptor superfamily. It exhibits a high sequence identity with 
another subfamily  member steriodogenic factor  1 (SF-1).  More specificaly, it is 
located in a subgroup (Ftz-fl or NR5A) characterised by the presence of a 30-residue 
sequence extension (Ftz-f1 box), that is located at the C-terminus of the DBD, shown 
below (Figure 5).
184
 
 
 
 
 
 
 
Figure 5: Schematic of LRH-1 protein structure.
184
 
 
This ‘box’ alows the Ftz-f1 receptors to selectively bind their cognate DNA response 
elements as monomers that have a 5’ extension in their NR DNA-binding motif. For a 
number  of  years  LRH-1  was considered to  be an ‘orphan’  nuclear receptor  with  no 
natural ligand, however recent studies have indicated that LRH-1 binds phosphatidyl 
At least three LRH-1 isoforms derived from alternative
splicing exist in humans[8 –10,13](Figure 2). The most
abundant isoform, LRH-1[9,10], is identical to the larger
isoform LRH-1v1, except for a deletion in the A/B domain
that corresponds to exon 2. Both isoforms appear to have
similar DNA-binding and transactivation capacities[10].
The smalest isoform, hLRH-1v2[8,10], contains an addi-
tional deletion within the D and E domains, caused by
another alternative splicing event in exon 5, and cannot
activate transcription[10,13]. A dominant negative pro-
tein[1,15,16]such as this has also been described in
Xenopus(xFF1rA) and zebraﬁsh (f1B), although it repre-
sents only a minority of the LRH-1 protein speciesin vivo
[15,17]. Multiple-promoter usage has been reported for
zebraﬁsh and frog LRH-1[5,17], indicating the presence of
complex regulatory systems that control LRH-1 expression.
In adult mammals, LRH-1expression s conﬁned
principaly to tissues of endodermal origin, such as the
liver, pancreas and intestine – justifying its functional
classiﬁcation as an enterohepatic NR[1,7,9,18]. LRH-1 is
also expressed in the ovary[3,19 – 23], pre-adipocyte[24]
and, at lower levels, in the placenta[23]. In the adrenal
[18,23]and testis[3,23], LRH-1 expression seems to be
species-speciﬁc[19]. The characterization of the 5
0
regu-
latory sequences of the human[13]and mouse[14]genes
encoding LRH-1 identﬁed sveral molecularplayers that
control LRH-1 expression. Three binding sites for GATA
transcription factors and one motif that recognizes Nkx
homeodomain proteins are coserved betweenth muse
[14]and human[13]LRH-1 promoter. Functional LRH-1
and hepatocyte nuclear factor (HNF)-4a(NR2A1) response
elements (REs) have been identiﬁed inthe mouse[14]
but not in the human LRH-1 promoter[13]. By contrast,
HNF-1 and HNF-3bactivate the human but not the mouse
LRH-1 promoter [13]. Hepatic and intestinal LRH-1
transcription is also induced by bile acids (BAs) in rats
and humans[25 – 28]– an efect probably mediated by the
farnesoid X receptor (FXR; NR1H4), which is an NR whose
activity is induced by BAs. Interestingly, expression of the
gene encoding LRH-1 by BAs is not regulated in the mouse
liver[29]. Finaly, tumor necrosis factora(TNF-a) induces
hepatic LRH-1 transcription in mice and humans[26],
although the transcription factors involved have not yet
been identiﬁed.
Structure and activity of LRH-1: aspirations of a solo
career
Most NRs form either homodimers (e.g. estrogen recep-
tors) or heterodimers with the retinoid X receptora
(RXRa; NR2B1) to bind their cognate response elements,
which are present in the promoter of their target genes.
However, members of the NR5A subfamily bind DNA with
highaﬁnity s monomers o th Ftz-F1-consensus binding
site YCA AGG YCR (where Y is any pyrimidine and R is
any purine)[30]. In the NR5A subfamily, speciﬁcity of
DNA binding is di atedbyth Ftz-F1box, which is a
stretch of 26 amino acids at the C terminus of the DBD, the
halmark feature of members of the Ftz-F1 subfamily
(Fgures 1,2). Th sequence of the Ftz-F1 box is highly
conserved fromDrosophilato human, and it targets the 5
0
extension (YCA) of the Ftz-F1 consensus site speciﬁcaly.
The LBD of most NRsconsistsof twelve conserved
a-helical regions, numbered H1 – H12, which are folded
into a three-layered, antiparalel helical sandwich with a
conservedb-turn betwen H5 and H6. The LBD also
contains the ligand-binding pocket, the size of which varies
among NRs. Ligand binding induces a reversible confor-
mationalchang ht repositions H12 in the LBD,
enabling coactivator recruitment and subsequent tran-
scriptional activation. Orphan members of the Ftz-F1
subfamily are constitutively active. Attempts to identify
natural ligands to explain this constitutive activity have
Figure 2. Structure of the gene, mRNAs and protein isoforms of human liver receptor homolog-1 (hLRH-1). The hLRH-1 genomic sequence spans more than 150 kilobases
and consists of eight exons. The hLRH-1 isoform is identical to hLRH-1v1 except for a deletion in the A/B domain, due to splicing of exon 2. The hLRH-1v2 isoform contains
a deletion within the D or E domain, resulting from an alternative splicing event in exon 5, in addition to the splicing of exon 2. As shown, speciﬁc exonsencode particular
hLRH-1 protein domains.
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inositols,
185
 albeit  not in the  LBD.  This  development revealed that  LRH-1  operates 
maximaly with a bound ligand and fueled the idea that specific smal molecules may 
be able to further modulate the proteins activity.  
 
Structuraly the LRH-1 LBD is composed of two short β-strands and twelve α-helices 
aranged into a three-layer  helical composite  with  helix  2 (purple) forming an 
additional layer in the canonical fold of the LBD, shown below (Figure 6). 
 
 
 
 
 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure 6: Crystal structure (front & side) of hLRH-1 (LBD): Helix 12 (red),  
Helix 2 (purple), Helices 4/5 (yelow), pdb. code 1YOK.
186
 
	  
	  
The two representations  of the  LRH-1  LBD shown above (Figure 6),  highlight the 
most activity relevant  helices.  Helices  4/5 (yelow) form and suround the ligand-
binding pocket in the overal nuclear receptor structure. The pocket itself is vast (820 
Å),  wel  defined and fuly enveloped  by  28 amino acid residues lining its  wals.
186
 
Furthermore, the ligand  binding  pocket is  very  hydrophobic, (underlined  by the co-
crystalised location  of the  12 terminal carbon atoms in  both acyl chains  of a 
phospholipid bound to LRH-1).
185
 Helix 12 (red) is vital for the activity of the protein. 
Unlike other NRs, this activity is independent of ligand binding. LRH-1 has no natural 
ligand that  binds in  direct  proximity to  H12 and therefore  no alosteric efect is 
observed.  As such  LRH-1 and al  other  members  of the  Ftz-f1 subfamily can  be 
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considered  being constitutively active.  This remarkable feature  has  been  understood 
through the application of structural and molecular studies. The N-terminal region of 
LBD (H1-3) is conserved among the  Ftz-f1 subfamily and shares litle sequence 
overlap  with the  other  NRs.  Helix  2 (purple)  has an extended rigid structure,  which 
indirectly provides stabilisation to H12-alowing it to reside in its active conformation.   
 
1.3. – LRH-1 Expression & Breast Cancer 
 
LRH-1 is expressed predominantly in the liver, smal intestine, preadipocytes and the 
adrenal and reproductive  glands.
187
 Biochemicaly  LRH-1  plays important tissue 
specific roles in metabolism, reverse cholesterol transport and bile acid homeostasis.
184
 
In terms of breast cancer it has been shown that LRH-1 regulates the transcription of 
genes responsible for hormone synthesis.
188
   
 
In the search for  novel chemotherapeutic targets  Ali et.  al., recently confirmed and 
built upon the earlier work of Annicote et. al., in establishing a link between LRH-1 
and  breast cancer.
182-183
 LRH-1  has  been  unequivocaly  proven to  be an estrogen 
regulated  gene.  RNA interference and  over-expression studies  were employed to 
examine the role of LRH-1 in both regulating breast cancer growth and identify further 
targets  of  LRH-1 action. Importantly it  was  observed that  LRH-1 is co-expressed in 
ERα-positive breast cancer cel lines, whereas no such expression was found in ERα-
negative cel lines. Furthermore, RNAi-mediated LRH-1 knock-down inhibited breast 
cancer cel  growth,  underlining the importance  of the  NR.
183
 The application  of 
reporter assays demonstrated that this is mainly due to the regulation of ER expression 
by  LRH-1 through  direct  binding to the  ER  gene  promoter. In short, the increased 
levels of estrogen in breast cancer cels led to increased recruitment of the ERα gene 
promoter. LRH-1 present in the same tissue binds to the ERα promoter, which drives 
the expression  of  ERα.  Estrogen then  binds to  ERα alowing further  downstream 
expression  of estrogen responsive  genes and  proteins that are required for continued 
breast cancer cel  growth and reduced apoptosis.
189
 Considering this, inhibition  of 
LRH-1 (through ligand binding, destabilising H12) could potentialy slow or stop the 
expression  of  ERα meaning the efects  of estrogen cannot  be  processed.  Thus 
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inhibition  of  LRH-1 could  provide either a  powerful adjuvant ‘targeted’ therapy for 
breast cancer, or a new treatment for endocrine resistant breast cancer.  
1.4. – Smal Molecule Agonists of LRH-1  
 
Having established an insight into the many roles of LRH-1 researchers were keen to 
design smal molecules that could further probe the functions of the nuclear receptor. 
The  2005  discovery that showed  LRH-1 could  bind  phospholipids,
185
 suggested that 
the receptors could be targeted with drugs and fueled efort in the area (Figure 7).  
 
 
 
 
 
 
 
 
  
Figure 7: Whitby analogues (6-8), isoquinoline 9 and phospholipids (10-11)
190
. 
	  
In 2006 Whitby et. al., described the first smal molecule agonists of LRH-1, 6 and 7. 
These compounds are characterised  by a cis-bicyclo[3,3,0]oct-2-ene core  with 
substitution at carbons 1-3. The two lead structures are inherently hydrophobic and as 
such were able to displace the endogenous bound phospholipid within the LBD, (EC
50 
=  430  nM).
190a
 These  observations  were characterised  using a  high-throughput 
fluorescence resonance energy transfer (FRET)-based assay to  detect interactions 
between the  LBD  of  LRH-1 and a  peptide  derived co-activator.  Unfortunately the 
stability  of these compounds  was poor (t
1/2 
=  12  h in  1M  AcOH).  Subsequent  SAR 
studies based upon a co-crystal structure of compound 6, shown below (Figure 8) led 
to the development of analogue 8, (Figure 7). As this compound displayed comparable 
agonistic activity to 6 and enhanced stability in acidic  media, the authors  were also 
able to  optimise  hydrophobic  overlap  with the  binding  pocket  using the information 
gleaned from 6.
190b
 Compounds 10 and 11 have also  been  disclosed as  LRH-1 
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agonists,  where they  were shown to  modulate the level  of blood  glucose in  diabetic 
mice.
190c
 Recently an isoquinoline-based agonist (9) of the close structural relative of 
LRH-1 (SF-1) has also been disclosed.
190d
  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure 8: Compound 6 co-crystalised in the LBD of human 
LRH-1.
190b
 
	  
The aforementioned studies are of huge importance in elucidating further biochemical 
roles for LRH-1 and SF-1. They also provide encouragement that smal molecules can 
be used to modulate NR activity in vivo. 
 
We  were inspired  by the  discovery  of smal  molecule agonists  of  LRH-1.  Though 
conversely, to target the undesired role of LRH-1 and estrogen in ERα-positive breast 
cancer antagonistic ligands  were required.  To  date  no such compounds  have  been 
described in the literature and this  provided an exciting and formidable chalenge in 
the search for a potentialy novel breast cancer treatment. 
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further SAR tudies,of which9wasmost ative (IC
50
=
200 M).
41,42
At high evels (10μM),9modestlysuppressed
doxycycline (DOX) induced proliferation of H295R cel line
with litle eﬀect ontheSF-1negative SW-13 cel line. Closely
related isoquinolines aﬀected both cel lines in a similar way,
suggesting a non-SF-1 mechanism. The SAR for these series
s ms complex; fr xample, repacing th mthoxy group in9
with ethoxy gave a compound highly active against a range of
other receptors and exhibiting strong cel toxicity, suggesting
transactivation assay artifacts (promiscuous inhibition of the
reporter system).
Although5and related compounds6have proven to be
excelent biological probes for LRH-1 and SF-1, they have a
number of limitations. Most important is that they are unstable to
acid, making handling diﬃcult and raising doubts about stability
during biological application. The series also shows litle discri-
mination between LRH-1 and SF-1. The aim of this work was
thusﬁrst to develop new series of compounds that were more
stable and easily handled than series6, but with at least compar-
able binding and eﬃcacy, and second toﬁnd compounds that
were selective for LRH-1 and/or SF-1.
’COCRYSTAL STRUCTURE OF 5 WITH hLRH-1
As a basis for the design of improved analogues of5, we solved
the cocrystal structure of compound5bound to the human LRH-
1 LBD (Figures 3 and 4). Although racemic5was used, the
1S,5R-bicyclo[3.3.0]oct-2-ene enantiomer cocrystalized with
LRH-1 LDB. Compound5occupied the same binding pocket
volume as the terminal 12 carbon atoms in both acyl chains of a
phospholipid bound in LRH-1.
35b
This smaler size permited
LRH-1 to contract, narowing the gap between the N-terminal
half of helix 3 (residues 338-350, yelow in the PL-bound
structure) and theβ-turn/helix 6 region (residues 408-427, orange
in the PL-bound structure) where the phospholipid headgroup is
situated in the PLþLRH-1 structure, and completely enclose
the ligand within the binding pocket. Making no polar interac-
tions with the protein,5was a compact, hydrophobic mass
complementing the inner surface of the binding pocket. There
wasπstacking between the His390 and the aniline of5with a
centroid-centroid distance of 3.8 Å and a deviation from
coplanarity of around 10.
Figure 3.CRtrace from the phospholipid
35b
(magenta, orange, and
yelow) and5(white) bound conformations of LRH-1 were super-
imposedfor comparson. Th pocket contracts around the smaler5,
with the biggest shifts occuring for residues 338-350 in helix 3 (yelow)
and residues 408-427 in theβ-turn and helix 6 (orange), where the
phospholipid headgroup protrudes.
Figure 4.Compound5is shown in the LRH-1 ligand binding pocket.
Contactng residues are indiated, long wth the His390-aniline
distance. The surface of the pocket is shown, colored by the nearest
atom type. The region of the pocket adjacent to helix 5 and theβ-turn
contain polar residues and several trapped water molecules.
Figur5.Two-dimensional compound interaction diagram depicting
adjacent residues and theπstacking interaction with His390. The crystal
structure is available from the RCSB with access code 3PLZ and is
further described in the Experimental Section.
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1.5. – Barrett Group Resorcylates as LRH-1 Antagonists  
 
In the Baret group much focus has been dedicated to natural products containing the 
resorcylate unit. This has resulted in the total syntheses of several natural products and 
further inspired the synthesis  of smaler  novel resorcylates.  These  natural  products 
exhibit a broad pharmacological profile and therefore the group sought to build on this 
through conducting a  broad screen assessment against several  biologicaly relevant 
targets.  For instance, the resorcylate  natural  product  Zearalone  displays  binding 
afinity towards  ERα.
191
 Considering the  homology throughout the  NR family, the 
group assessed the  biological activity  of  45 resorcylates against  LRH-1  using a 
mammalian two-hybrid (M2H) assay and a luciferase dual reporter assay, (see 1.6).
192
 
From the 45 compounds tested, seven displayed dose dependent antagonistic activity 
against  LRH-1 in the  M2H assay.  Furthermore, four compounds also  displayed 
activity in the reporter assay, shown below (Figure 9).   
 
	  
	  	  	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure 9: Top 4 (red) resorcylates active in M2H and LRH-1 reporter assay, (i. Normalised  
relative to renila luciferase), (see 1.6, (i. SF-1 Luc data not shown).  
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Although seven compounds displayed dose dependent activity, we concentrated upon 
the four most potent antagonists (annotated red, Figure 9). Moreover, these inhibitors 
displayed dose dependent activity in both assays, which provided strong evidence that 
the compounds  were  disrupting the interaction  between  LRH-1 and its co-activators. 
These compounds therefore served as a start  point for a ligand  based  drug  design 
efort.  
1.6. – LRH-1 Assay Overview  
Mammalian-2-Hybrid (M2H) 
 
The  biological testing  of  our compounds  was conducted  by our colaborators at 
Imperial Colege.
193
 The two assays employed are cel-based and assess the degree to 
which ligands afect  protein-protein interactions; a schematic  of the  M2H assay is 
shown below (Figure 10). 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure 10: Mammalian 2 Hybrid (M2H) assay. PGC1-α (orange), Gal4-AD/Gal4-BD 
(activating domain/binding domain, blue). Upstream activating sequence (UAS, blue). 
	  
The mammalian two-hybrid assay alows an initial insight into a pre-defined protein-
protein interaction. We employed this assay to assess the impact of resorcylates on the 
interaction  between the  LRH-1  LBD and  PCG1-α, (a  known co-activator  of the 
protein).  The  premise for the  M2H assay is the activation  of a  downstream reporter 
gene facilitated  by the  binding  of a transcription factor  onto an adjacent  upstream 
activating sequence (UAS). In  our two-hybrid screen the  Gal4 transcription factor is 
split into its binding domain (BD) and activating domain (AD). Ultimately the BD is 
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responsible for  binding to the  UAS and the  AD is responsible for the activation  of 
transcription. Fundamentaly these domains can act co-operatively when in proximity 
to  one another and therefore are capable  of activating transcription  without  being 
physicaly  bound together. Based  on this  principle, the  BD is fused to the  LBD  of 
LRH-1 and the AD is fused to the PCG1-α co-activator. Under normal conditions the 
LRH-1  LBD should  bind  PGC1-α which  brings the  AD and  BD  within suficient 
proximity to activate transcription at the UAS. Activation of this transcription leads to 
expression  of the luciferase enzyme through the adjacent  gene.  Luciferase catalyses 
the oxidation of luciferin to oxyluciferin and emits photons during the process. Having 
luciferin  present in the celular  media provides a fluorescent  phenotype that can  be 
used to directly monitor the binding between LRH-1 and PGC1-α. We can therefore 
postulate that if a ligand  binds to  LRH-1, it causes an alosteric shift in  protein 
conformation, which disrupts the normal mechanics of the protein-protein interaction 
between LRH-1 and PGC1-α. As such the relative proximity or duration of proximity 
between  Gal4 (AD/BD) is reduced. In turn this reduces the amount  of luciferase 
expressed and lowers the  observed relative fluorescent  phenotype. The M2H assay 
therefore acts as a good initial screen to assess whether or not the ligands are binding 
in an antagonistic  manner, relative to  PGC1-α.  The second assay refines this 
measurement  by analysing if the ligands can  display antagonistic activity in the 
presence of al other LRH-1 co-activators.  
Luciferase Dual Reporter Assay 
 
Genetic reporter assays are commonly employed to assess eukaryotic gene expression. 
The ‘dual reporter’  nomenclature refers to the simultaneous expression and 
measurement  of two individual reporter enzymes,  within a single system.  Typicaly, 
the ‘experimental’ reporter is corelated  with the efect  of specific experimental 
conditions, in our case (LRH-1 co-activator binding), while the activity of the ‘control’ 
reporter  provides an internal control that serves as a  baseline  phenotypic response. 
Normalisation  between the two reporter  phenotypes  minimises experimental eror 
caused by diferences in cel survival and transfection eficiency.
192
 We employed the 
standardised Firefly ‘experimental’ and Renila ‘reporter’ luciferase enzymes to assess 
the activity  of  our inhibitors towards  LRH-1. The mechanics  of the reporter assay, 
	   164	  
shown below (Figure 11) operate with a similar mechanism and phenotypic output to 
the M2H assay.  
 
 
	  
	  
	  
	  
	  
	  
	  
Figure 11: Reporter assay, LRH-1 LBD & BD (ligand binding domain/DNA binding domain, red). 
Upstream activating sequence (UAS, blue). 
 
Unlike the M2H assay, the LRH-1 LBD is not bound to any other transcription factor; 
therefore if LRH-1 binds any of its co-factors present in the cel, binding to the UAS 
wil occur causing expression of luciferase and consequently a fluorescent phenotype. 
This  process  difers from the  M2H assay in that the  LBD  of  LRH-1  must  only bind 
PGC1-α for transcription to occur. The reporter assay therefore ofers a more robust 
assessment of the efect of ligands in a ‘whole cel’ environment. 
	  
If a ligand shows antagonistic efects in the reporter assay, then you can ascertain with 
a  good level  of confidence that ligand  binding is causing a  drastic change in  protein 
conformation that inhibits the  binding  of al transcription factors, including the  ERα 
gene promoter. It is however possible that ligands are active in the M2H assay and not 
in the reporter (mediated by smal alosteric shift) and as such results must be treated 
with care and not fuly discredited (see 3.13). 
 
Having established that resorcylates can clearly modulate some LRH-1 transcription, 
we used these structures, shown in (Figure 9) as a starting point. Unlike the Ape1/Ref1 
project, no CADD analysis was conducted upon this ligand class. A CADD approach 
was deemed too subjective at this stage, as we could not say exactly where the ligands 
were  binding in the  LBD.  Furthermore the  potential  binding site is so  vast that 
modeling such ligands  would  prove  very  dificult and subsequent results  gained in 
silico would be purely speculative. Considering this, we decided to employ a ligand- 
based approach. In the event of gaining a more potent antagonist, we envisioned that 
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x-ray crystalography could  be employed to  provide  us  with the absolute  binding 
location and thus drive more focussed CADD studies and further ligand optimisation. 
1.7. – Objectives  
 
LRH-1  was identified in  2005  by Annicote
182
 as a  key regulator  of the estrogen 
response in  breast cancer cels through its interaction  with  ERα.  Within this study 
RNAi mediated knockdown of LRH-1 in ERα-positive MCF-7 breast cancer cels led 
to stunted tumour  growth in  mice, indicating a strong corelation  between  LRH-1 
activity and  breast cancer cel  proliferation. Inspired  by these  biochemical findings 
Whitby and co-workers (see 1.4) discovered several smal molecule agonists of LRH-
1, indicating that  NR activity could  be  modulated in a  dose  dependent  manner. In 
principle a selective smal molecule antagonist of LRH-1 could be a powerful weapon 
against ERα-positive breast and endocrine resistant cancers.  
 
Prior  work in the  Baret  group identified four smal  molecule resoryclate  based 
antagonists of  LRH-1.  These  observations  were confirmed in two  paralel assays 
conducted by our colaborators at Imperial Colege. These compounds showed activity 
in the low micromolar range and therefore require a great deal of optimisation if they 
are to advance to the clinic. 
 
The focus of the project was to use the structural information provided by these initial 
hits (Figure 9) and further functionalise the resorcylate core, so as to improve eficacy 
and contribute to a colaborative structure activity relationship study. In  doing so it 
was envisaged that information regarding the  binding location and  mode could  be 
obtained, alowing the drug development process to drive forward in a more informed 
manner.  
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2.0. – Overview - Resorcylic Acid Lactones (RALs)  
 
β-Resorcylic acid lactones (RALs), (overview below - Figure 12) constitute a group of 
naturally occuring polyketides, that typicaly contain a 6-alkyl-2,4-dihydroxybenzoic 
acid (β-resorcylate  unit) fused to a large  macrocyclic lactone ring.
194
 Since the 
isolation of radicicol (13) in 1953,
195
 more than thirty naturaly occuring RALs have 
been characterised and reported. To date this natural product class exhibits a wide and 
diverse range  of  biological activity,  which  has  been atributed to  variations in 
functionality upon the macrocyclic ring.     
 
 
 
 
 
	  
	  
	  
	  
	  
	  
	  
	  
 
Figure 12: Examples of RAL natural products and synthetic analogues BHP-170 and 329. 
 
 
(S)-Zearalenone (12) for instance displays activity as an estrogen agonist
196
, radicicol 
(13) is a  potent  HSP-90 inhibitor (20  nM),
197
 LL-Z1640-2 (14) is active against the 
TAK-1  kinases (8  nM),
198
 and aigialomycin (15) shows inhibitory activity against 
cyclin dependant kinases 1 and 5 (6 µM).
199
 Over the last five years the interest within 
the Baret Group surounding the chemistry and biology of the RAL natural product 
family  has  grown substantialy.  This resulted in the  publication  of  numerous  novel 
bio-mimetic total syntheses  of  RALs  utilising a  novel intramolecular  ketene 
trapping
200
 and a late stage aromatisation sequence.
201
 The synthetic  validation  of 
these transformations coupled with the potential pharmaceutical application fueled the 
group to further explore this  natural  product class.  The total syntheses, although 
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elegant and eficient, were generaly inherently time consuming. At this point Baret 
and  Patel, sought to employ the same  methodologies to  generate resorcylate amino 
acid derivatives as a potentialy novel pharmacophoric class, details shown in (Scheme 
5).
202
    
2.1. – Biosynthesis of RALs 
 
Colie first postulated the process by which the polyketide natural product classes are 
formed in  nature at the turn  of the  20
th
 century
203
.  Although these ideas  were 
pioneering, they received litle interest, as  methods for the analysis  of  biochemical 
pathways were not yet in existence. Fortunately in the late 1940’s these methods came 
to fruition  when  Birch
204
 and  Robinson
205
 formulated the curently accepted 
polyketide synthesis model, shown below (Scheme 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2: Accepted biosynthesis of RALs. 
 
 
The authors rationalised the idea that the  biosynthesis  of the  polyketides  was 
facilitated by coenzyme A and malonyl coenzyme A. Thus, the coenzyme A esters of 
acetic acid (18) or  higher  order carboxylates  would  undergo condensation  with 
malonyl coenzyme A to generate the coresponding thiol esters of β-keto acid (21) and 
CO
2
 as the by-product. The synthesis then propagates from 21 where further Claisen-
type condensations can  occur  with  malonyl coenzyme  A, afording  both  3,5-di and 
3,5,7-triketo acids (22). Having reached such structural complexity the polyketides can 
R SCoA
O
HO
O
SCoA
O
R
O
SEnz
O O
SEnz
O
R
O
O
SEnz
OO
R
O
O
O
OH
O
OH
R
OH
HO R
OH
O
OH
HO OH
R
O
+
-CO
2
-CO
2
HO
O
SCoA
O
HO
O
SCoA
O
17 18 19 21
22
25
2324
20
20
Aldol
Claisen
aromatisation
resorcylic acid
acylphloroglucinol
	   168	  
then undergo intramolecular Aldol or Claisen condensations to generate the resorcylic 
acid 24 or acylphloroglucinol 25 compound classes.
206
 
2.2. – Aromatisation of Triketo-esters - Harris  
 
In the 1970’s Haris et. al., published studies on the aromatisation of tri-keto esters in 
acidic or basic media.
206
 The authors heavily studied the reactivity of the methyl ester 
of 7-phenyl-3,5,7-trioxoheptanoic acid 26 (Scheme 3). 
 
 
 
 
 
 
 
 
 
 
Scheme 3: Harris’ synthesis of resoryclate 29. 
 
 
Haris and co-workers found that  under  most conditions (acidic/basic) the  principle 
mode of ring closure was via an Aldol cyclisation (27). It was noted that under weakly 
basic conditions intermediate 28 persists, though treatment with acid or stronger base 
alows smooth access to resorcylate 29. These discoveries provided a novel route for 
the synthesis  of aromatics and  other related cores.  The  methodology  did  however 
sufer from limitations,  predominantly the stability  of tri-keto esters (26).  This issue 
reduced the scope for  modifications that could  be  made  prior to aromatisation and 
therefore limited the chemical diversity that could be generated. 
2.3. – Barrett’s Methodologies 
 
Inspired  by the  work  of  Haris,  Baret  postulated the  use  of  keto-dioxinone 30 as a 
masked  di-keto ester.  Where for instance, thermolysis and trapping  of the 
subsequently formed ketene 34i with an alcohol provides the desired triketo-ester 37, 
shown  below (Scheme 4).  The syntheses  of  keto-dioxinones 32 was  previously 
known,
201b, 207
 although the  yields  were  poor and  often  variable. In  2011  Baret and 
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Patel reported an improved synthesis through a  diethylzinc  mediated  Claisen type 
condensation  between  dioxinone 30 and N-acetylimidazole,  which  provided  keto-
dioxinone 32 in 65-70% yield, highlighted below (Scheme 4).
202
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4: Brief overview of recent developments within the Barret Group. 
 
Keto-dioxinone 32 formed the  backbone  of al subsequent synthetic transformations. 
As shown in (Scheme 4), treatment of 32 with 2.1 eq. of LDA led to formation of the 
dilithium enolate that  upon transmetalation  with  diethylzinc can  be acylated 
selectively at the least hindered position with acyl imidazole 35-g or a Weinreb amide. 
Atempts to  purify the transient  diketo-dioxinone 34 failed,  however it  proved to  be 
suficiently stable to further  manipulation. In a  method analogous to  Haris’,  base 
mediated cyclisation-aromatisation alowed easy access to isopropylidene  protected 
resoryclate derivatives (35). Furthermore Baret took advantage of some earlier work 
by  Hyat and  discovered that  diketo-dioxinone 34 could  undergo thermal 
decomposition to generate the acyl ketene 34i. Subsequent trapping of the acyl ketene 
with methanol gave access to the tri-keto ester 37 that could undergo an intramolecular 
Aldol cyclisation/dehydration, generating resorcylic esters of type (38).
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The success of the methodology led to the eficient synthesis of otherwise dificult to 
access molecular architecture, subsequent synthesis of multiple natural products earlier 
overviewed (Figure 12), the  discovery  of  bioactive smal  molecules and alowed for 
rapid access to tri-keto esters. 
2.4. – o-Aminoalkyl Resorcylates as Potential LRH-1 Antagonists  
 
The wealth of biological activity displayed by the resorcylate natural product class has 
previously  been  discussed, (see 1.5).  To that end,  Patel and  Baret reported the 
conversion  of simple α-amino acids into resorcylates  bearing  diferential o-1-
aminoalkyl residues such as (39).  This approach  was  designed to assess these  novel 
derivatives as a potential new pharmacophore and to further guide the development of 
bioactive resorcylate containing molecules.  The associated retrosynthetic analysis  of 
this scafold is shown below (Scheme 5).
202
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5: Retrosynthetic analysis of o-Aminoalkyl functionalised resoryclates. 
 
 
It was thought that the aromatic resorcylate 39 could be accessed from a base mediated 
intramolecular  Aldol cyclisation-aromatisation  of transient  diketo-dioxinone 40. 
Subsequent ring  opening in  methanol  would then  provide the final  deprotected 
aromatic diol 39. The diketo-dioxinone 40 could then be synthesised via C-acylation 
of  keto-dioxinone 31 from either  Weinreb amide 41 or N-acylimidazole 42.  Prior to 
this, amino acids (44-45) could  be transformed readily in  one step to the required 
activated acids (41-42).
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Patel therefore sourced a range of commercialy available amino acids and synthesised 
several  unnatural α-amino acids  of  varying chemical  makeup and complexity.  The 
general approach to access these compounds is described below (Scheme 6).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 6: General forward synthesis for the conversion of α-amino acids into bioactive resorcylates.  
 
 
Depending on the inherent reactivity of the carboxylic acid carbon in 43 or 44 the α-
amino acids  were first converted into either the coresponding  Weinreb amide 41, 
upon treatment with N,O-dimethylhydroxylammonium chloride and CDI,
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 or the N-
acylimidazole 42 via treatment  with  CDI alone.
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 The  general lack  of reactivity 
shown  by carboxylic acids 43 was atributed to the steric congestion around the 
secondary centre  present.  As shown  previously (Scheme 4) keto-dioxinone 31 was 
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species to react at the least hindered position, thus forming the transient species (45-
46).  Exposure  of these compounds to  basic conditions facilitated the expected 
cyclisation-aromatisation cascade,  where the later  generaly required longer reaction 
times (ca. ~ 24 h). Final methanolysis of the isopropylidene esters (47-48) gave access 
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to the  desired  diol resorcylates (49-50) that  were assessed against several  biological 
targets including LRH-1.  
2.5. – Initial Resorcylate Biological Evaluation 
 
The  previously  discussed lead resorcylate structures are shown  below (Figure 13). 
Notably, within the figure is barbiturate derivative 51, which was reported in 2011 by 
the  Scripps Institute as  having antagonistic activity (IC
50 
– 5 µM) against  LRH-1.
209
 
To  date, this activity  has  not  been  validated at Imperial  Colege  however  we  were 
intrigued  by the  potential  pharmacophoric  overlap  between its structure and the lead 
resorcylate analogues (Figure 13). 
 
	  
	  
	  
	  
	  
Figure 13: Lead resorcylate analogues and associated lead  
Scripps compound 51. 
	  
The inhibitory  value associated to compound 51 was recorded in an  M2H assay 
closely related to  our  own. Interestingly the authors failed to comment  on a reporter 
assay, which suggested that further verification of activity was required. The Scripps 
compound 51 was synthesised in the  Baret  Group and tested in  both the  M2H and 
reporter assays. Unfortunately under our conditions compound 51 showed no activity 
against  LRH-1 (agonistic  or antagonistic).  The reason for this  disparity is curently 
unknown and stil  under investigation, though early indications suggest sub-optimal 
solubility. Although this observation was not ideal we wanted to explore the structure 
more and  postulated that ‘hybrid’ structures  of 51 and the resorcylate series could 
perhaps  yield interesting structure activity  data and increase solubility.  We therefore 
chose BHP170,  BHP  329 and  Scripps 51 as a starting  point to  design  novel 
resorcylate hybrids. 
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3.0. – LRH-1 Results & Discussion  
	  
3.1. – General Approach 
 
 
 
 
 
 
 
 
Figure 14: Ligand based approach to “hybrid” analogues. 
 
 
With a focussed starting point we assessed the key features of Scripps compound 51 
and BHP170 that we  wished to  hybridise (Figure 14).  We  quickly  hypothesised that 
the  2,4-dihydroxy and  2,4-dicarbonyl functionalities  may  occupy the same chemical 
space  within the  NR  by  virtue  of their  physical  properties (purple).  Furthermore,  we 
envisaged substitution with six-membered cyclic substituents at ring positions C2 and 
C4 of the resorcylate core, infered from structure 51 (Figure 14). Considering this, we 
began the synthesis of the first hybrid analogue series. 
3.2. – C6-Piperidine Substituted Resorcylates 
 
Our first approach  began  with the preparation  of resorcylate analogues containing a 
piperidine ring in the  C6  position  of the  main core. It  was thought that this  would 
provide excelent  pharmacophoric  overlap in the  C6  position  between BHP-170 and 
51. Incorporation of the piperidine ring at C6 satisfied the cyclic substitution patern 
seen in 51 and also the  hybridisation  of the  C6 substituent in BHP-170 (sp2-sp3). 
However, direct incorporation  of a  piperazine ring at  C6 (51) required  novel 
resorcylate methodology or traditional multistep synthesis, which wil be described in 
the later in the folowing section. 
 
As previously noted, the key material for the biomimetic synthesis of the resorcylate 
pharmacophore was keto-dioxinone 32. Patel and Baret’s improved synthesis of this 
synthon is shown below (Scheme 7).
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Scheme 7: Improved synthesis of Keto-dioxinone 32. 
 
 
Therefore commercialy available  dioxinone 30 was first reacted  with  LiHMDS 
folowed  by treatment  of the resulting enolate  with  Et
2
Zn at -20 °C.  Subsequent 
addition of N-acetylimidazole 31 at -10 °C gave keto-dioxinone 32 in good yield. This 
procedure avoided the formation  of the  doubly acetylated  product 32-s and is also 
scalable (~25  g) with  no  depreciation in the  observed  yield
202
.  With 32 in  hand,  we 
could commence the synthesis  of  C6 substituted  piperidine resorcylates,  beginning 
with the core 55, shown below (Scheme 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 8: Synthesis of C6 piperidine core 55 and N-benzyl analogue 59 
 
Patel and Baret discovered that carboxylic acids of type (52) were best activated as 
the N-acyl imidazoles when the α-carbon is a secondary centre. Thus, N-boc protected 
carboxylic acid 52 was converted to its coresponding acyl imidazole derivative upon 
treatment  with  CDI, in  good  yield. It is  noteworthy that such acyl imidazoles are 
synthesised  prior to  use, and cannot  be  purified  by column chromatography.  The 
O O
O
O O
O
O
i. LiN(SiMe
3
)
2 
THF -20 °C; Et
2
Zn
i.
N
O
N
30
32 (67-70%)
31
O O
O
O
32-s (0%)
O
BocNBocN
52 53
CDI
0 °C - rt 2 h
84%
OH
O
N
O
N
O O
O
O
32
i. LiN
i
Pr
2 
(2.1 eq.)
THF, -78 °C
i. Et
2
Zn (2.1 eq.)
53 -78 °C 3 h
O O
O
O
54
O
BocN
OO
O
HO
NBoc
75%
55
OOH
HO
NBoc
OMe
56
Cs
2
CO
3 
MeOH
Et
3
N CH
2
Cl
2
40 °C 24 h
60 °C 12 h
70%
OO
O
MeO
NH.TFA
57
i. MeI K
2
CO
3 
Acetone, Δ 16 h
i. TFA, CH
2
Cl
2 
0 °C rt
90% "two steps"
OO
O
MeO
N
58
Benzaldehyde, 
NaBH(OAc)
3 
AcOH
THF rt 6 h
60%
OOH
OMe
MeO
N
59
Cs
2
CO
3 
MeOH
60 °C 12 h
73%
	   175	  
dilithium enolate of keto-dioxinone 32 was generated upon treatment with LDA (2.1 
eq) at low temperature and subsequently transmetalated  with  Et
2
Zn to  produce the 
organo-zinc species that reacted  with acyl imidazole 53 to  give the transient  diketo-
dioxinone 54.  This intermediate species  was  directly subjected to a  base  mediated 
cyclisation/aromatisation to  provide the isopropylidene  protected  C6  piperidine 
containing resorcylate 55, in an excelent  yield  over two steps. The core resorcylate 
was then transesterified and  deprotected  using  Cs
2
CO
3
 in  methanol to  provide target 
analogue 56 in good yield. The core (55) was then further elaborated to provide higher 
order analogues.  Methylation  of the  C4  hydroxyl and acid  mediated  deprotection  of 
the carbamate  gave 57 in two steps.  Acid catalysed reductive amination  gave the 
isopropylidene  protected N-benzyl intermediate 58 in  moderate  yield.  Final  base-
mediated methanolysis provided the required mono-methylated N-benzyl piperidine 59 
analogue for biological assessment.   
 
 
 
 
 
 
Scheme 9: Synthesis of acyl imidazole 64. 
 
Having synthesised the N-benzyl  derivative,  we  wanted to  obtain an analogue that 
contained the N-3-chlorophenyl substituent shown in 51. We therefore postulated that 
such a compound could  be accessed readily folowing a  modified synthesis  of 
analogue 59 starting from acyl imidazole 64, shown above (Scheme 9). 
 
Amino ester 60 was subjected to a paladium mediated Buchwald-Hartwig amination 
with 3-chloroiodobenzene. This provided the required arylated product 62 as a single 
regioisomer in excelent yield. This outcome was made possible by virtue of a more 
facile oxidative addition and subsequent cross coupling into the Ar-I bond over the Ar-
Cl  bond.  Saponification  of ester 62 under standard conditions led to the isolation  of 
carboxylic acid 63 that in turn was transformed into the coresponding acyl imidazole 
in good yield. 
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Scheme 10: Synthesis of the N-3-chlorophenyl analogue 67. 
 
With the crude acyl imidazole in  hand the  Claisen condensation-cyclisation-
aromatisation cascade could then  be  performed.  Carying  out this transformation 
provided isopropylidene protected resorcylate 66 in a moderate yield over two steps. 
The reduction in  yield  was thought to arise from an increased  degree  of steric 
congestion upon the activated acyl imidazole 64. The synthesis was completed using 
the aforementioned  base-mediated  methanolysis  upon 66 that  gave the  desired 
resorcylate analogue 67 in good yield.  
3.3. – N-Functionalised C6-Piperidine Substituted Resorcylates 
 
Having established a reliable protocol to access 55 in good yield we decided to move 
our atention to  hybrid analogues containing  both the  piperidine functionality and a 
sulphonamide linker,  present in BHP leads 170 and 329. We rationalised that these 
analogues should be readily accessible from amine 68 through simple N-sulponylation, 
shown below (Scheme 11). 
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The elaborated target sulphonylated products 71 and 73 were an obvious choice due to 
the presence of these exact sidechains in the aforementioned biologicaly active  BHP 
resorcylates 170 and 329. The amine 68 was accessed through  deprotection  of 
carbamate 55 using  HCl in  dioxane.  The  previous synthesis (Scheme 8)  detailed the 
use of TFA for the cleavage of this protecting group, however on scale, HCl provided 
a  much cleaner transformation and any traces  quantities  of the  HCl  were easier to 
remove than TFA. Exposure of hydrochloride salt 68 to phenyl sulphonyl chloride in 
the presence of base aforded sulphonamide 72 in relatively low yield. It was thought 
that careful control of temperature should alow for exclusive reaction at the nitrogen 
centre due to its enhanced nucleophilicity over the phenolic oxygen. Sulphonamide 72 
was indeed  obtained as the  major  product, though  unwanted sulphonylated  by-
products did diminish the overal yield. Methanolysis of 72 under standard conditions 
gave the resorcylic ester 73 in moderate yield. Synthesis of heteroaryl sulphonamide 
derivative 70 was also achieved  using the same  procedure.  The  derivative (70) was 
obtained in good yield over two steps starting from hydrochloride salt 68. During the 
synthesis  of 70 the N-sulphonylated  product  was  not isolated and instead subjected 
directly to  methanolysis.  This two-step  procedure alowed for the isolation  of the 
desired product 71 in an improved yield of 51% over two steps, compared to 21% that 
was obtained in the synthesis of 73. 
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3.4. – C6-Piperidine Substituted Resorcylates Conformational 
Restriction of BHP-170 
 
Upon re-examination  of structures  of 51 and BHP170 we thought it  prudent to 
synthesise a  piperidine-substituted resorcylate from the α-amino acid 75.  Such an 
analogue alowed for the evaluation of the afects of conformational restriction upon 
the biologicaly active analogue BHP170, the synthesis is detailed below (Scheme 12). 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 12: Rationalisation and synthesis of conformationaly restricted C6 piperidine analogue. 
 
The synthesis began again with pre-functionalisation of the electrophile for the Claisen 
condensation-cyclisation-aromatisation cascade. Firstly α-amino acid 75 was N-
sulphonylated  under classical  Schoten-Baumann conditions in  good  yield.
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resorcylate 79 in excelent yield over the two steps. Base mediated methanolysis of 79 
provided the desired deprotected resorcylic ester 80 in 72% yield. 
 
Folowing from these results  we  decided that the  C6  piperidine series should  be 
extended a litle further, to examine the impact of changing the sulphonamide linkage 
to an amide linkage. Furthermore, we wished to explore what efect homologating the 
C4  hydroxyl to the  C4  benzyl ether 84,  had  upon  biological activity.  As  previously 
demonstrated (Scheme 11) such  modifications  were readily accessed from common 
intermediate 55, shown below (Scheme 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 13: Synthesis of 4’hydroxy benzyl analogue 84 and amide linker analogue 87. 
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the desired resorcylic ester 87 in an excelent yield. This pleasing outcome alowed for 
completion of the piperidine series of analogues.  
3.5. - C6 Piperazine Analogues 
 
As  previously  discussed in section (3.1)  we  wished to create a  hybrid series  of 
analogues based upon a pharmacophoric amalgamation of Scripps compound 51 and 
BHP resorcylate esters 170 and 329.  Having  quickly synthesised the  C6  piperidine 
hybrids, we now wanted to focus upon accessing the C6 piperazine analogues.  
 
Although the resorcylate methodology developed within the Baret group is versatile, 
to date no procedure exists that alows for incorporation of amine functionality directly 
into the C6 position of the resorcylate unit. The reason for this is due to the fact that 
the Claisen condensation-cyclisation-aromatisation cascade does not proceed past the 
condensation step.  The  presence  of the amide in 88ii confers a  huge  gain in 
electropositivity to the carbonyl  group,  which reduces susceptibility to  nucleophilic 
atack by the enol present in intermediate 88-iv (Scheme 14).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 14: General mechanism of the bio-mimetic cyclisation-aromatisation  
of diketo-dioxinones into the resorcyclic unit. 
 
To  overcome this issue  we chose to explore a  more classical synthetic approach 
towards introducing the C6 piperazine moiety into resorcylic ester analogues. 
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Retrosynthetic Analysis – C6 Piperazine Resorcylates  
 
In analysing the structure  of the resorcylate core,  we thought that  C6-piperazine 
resorcylate analogues could  be accessed starting from the  union  of triflate 92 and 
amine 93 or via a coupling  of  bromide 95 with amine 96.  The  more simple 
disconnection relies on a Buchwald Hartwig amination between compounds 92 and 93 
which should  both  be readily accessible from simple starting  materials and 
transformations.  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 15: Retrosynthetic analysis of C6 piperazine containing 
resorcylic esters. 
 
 
The second retrosynthetic approach relied on a final stage lithium halogen exchange to 
instal the methyl ester in the C1 position of the resorcylic core. Prior to this an initial 
regioselective  bromination  was required to instal the  pre-requisite  bromine for the 
lithiation step.  The simplified tricyclic core 94 was thought to  be accessible  by a 
Buchwald Hartwig amination between starting aryl halide 95 and piperazine 96. 
 
 
Towards C6-Piperazine Resorcylate Analogues – Synthesis I 
 
The forward synthesis  of 91 began  with the esterification  of commercial acid 97.
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over two steps.  This constituted the required synthetic  handle for the  Buchwald-
Hartwig amination, shown below (Scheme 16).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 16: First atempted forward synthesis of 104. 
 
 
The coresponding  piperazine coupling  partner 103 was  built rapidly from 
commercialy available  mono-protected  boc-piperazine 101.  Firstly, a  Buchwald-
Hartwig amination  between 101 and aryl iodide 61 provided the N-arylated  product 
102 in excelent yield. The carbamate functionality was deprotected upon exposure to 
TFA to  providing the  desired  piperazine coupling  product as the trifluoroacetate salt 
103.  With the two coupling  partners in  hand, the  key cross coupling reaction to 
provide 104 could now be performed. Subjection of triflate 100 and piperazine 103 to 
a Buchwald-Hartwig amination reaction using a standard Pd
2
(dba)
3
/rac-BINAP system 
led to the recovery  of starting  material.  The rationale for this  disappointing  outcome 
was  based  on the  postulation that the  oxidative addition into triflate 55 was 
problematic.  This  was  due to the  observation that al triflate material was recovered 
indicating no paladium insertion and also that the aromatic is relatively electron rich. 
Considering this, we sought to increase the electron density upon the Pd
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 centre by 
employing  Buchwald’s  Pd(OAc)
2
/SPhos system.
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 Employing this  modified 
procedure also resulted in the re-isolation  of starting  materials.  This  unfavourable 
reactivity  meant that a  new approach  was required and  we  quickly  moved to 
investigate a second synthetic route. 
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Synthesis II 
 
The first step in the second synthetic approach involved another  Buchwald-Hartwig 
amination  between  previously synthesised  TFA salt 103 and the commercialy 
available 3,5-dimethoxybromobenzene. Employing the conditions outlined in the first 
synthetic atempt (Scheme 16), this time resulted in the isolation  of the  desired N-
arylated tricyclic product 105 in excelent yield (Scheme 17).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 17: Second atempted forward synthesis of 104 and analogue 106. 
 
 
Successfuly obtaining 105 prompted us to reconsider the failure of the first approach 
to synthesise 104.  The  phenyl core in 100 was rationalised as  being  more electron 
deficient than in 3,5-dimethoxybromobenzene, due to the electron withdrawing nature 
of the ortho ester functionality.  We therefore  postulated that the electronics  of 
oxidative addition favoured the former case and therefore  our  observed results  were 
contradictory.  The  observed success  meant that electronics could  not feasibly  be the 
problem and instead  we cite steric congestion as a  possible source  of reactive 
detriment. With the tri-cycle in hand we then sought to validate the aromatic methyl 
substituents as viable protecting groups due to known problems of their removal at late 
stages.
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requisite  bromine for the  penultimate lithiation/esterification reaction.  The 
bromination  worked  wel, although suprisingly the  major  product  was the  undesired 
regioisomer 107. The desired product was obtained in 31% yield, which was deemed 
satisfactory. Unfortunately the desired regioisomer 108i was contaminated with 108i 
(traces identified in 
1
H  NMR) that could  not  be separated  by recrystalisation  or 
conventional chromatographic  methodologies.  Although this  was clearly 
disappointing, we were encouraged that regioisomers 107 and 108i could be separated 
by chromatography, and therefore decided to switch the order of reaction steps to suite 
our end goal.  
 
Synthetic Approach III  
 
As suggested,  we rationalised that  our synthetic targets could  be realised through a 
simple manipulation of the previously described reaction steps, shown below (Scheme 
18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 18: Successful synthesis of precursor 112. 
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exchange reaction. Upon ful conversion to the aryl lithium species, this intermediate 
was treated  with  methylcyanoformate (Mander’s reagent) to  generate to  desired 
methyl ester in  good  yield.
215
 Furthermore, the carbamate in 111 was then removed 
upon exposure to  HCl in  dioxane, to aford  HCl salt 112 as a  base compound for 
further elaboration.  
3.6. – C6 Piperazine Resorcylates - C4-Cyclohexyl Introduction     
 
In keeping with the synthesis of hybrid analogues, obtaining bromide 110i alowed us 
to consider the introduction  of the  C4 cyclohexyl functionality  present in the lead 
Scripps compound 51. In examining the literature, it  became apparent that  Suzuki 
methodology would be the best approach, owing to the commercial availability of the 
required  boron coupling  partners.  We  were aware that such a coupling reaction  was 
chalenging,  but encouraged  by  Molander’s excelent recent  developments in the 
utility of alkyl potassium trifluoroborates in Suzuki cross-coupling reactions.
216
 These 
alowed for the eficient coupling  of sp3-sp2 centres and  otherwise relatively 
electropositive  boron containing coupling  partners.
216b
 Table 1 outlines  our  work to 
this end.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Atempted Suzuki couplings to obtain the C4 substituted cyclohexyl hybrid core. 
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We initialy employed boronic acid 113 as the coupling partner in the Suzuki reaction 
(entry  1). In employing the conditions  outlined  by  Molander  we  unfortunately 
observed no conversion to the desired product 115. Instead we obtained a mixture of 
starting  materials and the  dehalogenated reduced  products 109.  Although this  was a 
negative result  we could conclude that the  oxidative addition  was  not a factor in the 
lack  of  observed  product. Instead  we  believed that the product resulted from an 
ineficient reductive elimination step, caused either by a lack of electronegativity upon 
boron  or  by a lack  of electropositivity at  paladium.
217
 We therefore changed the 
paladium/ligand complex and increased the temperature to 100 °C (entry 2), the same 
result  was  obtained.  At this  point  we looked towards the alkyl  potassium 
trifluoroborate 114 as an alternative coupling  partner.  This substrate  not  only 
possessed a  more electron  deficient  boron atom conducive to a  more energeticaly 
favourable reductive elimination but it also was located upon an sp2 centre, alowing 
for a  more eficient sp2-sp2  Suzuki coupling.  We employed the same  paladium 
source and ligands (entries  3 and  4)  varying  only solvent and temperature. In  both 
cases after  prolonged  heating (~  48  h) the same result  was  obtained, a  mixture  of 
starting materials and the product 109. Having explored two sources of paladium and 
base we decided not to pursue a classical screen of conditions. Re-examination of the 
literature reinforced the inherent  problems  with this  disconnetion and  made a ful 
Suzuki condition screen somewhat irelevant.  We therefore turned  or atention to 
obtaining 115 via diferent means.   
 
α-Arylation of 3,9-dibromocamphor 
 
In examining the literature, we found few examples  detailing the transformation 
required to achieve the synthesis  of 115.  Vailancourt and co-workers
218
 had 
performed some closely related work in the α-arylation of bromoketone 119 (Scheme 
19). 
 
 
 
 
 
Scheme 19: Literature precedent for the alkylation of 1,3,5-trisubstituted benzene derivative 117. 
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Lithium halogen exchange of aryl bromide 117 and subsequent transmetalation with 
CuI formed cuprate 118 that, when added as a solution in DMSO to 119, alowed for 
exclusive  displacement  of  bromine at the alpha  keto-carbon in  good  yield.  We 
rationalised that this study was comparable to our system in terms of the nucleophile, 
however to ensure a successful reaction, the choice  of electrophile  was also  of 
paramount importance.  Due to the  nature  of cuprate 118,  we  decided that the first 
electrophile of choice would be 3-bromocyclohexene 121, shown below (Scheme 20). 
 
 
 
 
 
 
 
 
Scheme 20: Successful arylation of 3-bromocyclohexene. 
 
 
Aryl cuprates are classified as soft nucleophiles, therefore to ensure a high probability 
of reaction success, the complementary electrophile should be of similar character. We 
observed and rationalised that in synthesis of 120 no displacement of the primary alkyl 
halide  occured and therefore such an electrophile  was  not suitable for cuprate 118. 
The α-bromoketone however provided an increased level of reactivity, due to both the 
inherent increased electronegativity at carbon  due to the carbonyl and its relative 
chemical softness.  Considering this,  3-bromocyclohexene 121 was selected in 
preference  of α-bromocyclohexanone as the electrophile.  Moreover, this choice 
reduced the amount  of chemical  manipulations required to reach the simpler 
cyclohexyl system after the arylation step, shown below (Scheme 21). 
 
 
 
 
 
 
 
Scheme 21: Successful C4 cyclohexenylation of bromide 110i. 
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upon  quenching the reaction, any traces  of  unreacted aryl lithium  or aryl cuprate 
reacted  with a  proton from  H
2
O,  generating 109 as an inseparable impurity.  The 
reaction sequence could  however  progress, separating  out 109 at a later stage. In 
moving forward, removal  of the  double  bond in 122 was achieved  under standard 
hydrogenation conditions leading to the isolation  of 123 in excelent  yield, although 
the material was crude. Notably, the solvent system had to be modified due to the low 
solubility of 122 in protic media, synthesis shown below (Scheme 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 22: Ful synthesis of C4 substituted cyclohexyl hybrid core 126. 
 
Having symmetrical 123 in hand, mono-bromination using NBS aforded 124, which 
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yield.  The lithiation/Mander’s reagent  quench  procedure  was repeated several times 
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times and increasing concentration failed to improve the yield. Switching to the more 
reactive methyl chloroformate electrophile also caused a severe decrease in yield (ca. 
5%).  The reasons for such  poor conversion  were atributed to steric congestion.  We 
postulated that the presence of the C4 cyclohexyl caused the adjacent methyl group to 
orient  over the  C2  position, thus impeding the required acylation reaction. 
Nevertheless, with syntheticaly useful amounts of 125 in hand, the carbamate group 
was removed under acidic conditions to generate the target elaborated amine core 126. 
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The syntheses  outlined in (Schemes 18 to 22) successfuly  yielded the  desired  C6-
piperazine  HCl salt 112 and the  C6-piperazine  C4-cyclohexyl  HCl salt 126.  Both  of 
these compounds could  now  be  used as a  base to  generate several  hybrid structures 
centred upon the BHP lead compounds 170 and 329 and Scripps compound 51. 
 
3.7. – Elaboration of Core Piperazines 112 and 126 
C6-Piperazine Functionalisation  
 
For strict comparative purposes we chose to functionalise the piperazine nitrogen with 
the aromatic sulphonyl sidechains  used in the synthesis  of the  piperidine series. 
Generating such a similar series of analogues was seen as a valuable way of enabling 
accurate determination of what bond geometries and functionalities were important in 
terms of biological activity in both the Scripps compound 51 and the BHP resorcylate 
leads. To begin, we elaborated upon amine 112 (Scheme 23). 
 
 
 
 
 
 
 
 
 
 
 
Scheme 23: Elaboration of HCl salt 112. 
 
Thus, HCl salt 112 was transformed into both sulphonamide 128 upon treatment with 
benzene sulphonyl chloride and into 127 upon treatment with the heteroaryl sulphonyl 
chloride shown.  Both analogues  were  obtained in  good  yields.  Finaly, hybrid 
compound 129 was  prepared via reaction  with  3-chloroiodobenzene 61 using the  
Buchwald-Hartwig amination protocol. This led to the isolation of 127, 128 and 129 in 
77%, 65% and 73% respectively.  
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C4-Cyclohexyl, C6-Piperazine Functionalisation 
 
Cyclohexyl amine core 126 was quickly transformed into analogues (130 – 132) using 
identical  protocols analogous to those employed above in (Scheme 23), synthesis 
shown below (Scheme 24). 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 24: Elaboration of HCl salt 126. 
 
Having  prepared al  key compound scafolds  only the  deprotection  of the aromatic 
phenyl  methyl ethers remained.  We  were confident that al reactions  would  proceed 
cleanly to give the desired diols based upon the result obtained upon test substrate 105 
as shown below in (Scheme 25).  Unfortunately, treatment  of 131 with  BBr
3 
at low 
temperature led to  decomposition. In fact, analysis  of reaction aliquots via 
1
H  NMR 
indicated clean removal  of  one  methyl  group.  Atempts to  drive the reaction to 
completion through increasing the equivalents  of  BBr
3 
led to rapid  decomposition. 
Interestingly, using excess BBr
3 
(10 eq.) at the start of the reaction as opposed to an 
incremental addition throughout the course of the reaction resulted in clean conversion 
to the bis-demethylated decarboxylated product 133, in good yield (Scheme 25). 
 
 
 
 
 
 
 
 
Scheme 25: Unsuccessful deprotection of 131 leading to decarboxylated product 133. 
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This outcome however, was disappointing and we were somewhat bafled as to why 
the  demethylation reaction  was so  problematic, considering that the successful 
demethylation of 105 under identical conditions proceeded in excelent yield (Scheme 
25). Aromatic methyl esters are known to be stable to such reaction conditions and the 
only other diference was the presence of the C4-cyclohexyl moiety. We hypothesised 
that the  penta-substitution  of the  phenyl ring  may inflict a  drastic change  upon the 
electronic nature of the π-system, resulting in the observed formation of product 133. 
We therefore switched  our atention to the  demethylation  of 129 assuming a 
comparable result (Scheme 26). 
 
 
 
 
 
 
Scheme 26: Unsuccessful deprotection of analogue 129. 
 
 
Subjecting dimethyl ether 129 to identical deprotection conditions outlined previously 
(Scheme 25) resulted in  both total  decomposition  of the starting  material and the 
observed formation  of a complex  mixture  of  products.  Notably,  obtaining the 
decarboxylated analogue 133 was stil  very interesting from a  biological testing 
perspective.  At this juncture,  we  decided to screen  deprotection conditions and the 
results are disclosed below in (Table 2).  
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particularly labile groups were present. As a result of this observation we switched our 
focus to the  use  of  more forcing conditions,  using less reactive reagents that stil 
deprotect aryl ethers via the same  mechanistic  pathway, entries (6,7 and  8).  Heating 
132 in concentrated aqueous  HCl for  prolonged reaction times led to  degradation  of 
the  molecule,  ultimately cleaving the sulphonamide.  Employing AlCl
3
/EtSH  on the 
other hand resulted in no reaction, alowing for complete recovery of starting material. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
no product isolated, starting material and decomposition observed.
 
 
Table 2: Screened deprotection conditions. 
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required  where a  protecting  group switch could  be  performed  before the 
cyclohexenylation was conducted.  
 
 
 
 
 
Figure 15: Compounds submited for biological evaluation 
 
Although the  demethylated compounds  were  not accessed, it  was stil  biologicaly 
relevant to assess the activity  of some  of the synthesised intermediates; (Figure 15) 
highlights the compounds submited for biological assessment from this campaign.  
 
3.8. – Doubly Functionalised C6-Piperazines 
 
Having established a synthesis of the piperidine and piperazine containing resorcylates 
we wanted to analyse what afect if any, larger molecules had upon biological activity. 
The LBD of LRH-1, as previously discussed is vast and hydrophobic. To that end we 
saw an  opportunity to further test the  durability of the resorcylate  methodology and 
prepare  biologicaly relevant compounds. In  keeping  with the  previously synthesised 
analogues,  we  decided to synthesise a  C6-piperazine resorcylate that  was  C6 
substituted through carbon instead of nitrogen (Scheme 27). 
 
 
 
 
 
 
 
 
 
 
Scheme 27: Synthesis of imidazole 140 and unexpected side product 139. 
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The commercialy available rac-carboxylic acid 135 was N-sulphonylated  under the 
familiar  Schoten  Baumann conditions afording  product 136 in excelent  yield.  The 
carboxylic acid was then transformed into the coresponding acyl imidazole 140 upon 
treatment  with  CDI in  good  yield. It  was thought that acid 136 could also  be 
elaborated into the N-arylated ester 138,  which could then  be activated as the acyl 
imidazole for  use in the  bio-mimetic resorcylate synthesis.  The acid  was therefore 
converted to its methyl ester and the tert-butoxycarbonyl group removed under acidic 
conditions, in good overal yield over the two steps, shown above (Scheme 27). The 
amine salt  was then exposed to the  previously employed  Buchwald-Hartwig 
conditions  using 61 as the coupling  partner.  Unfortunately, the  desired  product 138 
was not obtained. Instead a major by-product was isolated in 42% yield and tentatively 
assigned as vinylogous amide 139. This was an intriguing result and we postulate that 
traces of air within the reaction may have alowed for some oxidative turnover of the 
paladium catalyst facilitating the formation  of  product 139. Work concerning the 
elucidation  of the  mechanism leading to the formation  of this  product  wil  be 
undertaken in the future. Lacking 138 we  decided to  pursue the synthesis  of 
resorcylate 143 and elaborate upon the core at a later stage, shown below (Scheme 28).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 28: Synthesis of doubly substituted piperazine 148 and Buchwald-Hartwig product 146.  
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The dilithium enolate of keto-dioxinone 32 was generated upon treatment with LDA 
(2.1 eq) at -78 °C, subsequent transmetalation  with  Et
2
Zn and reaction  with acyl 
imidazole 141 gave the transient diketo-dioxinone 142. This intermediate species was 
directly subjected to a  base-mediated cyclisation/aromatisation sequence,  which 
provided the isopropylidene  protected  disubstituted  piperazine 143 in low  yield  over 
two steps.  The reason for such a  poor  outcome  was atributed to a lack  of eficient 
cyclisation-aromatisation. Prolonged exposure of diketo-dioxinone intermediate to the 
cyclisation-aromatisation  protocol failed to increase the  yield. Increasing the 
equivalents  of triethylamine as  wel as reaction temperature also  had  no efect  on 
conversion.  Futhermore, the isolation  of 143 proved  dificult, requiring  multiple 
rounds of flash chromatography and crystalisation to remove impurities. With 143 in 
hand the carbamate was removed under acidic conditions to generate amine salt 144 in 
excelent  yield. Alkylation at  both  nitrogen and  oxygen  generated the  desired larger 
hydrophobic structure 147 and  was achieved  by treating 144 with 3-chloro-benzyl 
bromide in the presence of Cs
2
CO
3
 giving the tetra-aromatic 147 in good yield. Base 
catalysed  methanolysis  of 147 removed the isopropylidene  protecting  group,  giving 
target 148. Having sought to N-arylate 144, we exposed it to the familiar Buchwald-
Hartwig conditions, which resulted in the formation of desired product 146 in a good 
yield. In  order to complete the synthesis al that remained  was the removal  of the 
isopropylidene protecting  group.  Unfortunately,  due to time constraints this 
transformation could not be undertaken. Nonetheless, we were stil delighted that the 
final protected compound could be realised using our methodology. 
 
3.9. – Resorcylate Methodology in the Synthesis of 6-Amino  
Derivatives  
 
In  disclosing the synthesis  of the  C6 piperazine  derivatives see (3.7) it should  be 
apparent that although  high  yielding, the synthesis required  over  10 transformations 
that were both time consuming and less eficient than the C6 piperidine syntheses. We 
therefore  hoped to exploit the resorcylate  methodology to  obtain rapid  bio-mimetic 
access to  C6-amino resorcylate  derivatives.  The success  of the speculative approach 
outlined below (Scheme 29) was reliant upon the formation of ketiminium ion 151b. 
There  was literature  precedent for the  ketiminium to form  under  both  Lewis  Acidic 
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and  protic conditions,
219
 although the selectivity  of the formation in the  presence  of 
multiple ketones was questionable. After exhaustive examination of the literature we 
decided to use N-methylaniline as a starting material due to its commercial availability 
and ‘pre-protected’ amine (Scheme 29).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 29: Postulated ketiminium formation-cyclisation-aromatisation. 
 
Therefore treatment  of aniline 149 with  CDI in  THF at reflux,
220
 aforded the 
imidazole 150 that was directly reacted under the normal conditions with the dianion 
of keto-dioxinone, to give diketo-dioxinone 151 in excelent yield. Unlike the diketo-
dioxinone dervatives that are transient and not isolated, the amido-keto-dioxinone 151 
could be purified via column chromatography due to its inherent stability. With 151 in 
hand  we atempted to aford the resorcylate  product 152 via exposing it to 
electrophilic activating agents and base, shown below (Scheme 30).  
 
 
 
 
 
 
 
 
Scheme 30: Atempted keteiminium formation and subsequent cyclisation/aromatisation. 
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aromatic  product 152. In  both cases  we  noted complete consumption  of starting 
material where analyses of spectral data of crude material indicated a complex mixture 
of  products,  missing indicative  proton signals at  C3  or  C5  present in the resorcylate 
core.  With  no signs  of immediate success  using this approach, the route  was 
abandoned and we looked at instaling a carboxylic acid as a masked amine into the 
C6 position upon the resorcylate core.  
3.10 – Dube’s Lossen Rearrangement
221
 
 
In  2009,  Dube and co-workers,
221 
published an elegant  CDI  mediated  Lossen 
rearangement of aromatic and aliphatic hydroxamic acids into the coresponding tert-
butoxycarbonyl  protected amines, shown  below (Scheme 31).  Considering this,  we 
postulated that the instalation of a carboxylic acid in the C6 position could provide the 
desired amine upon application of Dube’s procedure. Furthermore, the aromatic acid 
could  be  used as a  direct source  of  novel analogues  or  manipulated into the 
coresponding 6-amino functionalised core. 
 
  
 
 
 
 
 
 
 
Scheme 31: CDI mediated Lossen rearrangement Dube et. al., 
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below in (Scheme 32). 
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The synthesis began with the conversion of 2-furancarboxylic acid to Weinreb amide 
159. Treatment  of  Weinreb amide 159 with the  dianion  of 32 produced intermediate 
160 that was cyclised and aromatised under the standard conditions in excelent yield 
over the two steps. With resorcylate 161 in hand, the C4-hydroxyl was protected via a 
standard methylation protocol, forming 162. Having protected the core, we conducted 
the  key furan cleavage step  hoping to  obtain carboxylic acid 163 via a ruthenium 
tetraoxide mediated  oxidative  degradation  of furan 162.
222
 We  performed this 
experiment several times  but  unfortunately  obtained a  mixture  of the  desired  major 
product contaminated  with the  keto-acid.  Several atempts to improve the ratio  of 
these products  or stop the  by-product forming failed.  By invoking the reaction 
mechanism we saw no possible way to improve the undesirable outcome (Scheme 32). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 32: Atempted synthesis of carboxylic acid 163. 
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Scheme 33: 2
nd
 Atempted Synthesis of carboxylic acid 170 or hydroxyamic acid 171. 
 
Furthermore, it  was found that  harsh conditions  were required to  directly synthesise 
acid 170 from isopropylidenes type, (KOH,  DMSO/H
2
O,  120 °C)
223
.  We therefore 
employed classical inorganic bases of varying strength suspended in biphasic media, 
shown below entries 1-4, (Table 3).  
 
 
 
 
 
 
 
 
 
 
 
 
a 
No product isolated, always isolated a mixture of chromatographicaly inseparable products. 
Table 3: Atempted synthesis of C6 carboxylic or hydroxamic acid. 
 
Unfortunately  under al conditions,  poor selectively in ester saponification  was 
observed. Indeed the  best conditions  were found to  be  when  LiOH in  THF/H
2
O at 
Entry Compound R
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Yield
a
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3
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room temperature  was  used.  These conditions  provided 170 with some selectivity 
though it  was clear that  double saponification  was  occuring from the  onset  of the 
reaction, (based  on  monitoring  by 
1
H  NMR).  Disappointed  by these  outcomes  we 
atempted to obtain hydroxamic acid 171 directly. We thought that the ethyl ester was 
less stericaly hindered and more electrophilic than the adjacent isopropylidene, which 
provided a  useful  window  of reactivity.  Treating 167 with  various forms  of 
hydroxylamine (entries  5-7) resulted in the isolation  of  mixtures  of 
chromatographicaly inseparable  material. In  hindsight,  we rationalised that although 
the esters should  difer in reactivity the relative  nucleophilic strength  of 
hydroxylamine (due to the alpha efect)
224
 ofset this, causing the  observed  product 
distribution. 
 
Overal, in synthesising the  methylated  piperazine  hybrids  we established a robust 
scalable synthetic route.  However, the failure to  deprotect the  methyl ethers in the 
final step of the synthetic route was disappointing. Nonetheless, we made atempts to 
access the C6-piperazine analogues using novel resorcylate chemistries. Although this 
has been unsuccessful to date it provided a foundation for further work, see (3.13).   
3.11. – C6-Piperidine, C4-Cyclohexyl Resorcylates 
 
Having  prepared some  C6-piperazine,  C4-cyclohexyl analogues  we turned our 
atention to the  C6-piperidine,  C4-cyclohexyl  derivatives.  Unlike their  piperazine 
counterparts, the C6-piperidine series we viewed to be accessible from the established 
resorcylate methodologies outlined in this chapter. We postulated that analogues could 
be accessed folowing the identical reaction cascade, requiring  only  one  minor 
modification of the keto-dioxinone starting material 32, shown below (Scheme 34). 
 
 
 
 
 
 
Scheme 34: Synthesis of cyclohexyl substituted keto-dioxinone 173. 
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Therefore, to  prepare 172,  keto-dioxinone  was treated  with  1.2 eq.  of  LDA at low 
temperature. The resulting anion was then alowed to warm to room temperature over 
1  h so as to equilibrate to the  kinetic enolate to the thermodynamic enolate. 
Transmetalation  of this reactive intermediate to the coresponding zinc enolate and 
treatment with 3-cyclohexenyl bromide resulted in the formation of the desired keto-
dioxinone 172, as the major product in modest yield (Scheme 34). This relatively poor 
yield was atributed to the formation of a complex mixture of regioisomeric products.  
 
 
 
 
 
 
 
 
 
 
Scheme 35: Synthesis of C4 cyclohexyl, C6 piperidine substituted resorcylate hybrid compound 176. 
 
With 172 in  hand, the alkene  was eficiently  hydrogenated to  give the  desired 
cyclohexyl  keto-dioxinone 173,  which  upon subjection to the condensation-
cyclisation-aromatisation cascade, led to the formation of the required product in low 
yield, shown above (Scheme 35). Atempts to improve this outcome by prolonging the 
reaction time failed to increase the  yield and instead the formation  of  more 
unidentified by-products was observed. In moving forward, we atempted to deprotect 
crude 175 under the standard base-mediated methanolysis conditions. Although proton 
and mass analysis of methyl ester 176 appeared to corelate with the desired structure, 
obtaining suficiently pure material for biological assessment proved dificult.  
 
Having synthesised a relatively complete library  of  hybrid analogues,  we submited 
them for biological testing in the M2H and reporter cel based assays and the outcomes 
of this work wil be presented in the folowing section.  
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3.12. – Biological Assessment of Resorcylate Hybrids  
 
Twelve compounds  were submited for  biological assessment in  both the  M2H and 
reporter assays, the results are summarised below, (Table 4). 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Table 4: Relative percentage activity of compounds against LRH-1. Control conditions equate to 100% 
in both assays, (100% > indicates agonistic activity), (100% < indicates antagonistic activity). Shades 
indicate favourability of interaction, red (unfavourable), blue (favourable), white (neutral). 
 
Entry ICNR ID Compound
5 85 132
7 87 70
8 88 72
9 89 80
10 90 84
11 91 87
12 92 148
1 50 59
2 68 106
3 69 67
6 86
4 84 126
Structure
129
M2H @ 25 µM Reporter @ 25 µM
88% 197%
69% 117%
41% 92%
54% 105%
57% 112%
78% 74%
84% 128%
80%
166% 190%
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3.13. – Interpretation of the Biological Results  
 
The figures  outlined (Table 4) are  quite encouraging, though it is scientificaly 
dificult to find a  useful structure activity corelation  between them and  previously 
assayed compounds.   
 
 
	  
	  
	  
	  
 
Figure 15: Most active compounds. Lead compound 126 and inactive N-sulphonylated relative 132. 
(xx/xx = M2H/Reporter) relative percentage activity. 
	  
From the twelve compounds assayed, seven showed appreciable amounts  of 
antagonistic activity in the  M2H assay, indicating that these ligands  were causing a 
disruption in the protein-co-factor interaction between LRH-1 and PCG1-α, the most 
active compounds are  highlighted above (Figure 15).  Unfortunately  of these seven 
compounds,  only two  displayed activity in the reporter assay and  more importantly 
only  one (126) showed activity close to that  displayed  by BHP170 and BHP329. 
Interestingly compound 126 is  C4-cyclohexyl substituted, analogous to the  Scripps 
compound 51. Homologation through N-sulphonylation of the piperazine to 132 sees 
this activity  plummet in the  M2H assay and switch from antagonistic to agonistic 
activity in the reporter biological test. This was a curious observation and suggests that 
tetracyclic analogue 132 induces an alosteric shift, which is analogous to the Whitby 
compounds (6 – 8), (Figure 7).  Removing the  C4-cyclohexyl, the aryl  methyl ethers 
and switching from piperazine to piperidine substitution at C6 gave compound 72 that 
displayed  good  M2H activity and  near control activity in the reporter assay.  Upon a 
crude comparison of these hits, one could reasonably speculate that given the analogue 
series, compound size confers  beter reporter assay activity and that free  hydroxyl 
groups  may  not  be important for antagonist activity in either assay,  particularly 
underlined  by analogues 126 and 51.  These results  however,  must  be analysed  with 
some trepidation and in general only analogue 126 can be treated as a true antagonist 
of LRH-1, which has an approximate EC
50 
of 25 µM (Table 4). 
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 In analysing the efect of ring constraint and position of N-sulphonylation upon lead 
compounds BHP170 and 329,  we found that the initial  hits  had a  much improved 
activity profile than our analogues (Figure 16). 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure 16: Comparison of initial leads and ring constrained 
piperidine analogues. 
	  
Having synthesised these analogues (70, 72 and 80) we found that although biological 
activity was present in the M2H assay no significant activity was seen in the reporter 
assay.  We therefore, can tentatively conclude that  LRH-1 is stil able to  bind some 
relevant transcriptional co-factors. 
	  
Moving forward, from a compound design perspective, the biological results provided 
some interesting  data as to  which  direction to  proceed.  The  LRH-1 antagonist 126 
provides a  novel  C4-substituted structure  platform that could  provide a  base for 
development of a third generation of analogues, shown below (Figure 17). 
	  
	  
	  
	  
	  
	  
	  
 
 
Figure 17: Postulated 3
rd
 generation analogues. 
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To that end, cyclohexyl scafolds F1 – F5 should  be synthesised to evaluate the 
importance  of  both the  hydroxyl  groups and  C6 substituents in the core structure. 
Furthermore, incorporation  of the cyclohexyl  moiety into the initial leads  would 
generate analogues F4 and F5.  These structures contain a combination  of the 
functionality  present in the  most active analogues to  date and therefore are  of  high 
priority.  Of course, such a combination  of structural features  may  be  detrimental to 
activity simply  due to compound size.  However  having the  knowledge  of a large 
ligand-binding pocket in the LBD of LRH-1 means that this is an acceptable avenue of 
enquiry.  
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4.0. – Conclusions  
 
In conducting this study  we  have realised the  project  objectives and laid  both a 
foundation and direction for further  development  of resorcylate analogues as  novel 
antagonists of LRH-1 for the treatment of ERα-positive breast cancer.  
 
In combining the structural features  of  Scripps compound 51 and the  Baret  group 
leads BHP170 and 329,  we  discovered a  novel  LRH-1 antagonist (126) with an 
approximate EC
50 
of 25 µM. Furthermore, we found that conformational restriction of 
analogue BHP170 led to a reduction in compound eficacy and  whole cel activity, 
(reporter). 
 
As previously mentioned, interpretation of al other biological data is a limiting factor. 
It is hard to draw absolute conclusions from such a smal compound library and further 
synthesis should alow for a sharper refinement of structure activity relationships. We 
have also developed the resorcylate methodology a litle further, and gained access to 
compounds previously not synthesised within the group. Importantly, the synthesis of 
cyclohexyl  keto-dioxinone 173 could  provide rapid access to a series  of  biologicaly 
relevant analogues.  Access to the  piperazine analogues  was achieved  by classical 
means, though the free hydroxyl analogues are yet to be realised.  
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5.0. – Future Work 
 
To achieve the ultimate goal of obtaining a potent antagonist of LRH-1 we require the 
synthesis  of  numerous analogues.  The  project is curently in its infancy and through 
classical cycles  of synthesis,  biological evaluation  we  hope a clinicaly suitable 
candidate wil be discovered. The major limiting factor curently lies in the ambiguity 
surounding the absolute location of our antagonists with the macromolecular LBD of 
the  protein.  Future  work  must therefore focus  on  obtaining an  X-ray co-crystal 
structure  of the  protein and  bound ligand.  Only  when the ‘antagonistic location’ is 
defined three-dimensionaly can  we  pro-actively access compounds  with  desired 
clinical  potency.  This idea stems from the  perceived size  of the ligand-binding site 
within the  LBD. We stil  know litle about  which functionalities (red  Figure 18) are 
best suited to  which location  upon the resorcylic core, and  hence can suggest 
continued compound  development  based around F-6, shown  below (Figure 18). In 
principle,  we could synthesise a vast  number  of analogues  with far  greater size to 
utilise  presently  unknown  molecular space  within the three-dimensional structure  of 
the protein. 
 
 
 
 
 
 
Figure 18: Generic overview of future compound development, important functionality (blue), 
functionality to be explored (red).  
 
In closer relation to the work discussed in this chapter, the synthesis of the analogues 
outlined in (3.13 – Figure 17) is  of  paramount importance and the synthetic routes 
have  been  principaly identified, (see 3.6). In summation,  overal comparison  of  our 
results with Baret group coleagues and colaborators should add another dimension 
to the  project  development.  At  present,  we are just  beginning to  discover interesting 
features  of the resorcylate core and the relative substituents important for  biological 
activity (blue - Figure 17).  Continued inteligent synthesis and comparison should 
hopefuly provide us with a series of compounds to efectively target LRH-1 in vivo.  
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Our failed atempts to access the  C6  piperazines via a  modified  bio-mimetic  Baret 
approach forced us to postulate another future approach (Figures 19 – 20) below.  
 
 
 
 
 
 
 
 
 
Figure 19: Hsung’s Bronsted Acid-catalysed arene-ynamide cyclisation.
225
 
 
Richard  Hsung and co-workers recently  developed an eficient  keteniminium  Pictet-
Spengler cyclisation during the total syntheses of (±)-Desbromoarborescidines A and 
C, key mechanism found above (Figure 19). The authors eficiently demonstrated that 
a range  of  mild  Bronsted acids could afect the intramolecular cyclisation  of the 
aromatic ring onto the ynamide tether, (activated as keteniminium 177b). Considering 
this observation, we postulate a synthesis of C6 amino resorcylate 185 from ynamide 
181, (Figure 20). 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure 20: Proposed ‘direct’ synthesis of C6-amino resorcylates. 
	  
We envisage that  keto-dioxinone 181 might cyclise and aromatise in a  manner 
analogous to the syntheses  outlined  within this chapter.  Therefore,  Bronsted acid 
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activation  of the  ynamide 181 could constitute the  key reaction in alowing for the 
synthesis  of  C6 amino resorcylates in a seven-step sequence starting from 
commercialy available alkyne 178. Furthermore, this would be an improvement upon 
the  disclosed ten-step sequence, and also the  general compound scafold 185 is a 
useful analogue of lead compound BHP170.  
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EXPERIMENTAL  
	  
General Experimental Procedures 
 
 
Melting  points  were recorded  on a  Reichert-Thermovar  melting  point apparatus and 
are uncorected. Infrared spectra were recorded on a Unicam FTIR spectrometer with 
automated  background subtraction.  Reported absorptions are strong  or  medium 
strength unless stated otherwise and given in wavenumbers (cm-1). 
 
1
H NMR spectra were recorded on a Bruker DRX-400 spectrometer operating at 400 
MHz. 
13
C NMR spectra were recorded on a Bruker DRX-400 spectrometer operating 
at  100  MHz.  Chemical shifts (δ) are  quoted in  units  of  parts  per milion (ppm) 
downfield from tetramethylsilane and are referenced against a residual solvent  peak, 
CDCl3 (δH: 7.28, δC: 77.0), MeOD- d6 (δH: 3.31, δC: 49.0), THF-d8 (δH: 3.62, δC: 40.0), 
DMF-d6 (δH: 2.50, δC: 40.0), DMSO-d6 (δH: 2.50, δC: 40.0). Coupling constants (J) are 
quoted in Hertz (Hz) to the nearest 0.5 Hz. Spectra recorded at 400 (1H NMR) and 100 
(13C NMR) were caried out by the Imperial Colege London Department of Chemistry 
NMR  Service.  Low and  high resolution  mass spectrometry (EI,  CI,  FAB)  were 
recorded  by the Imperial  Colege  London  Department  of  Chemistry  Mass 
Spectrometry  Service  using a  Micromass  Platform I and  Micromass  AutoSpec-Q 
spectrometer. Elemental analysis was determined by the University of North London 
Analytical Service. 
 
Manipulations  of air  or  moisture sensitive  materials  were caried  out in  oven  dried 
glassware under an inert atmosphere of nitrogen or argon. Syringes, which were used 
to transfer reagents and solvents,  were  purged  with  nitrogen  or argon  prior to  use. 
Reaction solvents  were  distiled from  CaH
2
 (dichloromethane, toluene),  Na/Ph
2
CO 
(tetrahydrofuran,  diethyl ether)  or  obtained as  dry  or anhydrous from  Aldrich 
Chemical  Company (N,N-dimethylformamide, triethylamine, acetonitrile)  or  BDH 
(ethanol).  Other solvents and al reagents  were  obtained from commercial suppliers 
(Fluka; Aldrich Chemical Company; Lancaster Chemicals; ACBR) and were used as 
obtained if  purity  was  >98  %.  Al flash column chromatography  was caried  out  on 
Aldrich silica  gel  60,  particle size  0.040 – 0.063  mm  unless  otherwise stated.  Thin 
layer chromatography (TLC) was performed on pre-coated aluminium backed or glass 
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backed plates (Merck Kieselgel 60 F254), and visualised with ultraviolet light (366 nm 
and 254 nm) or potassium permanganate (KMnO4), vanilin or phosphomolybdic acid 
(PMA) stains as deemed appropriate. Note: Synthetic literature references corelate to 
experimental citations provided after bulk bibliographic references. 
 
 
Sodium-4-(benzyloxy)benzene sulphonate (82) 
	  
	  
	  
	  
4-hydroxybenzenesulfonic acid sodium salt (5.88  g,  30  mmol) and  benzyl  bromide 
(5.13 g, 30 mmol) were suspended in EtOH (35 mL) and stired at room temperature. 
Sodium  hydroxide (1.2  g,  30.0  mmol) in  H
2
O (30  mL)  was added and the  mixture 
heated at 100 °C for 18 h. The solution was alowed to cool to ambient temperature, 
alowing precipitation of a white crystaline solid. The solid was colected and washed 
with ice cold EtOH (2 x 10 mL) to aford the product as a white crystaline solid, (6.80 
g  78%);  Mp (EtOH);  295-297 °C; δ
H
 (400 MHz, d
6
 DMSO):  7.55 (d, J =  8.0,  2H), 
7.46-7.31 (m,  5H),  6.95 (d, J  = 8.1,  2H),  5.12 (s,  2H); δ
C 
(100 MHz, d
6
 DMSO): 
153.3,  140.9,  136.9,  128.4,  127.8, 127.6,  127.1, 116.3,  113.7,  70.1; m/z [EI
+
] found, 
286.0116 [M
+
], C
13
H
11
NaO
4
S requires, 286.0276; IR (neat) νmax; 3061 (br),  1595, 
1497, 1180, 857, 621; 
 
 
4-Benzyloxybenzenesulphonyl chloride (83) 
 
 
 
 
Thionyl chloride (1.77 g, 15.0 mmol) was added dropwise to a stired suspension of 
sodium salt (3.30 g, 11.5 mmol) in DMF (30 mL) at room temperature. The reaction 
mixture was stired for 5 min, poured onto ice, stired for a further 5 min alowing a 
precipitate to form.  The solids  were colected,  dissolved in  CH
2
Cl
2
 (25  mL) and 
washed with H
2
O (2 x 15 mL), brine, dried (MgSO
4
) and rotary evaporated to give the 
SO
3
Na
OBn
SO
2
Cl
OBn
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desired product as a white crystaline powder, (3.05 g 94%); Mp (EtOH); 101-103 °C; 
δ
H
 (400 MHz, CDCl
3
) 7.98 (d, J = 9.0, 2H), 7.48-7.43 (m, 5H), 7.13 (d, J = 9.1, 2H), 
5.19 (s,  2H); δ
C 
(100 MHz,  CDCl
3
);  164.0,  136.3,  135.3,  129.6,  128.9,  128.7,  127.5, 
115.6,  70.6; m/z [EI
+
] found,  282.0116 [M
+
], C
13
H
11
ClO
2
S requires,  282.0117; IR 
(neat) νmax; 3534, 1572, 1491, 1159, 698; 
 
 
4-Benzyloxy-N-(phenyl)benzenesulphonamide (84) 
 
 
 
 
Sulphonyl chloride 83 (1.00  g,  3.50  mmol) and aniline (318 µL, 3.50  mmol)  were 
dissolved in CH
2
Cl
2
 (25 mL). Pyridine (1.41 mL, 17.5 mmol) was added dropwise and 
the ensuing  mixture  was stired at room temperature for  18  h.  The reaction  mixture 
was  diluted  with  CH
2
Cl
2
 (25  mL) and  washed  with  1  M aqueous  HCl (15  mL), 
saturated aqueous  NaHCO
3
 (15  mL), and  brine (15  mL), the  organic  phase  was 
separated, dried (MgSO
4
) and rotary evaporated to give the desired product as crude 
white solid.  Recrystalisation from  EtOH  gave the  desired compound as a  white 
crystaline solid solid, (1.18  g  99%);  Mp (EtOH);  85-87 °C;  Rf (EtOAc/Petrol  1/1); 
0.58; δ
H
 (400 MHz, CDCl
3
); 7.74 (d, J = 8.9, 1H), 7.41-7.34 (m, 6H), 7.28-7.22 (m, 
2H),  7.11-7.09 (m,  3H),  6.97 (d, J = 8.9,  2H),  5.07 (s,  2H); δ
C 
(100 MHz,  CDCl
3
); 
162.2,  136.8,  135.8,  130.9,  129.4,  129.3,  128.7,  128.4,  127.5,  125.2,  121.5,  115.0, 
70.3,  50.8;  m/z [TOF  MS  ES
+
]
 
found 340.1006 [M  +  H]
+
, C
19
H
18
NO
3
S requires, 
340.1007; IR (neat) νmax; 3209, 1592, 1578, 1466, 1247, 1148, 1095, 923, 748, 692; 
 
 
 
 
 
 
 
 
HN
S
OBn
O
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4-Hydroxy-N-(phenyl)benzenesulphonamide (85) 
 
 
 
 
Sulphonamide 84 (850 mg, 2.50 mmol) was dissolved in EtOH (15 mL), and Raney 
nickel 50 % w/v (2 mL) was added. The reaction was stired under an atmosphere of 
hydrogen for  16  h.  The flask  was then  purged  with  nitrogen, the contents filtered 
through a plug of celite, rotary evaporated, and chromatographed (Petrol:EtOAc 1/1) 
to give the desired product as a white solid, (570 mg, 91%); Mp (EtOH); 122-124 °C; 
Rf (Hexanes/EtOAc, 1/1); 0.30; δ
H
 (400 MHz, d
4
 MeOH); 7.59 (d, J = 8.8, 2H), 7.20 
(m, 2H), 7.06 (m, 3H), 6.80 (d, J = 8.8, 2H); δ
C 
(100 MHz, d
4
 MeOH); 161.5, 137.8, 
129.6,  129.1,  128.6,  124.2,  120.9,  114.9; m/z [TOF  MS  ES
+
]
 
found 272.0357 [M  + 
Na]
+
, C
12
H
11
NNaO
3
S requires 272.0357; IR (neat) νmax; 3376 (br), 3266, 1582, 1496, 
1326, 1279, 1142, 1090, 920, 837, 698; 
 
 
Ethyl 2-phenoxyacetate (89) 
 
 
 
 
Phenol (12.0  g,  128.0  mmol), and ethyl  bromoacetate (21.29  g,  128.0  mmol) were 
combined with acetone (150 mL). K
2
CO
3
 (17.62 g, 128.0 mmol), was added and the 
mixture  heated at 60 °C for  16  h. The reaction  was evaporated to  dryness and the 
residue directly chromatographed (Petrol:EtOAc 4/1) to give the desired product as a 
light  yelow  oil, (20.0  g,  87%);  Rf (Petrol/EtOAc 4/1);  0.62; δ
H
 (400 MHz, CDCl
3
); 
7.26 (dd, J = 7.5, 1.1, 2H), 6.95 (t, J = 7.4, 1H), 6.89 (dd, J = 7.9, 1.1, 2H), 4.56 (s, 
2H), 4.22 (q, J = 7.1, 2H), 1.24 (t, J = 7.1, 3H); δ
C 
(100 MHz, CDCl
3
); 168.9, 157.8, 
129.6,  121.7,  114.7,  65.4,  61.3,  14.2; m/z [CI
+
] found  198.1128 [M  +  NH
4
]
+
, 
C
10
H
16
NO
3
 requires  198.1130;
 
IR (neat) νmax; 1756,  1733,  1599,  1494,  1190,  1086, 
752, 690; 
 
HN
S
OH
O
O
O
CO
2
Et
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Ethyl 2-(4-(chlorosulfonyl)phenoxy)acetate (90) 
 
 
 
 
 
Ethyl  2-phenoxyacetate (10.0  g,  56.0  mmol)  was  dissolved in  CH
2
Cl
2
 (100  ml) and 
cooled to  0 °C.  Chlorosulphonic acid (11.08  mL,  167.0  mmol),  was added  dropwise 
and the reaction  mixture  was alowed to  warm to room temperature  over  3  h.  The 
resultant  mixture  was  poured  onto an ice/ H
2
O slury (50  mL), saturated aqueous 
NaHCO
3
 (100 mL) was added and the product extracted with Et
2
O (3 x 90 ml). The 
combined organic extracts were washed with brine (2 x 50 mL), dried (MgSO
4
) and 
rotary evaporated, give the desired product as a white crystaline solid, (9.75 g, 60%); 
Mp (EtOH); 31-34 °C; Rf (Hexanes/EtOAc, 4/1); 0.46; δ
H
 (400 MHz, CDCl
3
); 7.92 (d, 
J = 9.0, 2H), 7.03 (d, J = 9.1, 2H), 4.72 (s, 2H), 4.24 (q, J = 7.1, 2H), 1.27 (t, J = 7.1, 
3H); δ
C 
(100  MHz,  CDCl
3
); 167.6,  162.9,  136.9,  129.6,  115.4,  65.3,  61.9,  14.1 IR 
(neat) νmax; 2990, 1741, 1592, 1579, 1491, 1444, 1373, 1164, 1075, 838, 666; 
 
 
General Procedure A:  
 
Synthesis of Sulphonamides (91 – 97) 
 
(90) (500 mg, 1.70 mmol) and the appropriate aniline derivative (1.0 eq, 1.70 mmol), 
were dissolved in CH
2
Cl
2
 (7 ml) and stired for 10 min at room temperature. Pyridine 
(187 µL, 2.40 mmol) was then added dropwise and the reaction mixture stired fpr 2 h 
at room temperature.  The  mixture  was then  diluted  with  CH
2
Cl
2
 (30  mL) and 
quenched with H
2
O (20 mL). The mixture was extracted with CH
2
Cl
2
 (3 x 15 ml), the 
combined organics were dried (MgSO
4
) and rotary evaporated to yield a crude residue. 
Subsequent recrystalisation with EtOH gave the desired sulphonamides as crystaline 
solids.  
 
 
O
CO
2
Et
SO
2
Cl
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Ethyl 2-(4-(N-(2-ethylphenyl)sulfamoyl)phenoxy)acetate (91) 
 
 
 
 
Employing General Procedure A; (90) (500 mg, 1.70 mmol), and 2-ethylaniline (208 
µL,  1.70  mmol);  The  desired  product  was  obtained as a  white crystaline solid, (420 
mg 68%); Mp (EtOH); 75-77 °C; δ
H
 (400 MHz, CDCl
3
); 7.68 (d, J = 9.0, 2H), 7.31 
(m, 1H), 7.14 (m, 3H), d (6.91, J = 9.0, 2H), 4.66 (s, 2H), 4.28 (q, J = 7.2, 2H), 2.39 
(q, J = 7.6,  2H),  1.29 (t, J = 7.2,  3H),  1.05 (t, J = 7.7,  3H); δ
C 
(100  MHz,  CDCl
3
); 
167.9, 161.2, 137.1, 133.8, 132.4, 129.4, 128.9, 126.8, 126.5, 124.3, 114.8, 65.3, 61.7, 
23.7,  14.1; m/z [TOF  MS  ES
+
]
 
found 364.1208 [M  +  H]
+
, C
18
H
22
NO
5
S requires 
364.1219; IR (neat) νmax; 3230, 1735, 1595, 1492, 1331, 1207, 1157, 1094, 838, 676; 
 
 
Ethyl 2-(4-(N-phenylsulfamoyl)phenoxy)acetate (92) 
 
 
 
 
Employing General Procedure A; (90) (500 mg, 1.70 mmol), and aniline (153 µL, 1.70 
mmol); The desired product was obtained as a white crystaline solid, (550 mg, 96%); 
Mp (EtOH); 103-105 °C; δ
H
 (400 MHz, CDCl
3
) 7.75 (d, J = 9.0, 2H), 7.26-7.22 (m, 
2H), 7.15-7.04 (m, 3H), 6.90 (d, J = 8.9, 2H), 4.65 (s, 2H), 4.28 (q, J = 7.1, 2H), 1.29 
(t, J = 7.0, 3H); δ
C 
(100 MHz, CDCl
3
); 168.0, 161.2, 136.6, 131.8, 129.5, 129.3, 125.4, 
121.6,  114.8,  65.3,  61.7,  14.1; m/z [TOF  MS  ES
+
]
 
found,  336.0911 [M  + H]
+
, 
C
16
H
18
NO
5
S requires, 336.0906; IR (neat) νmax; 3240, 1726, 1594, 1580, 1496, 1221, 
1146, 1093, 1073, 924, 757, 669;  
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Ethyl 2-(4-(N-(4-fluorophenyl)sulfamoyl)phenoxy)acetate (93) 
 
 
 
 
 
Employing General Procedure A; (90) (500 mg, 1.70 mmol), and 4-fluoroaniline (159 
µL,  1.70  mmol);  The  desired  product  was  obtained as a  white crystaline solid, (498 
mg 83%); Mp (EtOH); 97-99 °C; δ
H
 (400 MHz, CDCl
3
); 7.67 (d, J = 8.9, 2H), 7.03 
(m,  2H),  6.96 (d, J = 8.4,  2H),  6.91 (d, J = 8.9,  2H),  4.67 (s,  2H),  4.30 (q, J = 7.1, 
2H),  1.20 (t, J = 7.2,  3H); δ
C 
(100  MHz,  CDCl
3
); 167.9,  161.9,  161.3,  159.5,  132.2, 
131.4, 129.5, 124.9, 124.8, 116.3, 116.0, 114.9, 65.3, 61.8, 14.1; m/z [TOF MS ES
-
] 
found 354.0795 [M + H]
+
, C
16
H
17
FNO
5
S requires, 354.0811; IR (neat) νmax;  3247, 
1732, 1593, 1503, 1335, 1210, 1095, 917, 844, 669; 
 
 
Ethyl 2-(4-(N-(2,5-dimethylphenyl)sulfamoyl)phenoxy)acetate (94) 
 
 
 
 
Employing General Procedure A; (90) (500 mg, 1.70 mmol), and 2,5-dimethylaniline 
(210 µL,  1.70  mmol);  The  desired  product  was  obtained as a  white crystaline solid, 
(410 mg 66%); Mp (EtOH); 121-123 °C; δ
H
 (400 MHz, CDCl
3
); 7.67 (d, J = 8.9, 2H), 
7.16 (s, 1H), 6.96 (d, J = 7.7, 1H), 6.92 (d, J = 7.7, 1H), 6.91 (d, J = 8.9, 2H), 4.66 (s, 
2H),  4.29 (q, J = 7.2,  2H),  2.29 (s,  3H),  1.93 (s,  3H),  1.30 (t, J = 7.2,  3H); δ
C 
(100 
MHz,  CDCl
3
); 167.9,  161.2,  136.7,  134.2,  132.5,  130.5,  129.3,  128.2,  127.1,  125.2, 
114.7,  65.3,  61.2,  21.0,  17.1,  14.1; m/z [TOF  MS  ES
+
]
 
found,  364.1203 [M  +  H]
+
, 
C
18
H
22
NO
5
S requires, 364.1219; IR (neat) νmax; 3247, 1734, 1592, 1442, 1203, 1155, 
1093, 837, 713, 698; 
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S
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O
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Ethyl 2-(4-(N-(2,4-dimethylphenyl)sulfamoyl)phenoxy)acetate (95) 
 
 
	  
	  
	  
	  
Employing General Procedure A; (90) (500 mg, 1.70 mmol), and 2,4-dimethylaniline 
(208 µL,  1.70  mmol);  The  desired  product  was  obtained as a  white crystaline solid, 
(573 mg 93%); Mp (EtOH); 125-127 °C; δ
H
 (400 MHz, CDCl
3
); 7.66 (d, J = 8.9, 2H), 
7.14 (d, J = 8.0, 1H), 6.94 (d, J = 7.6, 1H), 6.91 (d, J = 8.9, 2H), 6.90 (m, 1H), 4.67 
(s, 2H), 4.29 (q, J = 7.2, 2H), 2.27 (s, 3H), 1.97 (s, 3H), 1.30 (t, J = 7.1, 3H); δ
C 
(100 
MHz,  CDCl
3
); 167.9,  161.1,  136.4,  132.6,  132.1,  131.6,  131.5,  129.4,  127.5,  125.3, 
114.7,  65.3,  61.7,  20.9,  17.5,  14.1; m/z [TOF  MS  ES
+
]
 
found,  364.1207 [M  +  H]
+
, 
C
18
H
22
NO
5
S requires, 364.1203; IR (neat) νmax; 3243, 1739, 1593, 1497, 1332, 1299, 
1236, 1161, 832, 682; 
	  
	  
Ethyl 2-(4-(N-(4-fluoro-2-methylphenyl)sulfamoyl)phenoxy)acetate (96) 
	  
	  
	  
	  
	  
	  
	  
Employing  General  Procedure  A; (90) (500  mg,  1.70  mmol), and  2-methyl-4-
fluoroaniline (188 µL,  1.70  mmol);  The  desired  product  was  obtained as a  white 
crystaline solid, (514 mg 65%); Mp (EtOH); 124-126 °C; δ
H
 (400 MHz, CDCl
3
); 7.63 
(d, J = 9.0, 2H), 7.19 (m, 1H), 6.91 (d, J = 9.0, 2H), 6.84 (m, 2H), 4.67 (s, 2H), 4.30 
(q, J = 7.2,  2H),  1.99 (s,  3H),  1.30 (t, J = 7.1,  3H); δ
C 
(100  MHz,  CDCl
3
); 167.9, 
162.3,  161.3,  159.8,  135.7,  135.6,  132.2,  130.1,  129.4,  127.8,  117.3,  114.8,  113.6, 
65.3, 61.7, 17.8, 14.1; m/z [TOF MS ES
+
]
 
found, 368.0951 [M + H]
+
, C
17
H
19
FNO
5
S 
requires, 368.0968; IR (neat) νmax; 3200, 1732, 1593, 1494, 1428, 1221, 1159, 1095, 
837, 805, 696; 
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Ethyl 2-(4-(N-(4-chlorophenyl)sulfamoyl)phenoxy)acetate (97) 
 
	  
	  
	  
	  
	  
Employing General Procedure A; (90) (500 mg, 1.70 mmol), and 4-chloroaniline (217 
mg, 1.70 mmol); The desired product was obtained as a white crystaline solid, (325 
mg 52%); Mp (EtOH); 122-126 °C; δ
H
 (400 MHz, CDCl
3
); 7.71 (d, J = 9.0, 2H), 7.21 
(d, J = 8.8, 2H), 7.03 (d, J = 8.7, 2H), 6.91 (d, J = 8.9, 2H), 4.65 (s, 2H), 4.29 (q, J = 
7.1,  2H),  1.29 (t, J  = 7.1,  3H); δ
C 
(100  MHz,  CDCl
3
); 168.4,  161.4,  135.2,  131.4, 
130.8,  129.5,  129.4,  122.9,  114.9,  65.3,  61.8,  14.1;  m/z [TOF  MS  ES
+
]
 
found, 
370.0438 [M + H]
+
, C
16
H
17
ClNO
5
S requires, 370.0516; IR (neat) νmax; 3264, 1726, 
1595, 1580, 1490, 1222, 1161, 1073, 837; 
 
 
General Procedure B: 
 
Saponification of sulphonamides (98 - 104) 
 
The appropriate ester (100  mg  1.0 eq),  was suspended in  THF (1  mL) and  1  M 
aqueous LiOH (2 ml), and the mixture was heated at reflux for 6 h. The reaction was 
the evaporated to dryness and the residue taken up in H
2
O (15 mL) and Et
2
O (20 mL). 
The layers  were separated and the aqueous extracted  with  Et
2
O (2  x  15  mL).  The 
aqueous layer was then acidified to pH 4 and re-extracted with Et
2
O (4 x 25 mL), the 
combined  organic extracts  were  dried (MgSO
4
), and rotary evaporated to  give the 
desired acid as a pure white solid;  
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2-(4-(N-(2-Ethylphenyl)sulfamoyl)phenoxy)acetic acid (98) 
 
	  
	  
	  
	  
Employing General Procedure B; (91) (100 mg, 0.27 mmol); The desired product was 
obtained as a white crystaline solid, (47 mg 52%); Mp (EtOH); 271-274 °C; δ
H
 (400 
MHz, d
4
 MeOH); 7.63 (d, J = 8.9. 2H), 7.21-7.14 (m, 2H), 7.09-6.98 (m, 4H), 4.77 (s, 
2H),  2.51 (q, J = 7.6,  2H),  1.05 (t, J = 7.5,  3H); δ
C 
(100  MHz,  d
4
 MeOH); 170.4, 
161.3,  140.7,  134.0,  132.8,  128.9,  128.7,  128.7,  126.9,  126.7,  125.8,  125.8,  114.4, 
64.5, 23.2, 13.5; m/z [TOF MS ES
-
] found 334.0757 [M - H]
-
, C
16
H
16
NO
5
S requires, 
334.0749; IR (neat) νmax; 2978 (br), 1729, 1660, 1620, 1433, 1323, 1154, 1034, 975, 
858, 688; 
 
	  
2-(4-(N-phenylsulfamoyl)phenoxy)acetic acid (99) 
	  
	  
	  
	  
	  
	  
Employing General Procedure B; (92) (100 mg, 0.30 mmol); The desired product was 
obtained as a white crystaline solid, (86 mg 93%); Mp (EtOH); 145-147 °C; δ
H
 (400 
MHz, d
4
 MeOD); 7.71 (d, J = 8.9, 2H), 7.23 (dt, J = 8.3, 1.2, 2H), 7.11-7.01 (m, 3H), 
7.00 (d, J  = 8.9,  2H),  4.73 (s,  2H); δ
C 
(100  MHz,  d
4
 MeOH); 170.4,  161.3,  137.7, 
132.0, 128.9, 128.7, 124.3, 120.9, 114.4, 64.4; m/z [TOF MS ES
-
] found 306.0438 [M 
- H]
-
, C
14
H
12
NO
5
S requires, 306.0436; IR (neat) νmax; 3280,  3000-2700 (br),  1700, 
1581, 1492, 1304, 1245, 1151, 916, 833, 695; 
	  
	  
	  
	  
	  
	  
	  
	  
	  
HN
S
O
O
O
CO
2
H
HN
S
O
O
O
CO
2
H
	   220	  
2-(4-(N-(4-fluorophenyl)sulfamoyl)phenoxy)acetic acid (100) 
 
	  
	  
	  
	  
	  
Employing General Procedure B; (93) (100 mg, 0.28 mmol); The desired product was 
obtained as a white crystaline solid, (35 mg 39%); Mp (EtOH); 173-176 °C; δ
H
 (400 
MHz, d
4
 MeOD); 7.66 (d, J = 9.0, 2H), 7.09 (dd, J = 7.1, 4.8, 2H), 7.02 (d, J = 9.0, 
2H), 6.99-6.95 (m, 2H), 4.75 (s, 2H); δ
C 
(100 MHz, d
4
 MeOH); 170.4, 161.4, 159.0, 
133.7,  131.7,  128.9,  128.9,  123.8,  123.7,  115.4,  115.2,  114.4,  64.6,  22.8;  m/z [TOF 
MS ES
-
] found 324.0347 [M - H]
-
, C
14
H
11
FNO
5
S requires, 324.0342; IR (neat) νmax; 
3297, 3000-2500 (br), 1729, 1700, 1504, 1433, 1245, 1150, 1092, 822, 671; 
 
 
2-(4-(N-(2,5-dimethylphenyl)sulfamoyl)phenoxy)acetic acid (101) 
 
	  
	  
	  
	  
Employing General Procedure B; (94) (100 mg, 0.27 mmol); The desired product was 
obtained as a white crystaline solid, (82 mg 91%); Mp (EtOH); 161-163 °C; δ
H
 (400 
MHz, d
4
 MeOD); 7.61 (d, J = 8.7, 2H), 7.03 (d, J = 8.9, 2H), 7.00 (d, J = 7.9, 1H), 
6.92 (d, J = 7.8,  1H),  6.88 (s,  1H),  4.77 (s,  2H),  2.22 (s,  3H),  1.97 (s,  3H); δ
C 
(100 
MHz, d
4
 MeOH); 170.4, 161.4, 135.8, 134.5, 132.9, 131.2, 131.2, 130.2,130.2, 128.9, 
127.4,  127.1,114.3,  64.4,  19.5,  16.1; m/z [TOF  MS  ES
-
] found 334.0746 [M - H]
-
, 
C
16
H
16
NO
5
S requires, 334.0749; IR (neat) νmax; 3300,  3000-2500 (br),  1707,  1596, 
1389, 1304, 1159, 1092, 835, 666 (s); 
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2-(4-(N-(2,4-dimethylphenyl)sulfamoyl)phenoxy)acetic acid (102) 
	  
	  
	  
	  
	  
	  
Employing General Procedure B; (95) (100 mg, 0.27 mmol); The desired product was 
obtained as a white crystaline solid, (75 mg 83%); Mp (EtOH); 167-169 °C; δ
H
 (400 
MHz, d
4
 MeOD); 7.60 (d, J = 8.9, 2H), 7.07 (d, J = 8.9, 2H), 6.94 (s, 1H), 6.90 (m, 
2H), 4.76 (s, 2H), 2.25 (s, 3H), 1.99 (s, 3H); δ
C 
(100 MHz, d
4
 MeOH); 170.5, 161.3, 
136.4, 134.5, 132.8, 132.1, 131.0, 128.9, 128.9 126.9, 126.9 126.7, 114.3, 64.4, 19.5, 
16.6; m/z [TOF MS ES
-
] found 334.0745 [M - H]
-
, C
16
H
16
NO
5
S requires, 334.0749; IR 
(neat) νmax; 3254,  3000-2500 (br),  1707,  1595,  1497,  1240,  1151,  1093,  903,  835, 
604; 
	  
 
2-(4-(N-(4-fluoro-2-methylphenyl)sulfamoyl)phenoxy)acetic acid (103) 
 
	  
	  
	  
	  
	  
Employing General Procedure B; (96) (100 mg, 0.27 mmol); The desired product was 
obtained as a white crystaline solid, (25 mg 28%); Mp (EtOH); 177-179 °C; δ
H
 (400 
MHz, d
4
 MeOD); 7.61 (d, J = 8.9, 2H), 7.04 (d, J = 8.9, 2H), 7.01-6.99 (m, 1H), 6.90 
(dd, J = 9.4, 2.8, 1H), 6.85-6.82 (m, 1H), 4.78 (s, 2H), 2.04 (s, 3H); δ
C 
(100 MHz, d
4
 
MeOH); 170.4,  162.4,  161.4,  159.9,  138.0,  137.9,  132.6,  130.9,  129.5,  128.9,  116.6, 
114.5, 112.5, 64.4, 16.8; m/z [TOF MS ES
-
] found 338.0487 [M - H]
-
, C
15
H
13
FNO
5
S 
requires, 338.0498; IR (neat) νmax; 3255, 1780, 1732, 1594, 1320, 1202, 1141, 1078, 
912, 835, 729; 
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Ethyl 2-(4-(N-(4-chlorophenyl)sulfamoyl)phenoxy)acetic acid (104) 
	  
	  
	  
	  
	  
	  
Employing General Procedure B; (97) (100 mg, 0.27 mmol); The desired product was 
obtained as a white crystaline solid, (55 mg 57%); Mp (EtOH); 170-173 °C; δ
H
 (400 
MHz, d
4
 MeOD); 7.71 (d, J = 8.9, 2H), 7.22 (d, J = 8.8, 2H), 7.09 (d, J = 8.8, 2H), 
7.03 (d, J = 8.9,  2H),  4.75 (s,  2H); δ
C 
(100  MHz,  d
4
 MeOH); 170.5,  161.5,  136.6, 
131.6,  129.6,  128.9,  128.8,  122.3,  114.5,  64.45; m/z [TOF  MS  ES
-
] found 340.0082 
[M - H]
-
, C
14
H
12
ClNO
5
S requires, 340.0046; IR (neat) νmax; 1725, 1691, 1489, 1217, 
1139, 1081, 803, 726, 664; 
	  
 
2-Bromo-1-(2,4-dimethoxyphenyl)ethanone (114) 
 
 
 
 
 
 
A  purged (N
2
) reaction  vessel  was charged with  AlCl
3
 (61  mg,  0.45  mmol), 
Nitroethane (3  mL) and  1,3-dimethoxybenzene (189 µL,  1.40 mmol).  The ensuing 
mixture  was alowed to stir at room temperature for  20 min. Bromoacetyl bromide 
(157 µL, 1.80 mmol) was added dropwise and the reaction heated to 40 °C for 1 hour. 
The mixture was alowed to cool to ambient temperature and quenched carefuly with 
1 M aqeuous HCl (10 mL). The product was extracted with Et
2
O (3 x 15 mL), and the 
combined  organics  were  washed  with  1  M aqueous NaOH (15 mL),  H
2
O (15 mL), 
dried (MgSO
4
)
,
 rotary evaporated, and chromatographed (Petrol:EtOAc  4/1) to  give 
the desired product as a white crystaline solid, (320 mg, 89%); Mp (EtOH); 86-89 °C; 
Rf (Petrol/EtOAc 4/1); 0.35; δ
H
 (400 MHz, CDCl
3
); 7.88 (d, J = 8.8, 1H) 6.54 (dd, J = 
8.8, 2.2, 1H), 6.45 (d, J = 2.2, 1H), 4.56 (s, 2H), 3.91 (s, 3H), 3.85 (s, 3H); δ
C
 (100 
MHz,  CDCl
3
);  190.0,  165.4,  160.9,  132.5,  117.7,  104.5,  98.1,  55.9,  55.2,  37.8; m/z 
[TOF  MS  ES
+
]
 
found  257.9333 [M  +  H]
+
, C
10
H
11
BrO
3 
requires 257.989; IR (neat) 
HN
S
O
O
O
CO
2
H
Cl
MeO
OMe
O
Br
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νmax; 3013, 2841, 1661, 1594, 1574, 1467, 1334, 1273, 1019, 990, 828, 679; 
	  
	  
General Procedure C: 
 
Synthesis of Thioureas  
 
Acetone was dried over CaCl
2
 48 hours prior to use. Ammonium isothiocyanate (500 
mg,  6.50 mmol) and  Benzoyl chloride (839  mg,  6.00  mmol)  were suspended in 
acetone (4 mL) and heated at 60 °C for 10 min. Desired amine (6.00 mmol, 1 eq.) in 
acetone (2 mL) was added to the resulting yelow precipitate and heated at 60 °C for 
10 min. The reaction mixture was then poured onto cold H
2
O (15 mL) and stired at 
room temperature for  10  min. The resulting  precipitate  was separated  via filtration, 
briefly dried in air, suspended in 2.5 M aqueous NaOH (25 mL) and heated to 100 °C 
for  30 min.  The solution  was alowed to cool to ambient temperature and acidified 
with concentrated HCl (4  mL), alowing the formation  of a  white  precipitate. The 
mixture was then made slightly basic ~ pH 9 via the addition of ammonium hydroxide 
50%  v/v. The solution  was then alowed to rest, and the  precipitate separated  by 
filtration.  The colected solid  was recrystalised from EtOH to  yield the  desired 
thiourea in crystaline form. 
 
 
1-Phenylthiourea (120) 
 
  
 
Employing  General  Procedure  C;  Aniline (558  mg,  6.00  mmol)  was added to the 
reaction  mixture. Recrystalisation from  EtOH gave the  desired  product as  white 
crystaline needles, (510 mg, 51%); Mp (EtOH); 146-148 °C; δ
H
 (400 MHz, CDCl
3
); 
7.36 (m, 2H), 7.34 (t, J = 7.5, 1H), 7.26 (d, J = 8.9); 
 
 
 
H
N NH
2
S
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1-(4-Methylpyridin-2-yl)thiourea (121) 
 
 
 
Employing General Procedure C; 2-Aminopyridine (648 mg, 6.0 mmol) was added to 
the reaction  mixture. Recrystalisation from  EtOH gave the  desired  product as white 
crystaline needles, (650 mg, 65%); (400 MHz, d
6
 DMSO); 8.10 (d, J = 5.2, 1H), 6.94 
(s, 1H), 6.89 (d, J = 5.4, 1H), 2.27 (s, 3H); 
 
 
1-(3,4-Dimethylphenyl)thiourea (122) 
 
 
 
Employing  General  Procedure  C; 3,4-Dimethylaniline (727  mg,  6.0 mmol)  was 
added to the reaction mixture. Recrystalisation from EtOH gave the desired product 
as white crystaline  needles, (606  mg,  56%); δ
H
 (400  MHz,  d
4
 MeOH);  7.17 (d, J = 
7.9, 1H), 7.07 (s, 1H), 7.02 (d, J = 7.9, 1H), 2.29 (s, 3H), 2.28 (s, 3H);  
 
 
1-(4-Fluoro-2-methylphenyl)thiourea (123) 
 
 
 
Employing General Procedure C; 2-Methyl-4-fluoroaniline (783 mg, 6.0 mmol) was 
added to the reaction mixture. Recrystalisation from EtOH gave the desired product 
as a light pink crystaline solid, (416 mg, 38%); δ
H
 (400 MHz, CDCl
3
); 7.16 (dd, J = 
8.6, 5.4, 1H), 6.96 (dd, J = 9.1, 2.8, 1H), 6.90 (dt, J = 8.2, 2.9, 1H), 2.26 (s, 3H); 
 
 
1-(3-Methyl-1H-pyrazol-4-yl)thiourea (124) 
 
 
 
Employing  General  Procedure  C; 3-Amino-5-methylpyrazole (582  mg,  6.00 mmol) 
N
H
N NH
2
S
H
N NH
2
S
H
N NH
2
S
F
HN
N
NH
S
NH
2
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was added to the reaction  mixture. Recrystalisation from  EtOH  EtOH gave the 
desired product as white crystaline needles, (326 mg, 35%); δ
H
 (400 MHz, d
6 
DMSO); 
12.17 (s, 1H), 10.21 (s, 1H), 9.06 (s, 1H), 8.40 (s, 1H), 5.66 (s, 1H), 2.18 (s, 3H);  
 
 
1-(2,4-Dimethylphenyl)thiourea (125) 
 
 
 
Employing  General  Procedure  C;  2,4-Dimethylaniline (783  mg,  6.0 mmol)  was 
added to the reaction mixture. Recrystalisation from EtOH gave the desired product 
as a light  pink crystaline solid, (416  mg,  41%); δ
H
 (400  MHz,  d
4
 MeOH);* 7.14 (s, 
1H), 7.07 (s, 2H), 2.33 (s, 3H), 2.25 (s, 3H); 
 
 
1-(2,5-Dimethylphenyl)thiourea (126) 
 
 
 
 
Employing  General  Procedure  C; 2,5-Dimethylaniline (783  mg,  6.0 mmol)  was 
added to the reaction mixture. Recrystalisation from EtOH gave the desired product 
as a light pink crystaline solid, (483 mg, 45%); δ
H
 (400 MHz, CDCl
3
); 7.10 (d, J = 
7.8, 1H), 7.00 (d, J = 7.8, 1H), 6.96 (s, 1H), 2.25 (s, 3H), 2.19 (s, 3H); 
 
 
1-(2-Ethylphenyl)thiourea (127) 
 
 
 
 
 
Employing  General  Procedure  C; 2-Ethylaniline (727  mg,  6.0 mmol)  was added to 
the reaction  mixture. Recrystalisation from  EtOH gave the  desired  product as  white 
crystaline needles, (245 mg, 23%); δ
H
 (400 MHz, d
6 
DMSO); 12.95 (brs, 1H), 9.40 (s, 
1H), 752-7.50 (m, 2H), 7.31-7.27 (m, 2H), 2.56 (q, J = 7.2, 2H), 1.12 (t, J = 7.2, 3H) 
H
N NH
2
S
H
N NH
2
S
H
N NH
2
S
	   226	  
1-(1,3-dimethyl-1H-pyrazol-5-yl)thiourea (129) 
 
 
 
 
Employing  General  Procedure  C; 5-Amino-1,3-dimethylpyrazole (666 mg,  6.00 
mmol)  was added to the reaction  mixture. Recrystalisation from  EtOH gave the 
desired  product as a light  yelow crystaline solid, (600 mg, 59%); δ
H
 (400  MHz,  d
6
 
DMSO); 9.59 (brs, 1H, NH), 8.03-7.54 (brs, 2H, NH
2
), 5.92 (s, 1H), 3.54 (s, 3H), 2.09 
(s, 3H); 
 
1-(naphthalen-1-yl)thiourea (130) 
 
 
 
 
Employing General Procedure C; 1-aminonapthalene (858 mg, 6.00 mmol) was added 
to the reaction  mixture. Recrystalisation from  EtOH gave the  desired product as a 
light  purple crystaline solid, (921  mg,  76%); δ
H
 (400  MHz,  d
6
 DMSO); 10.06 (brs, 
1H, NH), 7.96 (dd, J = 6.8, 3.1, 2H), 7.84 (dd, J =7.3, 1.8, 1H), 7.80-7.29 (brs, 2H, 
NH
2
), 7.57-7.49 (m, 4H);  
 
 
 1-(3-Chlorophenyl)thiourea (131) 
 
 
 
 
Employing General Procedure C; 3-chloroaniline (633 µL, 6.0 mmol) was added to 
the reaction mixture. Recrystalisation from EtOH gave the desired product as a light 
yelow crystaline solid, (712 mg, 64%); δ
H
 (400 MHz, d
6
 DMSO); 9.82 (s, 1H, NH), 
7.72-7.70 (m, 1H), 7.36-7.30 (m, 2H), 7.16-7.13 (m, 1H); 
 
 
NH
N
N
H
2
N
S
HN NH
2
S
HN NH
2
S
Cl
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4-(2-(biphenyl-2-ylamino)thiazol-4-yl)benzene-1,3-diol (132) 
 
 
 
 
Employing General Procedure C; 2-Aminobiphenyl (1.01 g, 6.00 mmol) was added to 
the reaction mixture. Recrystalisation from EtOH gave the desired product as a light 
brown crystaline solid, (955 mg, 70%); δ
H
 (400 MHz, d6 DMSO); 9.22 (s, 1H, NH), 
7.44 (m, 4H), 7.38-7.34 (m, 6H); 
 
 
(S)-3-(4-hydroxyphenyl)-2-thioureidopropanoic acid (133)
1 
 
 
 
 
i.  L-Tyrosine  methyl ester  1 (500  mg,  2.16  mmol) and  disopropylethylamine (1.13 
mL, 6.49 mmol) were dissolved in CH
2
Cl
2
 (15.0 mL) and the solution was cooled to 0 
°C. Ethoxycarbonyl isothiocyanate (382 µL, 3.24 mmol) was added dropwise, and the 
mixture was alowed to warm to ambient temperature over 30 min. CH
2
Cl
2
 (20 mL) 
was added, and the organic layer was washed with water (20 mL), 1 M aqueous HCl 
(20 mL), brine (20 mL), dried (MgSO
4
), and rotary evaporated to give the intermediate 
carbamate as a yelow oil; i. The crude carbamate (410 mg, 1.26 mmol) was dissolved 
in a 1:1 solution of 1 M aqueous NaOH and MeOH (20 mL). The solution was heated 
to 100 °C for 30 min. The solution was the alowed to cool to ambient temperature and 
acidified ~ pH 3 using 1 M HCl. The product was extracted with EtOAc (3 x 15 mL). 
The combined organic extracts were dried (MgSO
4
), and rotary evaporated to give the 
desired product as yelow crystaline needles (264 mg, 51%); δ
H
 (400 MHz, MeOD
4
); 
7.05 (d, J = 8.4, 2H), 6.74 (d, J = 8.5, 2H), 5.20 (m, 1H), 3.22 (dd, J =14.0, 5.3, 1H), 
3.02 (dd, J =14.2, 6.2, 1H); δ
C
 (100 MHz, MeOD
4
); 183.3, 173.8, 156.0, 130.2, 130.0, 
127.2, 114.9, 114.8, 58.5, 36.5; (data matched literature); 
 
 
HN NH
2
S
HO
CO
2
H
HN
S
NH
2
HO
CO
2
Me
HN
S
H
N
CO
2
Et
HO
CO
2
Me
NH
2
i. i.
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2-Bromo-1-(2,4-dihydroxyphenyl)ethanone (138) 
 
 
 
 
 
 
Compound 114 (330 mg, 1.28 mmol) was dissolved in CH
2
Cl
2
 (30 mL) and cooled to 
-78 °C. BBr
3 
(1.0 M in CH
2
Cl
2
) (10.28 mL, 10.28 mmol) was added dropwise over 15 
minutes and the ensuing mixture stired for 4 hours. The reaction was quenched with 
MeOH (20  mL), evaporated to  dryness and the residue  directly chromatographed 
(CH
2
Cl
2
:EtOAc 5/1) to give the desired product as a white crystaline solid, (82 mg, 
88%); Rf (CH
2
Cl
2
/EtOAc 3/1); 0.23; Light yelow crystaline solid, (153, mg, 52%); 
δ
H
 (400 MHz, d
6
 DMSO); 11.84 (s, 1H, OH), 10.76 (s, 1H, OH), 7.79 (d, J = 8.8, 1H), 
6.41 (dd, J = 8.8,  2.3,  1H),  6.33 (d, J = 2.3,  1H); δ
C
 (100  MHz  d
6 
DMSO); 194.6, 
165.7, 164.4, 133.9, 111.6, 109.0, 103.0, 34.2; (data matched commercial source); 
 
 
2-Bromo-1-(2-methoxy-4-hydroxyphenyl)ethanone (139) 
 
 
 
 
Compound 114 (100 mg, 0.38 mmol) was dissolved in CH
2
Cl
2
 (5 mL) and cooled to -
78 °C. BBr
3 
(1.0  M in  CH
2
Cl
2
) (2.28  mL,  2.28  mmol) was added  dropwise  over  15 
minutes and the ensuing mixture stired for 1 hour. The reaction was quenched with 
MeOH (2  mL), evaporated to  dryness and the residue  directly chromatographed 
(Petrol:EtOAc  6/1) to  give the desired  product as a white crystaline solid, (82  mg, 
88%);  Rf (Petrol/EtOAc  4/1); 0.41; Mp (EtOAc);  63-65 °C; δ
H
 (400  MHz,  CDCl
3
); 
7.67 (d, J = 8.9, 1H), 6.52 (dd, J = 8.9, 2.5, 1H), 6.47 (d, J = 2.5, 1H), 4.39 (s, 2H), 
3.88 (s,  3H); δ
C
 (100  MHz  CDCl
3
); 195.1,  166.9,  166.3,  131,9,  111.2,  108.4,  101.2, 
55.7,  29.6; m/z [TOF  MS  ES
+
]
 
found 244.9807 [M  +  H]
+
, C
9
H
10
BrO
3 
requires 
244.9813; IR (neat) ν
max
; 2952, 1619, 1575, 1507, 1494, 1441, 1209, 1129, 1020, 954, 
845; 
 
 
OH O
MeO
Br
OH O
HO
Br
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General Procedure Di: 
 
Synthesis of Thiazoles 
 
Thiourea (0.43  mmol,  1 eq.) and  2-Bromo-1-(2,4)-dihydroxyacetophenone (0.43 
mmol, 1 eq.) were suspended in EtOH (5 mL) and heated to 80 °C for a duration of 14 
hours.  The reaction  mixture  was alowed to cool to ambient temperature and the 
solvent removed via rotary evaporation. The resulting crude solid was either 
recrystalised from  EtOH/Pentanes,  or column chromatographed  using the stated 
solvent system. (note: some Ar-H thiazole singlets are missing, due to D/H exchange 
in d
4 
MeOH on the NMR timescale, such compounds are marked with an asterix). 
 
4-(2-(4-Methylpyridin-2-ylamino)thiazol-4-yl)benzene-1,3-diol (31-S) 
 
 
 
 
Employing  General  Procedure  Di; 2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
0.43 mmol) and 121 (72 mg, 0.43 mmol) were suspended in EtOH (5 mL) and heated 
to 80 °C for a  duration  of  14  hours. Recrystalisation from  EtOH gave the  desired 
product as a white crystaline solid, (78 mg, 61%); Mp (EtOH); 227-229 °C; δ
H
 (400 
MHz, d
4
 MeOH); 8.32 (d, J = 5.7, 1H), 7.66 (d, J = 9.0, 1H), 7.37 (s, 1H), 7.16 (d, J = 
5.6,  1H),  7.06 (s,  1H),  6.46 (m,  2H),  2.50 (s,  3H); δ
C
 (100  MHz  d
4
 MeOH);  161.5, 
160.2, 155.3, 149,9, 144.8, 140.2, 128.7, 119.3, 112.6, 108.2, 106.7, 102.5, 17.9; m/z 
[TOF MS ES
+
] found 300.0815 [M + H]
+
, C
15
H
14
N
3
O
2
S requires 300.0807; IR (neat) 
cm
-1
 ν
max
; 3200–2800 (br), 1618, 1541, 1483, 1463, 1324, 1164, 977, 847, 811; 
 
 
4-(2-(3,4-Dimethylphenylamino)thiazol-4-yl)benzene-1,3-diol (34-S) 
 
 
 
 
Employing  General  Procedure  Di; 2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
OH
HO
N
S
NH
N
OH
HO
N
S
NH
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0.43 mmol) and 122 (77 mg, 0.43 mmol) were suspended in EtOH (5 mL) and heated 
to 80 °C for a  duration  of  14  hours. Recrystalisation from  EtOH gave the  desired 
product as a white crystaline solid, (87 mg, 65 %); Mp (EtOH); 123-125 °C; δ
H
 (400 
MHz, d
6
 DMSO); 10.68 (s, 1H, OH), 7.54 (d, J = 8.6, 1H), 7.25-7.08 (m, 3H), 7.08 (s, 
1H), 6.39 (d, J = 2.3, 1H), 6.34 (dd, J = 8.5, 2.3, 1H), 2.24 (s, 3H), 2.20 (s, 3H); δ
C
 
(100 MHz d
6
 DMSO); 165.4, 159.4, 156.7, 137.8, 132.4, 130.8, 129.0, 120.9, 120.1, 
117.2,  109.7,  107.8,  107.2,  103.4,  100.4,  20.1,  19.2; m/z [TOF  MS  ES
+
] found 
313.1015 [M + H]
+
, C
17
H
17
N
2
O
2
S requires 313.1011; IR (neat) ν
max
; 3200-2800 (br), 
1614, 1598, 1518, 1449, 1270, 1171, 983, 705; 
 
 
4-(2-(Pyridin-2-ylamino)thiazol-4-yl)benzene-1,3-diol (143) 
 
 
 
 
 
 
Employing  General  Procedure  Di; 2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
0.43  mmol) and 2-pyridylthiourea (66  mg,  0.43  mmol) were suspended in  EtOH (5 
mL) and heated to 80 °C for a duration of 14 hours. Recrystalisation from EtOH gave 
the desired product as a white crystaline solid, (91 mg, 74%); Mp (EtOH); 191-194 
°C; δ
H
 (400 MHz, d
6
 DMSO); 12.21 (s, 1H, OH), 9.29 (s, 1H, OH), 8.46 (m, 1H), 7.91 
(m, 1H), 7.64 (d, J = 8.6, 1H), 7.36 (s, 1H), 7.24 (d, J = 8.4, 1H), 7.14 (m, 1H), 6.44 
(d, J = 2.3, 1H), 6.37 (dd, J = 8.6, 2.3, 1H); δ
C
 (100 MHz d
6 
DMSO); 160.1, 159.5, 
156.6, 150.7, 145.9, 139.9, 129.1, 118.1, 112.5, 109.3, 108.0, 104.2, 103.4; m/z [TOF 
MS  ES
+
] found
 
286.0646 [M  +  H]
+
, C
14
H
12
N
3
O
2
S requires 286.0650; IR (neat) ν
max
; 
3200-2700 (br) 1615, 1529, 1433, 1372, 1224, 1176, 872, 812, 778; 
 
 
 
 
 
 
 
OH
HO
N
S
NH
N
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4-(2-(3-Methylpyridin-2-ylamino)thiazol-4-yl)benzene-1,3-diol (144) 
 
 
 
 
Employing  General  Procedure  Di; 2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
0.43 mmol) and 1-(4-methylpyridin-2-yl)thiourea (66 mg, 0.43 mmol) were suspended 
in EtOH (5 mL) and heated to 80 °C for a duration of 14 hours. Recrystalisation from 
EtOH gave the desired product as a white crystaline solid, (95 mg, 74%); Mp (EtOH); 
201-204 °C; δ
H
 (400  MHz,  d
4
 MeOH);  8.31 (d, J = 4.7,  1H),  7.78 (d, J = 7.2,  1H), 
7.62 (d, J = 8.6, 1H), 7.39 (s, 1H), 7.13 (dd, J = 7.1, 5.2, 1H), 6.46 (d, J = 2.2, 1H), 
6.37 (dd, J = 8.6, 2.4, 1H) 2.42 (s, 3H); δ
C
 (100 MHz d
4
 MeOH); 160.8, 159.7, 156.4, 
148.7,  140.5,  129.1,  118.7,  108.2,  104.7,  103.5,  17.2; m/z [TOF  MS  ES
+
] found 
300.0829 [M + H]
+
, C
15
H
14
N
3
O
2
S requires 300.0807; IR (neat) ν
max
; 3433 (w), 2251 
(w), 1662 (s), 1052 (s), 821 (s), 758 (s); 
 
 
 
4-(2-(Phenylamino)thiazol-4-yl)benzene-1,3-diol (145) 
 
 
 
 
 
Employing  General  Procedure  Di; 2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
0.43 mmol) and 120 (65 mg, 0.43 mmol) were suspended in EtOH (5 mL) and heated 
to 80 °C for a  duration  of  14  hours. Recrystalisation from  EtOH gave the  desired 
product as a light yelow crystaline solid, (62 mg, 51 %); Mp (EtOH); 228-231 °C; δ
H
 
(400 MHz, d
6
 DMSO); 10.21 (brs, 2H, OH), 7.60-7.53 (m, 3H), 7.43 (t, J = 7.4, 2H), 
7.15 (s,  1H),  7.14-7.12 (m,  1H),  6.45-6.42 (m,  1H),  6.36 (d, J = 8,0,  1H); δ
C
 (100 
MHz d
6
 DMSO); 164.6, 159.3, 156.7, 140.3, 131.0, 129.9, 129.7, 129.2, 123.9, 119.1, 
118.3  107.8,  107.0,  103.4,  101.1; m/z [TOF  MS  ES
+
] found 285.0689 [M  +  H]
+
, 
C
15
H
13
N
2
O
2
S requires 285.0698; IR (neat) cm
-1
 ν
max
; 3200-2600 (br),  3131,  1614, 
1572, 1507, 1449, 1212, 1175, 851, 747; 
 
 
OH
HO
N
S
NH
N
OH
HO
N
S
NH
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4-(2-(2-Hydroxyphenylamino)thiazol-4-yl)benzene-1,3-diol (146) 
 
 
 
 
Employing  General  Procedure  Di; 2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
0.43 mmol) and and 2-hydroxyphenylthiourea (72 mg, 0.43 mmol) were suspended in 
EtOH (5 mL) and heated to 80 °C for a duration of 14 hours. Recrystalisation from 
EtOH gave the desired product as a white crystaline solid, (94 mg, 73%); Mp (EtOH); 
157-159 °C; δ
H
 (400 MHz, d
4
 MeOH)
*
; 7.46 (m, 2H), 7.24 (dt, J = 7.3, 1.4, 1H), 7.01 
(m,  2H),  6.45 (m,  2H); δ
C
 (100  MHz  d
4
 MeOH); 167.8,  160.4,  155.6,  150.3,  138.3, 
128.7,  128.5,  124.5,  122.8,  119.9,  116.3,  116.3,  108.7,  106.4,  102.5; m/z [TOF  MS 
ES
+
] found 301.0648 [M + H]
+
, C
15
H
13
N
2
O
3
S requires 301.0647; IR (neat) ν
max
; 3200-
2800 (br), 1618, 1578, 1508, 1450, 1267, 1164, 1097, 728, 699; 
 
 
4-(2,4-Dihydroxyphenyl)-N-(4-fluorophenyl)thiazol-2-amine (147) 
 
 
 
 
 
Employing  General  Procedure  Di;  2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
0.43 mmol) and 4-fluorothiourea (72 mg, 0.43 mmol) were suspended in EtOH (5 mL) 
and heated to 80 °C for a duration of 14 hours. Recrystalisation from EtOH gave the 
desired product as a yelow crystaline solid, (55 mg, 42%); Mp (EtOH); 176-179 °C; 
δ
H
 (400 MHz, d
6
 DMSO; 10.86 (s, 1H, OH), 8.68 (s, 2H, het-H), 7.58-7.55 (m, 2H), 
7.56 (d, J = 8.7, 1H), 7.26 (m, 2H), 7.12 (s, 1H), 6.43 (d, J = 2.2, 1H), 6.35 (dd, J = 
8.5, 2.3, 1H); δ
C
 (100 MHz d
6
 DMSO; 164.9, 162.9, 159.3, 156.6, 145.9, 144.6, 136.7, 
131.2,  129.3,  121.4,  116.5,  110.2,  107.7,  103.4,  101.2; m/z [TOF  MS  ES
+
] found 
303.0612 [M + H]
+
, C
15
H
12
FN
2
O
2
S requires 303.0604; IR (neat) ν
max
 ; 3200-3600 (br), 
1613, 1582, 1504, 1449, 1234, 1209, 1156, 818; 
 
 
 
 
OH
HO
N
S
NH
OH
OH
HO
N
S
NH
F
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4-(2-(Butylamino)thiazol-4-yl)benzene-1,3-diol (148) 
 
 
 
 
Employing  General  Procedure  Di; 2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
0.43  mmol) and n-butylthiourea (57  mg,  0.43  mmol) ) were suspended in  EtOH (5 
mL) and heated to 80 °C for a duration of 14 hours. Recrystalisation from EtOH gave 
the  desired  product as a white crystaline solid, (41  mg,  36%);  Mp (EtOH); 211-
214°C; δ
H
 (400 MHz, d
4
 MeOH); 7.38 (d, J = 8.3, 1H), 7.09 (s, 1H), 6.44 (d, J = 7.7, 
1H), 6.41 (dd, J = 8.3, 2.2, 1H), 3.45 (t, J = 7.0, 2H), 1.75 (m, 2H), 1.51 (m, 2H), 1.03 
(t, J = 7.3,  3H); δ
C
 (100  MHz  d
4
 MeOH);  164.3,  160.4,  155.8,  137.9,  129.1,  107.7, 
106.6,  102.4,  46.3,  29.9,  19.5,  12.5; m/z [TOF  MS  ES
+
] found  265.1015 [M  +  H]
+
, 
C
13
H
16
N
2
O
2
S requires 265.1011; IR (neat) ν
max
; 3300 – 2800 (br, s),  1615 (s),  1598 
(s), 1505 (s), 1270 (s), 1171 (s), 1116 (s), 857 (s), 741 (s), 705 (s); 
 
 
 
4-(2-(3,4-Dichlorophenylamino)thiazol-4-yl)benzene-1,3-diol (149) 
 
 
 
 
Employing  General  Procedure  Di; 2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
0.43  mmol) and 1-(3,4-dichlorophenyl)-2-thiourea (95  mg,  0.43  mmol) were 
suspended in  EtOH (5  mL) and  heated to 80 °C for a  duration  of  14  hours. 
Recrystalisation from  EtOH gave the  desired  product as a yelow crystaline solid, 
(118 mg, 78%); Mp (EtOH); 142-144 °C; δ
H
 (400 MHz, d
6
 DMSO); 8.02 (d, J = 2.2, 
1H), 7.72 (d, J = 8.5, 1H), 7.50 (m, 2H), 7.29 (s, 1H), 6.41 (d, J = 2.0, 1H), 6.33 (dd, J 
= 8.5,  2.0,  1H); δ
C
 (100  MHz  d
6
 DMSO);  161.8,  158.6,  156.7,  147.6,  141.4,  131.7, 
131.4,  129.5,  122.8,  117.6,  112.2,  107.5,  103.4,  103.1; m/z [TOF  MS  ES
+
] found 
352.9839 [M  +  H]
+
, C
15
H
10
Cl
2
N
2
O
2
S requires 352.9918; IR (neat) ν
max
;  3200-2600 
(br), 1607, 1560, 1505, 1470, 1317, 1172, 1030, 978; 
 
 
HO
N
S
NH
OH
OH
HO
N
S
NH
Cl
Cl
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4-(2-(4-methylpyridin-2-ylamino)thiazol-4-yl)benzonitrile (150) 
 
 
 
 
Employing  General  Procedure  Di; 2-Bromo-4-cyanoacetophenone (200  mg,  0.9 
mmol) and pyridylthiourea (149 mg, 0.9 mmol) were suspended in EtOH (5 mL) and 
heated to 80 °C for a  duration  of  14  hours. Recrystalisation from  EtOH gave the 
desired product as a yelow crystaline solid, (189 mg, 72%); Mp (EtOH); 255-257 °C; 
δ
H
 (400 MHz, CDCl
3
)
*
; 8.18 (d, J = 5.4, 1H), 8.09 (d, J = 8.7, 2H), 7.87 (d, J = 8.7, 
2H), 7.73 (s, 1H), 6.92 (d, J = 5.2, 1H), 2.30 (s, 3H); δ
C
 (100 MHz, CDCl
3
); 160.1, 
151.4,  146.9,  145.4,  138.7,  132.7,  126.2,  118.9,  117.8,  110.9,  109.8,  109.5,  109.5, 
20.8; m/z [TOF MS ES
+
] found 293.0854 [M + H]
+
, C
16
H
13
N
4
S requires 293.0861; IR 
(neat) ν
max
; 3101, 2694, 2221, 1650, 1590, 1515, 1202, 1067, 881, 795; 
 
 
 
4-(2-(pyridin-3-ylamino)thiazol-4-yl)benzene-1,3-diol (151) 
 
 
 
 
 
Employing General Procedure Di; 2-Bromo-2,4-dihydroxyacetophenone (50 mg, 0.22 
mmol) and 3-pyridylthiourea (33  mg,  0.22  mmol) were suspended in  EtOH (5  mL) 
and heated to 80 °C for a duration of 14 hours. Recrystalisation from EtOH gave the 
desired product as a yelow crystaline solid, (54 mg, 90%); Mp (EtOH); 227-229 °C; 
δ
H
 (400 MHz, d
6
 DMSO); 9.43 (d, J = 1.7, 1H), 8.50 (m, 2H), 7.96 (dd, J = 8.7, 2.9, 
1H), 7.86 (d, J = 8.5, 1H), 7.39 (s, 1H), 6.44 (d, J = 2.2, 1H), 6.35 (dd, J = 8.5, 2.3, 
1H); δ
C
 (100 MHz, d
6
 DMSO); 160.4, 158.4, 156.6, 147.8, 140.5, 135,2, 131.3, 130.7, 
130.1,  127.5,  112.8,  107.3,  105.3, 103.3; m/z [TOF  MS  ES
+
] found 286.0636 [M  + 
H]
+
, C
14
H
12
N
3
O
2
S requires 286.0650; IR (neat) cm
-1
 ν
max
 =:  3100-2700 (br),  1629, 
1599, 1537, 1450, 1291, 1160, 1120; 
 
 
 
NC
N
S
NH
N
OH
HO
N
S
NH
N
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N-(4-methylpyridin-2-yl)-4-phenylthiazol-2-amine (152) 
 
 
 
 
 
Employing  General  Procedure  Di;  2-Bromoacetophenone (100  mg,  0.44  mmol) and 
pyridylthiourea (84 mg, 0.44 mmol) were suspended in EtOH (5 mL) and heated to 80 
°C for a duration of 14 hours. Recrystalisation from EtOH gave the desired product as 
a yelow crystaline solid, (116 mg, 87%); Mp (EtOH); 246-248 °C; δ
H
 (400 MHz, d
6
 
DMSO); 8.32 (d, J = 5.7, 1H), 7.99 (d, J = 7.5, 2H), 7.61 (s, 1H), 7.45 (t, J = 7.4, 2H), 
7.35 (t, J = 7.3,  1H),  7.11 (s,  1H),  7.02 (d, J = 5.3,  1H); δ
C
 (100  MHz,  d
6
 DMSO); 
158.8,  151.6,  149.7,  146.1,  145.9,  134.5,  129.1,  128.8,  128.3,  126.3,  118.4,  112.1, 
107.1, 94.8, 21.5; m/z [TOF MS ES
+
] found 268.0000 [M + H]
+
, C
15
H
13
N
3
S requires 
268.0908; IR (neat) ν
max
; 3000-2600 (br), 2772, 1650, 1609, 1589, 1522, 1196, 1073, 
780, 756; 
 
 
 4-(2-(pyridin-2-ylethylamino)thiazol-4-yl)benzene-1,3-diol (153) 
 
 
 
 
 
Employing General Procedure Di; 2-Bromo-2,4-dihydroxyacetophenone (50 mg, 0.22 
mmol) and N-[2-(2-Pyridinyl)ethyl]thiourea (39  mg,  0.22  mmol) were suspended in 
EtOH (1  mL) and heated to 80 °C for a  duration  of  14  hours.  The reaction  was 
evaporated to  dryness and  directly chromatographed (CH
3
Cl:MeOH  9/1) to  give the 
desired product as a light yelow crystaline solid, (31 mg, 46%); Rf (CH
3
Cl/MeOH) 
(10/1); 0.33; Mp (Et
2
O): 131-133 °C; δ
H
 (400 MHz, MeOD
4
); 8.49 (m, 1H), 7.74 (td, J 
= 7.7, 1.8, 1H), 7.42 (d, J = 8.3, 1H), 7.34 (d, J = 7.8, 1H), 7.25 (ddd, J = 7.6, 5.2, 
0.9, 1H), 6.61 (s, 1H), 6.33-6.29 (m, 2H), 3.69 (t, J = 7.1, 1H), 3.13 (t, J = 7.1, 1H); δ
C
 
(100  MHz, MeOD
4
);  168.8,  158.7,  158.4,  156.9,  148.6,  148.4,  137.3,  126.6,  123.9, 
121.8, 110.7, 102.7, 95.9, 44.6, 36.8; m/z [TOF MS ES+] found 314.0965 [M + H
+
], 
C
16
H
16
N
3
O
2
S
 
requires  314.0963; IR (neat) ν
max
;  3300-2700 (br),  2418,  1547,  1438, 
1319, 1247, 1160, 1052, 970;  
N
S
NH
N
OH
HO
N
S
NH
N
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4-(2-aminothiazol-4-yl)benzene-1,3-diol (154) 
 
 
 
 
Employing  General  Procedure  Di; 2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
0.44 mmol) and thiourea (32  mg,  0.44  mmol) were suspended in EtOH (1  mL) and 
heated to 80 °C for a  duration  of  14  hours. Recrystalisation from  EtOH gave the 
desired product as a yelow crystaline solid, (141 mg, 81%); Mp (EtOH): 200-205 °C; 
δ
H
 (400 MHz, MeOD
4
); 7.40 (d, J = 8.3, 1H), 6.91 (s, 1H), 6.46 (d, J = 2.1, 1H), 6.44 
(dd, J = 8.7, 2.4, 1H); δ
C
 (100 MHz, CDCl
3
); 169.9, 160.3, 155.6, 136.9, 132.4 128.7, 
107.9,  106.4,  102.5; m/z [TOF  MS  ES+] found 209.0384 [M  +  H
+
], C
9
H
9
N
2
O
2
S 
requires  209.0385; IR (neat) ν
max
;  3500-2700 (br),  1607,  1557,  1454,  1312,  1266, 
1169, 977; 
 
 
4-(2-(1,3-dimethyl-1H-pyrazol-5-ylamino)thiazol-4-yl)benzene-1,3-diol (155) 
 
 
 
 
Employing  General  Procedure  Di; 2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
0.44 mmol) and 129 (76 mg, 0.44 mmol) were suspended in EtOH (1 mL) and heated 
to 80 °C for a  duration  of  14  hours.  The reaction  was evaporated to  dryness and 
directly chromatographed (CH
2
Cl
2
:MeOH  20/1) to  give the  desired  product as a 
yelow crystaline solid, (77 mg, 61%); Mp (MeOH); 235-237 °C; Rf (CH
2
Cl
2
/MeOH) 
(95/5); 0.16; δ
H
 (400 MHz, MeOD
4
); 7.46 (d, J = 8.5, 1H), 6.79 (s, 1H), 6.38 (d, J = 
2.5, 1H), 6.36 (dd, J = 8.5, 2.3, 1H), 6.12 (s, 1H), 3.71 (s, 3H), 2.24 (s, 3H); δ
C
 (100 
MHz, MeOD
4
); 165.9, 159.5, 157.6, 149.3, 148.5, 140.9, 127.9, 111.2, 108.4, 103.9, 
99.7,  97.4,  34.9,  13.7; m/z [TOF  MS  ES+] found 303.0915 [M  +  H
+
], C
14
H
15
N
4
O
2
S
 
requires  303.0916; IR (neat) ν
max
;  3223,  3200-2700 (br),  2251,  1568,  1532,  1438, 
1293, 1132, 972, 818; 
 
 
HO
N
S
NH
2
OH
OH
HO
N
S
NH
N
N
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4-(2-(naphthalen-2-ylamino)thiazol-4-yl)benzene-1,3-diol (156) 
 
 
 
 
 
Employing  General  Procedure Di; 2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
0.44 mmol) and 130 (89 mg, 0.44 mmol) were suspended in EtOH (1 mL) and heated 
to 80 °C for a  duration  of  14  hours.  The reaction  was evaporated to  dryness and 
triturated  with  MeOH/Et
2
O to  give the  desired  product as a purple crystaline solid, 
(99 mg, 67%); Mp (Et
2
O); 39-42 °C; δ
H
 (400 MHz, CDCl
3
); 8.09-8.04 (m, 1H), 7.96-
7.91 (m,  1H),  7.79 (d, J = 8.3,  1H),  7.72 (dd, J = 7.4,  0.8,  1H),  7.58-7.50 (m,  3H), 
7.44 (d, J = 8.5, 1H), 6.61 (s, 1H), 6.49 (d, J = 2.5, 1H), 6.42 (dd, J = 8.5, 2.5, 1H); δ
C
 
(100  MHz,  CDCl
3
);  166.9,  158.9,  157.1,  148.0,  136.8,  134.6,  133.9,  129.7,  128.7, 
128.4,  127.0,  126.4,  124.7,  122.7,  118.3,  115.4,  107.7,  106.6,  103.4; m/z [TOF  MS 
ES+] found 335.0857 [M + H
+
], C
19
H
15
N
2
O
2
S
 
requires 335.0854; IR (neat) ν
max
; 3500-
2800 (br), 3293, 1703, 1598, 1539, 1448, 1159, 1114, 1039, 974; 
 
 
 4-(2-(3-chlorophenylamino)thiazol-4-yl)benzene-1,3-diol (157) 
 
 
 
 
 
Employing  General  Procedure  Di;  2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
0.44 mmol) and 131 (83 mg, 0.44 mmol) were suspended in EtOH (1 mL) and heated 
to  80 °C for a  duration  of  14  hours.  The reaction  was evaporated to  dryness and 
directly chromatographed (CH
2
Cl
2
:MeOH 99/1) to give the desired product as a light 
yelow crystaline solid, (56 mg, 39%); Mp (MeOH); 153-155 °C; Rf (CH
2
Cl
2
/MeOH) 
(95/5); 0.39; δ
H
 (400 MHz, d
6
 DMSO); 10.57 (s, 1H, OH), 9.86 (s, 1H, OH), 7.70 (d, J 
= 8.4, 1H), 7.61 (d, J = 8.9, 2H), 7.43 (d, J = 8.8, 2H), 7.20 (s, 1H), 6.38 (d, J = 2.4, 
1H), 6.34 (dd, J = 8.6, 2.4, 1H); δ
C
 (100 MHz, d
6
 DMSO); 162.9, 158.7, 156.7, 147.1, 
140.1,  129.5,  129.3,  125.8,  119.5,  111.6,  107.6,  103.3,  101.9;  m/z [TOF  MS  ES+] 
found 319.0310 [M  +  H
+
], C
15
H
12
ClN
2
O
2
S
 
requires  319.0308; IR (neat) ν
max
;  3200-
2600 (br), 3146, 1613, 1582, 1504, 1449, 1179, 1171, 831; 
OH
HO
N
S
NH
OH
HO
N
S
NH
Cl
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4-(2-(biphenyl-2-ylamino)thiazol-4-yl)benzene-1,3-diol (158) 
 
 
 
 
 
Employing  General  Procedure  Di; 2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
0.44 mmol) and 132 (83 mg, 0.44 mmol) were suspended in EtOH (1 mL) and heated 
to 80 °C for a  duration  of  14  hours.  The reaction  was evaporated to  dryness and 
directly chromatographed (CH
2
Cl
2
:MeOH  99/1) to  give the  desired  product as an 
orange crystaline solid, (40  mg,  25%);  Mp (MeOH); 42-44 °C;  Rf (CH
2
Cl
2
/MeOH) 
(20/1); 0.53; δ
H
 (400  MHz, d
6
 Acetone); 8.82 (brs,  1H),  8.50 (brs,  1H),  7.82 (d, J = 
8.0,  1H),  7.54-7.30 (m,  9H),  6.98 (s,  1H),  6.86 (s,  1H),  6.40-6.38 (m,  2H); δ
C
 (100 
MHz,  d
6
 Acetone); 166.8,  158.7,  157.7,  148.9,  137.5,  137.4,  135.6,  133.9,  131.1, 
129.2, 128.6, 128.5, 127.5, 127.1, 125.5, 125.2, 123.5, 110.5, 107.3, 103.3, 97.8; m/z 
[TOF MS ES+] found 361.1006 [M + H
+
], C
21
H
17
N
2
O
2
S
 
requires 361.1011; IR (neat) 
ν
max
; 3500-2800 (br), 2945, 1599, 1537, 1434, 1296, 1156, 1118, 973, 746; 
 
 
 
4-(2-(benzo[d][1,3]dioxol-5-ylamino)thiazol-4-yl)benzene-1,3-diol (159) 
 
 
 
 
 
Employing  General  Procedure  Di; 2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
0.44 mmol) and methylene-dioxythiourea (86  mg,  0.44  mmol) were suspended in 
EtOH (1  mL) and  heated to 80 °C for a  duration  of  14  hours.  The reaction  was 
evaporated to dryness and directly chromatographed (CH
2
Cl
2
:EtOAc 6/1) to give the 
desired  product as an  orange crystaline solid, (82  mg,  57%); Mp (EtOAc); 158-160 
°C; Rf (CH
2
Cl
2
/EtOAc) (3/1); 0.59; δ
H
 (400 MHz, d
6
 DMSO); 11.02 (s, 1H), 10.16 (s, 
1H), 9.47 (s, 1H), 7.64 (d, J = 9.1, 1H), 7.21 (s, 1H), 7.08 (s, 1H), 6.92 (m, 2H), 6.33-
6.30 (m,  2H),  6.01 (s,  2H);  δ
C
 (100  MHz,  d
6
 DMSO);  163.9,  158.7,  156.9,  148.0, 
142.7, 135.9, 128.7, 112.1, 111.6, 111.1, 108.9, 107.6, 103.4, 101.5, 100.8, 100.2; m/z 
OH
HO
N
S
NH
OH
HO
N
S
NH
O
O
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[TOF MS ES+] found 329.0602 [M + H
+
], C
16
H
13
N
2
O
4
S
 
requires 329.0596; IR (neat) 
ν
max
; 3447, 3275, 3100-2700 (br), 1566, 1500, 1435, 1292, 1053, 974; 
 
 
(S)-2-(4-(2,4-dihydroxyphenyl)thiazol-2-ylamino)-3-(4-hydroxyphenyl)propanoic acid 
(160) 
 
 
 
 
 
Employing  General  Procedure  Di; 2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
0.44 mmol) and 133 (102 mg, 0.40 mmol) were suspended in EtOH (1 mL) and heated 
to 80 °C for a duration of 14 hours. The reaction was evaporated to dryness, and the 
residue  directly chromatographed (CH
2
Cl
2
:MeOH:FA  95/2.5/1) to  give the desired 
product as yelow crystaline needles, (93 mg, 63%); α
D
 = -42.6 ° (c = 10.4 mg/mL, 
MeOH); Mp (MeOH);  141-143 °C; Rf (CH
2
Cl
2
/MeOH/FA) (95/5/1); 0.13; δ
H
 (400 
MHz, MeOD
4
); 7.43 (d, J = 8.0,  1H),  7.11 (d, J = 7.6,  2H),  6.73 (d, J = 7.6,  2H), 
6.33-6.31 (m,  2H),  4.47 (brm,  1H),  3.38 (brs,  1H),  3.19 (dd, J =13.5,  4.8,  1H),  3.04 
(dd, J = 13.4,  8.0, 1H); δ
C
 (100  MHz,  MeOD
4
); 174.4,  167.8,  158.4,  156.7,  155.9, 
130.5,  129.9,  127.7,  126.8,  114.8,  110.5,  107.1,  102.7,  98.9,  59.7,  48.5,  36.6; m/z 
[TOF MS ES+] found 373.0859 [M + H
+
], C
18
H
17
N
2
O
5
S
 
requires 373.0858; IR (neat) 
ν
max
; 3500-2700 (br), 3204, 1595, 1513, 1446, 1314, 1232, 1172, 1112, 830; 
 
 
4-(2-(m-tolylamino)thiazol-4-yl)benzene-1,3-diol (161) 
 
 
 
 
 
Employing  General  Procedure  Di; 2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
0.44 mmol) and 3-methylphenylthiourea (73 mg, 0.44 mmol) were suspended in EtOH 
(1 mL) and heated to 80 °C for a duration of 14 hours. Recrystalisation from EtOH 
gave the desired product as yelow crystaline needles (37 mg, 28%); Mp (Et
2
O); 31-
OH
HO
N
S
NH
OH
HO
N
S
NH
HO
2
C
OH
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33 °C; Rf (CH
2
Cl
2
/EtOAc) (3/1); 0.68; δ
H
 (400 MHz, d
6
 DMSO); 11.09 (s, 1H), 10.28 
(s, 1H), 9.49 (s, 1H), 7.66 (d, J = 9.1, 1H), 7.33-7.31 (m, 2H), 7.24 (t, J = 7.7, 1H), 
7.12 (s, 1H), 6.83 (d, J = 7.4, 1H), 6.34-6.31 (m, 2H), 2.32 (s, 3H); δ
C
 (100 MHz, d
6
 
DMSO); 163.4, 158.8, 156.9, 148.0, 141.2, 138.9, 129.5, 128.7, 123.1, 118.4, 114.9, 
111.5,  107.7,  103.4,  100.4,  21.8; m/z [TOF  MS  ES+] found 299.0852 [M  +  H
+
], 
C
16
H
15
N
2
O
2
S
 
requires 299.0854; IR (neat) ν
max
; 3239 (m), 3200-2700 (brw), 1599 (m), 
1539 (s), 1444 (s), 1292 (s), 1159 (s), 1115 (s), 972 (s); 
 
 
4-(2-(3-ethylphenylamino)thiazol-4-yl)benzene-1,3-diol (162) 
 
 
 
 
 
Employing  General  Procedure  Di; 2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
0.44 mmol) and 3-ethylphenylthiourea (79 mg, 0.44 mmol) were suspended in EtOH 
(1 mL) and heated to 80 °C for a duration of 14 hours. The reaction was evaporated to 
dryness, and the residue  directly chromatographed (CH
2
Cl
2
:EtOAc  8/1) to  give the 
desired product as a light brown crystaline solid, (61 mg, 44%); Mp (EtOAc); 46-49 
°C; Rf (CH
2
Cl
2
/EtOAc) (3/1); 0.76; δ
H
 (400 MHz, d
6
 DMSO); 10.45 (s, 1H, OH), 7.55 
(dd, J = 7.4, 1.8, 1H), 7.46 (d, J = 8.6, 1H), 7.37 (dd, J = 7.1, 1.7, 1H), 7.36-7.26 (m, 
2H), 7.02 (s, 1H), 6.38 (d, J = 2.1, 1H), 6.32 (dd, J = 8.7, 2.3, 1H), 2.66 (q, J = 7.5, 
2H), 1.14 (t, J = 7.5, 3H); δ
C
 (100 MHz, d
6
 DMSO); 164.4, 161.5, 142.3, 138.0, 134.8, 
134.5,  133.6,  132.4,  129.7,  113.7,  112.6,  108.1,  107.7,  105.1,  28.9,  19.8; m/z [TOF 
MS ES+] found 313.1003 [M + H
+
], C
17
H
17
N
2
O
2
S
 
requires 313.1011; IR (neat) ν
max
; 
3500-2700 (br), 3298, 2967, 1597, 1537, 1445, 1395, 1294, 1115, 972, 689; 
 
 
 
 
 
 
 
 
 
 
OH
HO
N
S
NH
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4-(2-(3,6-dimethylphenylamino)thiazol-4-yl)benzene-1,3-diol (163) 
 
 
 
 
 
 
 
Employing  General  Procedure  Di; 2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
0.44 mmol) and 3,5dimethylphenylthiourea (79  mg,  0.44  mmol) were suspended in 
EtOH (1  mL) and  heated to 80 °C for a  duration  of  14  hours.  The reaction  was 
evaporated to dryness, and the residue directly chromatographed (CH
2
Cl
2
:EtOAc 8/1) 
to give the desired product as a yelow crystaline solid, (36 mg, 53%); Mp (EtOH); 
177-179 °C; δ
H
 (400 MHz, d
6
 DMSO); 10.65 (s, 1H, OH), 7.43 (d, J = 8.6, 1H), 7.39 
(d, J = 8.0, 1H), 7.23-7.11 (m, 2H), 7.03 (s, 1H), 6.45 (d, J = 2.1, 1H), 6.35 (dd, J = 
8.6, 2.2, 1H), 2.30 (s, 3H), 2.25 (s, 3H); δ
C
 (100 MHz, d
6
 DMSO); 168.8, 159.9, 156.6, 
137.4,  134.9,  133.3,  132.4,  129.2,  128.3,  124.8,  107.9,  103.4,  100.7,  19.0,  17.9; m/z 
[TOF MS ES+] found 313.1009 [M + H
+
], C
17
H
17
N
2
O
2
S
 
requires 313.1011; IR (neat) 
ν
max
; 3300-2750 (br), 3123, 1614, 1572, 1487, 1456, 1316, 1212, 1169, 1118; 
 
 
4-(2-(benzylamino)thiazol-4-yl)benzene-1,3-diol (164) 
 
 
 
 
 
 
Employing  General  Procedure  Di; 2-Bromo-2,4-dihydroxyacetophenone (100  mg, 
0.44 mmol) and benzylthiourea (79 mg, 0.44 mmol) were suspended in EtOH (1 mL) 
and  heated to 80 °C for a  duration  of  14  hours.  The reaction  was evaporated to 
dryness, and the residue  directly chromatographed (CH
2
Cl
2
:EtOAc  8/1) to  give the 
desired product as a yelow crystaline solid, (41 mg, 64%); Mp (EtOH); 102-105 °C; 
δ
H
 (400 MHz, d
6
 DMSO); 9.69 (s, 1H, OH), 7.41-7.29 (m, 7H), 6.94 (s, 1H), 6.43 (d, J 
= 2.0, 1H), 6.33 (dd, J = 8.5, 2.0, 1H), 4.61 (s, 2H); δ
C
 (100 MHz, d
6
 DMSO); 173.7, 
164.8,  161.4,  141.4,  134.4,  133.9,  133.4,  133.0,  132.9,  132.0,  112.5,  108.5,  105.6, 
70.1; m/z [TOF MS ES+] found 299.0857 [M + H
+
], C
16
H
15
N
2
O
2
S
 
requires 299.0854; 
IR (neat) ν
max
; 3200-2600 (br), 1597, 1495, 1452, 1314, 1168, 1117, 1068, 977; 
N
S
NH
OH
HO
OH
HO
N
S
NH
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4-(2-(4-(trifluoromethyl)pyridin-2-yl)-4-(2,4-dimethoxyphenyl)thiazol-2-amine 
(167) 
 
 
 
 
 
 
2-Chloro-4-(trifluoromethyl)pyridine (65 µL,  0.51 mmol),  Pd
2
(dba)
3
 (11.5  mg,  0.013 
mmol), SPhos (16.1  mg,  0.026 mmol), and NaO
t
Bu (100 mg,  1.05 mmol)  were 
suspended in toluene (1.5 mL). After 5 min of stiring amine 165 (100 mg, 0.42 mmol) 
was added and the mixture heated for 16 h at 95 °C . The reaction mixture was cooled 
to ambient temperature, diluted with EtOAc (50 mL) and poured into water (35 mL). 
The aqueous phase was extracted with EtOAc (2 × 30 mL), combined organic extracts 
were  washed  with  brine,  dried (MgSO
4
) rotary evaporated, and chromatographed 
(CH
2
Cl
2
:Et
2
O 50/1) to give the desired product as an orange crystaline solid, (83 mg, 
52%); Mp (Et
2
O); 64-66 °C; Rf (CH
2
Cl
2
/Et
2
O) (95/5); 0.50; δ
H
 (400  MHz, CDCl
3
); 
8.47 (d, J =5.3, 1H), 8.06 (d, J =8.5, 1H), 7.42 (s, 1H), 6.94 (d, J = 5.4, 1H), 6.61 (d, J 
= 2.2, 1H), 6.47 (s, 1H), 6.45 (dd, J = 8.6, 2.3, 1H), 3.98 (s, 3H), 3.80 (s, 3H); δ
C
 (100 
MHz,  CDCl
3
); 160.5,  159.8,  158.1,  152.1,  151.1,  147.8,  144.9,  139.3,  130.2,  116.3, 
110.9, 108.8, 107.0, 104.9, 98.9, 55.4, 55.3; m/z [TOF MS ES+] found 382.0822 [M + 
H
+
], C
17
H
15
F
3
N
3
O
2
S
 
requires 382.0837; IR (neat) ν
max
; 2932, 1611, 1553, 1398, 1322, 
1129, 1081, 1032, 815; 
 
 
4-(2-(4-(trifluoromethyl)pyridin-2-ylamino)thiazol-4-yl)benzene-1,3-diol (168) 
 
 
 
 
 
Compound 167 (60 mg, 0.16 mmol) was dissolved in CH
2
Cl
2
 (750 µL) and cooled to -
78 °C. BBr
3  
(1.0  M in  CH
2
Cl
2
) (472 µL, 0.47 mmol) was added  dropwise over  10 
minutes and the ensuing mixture stired for 4 hours. The reaction was quenched with 
MeOH (2  mL), evaporated to  dryness and the residue  directly chromatographed 
OMe
MeO
N
S
NH
N
F
3
C
OH
HO
N
S
NH
N
F
3
C
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(CH
2
Cl
2
:Et
2
O 15/1) to give the desired product as a light yelow powder solid, (43 mg, 
78%); Mp (Et
2
O); decomposed  >200 °C; Rf (CH
2
Cl
2
/Et
2
O) (10/1);  0.75; δ
H
 (400 
MHz, d
6
 DMSO); 9.45 (brs, 2H), 8.61 (d, J = 5.3, 1H), 7.66 (d, J = 8.5, 1H), 7.43 (s, 
1H),  7.39 (s,  1H),  7.31 (d, J =5.3,  1H),  6.38 (s,  1H),  6.34 (dd, J =8.5,  2.3,  1H); δ
C
 
(100 MHz, d
6
 DMSO); 158.9, 157.2, 156.8, 152.4, 149.1, 138.6, 130.8, 128.7, 111.8, 
110.7,  107.8,  107.3,  106.9,  104.6,  103.4; m/z [TOF  MS  ES+] found 354.0517 [M  + 
H
+
], C
15
H
11
F
3
N
3
O
2
S
 
requires 354.0524; IR (neat) ν
max
; 3200-2900 (brw), 3119, 2300, 
1610, 1555, 1432, 1333, 1161, 1136, 844; 
 
 
 
General Procedure D: 
 
Synthesis of Thiazoles  
 
Thiourea (0.43 mmol, 1 eq.) and 2-Bromo-1-(2,4)-dimethoxyacetophenone 114 (0.43 
mmol, 1 eq.) were suspended in EtOH (5 mL) and heated to 80 °C for a duration of 14 
hours.  The reaction  mixture  was alowed to cool to ambient temperature and the 
solvent removed via rotary evaporation. The resulting crude solid was either 
recrystalised from EtOH, or column chromatographed using the stated solvent system. 
 
 
4-(2,4-Dimethoxyphenyl)-N-phenylthiazol-2-amine (169) 
 
 
 
 
 
Employing  General  Procedure  D; 114 (110  mg,  0.43  mmol) and 120 (65  mg,  0.43 
mmol) were suspended in EtOH (5 mL) and heated to 80 °C for a duration of 14 hours. 
Recrystalisation from EtOH gave the desired product as a white crystaline solid, (49 
mg, 82%); Mp (EtOH); 184-186 °C; δ
H
 (400 MHz, CDCl
3
); 7.64 (d, J = 8.6, 1H), 7.47 
(m, 4H), 7.32 (m, 1H), 6.70 (s, 1H), 6.62 (dd, J = 8.5, 2.4, 1H), 6.58 (d, J = 2.3, 1H) 
4.09 (s,  3H),  3.82 (s,  3H); δ
C
 (100  MHz  CDCl
3
);  166.7,  162.7,  157.6,  137.8,  136.8, 
130.1,  129.4,  127.2,  127.0,  108.7,  105.9,  98.9,  97.9,  56.2,  55.6; m/z [TOF  MS  ES
+
]
 
OMe
MeO
N
S
NH
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found 313.1010 [M  +  H]
+
, C
17
H
17
N
2
O
2
S requires 313.1011; IR (neat) νmax; 3177, 
2779, 1607, 1581, 1487, 1212, 1157, 1052, 831, 758, 702; 
 
 
4-(2,4-Dimethoxyphenyl)-N-(4-methylpyridin-2-yl)thiazol-2-amine (170) 
 
 
 
 
 
 
Employing  General  Procedure  D; 114 (110  mg,  0.43  mmol) and 121 (72  mg,  0.43 
mmol) were suspended in EtOH (5 mL) and heated to 80 °C for a duration of 14 hours. 
Recrystalisation from  EtOH  yields gave the  desired  product as a white crystaline 
solid, (105 mg, 75%); Mp (EtOH); 132-134 °C; δ
H
 (400 MHz, CDCl
3
); 8.26 (d, J = 
4.9, 1H), 7.63 (d, J = 8.6, 1H), 7.22 (s, 1H), 6.95 (d, J = 4.8, 1H), 6.89 (s, 1H), 6.63 
(dd, J = 8.7, 2.1, 1H), 6.58 (d, J = 2.1, 1H), 4.13 (s, 3H), 3.87 (s, 3H) 2.41 (s, 3H); δ
C
 
(100  MHz  CDCl
3
);  162.5,  160.9,  157.4,  150.5,  145.9,  137.2,  129.3,  120.9,  113.3, 
105.9,  103.9,  98.8,  56.3,  55.5,  21.0; m/z [TOF  MS  ES
+
]
 
found 328.1130 [M  +  H]
+
, 
C
17
H
18
N
3
O
2
S requires 328.1120; IR (neat) νmax; 2930, 2789, 1652, 1614, 1591, 1455, 
1289, 1253, 1210, 1022, 816, 791; 
 
 
4-(2,4-Dimethoxyphenyl)-N-(3,4-dimethylphenyl)thiazol-2-amine (171) 
 
 
 
 
 
 
Employing General  Procedure  D; 114 (110  mg,  0.43  mmol) and 122 (77  mg,  0.43 
mmol) were suspended in EtOH (5 mL) and heated to 80 °C for a duration of 14 hours. 
Recrystalisation from EtOH gave the desired product as a white crystaline solid, (107 
mg, 73%); Mp (EtOH); 189-192 °C; δ
H
 (400 MHz, CDCl
3
); 7.67 (d, J = 8.7, 1H), 7.22 
(m, 2H), 7.15 (dd, J = 7.9, 2.5, 1H), 6.67 (s, 1H), 6.62 (dd, J = 8.7, 2.4), 6.58 (d, J = 
2.3), 4.09 (s, 3H), 3.87 (s, 3H), 2.31 (s, 3H), 2.29 (s, 3H); δ
C
 (100 MHz CDCl
3
); 167.1, 
162.6,  157.8,  138.7,  137.6,  136.1,  134.6,  130.9,  129.4,  122.7,  118.2.  108.8,  105.8, 
OMe
MeO
N
S
NH
N
OMe
MeO
N
S
NH
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98.9,  97.8,  56.2,  55.6,  19.8,  19.4; m/z [TOF  MS  ES
+
]
 
found 341.1336 [M  +  H]
+
, 
C
19
H
21
N
2
O
2
S requires 341.1324; IR (neat) νmax; 2840, 1616, 1574, 1483, 1216, 1160, 
1020, 827, 758;  
 
 
4-(2,4-Dimethoxyphenyl)-N-(3-methylpyridin-2-yl)thiazol-2-amine (172) 
 
 
 
 
Employing  General  Procedure  D; 114 (110  mg,  0.43  mmol) and pyridylthiourea (46 
mg, 0.43 mmol) were suspended in EtOH (5 mL) and heated to 80 °C for a duration of 
14 hours. Recrystalisation from EtOH gave the desired product as a white crystaline 
solid, (86 mg, 61%); Mp (EtOH); 250-252 °C; δ
H
 (400 MHz, CDCl
3
); 8.29 (d, J = 5.4, 
1H), 7.79 (d, J = 8.7, 1H), 7.62 (d, J = 7.3, 1H), 7.08 (dd, J = 7.6, 2.4, 1H), 7.01 (s, 
1H), 6.66 (dd, J = 8.7, 2.4, 1H), 6.59 (d, J = 2.4, 1H), 4.07 (s, 3H), 3.88 (s, 3H), 2.70 
(s, 3H); δ
C
 (100 MHz CDCl
3
); 162.4, 160.3, 157.8, 147.6, 143.1, 139.7, 136.2, 125.7, 
119.4, 105.6, 105.5, 99.0, 56.1, 55.6, 18.1; m/z [TOF MS ES
+
]
 
found 328.1124 [M + 
H]
+
, C
17
H
18
N
3
O
2
S requires 328.1120; IR (neat) νmax; 3013, 2833, 1613, 1586, 1556, 
1416, 1318, 1162, 1020, 832, 775; 
 
 
4-(2,4-Dimethoxyphenyl)-N-(pyridin-2-yl)thiazol-2-amine (173) 
  
 
 
 
 
Employing  General Procedure  D; 114 (110  mg,  0.43  mmol) and pyridylthiourea (66 
mg, 0.43 mmol) were suspended in EtOH (5 mL) and heated to 80 °C for a duration of 
14 hours. Recrystalisation from EtOH gave the desired product as a white crystaline 
solid, (61 mg, 45%); Mp (EtOH); 205-208 °C; δ
H
 (400 MHz, CDCl
3
); 8.44 (d, J = 4.2, 
1H), 7.80 (t, J = 7.5 1H), 7.65 (d, J = 8.6, 1H), 7.43 (d, J = 8.1, 1H), 7.14 (dd, J = 6.8, 
1.2, 1H), 6.91 (s, 1H), 6.63 (dd, J = 8.6, 2.3, 1H), 6.60 (d, J = 2.3, 1H), 4.06 (s, 3H), 
OMe
MeO
N
S
NH
N
OMe
MeO
N
S
NH
N
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3.89 (s,  3H); δ
C
 (100  MHz  CDCl
3
);  162.6,  157.8,  157.6,  157.2,  156.3,  146.3,  138.7, 
129.3, 119.5, 113.1, 106.1, 103.8, 98.9, 56.3, 55.6; m/z [TOF MS ES
+
]
 
found 314.0968 
[M + H]
+
, C
16
H
16
N
3
O
2
S requires 314.0963; IR (neat) νmax; 3190, 2696, 1615, 1555, 
1480, 1431, 1214, 1161, 1144, 1015, 826, 770, 723; 
 
 
1-(4-(4-(2,4-Dimethoxyphenyl)thiazol-2-ylamino)phenyl)ethanone (174) 
 
 
 
 
 
 
 
Employing General Procedure D; 114 (110 mg, 0.43 mmol) and  (83 mg, 0.43 mmol) 
were suspended in  EtOH (5  mL) and  heated to 80 °C for a  duration  of  14  hours. 
Recrystalisation from EtOH gave the desired product as a white crystaline solid, (88 
mg, 58 %); Mp (EtOH); 198-200°C; δ
H
 (400 MHz, CDCl
3
); 8.08 (d, J = 8.7, 2H), 7.67 
(d, J = 8.7, 1H), 7.55 (d, J = 6.5, 2H), 6.82 (s, 1H), 6.64 (dd, J = 8.8, 2.4, 1H), 6.59 
(d, J = 2.3, 1H), 4.12 (s, 3H), 3.89 (s, 3H), 2.64 (s, 3H); δ
C
 (100 MHz CDCl
3
); 196.4, 
164.3, 162.6, 157.8, 141.1, 139.2, 134.1, 130.3, 129.6, 118.7, 109.3, 105.9, 99.5, 98.9, 
56.2, 55.6, 26.5; m/z [TOF MS ES
+
]
 
found 355.1121 [M + H]
+
, C
19
H
19
N
2
O
3
S requires 
355.1116; IR (neat) νmax; 2678,  1678,  1599,  1559,  1505,  1447,  1358,  1269,  1180, 
1020, 818, 779, 746, 647; 
 
 
4-(2,4-Dimethoxyphenyl)-N-(4-fluorophenyl)thiazol-2-amine (175) 
 
 
 
 
 
 
Employing  General Procedure  D; 114 (110  mg,  0.43  mmol) and 4-
fluorophenylthiourea (73 mg, 0.43 mmol) were suspended in EtOH (5 mL) and heated 
to 80 °C for a  duration  of  14  hours. Recrystalisation from  EtOH gave the  desired 
product as a white crystaline solid, (116 mg, 82%); Mp (EtOH); 181-183 °C; δ
H
 (400 
OMe
MeO
N
S
NH
O
OMe
MeO
N
S
NH
F
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MHz,  CDCl
3
);  7.66 (d, J = 8.7,  1H),  7.45 (m,  2H),  7.20 (m,  2H),  6.82 (s,  1H),  6.64 
(dd, J = 8.7, 2.4, 1H), 6.60 (d, J = 2.4, 1H), 4.12 (s, 3H), 3.89 (s, 3H); δ
C
 (100 MHz 
CDCl
3
);  167.5,  162.7,  162.4,  159.8,  157.7,  137.9, 132.9,  129.3,  123.8,  117.2,  117.1, 
108.6,  106.0,  98.9,  97.8,  56.3,  55.6; m/z [TOF  MS  ES
+
]
 
found 331.0981 [M  +  H]
+
, 
C
17
H
16
FN
2
O
2
S requires 331.0917; IR (neat) νmax; 2671,  1610,  1587,  1517,  1492, 
1462, 1288, 1212, 1148, 1049, 1015, 833, 759, 680; 
 
 
4-(2,4-Dimethoxyphenyl)-N-(3,5-dimethylphenyl)thiazol-2-amine (176) 
 
 
 
 
 
Employing General Procedure D; 114 (110 mg, 0.43 mmol) and 3,5-dimethylthiourea 
(77  mg,  0.43  mmol) were suspended in  EtOH (5  mL) and  heated to 80 °C for a 
duration of 14 hours. Recrystalisation from EtOH gave the desired product as a white 
crystaline solid, (94 mg, 64%); Mp (EtOH); 206-209 °C; δ
H
 (400 MHz, CDCl
3
); 7.70 
(d, J = 8.6, 1H), 7.24 (m, 2H), 7.12 (d, J = 7.7), 6.64 (m, 2H), 6.58 (d, J = 2.3, 1H), 
4.09 (s,  3H),  3.89 (s,  3H),  2.44 (s,  3H),  2.37 (s,  3H); δ
C
 (100  MHz  CDCl
3
); 169.5, 
162.4,  157.7,  138.8,  137.7,  133.8,  133.4,  132.6,  129.3,  128.0,  123.4,  109.03,  105.8, 
98.9,  98.3,  56.2,  55.6,  21.1,  18.3; m/z [TOF  MS  ES
+
]
 
found 341.1332 [M  +  H]
+
, 
C
19
H
20
N
2
O
2
S requires 341.1324; IR (neat) νmax; 2918, 1616, 1597, 1488, 1455, 1279, 
1215, 1159, 1044, 830, 763; 
 
 
4-(2,4-Dimethoxyphenyl)-N-(2,5-dimethylphenyl)thiazol-2-amine (177) 
 
 
 
 
Employing  General  Procedure  D; 114 (110  mg,  0.43  mmol) and 126 (77  mg,  0.43 
mmol) were suspended in EtOH (5 mL) and heated to 80 °C for a duration of 14 hours. 
Recrystalisation from EtOH gave the desired product as a white crystaline solid, (104 
mg, 71%); Mp (EtOH); 206-209 °C; δ
H
 (400 MHz, CDCl
3
); 7.70 (d, J = 8.7), 7.29 (s, 
OMe
MeO
N
S
NH
OMe
MeO
N
S
NH
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2H), 7.17 (s, 1H), 7.10 (d, J = 7.9), 6.65 (m, 2H), 6.59 (d, J = 2.4, 1H), 4.09 (s, 3H), 
3.89 (s,  3H),  2.45 (s,  3H),  2.38 (s,  3H); δ
C
 (100  MHz  CDCl
3
);  169.7, 162.5,  157.8, 
140.2, 137.9, 135.4, 130.2, 129.3, 129.1, 127.4, 123.9, 109.0, 105.8, 98.9, 98.1, 56.2, 
55.6, 23.7, 17.6; m/z [TOF MS ES
+
]
 
found 341.1332 [M + H]
+
, C
19
H
21
N
2
O
2
S requires 
341.1324; IR (neat) νmax; 2838,  1614,  1578,  1561,  1507,  1460,  1268,  1213,  1173, 
1021, 817, 741, 703; 
 
4-(2,4-Dimethoxyphenyl)-N-(2-ethylphenyl)thiazol-2-amine (178) 
 
 
 
 
Employing  General  Procedure  D; 114 (110  mg,  0.43  mmol) and 127 (77  mg,  0.43 
mmol) were suspended in EtOH (5 mL) and heated to 80 °C for a duration of 14 hours. 
Recrystalisation from EtOH gave the desired product as a white crystaline solid, (86 
mg, 59%); Mp (EtOH); 197-199 °C; δ
H
 (400 MHz, CDCl
3
); 7.71 (d, J = 8.6, 1H), 7.36 
(m, 4H), 6.65 (dd, J = 8.7, 2.5, 1H), 6.66 (s, 1H), 6.60 (d, J = 2.4, 1H), 4.10 (s, 3H), 
3.89 (s, 3H), 2.86 (q, J = 7.6, 2H), 1.30 (t, J = 7.5, 3H); δ
C
 (100 MHz CDCl
3
); 169.7, 
162.5,  157.8,  140.2,  137.9,  135.4,  130.2,  129.3,  129.1,  127.4,  123.9,  109.0,  105.8, 
98.9,  98.1,  56.2,  55.6,  24.7,  14.8; m/z [TOF  MS  ES
+
]
 
found  341.1269 [M  +  H]
+
, 
C
19
H
21
N
2
O
2
S requires 341.1324; IR (neat) νmax; 2966, 1614, 1578, 1561, 1507, 1460, 
1268, 1213, 1173, 1021, 817, 741, 703; 
 
 
2-(4-(2,4-Dimethoxyphenyl)thiazol-2-ylamino)phenol (179) 
 
 
 
 
Employing  General  Procedure  D; 114 (110  mg,  0.43  mmol) and 2-
hydroxyphenylthiourea (72  mg,  0.43  mmol) were suspended in  EtOH (5  mL) and 
heated to 80 °C for a  duration  of  14  hours. Recrystalisation from  EtOH gave the 
desired product as a white crystaline solid, (107 mg, 73%); Mp (EtOH); 200-202 °C; 
δ
H
 (400 MHz, d
4 
MeOH); 7.56 (d, J = 8.6, 1H), 7.43 (dd, J = 7.9, 1.5, 1H), 7.28 (dt, J 
OMe
MeO
N
S
NH
OMe
MeO
N
S
NH
OH
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= 8.1, 1.31 1H), 7.05 (s, 1H), 7.01 (dt, J = 7.8, 1.3, 1H), 6.74 (d, J = 2.3), 6.64 (dd, J 
= 8.6,  2.4,  1H),  3.98 (s,  3H),  3.89 (s,  3H); δ
C
 (100  MHz  d
4 
MeOH);  162.9,  157.7, 
150.7,  129.7,  128.8,  128.7,  124.4,  123.9,  123.5,  119.9,  116.4,  112.8,  109.4,  105.7, 
98.4, 55.1, 54.7; m/z [TOF MS ES
+
]
 
found 329.0959 [M + H]
+
, C
17
H
17
N
2
O
3
S requires 
329.0960; IR (neat) νmax; 3154, 1616, 1580, 1508, 1461, 1214, 1023, 917, 818, 743, 
704; 
 
 
4-(2,4-Dimethoxyphenyl)-N-(3-methyl-1H-pyrazol-4-yl)thiazol-2-amine (180) 
 
 
 
 
 
Employing General  Procedure  D; 114 (105  mg,  0.43  mmol) and 124 (67  mg,  0.43 
mmol) were suspended in EtOH (5 mL) and heated to 80 °C for a duration of 14 hours. 
Recrystalisation from EtOH gave the desired product as a white crystaline solid, (86 
mg, 48%); Mp (EtOH); 152-155 °C; δ
H
 (400 MHz, d
4
 MeOH); 7.69 (d, J = 8.7, 1H), 
7.24 (s, 1H), 6.72 (d, J = 2.3, 1H), 6.69 (dd, J = 8.7, 2.4, 1H), 5.92 (s, 1H), 4.11 (s, 
3H), 3.89 (s, 3H), 3.33 (s, 3H); δ
C
 (100 MHz d
4
 MeOH); 162.8, 156.9, 146.7, 141.5, 
129.8, 129.8, 129.2, 108.4, 106.6, 98.4, 92.6, 55.6, 54.8, 9.4; m/z [TOF MS ES
+
]
 
found 
317.1065 [M  +  H]
+
, C
15
H
17
N
4
O
2
S requires 317.1072; IR (neat) νmax; 2893,  1608, 
1570, 1538, 1496, 1457, 1366, 1206, 1157, 1022, 901, 821, 707;  
 
 
 
N-(4-Chloropyridin-2-yl)-4-(2,4-dimethoxyphenyl)thiazol-2-amine (181) 
 
 
 
 
 
Employing General Procedure D; 114 (105 mg, 0.43 mmol) and 1-(4-chloropyridin-2-
yl)thiourea (80 mg, 0.43 mmol) were suspended in EtOH (5 mL) and heated to 80 °C 
for a duration of 14 hours. Recrystalisation from EtOH gave the desired product as a 
white crystaline solid, (86  mg,  48%);  Mp (EtOH); 207-210 °C; δ
H
 (400  MHz,  d
4
 
MeOH); 8.54 (s, 1H), 7.99 (d, J = 7.7, 1H), 7.70 (d, J = 8.4, 1H) 7.25 (d, J = 8.7, 1H), 
OMe
MeO
N
S
NH
N
N
H
OMe
MeO
N
S
NH
N
Cl
	   250	  
6.78 (s, 1H), 6.73 (d, J = 2.4, 1H), 6.64 (dd, J = 8.3, 2.4, 1H), 4.07 (s, 3H), 3.91 (s, 
3H); m/z [TOF  MS  ES
+
]
 
found 348.0576 [M  +  H]
+
, C
16
H
15
ClN
3
O
2
S requires 
348.0574; IR (neat) νmax; 3194, 2672, 1612, 1583, 1457, 1376, 1207, 1022, 829, 775; 
 
 
N-butyl-4-(2,4-Dimethoxyphenyl)thiazol-2-amine (182) 
 
 
 
 
Employing General Procedure D; 114 (110 mg, 0.43 mmol) and n-Butylthiourea (57 
mg, 0.43 mmol) were suspended in EtOH (5 mL) and heated to 80 °C for a duration of 
14 hours. Recrystalisation from EtOH gave the desired product as a white crystaline 
solid, (57 mg, 41%); Mp (EtOH); 187-189 °C; δ
H
 (400 MHz, CDCl
3
); 7.56 (d, J = 8.6, 
1H), 6.53 (dd, J = 8.7, 2.4, 1H), 6.48 (d, J = 2.4), 3.99 (s, 3H), 3.81 (s, 3H), 3.27 (q, J 
= 6.9, 2H), 1.77-1.70 (m, 2H), 1.54-1.42 (m, 2H), 0.94 (t, J = 7.3, 3H); δ
C
 (100 MHz, 
CDCl
3
); 169.3, 162.4, 157.6, 137.7, 129.3, 108.9, 105.9, 98.8, 98.1, 56.1, 55.6, 47.5, 
30.1, 20.0, 13.5; m/z [TOF MS ES
+
]
 
found 292.1241 [M + H]
+
, C
15
H
20
N
2
O
2
S requires 
292.1245; IR (neat) ν
max
; 1610, 1572, 1511, 1310, 1214, 1011, 903, 828, 755, 698; 
 
 
 4-(2,4-Dimethoxyphenyl)-N-thiazol-2-amine (183)
1
 
 
 
 
 
Employing General Procedure Di; 2-Bromo-2,4-dimethoxyacetophenone (800 mg, 3.1 
mmol) and thiourea (285 mg, 3.75 mmol) were suspended in EtOH (5 mL) and heated 
to 80 °C for a duration of 14 hours. The reaction was evaporated to dryness, triturated 
with Et
2
O and the solids colected via filtration to give the desired product as a light 
pink crystaline solid, (542 mg, 74%); δ
H
 (400 MHz, d
6
 DMSO); 9.04 (brs, 2H, NH
2
), 
7.53 (d, J = 8.6, 1H), 7.03 (s, 1H), 6.72 (d, J = 2.3, 1H), 6.66 (dd, J = 8.7, 2.3, 1H), 
3.89 (s, 3H), 3.83 (s, 3H); δ
C
 (100 MHz, d
6
 DMSO); 184.3, 169.7, 162.2, 157.9, 135.6, 
130.1, 110.2, 106.3, 103.5, 99.3, 56.5, 56.1; (data matched literature); 
 
 
OMe
MeO
N
S
NH
MeO
N
S
NH
2
OMe
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2-(2-(2,3-Dimethylphenylamino)thiazol-4-yl)-5-methoxyphenol (184) 
 
 
 
 
 
Employing  General  Procedure  D; (139) (105  mg,  0.43  mmol) and 122 (77  mg,  0.43 
mmol) were suspended in EtOH (5 mL) and heated to 80 °C for a duration of 14 hours. 
Recrystalisation from EtOH gave the desired product as a white crystaline solid, (86 
mg, 59%); Mp (EtOH); 171-173 °C; δ
H
 (400 MHz, d
4 
MeOH); 7.54 (d, J = 8.7, 1H), 
7.31 (d, J = 8.1, 1H), 7.25 (d, J = 1.8, 1H), 7.20 (dd, J = 8.0, 1.8, 1H), 6.60 (dd, J = 
8.7, 2.4, 1H), 6.54 (d, J = 2.4), 3.83 (s, 3H), 2.35 (s, 3H), 2.33 (s, 3H); δ
C
 (100 MHz d
4 
MeOH);  162.4,  155.6,  138.8,136.6,  135.1,  130.9,  130.8,  128.3,  122.9,  119.3,  107.5, 
106.4,  101.1,  54.5,  18.5,  18.1; m/z [TOF  MS  ES
+
]
 
found 327.1164 [M  +  H]
+
, 
C
18
H
19
N
2
O
2
S requires 327.1167; IR (neat) ν
max
; 3100–2650 (br),  1612,  1573,  1533, 
1517, 1446, 1256, 1209, 1115, 1030, 966, 844, 745, 693; 
 
 
tert-butyl 2-(4-chlorophenyl)-1H-pyrole-1-carboxylate (230) 
 
 
 
 
 
N-Boc-2-pyroleboronic acid (250 mg, 1.18 mmol), Pd(OAc)
2
 (2.6 mg, 0.012 mmol), 
and Na
2
CO
3 
(167 mg, 1.57 mmol) were suspended in Acetone/H
2
O 1/1 (6 mL). After 5 
min of stiring 4-chloroiodobenzene (187 mg, 0.79 mmol) was added and the mixture 
heated at 40 °C for  16  h. The reaction  mixture  was cooled to ambient temperature, 
diluted with EtOAc (20 mL) and poured into water (15 mL). The aqueous phase was 
extracted  with  EtOAc (2 ×  30 mL), combined  organic extracts  were  washed  with 
brine,  dried (MgSO
4
) rotary evaporated, and chromatographed (Petrol:Et
2
O  20/1) to 
give the desired product as a colourless oil, (216 mg, 98%); Rf (Petrol/Et
2
O) (20/1); 
0.63; δ
H
 (400 MHz, CDCl
3
); 7.39 (dd, J = 3.4, 1.9, 1H), 7.36 (d, J = 8.7, 2H), 7.32 (d, 
J = 8.7, 2H), 6.26 (t, J = 3.2, 1H), 6.22 (dd, J = 3.4, 1.9, 1H), 1.44 (s, 9H); δ
C
 (100 
MHz,  CDCl
3
); 149.2,  133.8,  133.2,  132.8,  130.5,  127.8,  122.9,  114.8,  110.7,  83.9, 
N
S
NH
OH
MeO
N
Boc
Cl
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28.0; m/z [TOF MS ES+] found 278.0951 [M + H
+
], C
15
H
17
ClNO
2 
requires 278.0948; 
IR (neat) ν
max
; 2927, 1739, 1465, 1370, 1308, 1143, 972, 841, 727; 
 
 
 
 
(E)-tert-butyl-2-(4-chlorophenyl)-5-(3-ethoxy-3-oxoprop-1-enyl)-1H-pyrole-1-
carboxylate (235) 
 
 
 
 
 
Boc-pyrole 230 (200  mg,  0.72  mmol), ethyl acrylate (51 µL,  0.48  mmol) and 
Pd(OAc)
2
 (10.7  mg,  0.048  mmol)  were suspended in  AcOH:dioxane:DMSO (3:9:1) 
(350 µL). The reaction was stired under an atmosphere of oxygen at 35 °C for 16 h. 
The reaction  was  diluted  with EtOAc (30  mL), and the  organic  phase  washed  with 
saturated aqueous  NaHCO
3 
(15  mL),  H
2
O and  brine.  The separated  organics  were 
dried (MgSO
4
), rotary evaporated and chromatographed (Petrol:Et
2
O 5/1) to give the 
desired product as a yelow oil, (163 mg, 60%); Rf (Petrol/Et
2
O) (10/1); 0.21; δ
H
 (400 
MHz, CDCl
3
); 8.13 (d, J = 15.9, 1H), 7.37 (d, J = 8.6, 2H), 7.26 (d, J = 8.6, 2H), 6.73 
(d, J = 3.6,  1H),  6.27 (d, J = 15.9,  1H),  6.25 (d, J =3.6,  1H),  4.27 (q, J = 7.2,  2H), 
1.40 (s, 9H), 1.35 (t, J = 7.2, 3H); δ
C
 (100 MHz, CDCl
3
); 167.1, 149.1, 137.5, 134.4, 
133.6,  132.6,  132.5,  129.7,  128.2,  116.5,  114.1,  113.3,  85.3,  60.3,  27.5,  14.4; m/z 
[TOF MS ES+] found 376.1304 [M + H
+
], C
20
H
23
ClNO
4 
requires 376.1316; IR (neat) 
ν
max
 =: 2979, 1744, 1705, 1620, 1464, 1299, 1143, 1075, 793; 
 
 
(E)-1-(4-chlorophenyl)-3-(furan-2-yl)prop-2-en-1-one (240) 
 
 
 
 
 
4-Chloroacetophenone (6.30 mL, 48.5 mmol) and furfural (4.42 mL, 53.3 mmol) were 
dissolved in MeOH (30 mL) and cooled to 0 °C. Freshly prepared sodium methoxide 
(1.11  g,  48.5  mmol) in  MeOH (50  mL)  was added and the ensuing  mixture  was 
N
Boc
Cl
CO
2
Et
Cl
O
O
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alowed to  warm to room temperature  over  6  h.  The reaction  was  quenched  via the 
addition of 1 M aqueous HCl (50 mL) and the mixture was evaporated to dryness. The 
resulting residue was then suspended in Et2O (100 mL) and the organic phase washed 
with 0.5 M aqueous HCl (20 mL), H
2
O and brine. The separated organics were dried 
(MgSO
4
),
 
rotary evaporated to  give the  desired  product as a  pure  orange crystaline 
solid, (11.10 g, 98%); Mp (Et
2
O): 36-38 °C; δ
H
 (400 MHz, CDCl
3
); 7.99 (d, J = 8.6, 
2H), 7.62 (d, J = 15.3, 1H), 7.55 (d, J = 1.4, 1H), 7.48 (d, J = 8.6, 2H), 7.43 (d, J = 
15.4,  1H),  6.76 (d, J = 3.4,  1H),  6.54 (dd, J = 3.4,  1.9,  1H); δ
C
 (100  MHz,  CDCl
3
); 
188.5,  151.6,  145.1,  139.2,  136.5,  131.1,  129.8,  118.7,  116.7,  112.8; m/z [TOF  MS 
ES+] found 233.0368 [M + H
+
], C
13
H
10
ClO
2 
requires 233.0369; IR (neat) ν
max
; 3339, 
1657, 1593, 1476, 1400, 1282, 1007, 749; 
 
 
ethyl 7-(4-chlorophenyl)-4,7-dioxoheptanoate (241) 
 
 
 
 
 
Furan 240 (11.10  g,  47.6  mmol) and concentrated  HCl (57  mL)  were  dissolved in 
EtOH (200  mL) and  heated at  90 °C for  16  h.  The reaction  was cooled to ambient 
temperature and evaporated to dryness. The resulting residue was dissolved in CH
2
Cl
2 
(200 mL) and washed with saturated aqueous NaHCO
3 
(100 mL), H
2
O and brine. The 
separated  organics  were  dried (MgSO
4
), rotary evaporated and chromatographed 
(Petrol:Et
2
O 10/1) to give the desired product as an orange crystaline solid, (5.28 g, 
37%); Mp (Et
2
O): 54-56 °C; Rf (Petrol/Et
2
O) (10/1); 0.15; δ
H
 (400 MHz, CDCl
3
); 7.91 
(d, J = 8.5, 2H), 7.43 (d, J = 8.5, 2H), 4.13 (q, J = 7.2, 2H), 3.27 (t, J = 6.6, 2H), 2.92 
(t, J = 6.6, 2H), 2.87 (t, J = 6.6, 2H), 2.62 (t, J = 6.6, 2H), 1.26 (t, J = 7.1, 2H); δ
C
 
(100 MHz, CDCl
3
); 204.8, 197.3, 172.8, 139.5, 134.9, 129.5, 128.9, 60.0, 37.2, 36.2, 
32.3, 28.0, 14.2; m/z [TOF MS ES+] found 297.0885 [M + H
+
], C
15
H
18
ClO
4 
requires 
297.0894; IR (neat) ν
max
; 1725, 1701, 1671, 1587, 1321, 1206, 1170, 1010, 793; 
 
 
 
Cl
O
O
OEt
O
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(1-(carboxymethyl)-5-(4-chlorophenyl)-1H-pyrol-2-yl)propanoic acid (N.1) 
 
 
 
 
 
 
i. Diketoester 241 (250 mg, 0.84 mmol), glycine (63 mg, 0.84 mmol) and pTSA (16 
mg, 0.084 mmol) were suspended in EtOH (2 mL) and heated at 80 °C over 16 h. The 
reaction was evaporated to dryness and the residue taken up in 1 M aqueous NaOH (2 
mL) and THF (1 mL). i. The solution was stired for 1 h at room temperature and the 
diluted with Et
2
O (10 mL). The layers were separated and the aqueous extracted with 
Et
2
O (2 x 10 mL). The aqueous layer was then acidified to pH 2 and re-extracted with 
Et
2
O (4  x  15  mL), the combined  organic extracts  were  dried (MgSO
4
) and rotary 
evaporated to  give the  desired  product as a cream crystaline solid, (124 mg, 24%) 
‘over two steps’; Mp (MeOH): 158-160 °C; δ
H
 (400 MHz, MeOD
4
); 7.39 (d, J = 8.4, 
2H), 7.29 (d, J = 8.5, 2H), 6.11 (d, J = 3.6, 1H), 5.99 (d, J = 3.7, 1H), 5.01 (brs, 2H, 
OH), 4.63 (s, 2H), 2.85 (t, J = 7.5, 2H), 2.70 (t, J = 7.5, 2H); δ
C
 (100 MHz, MeOD
4
); 
175.3, 171.6, 134.0, 133.2, 132.5, 132.2, 129.8, 128.3, 108.2, 105.6, 45.3, 32.5, 21.4; 
m/z [TOF  MS  ES+] found 308.0684 [M  + H
+
], C
15
H
13
ClNO
4 
requires 308.0690; IR 
(neat) ν
max
; 3200-2700 (brs), 1701, 1425, 1249, 1209, 1097, 826, 756; 
 
 
 
ethyl 7-(4-chlorophenyl)-2,4,7-trioxoheptanoate (246)
 
 
 
 
 
 
Benzoyl propionic acid (5.00 g, 23.5 mmol) was dissolved in THF and cooled to 0 °C. 
CDI (3.82 g, 23.5 mmol) was added portionwise and the ensuing mixture was warmed 
to ambient temperature over 16 h. Isopropylmagnesium chloride in THF (2.0 M; 17.6 
mL, 35.2 mmol) was dissolved in THF (10 mL) and cooled to 0 °C. Ethyl hydrogen 
malonate (4.18 mL, 35.2 mmol) was added dropwise to the solution and the of white 
slury was stired for 30 min at 0 °C and 1 h at 70 °C. The dianion malonate solution 
Cl
O
O
OEt
O
N
Cl
CO
2
H
CO
2
H
Cl
O
O
OEt
O
N
Cl
CO
2
Et
CO
2
Et
i.
i.
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was then cooled to 0 °C and the previously prepared imidazolide solution added in one 
portion. The resulting green solution was alowed to stir at room temperature for 4 h. 
The reaction  was  quenched  with  1  M aqueous  HCl (60  mL) and the aqueous  phase 
extracted with EtOAc (4 x 40 mL). The combined organic extracts were washed with 
brine, dried (MgSO
4
) rotary evaporated, and chromatographed (CH
2
Cl
2
:Et
2
O 50/1) to 
give the desired product as a light pink oil, (3.89 g, 59%); Rf (CH
2
Cl
2
/Et
2
O) (20/1); 
0.53; δ
H
 (400 MHz, CDCl
3
); 7.92 (d, J = 8.5, 2H), 7.45 (d, J = 8.5, 2H), 4.23 (q, J = 
7.1, 2H), 3.59 (s, 2H), 3.29 (t, J = 6.2, 2H), 3.01 (t, J = 6.2, 2H), 1.30 (t, J = 7.1, 3H); 
δ
C
 (100  MHz,  CDCl
3
);  201.6,  196.9,  167.1,  139.7,  134.8,  129.5,  128.9,  61.4,  49.5, 
41.7,  36.5,  32.4,  14.1; m/z [TOF  MS  ES+] found 283.0733 [M  +  H
+
], C
14
H
16
ClO
4 
requires 283.0737; IR (neat) ν
max
; 1726,  1686,  1590,  1323,  1264,  1181,  1149,  1091, 
1030; 
 
 
3-(1-(carboxymethyl)-5-(4-chlorophenyl)-1H-pyrol-2-yl)ethanoic acid (N.1.1) 
 
 
 
 
 
 
i. Diketoester 246 (300 mg, 1.06 mmol), glycine (79 mg, 1.06 mmol) and pTSA (20 
mg, 0.11 mmol) were suspended in EtOH (2 mL) and heated at 80 °C over 16 h. The 
reaction was evaporated to dryness and the residue taken up in 1 M aqueous NaOH (2 
mL) and THF (1 mL). i. The solution was stired for 1 h at room temperature and the 
diluted with Et
2
O (10 mL). The layers were separated and the aqueous extracted with 
Et
2
O (2 x 10 mL). The aqueous layer was then acidified to pH 2 and re-extracted with 
Et
2
O (4  x  15  mL), the combined  organic extracts  were  dried (MgSO
4
), rotary 
evaporated and chromatographed (CH
3
Cl:MeOH:FA  20/1/0.1) to  give the  desired 
product as a light pink crystaline solid, (77 mg, 25%) ‘over two steps’; Mp (MeOH): 
142-144 °C; Rf (CH
3
Cl/MeOH/FA) (10/1/0.1); 0.41; δ
H
 (400 MHz, CDCl
3
); 7.41 (d, J 
=8.6, 2H), 7.32 (d, J = 8.6, 2H), 6.14 (d, J =3.5, 1H), 6.12 (d, J =3.5, 1H), 4.98 (brs, 
2H),  4.70 (s,  2H),  3.65 (s,  2H); δ
C
 (100  MHz,  CDCl
3
);  172.9,  171.3,  134.0,  132.8, 
132.2,  130.0,  128.3,  127.7,  108.8,  108.3,  45.6,  32.2; m/z [TOF MS  ES+] found 
Cl
O
O
OEt
O
N
Cl
CO
2
H
CO
2
H
N
Cl
CO
2
Et
CO
2
Et
i.
i.
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292.0394 [M - H
+
], C
14
H
11
ClNO
4 
requires  292.0377; IR (neat) ν
max
;  3300-2700 (br), 
1706, 1414, 1386, 1279, 1094, 830, 753, 697; 
 
 
 
S)-2-(2-(2-carboxyethyl)-5-(4-chlorophenyl)-1H-pyrol-1-yl)-3-(1H-indol-3-yl) 
propanoic acid (250) 
 
 
 
 
 
 
 
 
i. Diketoester 241 (300 mg, 1.12 mmol), L-tryptophan (227 mg, 1.12 mmol) and pTSA 
(22 mg, 0.11 mmol) were suspended in EtOH (2 mL) and heated at 80 °C over 16 h. 
The reaction  was evaporated to  dryness and the residue taken  up in  1  M aqueous 
NaOH (2  mL) and  THF (1  mL). i.  The solution  was stired for  1  h at room 
temperature and the  diluted  with  Et
2
O (10  mL). The layers  were separated and the 
aqueous extracted with Et
2
O (2 x 10 mL). The aqueous layer was then acidified to pH 
2 and re-extracted with Et
2
O (4 x 15 mL), the combined organic extracts were dried 
(MgSO
4
), rotary evaporated and chromatographed (CH
3
Cl:MeOH:FA  20/1/0.1) to 
give the  desired  product as a colourless crystaline solid, (67  mg, 14%) ‘over two 
steps’; α
D
 = -125.0 ° (c  =  11.2  mg/mL,  MeOH); Mp (MeOH):  63-65 °C; Rf 
(CH
3
Cl/MeOH/FA) (10/1/0.1);  0.52; δ
H
 (400  MHz, MeOD
4
);  7.28 (d, J = 8.1,  1H), 
7.04 (t, J = 8.1, 1H), 6.94 (J = 8.1, 1H), 6.91 (d, J = 8.1, 2H), 6.79 (t, J = 7.5, 1H), 
6.57 (d, J = 6.5, 2H), 6.50 (s, 1H), 6.02 (d, J = 3.5, 1H), 5.79 (d, J = 3.5, 1H), 5.08 
(dd, J = 10.7, 4.2, 1H), 3.59 (dd, J = 14.8, 4.2, 1H), 3.27 (dd, J = 14.6, 10.9, 1H), 3.14 
(dt, J = 15.4, 7.7, 1H), 2.93 (dt, J = 15.2, 6.8, 1H), 2.81-2.72 (m, 2H); δ
C
 (100 MHz, 
MeOD
4
); 175.4, 173.3, 136.4, 134.9, 132.5, 132.2, 132.1, 130.2, 127.4, 127.1, 123.0, 
120.7, 118.3, 117.1, 110.6, 109.4, 107.3, 106.6, 58.5, 32.8, 27.0, 22.6; m/z [TOF MS 
ES+] found 435.1124 [M - H
+
], C
24
H
20
ClN
2
O
4 
requires 435.1112; IR (neat) νmax  =: 
3500-2800 (br), 1705, 1454, 1415, 1230, 1093, 1013, 830, 738; 
 
 
N
Cl
CO
2
H
CO
2
H
Cl
O
O
OEt
O
N
Cl
CO
2
Et
CO
2
Et
i.
i.
NH NH
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2-(2-(2-carboxyethyl)-5-(4-chlorophenyl)-1H-pyrol-1-yl)-3-hydroxypropanoic acid 
(251) 
 
 
 
 
 
 
i. Diketoester 241 (250 mg, 0.84 mmol), DL-serine (88 mg, 0.84 mmol) and pTSA (16 
mg, 0.084 mmol) were suspended in EtOH (2 mL) and heated at 80 °C over 16 h. The 
reaction was evaporated to dryness and the residue taken up in 1 M aqueous NaOH (2 
mL) and THF (1 mL). i. The solution was stired for 1 h at room temperature and the 
diluted with Et
2
O (10 mL). The layers were separated and the aqueous extracted with 
Et
2
O (2 x 10 mL). The aqueous layer was then acidified to pH 2 and re-extracted with 
Et
2
O (4  x  15  mL), the combined organic extracts  were  dried (MgSO
4
), rotary 
evaporated and chromatographed (CH
3
Cl:MeOH:FA  20/1/0.1) to  give the  desired 
product as a cream crystaline solid, (44 mg, 15%) ‘over two steps’; Mp (MeOH): 46-
48 °C; Rf (CH
3
Cl/MeOH/FA) (20/1/0.1);  0.43; δ
H
 (400  MHz, MeOD
4
);  7.30 (d, J = 
8.9, 2H), 7.28 (d, J = 8.9, 2H), 5.97 (d, J = 3.6, 1H), 5.91 (d, J = 3.6, 2H), 4.89 (m, 
1H), 4.09 (dd, J = 11.8, 6.0, 1H), 3.76 (dd, J = 11.8, 6.0, 1H), 2.87 – 2.68 (m, 2H), 
2.63 – 2.58 (m, 2H); δ
C
 (100 MHz, MeOD
4
); 173.7, 170.1, 132.7, 131.9, 131.1, 129.3, 
126.5, 107.0, 104.9, 59.6, 58.2, 31.2, 20.8; m/z [TOF MS ES+] found 338.0752 [M + 
H
+
], C
16
H
17
ClNO
5 
requires 338.0795; IR (neat) ν
max
;  3500-2700 (br),  1708,  1510, 
1413, 1209, 1091, 1014, 829; 
 
 
 
 
 
 
 
 
 
 
N
Cl
CO
2
H
CO
2
H
Cl
O
O
OEt
O
N
Cl
CO
2
Et
CO
2
Et
i.
i.
OH OH
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(S)-2-(2-(2-carboxyethyl)-5-(4-chlorophenyl)-1H-pyrol-1-yl)-3-phenyl 
propanoic acid (252) 
 
 
 
 
 
 
i.  Diketoester 241 (300  mg,  1.12  mmol),  L-phenylalanine (185  mg,  1.12  mmol) and 
pTSA (22 mg, 0.11 mmol) were suspended in EtOH (2 mL) and heated at 80 °C over 
16 h. The reaction was evaporated to dryness and the residue taken up in 1 M aqueous 
NaOH (2  mL) and  THF (1  mL). i.  The solution  was stired for  1  h at room 
temperature and the  diluted  with  Et
2
O (10  mL). The layers  were separated and the 
aqueous extracted with Et
2
O (2 x 10 mL). The aqueous layer was then acidified to pH 
2 and re-extracted with Et
2
O (4 x 15 mL), the combined organic extracts were dried 
(MgSO
4
), rotary evaporated and chromatographed (CH
3
Cl:MeOH:FA  20/1/0.1) to 
give the  desired  product as a colourless crystaline solid, (52  mg,  12%) ‘over two 
steps’; α
D
 = -73.2 ° (c  = 10.1 mg/mL,  MeOH); Mp (MeOH): 59-61 °C; Rf 
(CH
3
Cl/MeOH/FA) (10/1/0.1);  0.47; δ
H
 (400  MHz, MeOD
4
);  7.19 (d, J = 8.4,  2H), 
7.13 (d, J = 7.3, 1H), 7.05 (t, J = 7.5, 2H), 6.76 (d, J = 7.6, 2H), 6.65 (d, J = 7.3, 2H), 
6.03 (d, J = 3.5, 1H), 5.83 (d, J = 3.6, 1H), 4.98 (dd, J = 11.5, 4.0, 1H), 3.38-3.32 (m, 
1H),  3.23-3.06 (m,  2H),  2.93-2.80 (m,  1H),  2.77 (t, J  = 5.8,  2H); δ
C
 (100  MHz, 
MeOD
4
); 175.3,  172.8,  137.2,  132.7,  132.4,  132.3,  130.6,  128.7,  127.8,  127.7,126.1, 
107.7,  106.8,  59.5,  37.2,  32.7,  22.6;  m/z [TOF  MS  ES+] found 396.1009 [M - H
+
], 
C
22
H
19
ClNO
4 
requires  396.1003; IR (neat) ν
max
; 3300-2700 (br),  1697,  1468,  1428, 
1230, 1093, 829, 763; 
 
 
 
 
 
 
N
Cl
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2
H
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2
H
Cl
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O
OEt
O
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(S)-2-(2-(2-carboxyethyl)-5-(4-chlorophenyl)-1H-pyrol-1-yl)-3-(3,4-
dihydroxyphenyl) propanoic acid (253) 
 
 
 
 
 
 
 
 
 
i.  Diketoester 241 (300  mg,  1.12  mmol),  3,4-dihydroxy-L-phenylalanine (220  mg, 
1.12  mmol) and  pTSA (22  mg,  0.11  mmol)  were suspended in  EtOH (2  mL) and 
heated at  80 °C over  16  h.  The reaction  was evaporated to  dryness and the residue 
taken up in 1 M aqueous NaOH (2 mL) and THF (1 mL). i. The solution was stired 
for  1  h at room temperature and the  diluted  with  Et
2
O (10  mL). The layers  were 
separated and the aqueous extracted  with  Et
2
O (2  x  10  mL).  The aqueous layer  was 
then acidified to pH 2 and re-extracted with Et
2
O (4 x 15 mL), the combined organic 
extracts  were  dried (MgSO
4
), rotary evaporated and chromatographed 
(CH
3
Cl:MeOH:FA  10/1/0.1) to  give the  desired  product as a colourless crystaline 
solid, (86  mg,  18%) ‘over two steps’; Mp (Et
2
O):  55-57 °C; Rf (CH
3
Cl/MeOH/FA) 
(10/1/0.1); 0.33; δ
H
 (400 MHz, MeOD
4
); 7.16 (d, J = 8.5, 2H), 6.76 (d, J = 7.5, 2H), 
6.41 (d, J = 8.0, 1H), 6.03 (d, J = 1.8, 1H), 5.95 (d, J =3.5, 1H), 5.93 (dd, J =8.1, 1.9, 
1H), 5.79 (d, J =3.6, 1H), 4.81 (dd, J = 11.2, 3.7, 1H), 3.14 (dd, J = 14.0, 3.7, 1H), 
3.05-2.90 (m,  2H),  2.85-2.77 (m,  1H),  2.88-2.65 (m,  2H); δ
C
 (100  MHz,  MeOD
4
); 
173.8,  171.4,  149.2,  143.0,  142.0,  131.0,  130.9,  130.8,  129.1,  127.1,  126.0,  118.4, 
114.2, 113.1, 106.0, 105.1, 58.4, 35.1, 31.2, 21.0; m/z [TOF MS ES+] found 430.1044 
[M  +  H
+
], C
22
H
21
ClNO
6 
requires  430.1057; IR (neat) ν
max
; 3500-2700 (br),  1706, 
1514, 1414, 1260, 1192, 1093, 829, 791; 
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(S)-2-(2-(2-carboxyethyl)-5-(4-chlorophenyl)-1H-pyrol-1-yl)-3-(4-fluorophenyl) 
propanoic acid (254) 
 
 
 
 
 
 
 
 
i.  Diketoester 241 (250  mg,  0.84  mmol),  4-fluoro-DL-phenylalanine (170  mg,  0.93 
mmol) and pTSA (18 mg, 0.93 mmol) were suspended in EtOH (2 mL) and heated at 
80 °C over 16 h. The reaction was evaporated to dryness and the residue taken up in 1 
M aqueous NaOH (2 mL) and THF (1 mL). i. The solution was stired for 1 h at room 
temperature and the  diluted  with  Et
2
O (10  mL). The layers  were separated and the 
aqueous extracted with Et
2
O (2 x 10 mL). The aqueous layer was then acidified to pH 
2 and re-extracted with Et
2
O (4 x 15 mL), the combined organic extracts were dried 
(MgSO
4
), rotary evaporated and chromatographed (CH
3
Cl:MeOH:FA  50/1/0.1) to 
give the desired product as a colourless crystaline solid, (62 mg, 18%); Mp (MeOH): 
44-46 °C; Rf (CH
3
Cl/MeOH/FA) (10/1/0.1); 0.44; δ
H
 (400 MHz, MeOD
4
); 7.23 (d, J 
= 8.3, 2H), 6.84 (d, J = 7.6, 2H), 6.67 (t, J = 8.7, 2H), 6.63 (dd, J = 8.2, 5.6, 2H), 6.04 
(d, J = 3.4, 1H), 5.86 (d, J = 3.4, 1H), 5.00 (dd, J = 11.4, 3.7, 1H), 3.22-3.05 (m, 2H), 
2.87 (dd, J = 15.5, 6.8, 1H), 2.79-2.76 (m, 2H); δ
C
 (100 MHz, MeOD
4
); 175.3, 173.9, 
133.0,  132.4,  132.2,  131.7,  130.5,  130.4,  130.3,  127.8,  114.3,  114.1,  107.7,  106.9, 
59.5, 36.4, 32.5, 22.5; m/z [TOF MS ES+] found 416.1063 [M + H
+
], C
22
H
20
ClFNO
4 
requires 416.1065; IR (neat) νmax =: 3500-2700 (br), 2928, 1714, 1477, 1417, 1223, 
1099, 830; 
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(S)-1-tert-butyl 2-methyl 5-oxopyrolidine-1,2-dicarboxylate (262) 
 
 
 
 
 
i. Methyl Ester Formation: L-pyroglutamic acid (10.00 g, 77.4 mmol) was dissolved in 
MeOH (50 mL) and the solution was cooled to 0 °C. SOCl
2 
(562 µL, 7.74 mmol) was 
added dropwise and the ensuing mixture alowed to warm to room temperature. After 
3 h the reaction was quenched via addition of solid NaHCO
3
 (2.60 g, 30.9 mmol) and 
the resulting suspension was alowed to stir for 30 min. The mixture was then filtered 
through celite, and rotary evaporated to obtain the intermediate ester as a yelow oil, 
which  was  used  without further  purification; i. N-Boc  Protection: Ester 262i and 
DMAP (945 mg, 8.13 mmol) were dissolved in MeCN (50 mL) and cooled to 0 °C. 
Boc
2
O (17.73 g, 81.3 mmol) was added portionwise, and the mixture was alowed to 
stir  overnight.  The reaction  was evaporated to dryness and the resulting  brown  oil 
chromatographed, (CH
2
Cl
2
:EtOAc  5/1), to  give the  desired  product as a yelow 
crystaline solid (16.14 g, 79% ‘two steps’); α
D
 = -15.3 ° (c = 10.0 mg/mL, CH
2
Cl
2
); 
Mp (Et
2
O);  32-34 °C; Rf (CH
2
Cl
2
/EtOAc) (5/1);  0.50; δ
H
 (400  MHz, CDCl
3
);  4.62 
(dd, J = 9.5, 3.0, 1H), 3.79 (s, 3H), 2.68-2.59 (m, 1H), 2.51 (ddd, J = 12.9, 9.4, 3.6, 
1H), 2.38-2.27 (m, 1H), 2.07-2.00 (m, 1H), 1.49 (s, 9H);	  δ
C
 (100 MHz, CDCl
3
); 173.3, 
171.8, 149.3, 83.6, 58.8, 52.6, 31.1, 27.9, 21.5; m/z [TOF MS ES+] found 266.0999 
[M + Na
+
], C
11
H
17
NO
5
Na requires, 266.1004; IR (neat) ν
max
; 1736, 1701, 1310, 1210, 
1141, 955, 784; 
 
 
 
(S)-methyl 2-(tert-butoxycarbonylamino)-5-(4-chlorophenyl)-5-oxopentanoate (265) 
 
 
 
 
 
4-chloroiodobenzene (7.56 g, 31.7 mmol) was dissolved in THF (60 mL) and cooled 
to  0 °C. Isopropylmagnesium chloride in  THF (2.0  M;  15.85  mL,  31.7  mmol)  was 
Cl
O
CO
2
Me
NHBoc
N
H
O
CO
2
H
N
Boc
O
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2
Me
i. SOCl
2
 MeOH
i. Boc
2
O MeCN
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added and the ensuing  mixture stired for  2  h at  0 °C.  Carbamate 262 (8.50  g,  34.9 
mmol) was dissolved in THF (50 mL) and cooled to -78 °C. The Grignard was then 
cannulated into the carbamate solution over 15 min, and the mixture stired for 2 h at -
78 °C. The reaction was quenched via the addition of 1 M aqueous HCl (40 mL) and 
diluted with Et
2
O (100 mL). The product was extracted with Et
2
O (3 x 60 mL) and the 
combined  organics  washed  with  H
2
O (60  mL),  brine,  dried (MgSO
4
), rotary 
evaporated and chromatographed (CH
2
Cl
2
/EtOAc 15/1) to give the desired product as 
a light  yelow  oil, (6.01  g,  70%); Rf (CH
2
Cl
2
/EtOAc) (10/1);  0.63; α
D
 = -4.9 ° (c  = 
12.1 mg/mL, CH
3
Cl); δ
H
 (400 MHz, CDCl
3
); 7.90 (d, J = 8.6, 2H), 7.45 (d, J = 8.6, 
2H), 5.19 (brs, NH 1H), 4.40 (m, 1H), 3.77 (s, 3H), 3.15-2.99 (m, 2H), 2.37-2.25 (m, 
1H),  2.13-2.06 (m,  1H),  1.43 (s,  9H); δ
C
 (100 MHz,  CDCl
3
); 197.6,  172.8,  155.5, 
139.6,  134.9,  129.5,  128.8,  80.1,  52.9,  34.5,  28.2,  26.5; m/z [TOF  MS  ES+] found 
378.1075 [M  +  H
+
], C
17
H
22
ClNNaO
5 
requires  378.1084; IR (neat) ν
max
;  2977,  1742, 
1687, 1497, 1366, 1207, 1160, 1091, 913;  
 
 
(2S,5R)-methyl 5-(4-chlorophenyl)pyrolidine-2-carboxylate (267) 
 
 
 
 
 
i. Ketone 265 (5.40 g, 15.2 mmol) and TFA (10.83 mL, 152.1 mmol) were dissolved 
in CH
2
Cl
2
 (15 mL) and cooled to 0 °C. The resulting mixture was alowed to warm to 
room temperature over 2 h. The reaction was then diluted with CH
2
Cl
2
 (70 mL) and 
washed  with  H
2
O (10  x  20  mL).  The  organics  were then  dried (MgSO
4
) and rotary 
evaporated to  give the crude imine intermediate,  which  was  used  without further 
purification; i.  The imine  was  dissolved in EtOAc (4 mL) and was added to a 
suspension  of  5%  Pt/C (1.60 g,  1.51  mmol) in 
i
PrOH (15 mL)  which  had  been 
activated  by  bubbling  hydrogen through the solution for  10  min.  The reaction  was 
stired under an atmosphere  of  hydrogen for  16 h, the flask  was then  purged  with 
nitrogen, filtered, rotary evaporated and chromatographed (CH
2
Cl
2
:EtOAc  5/1), to 
give the desired product as a colourless oil, (2.66 g, 73%); Rf (CH
2
Cl
2
/EtOAc) (5/1); 
0.29; α
D
 = 35.6 ° (c = 19.1 mg/mL, CH
3
Cl); δ
H
 (400 MHz, CDCl
3
); 7.41 (d, J =8.5, 
Cl
O
CO
2
Me
NHBoc
N
CO
2
Me
Cl
N
H
CO
2
Me
Cl
i. i.
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2H), 7.31 (d, J = 8.5, 2H), 4.21 (dd, J = 9.0, 5.8, 1H), 3.96 (dd, J = 8.3, 5.0, 1H), 3.79 
(s,  3H),  2.34 (brs,  1H,  NH),  2.24-2.11 (m,  3H),  1.72-1.67 (m,  1H); δ
C
 (100  MHz, 
CDCl
3
); 175.5, 142.2, 132.7, 128.5, 128.1, 62.8, 59.9, 52.2, 34.4, 30.3; m/z [TOF MS 
ES+] found 240.0789 [M + H
+
], C
12
H
15
ClNO
2
 requires 240.0791; IR (neat) ν
max
; 2950, 
1733, 1490, 1434, 1202, 1168, 1088, 1013, 822; 
 
 
(2S,5R)-1-tert-butyl 2-methyl 5-(4-chlorophenyl)pyrolidine-1,2-dicarboxylate (268) 
 
 
 
 
 
 
Ester 267 (2.00  g,  8.64  mmol) and  DMAP (107  mg,  0.86  mmol)  were  dissolved in 
MeCN (12  mL) and cooled to  0 °C.  Boc
2
O (3.77  g,  17.3  mmol)  was added 
portionwise, and the  mixture  was alowed to stir  overnight.  The reaction  was 
evaporated to dryness and chromatographed, (CH
2
Cl
2
:EtOAc 10/1), to give the desired 
product as a colourless oil, (2.87 g, 98%); Rf (CH
2
Cl
2
/EtOAc) (10/1); 0.63; α
D
 = 43.8 
° (c  = 15.5 mg/mL,  CH
3
Cl); δ
H
 (400  MHz,  d
6
 DMSO  353K);  7.53 (d, J = 8.5,  2H), 
7.34 (d, J = 8.5,  2H),  4.81-4.77 (m,  1H),  4.36 (dd, J = 7.9,  6.1,  1H),  3.72 (s,  3H), 
2.37-2.30 (m, 1H), 2.25-2.18 (m, 1H), 1.91-1.86 (m, 1H), 1.79-1.73 (m, 1H), 1.22 (s, 
9H); δ
C
 (100 MHz, d
6
 DMSO 353K); 172.7, 152.9, 142.7, 130.6, 127.5, 127.3, 78.8, 
61.9,  59.7,  51.3, 33.8,   27.8,  27.3; m/z [TOF  MS  ES+] found 362.1151 [M  +  H
+
], 
C
17
H
22
ClNNaO
4 
requires 362.1135; IR (neat) νmax =: 2977, 1793, 1745, 1695, 1492, 
1388, 1165, 1072, 830; 
 
 
 
 
 
 
 
N
Boc
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2
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(2R,5S)-tert-butyl 2-(4-chlorophenyl)-5-(hydroxymethyl)pyrolidine-1-carboxylate 
(269) 
 
 
 
 
 
Ester 268 (2.80  g,  8.23  mmol)  was  dissolved in  THF (10  mL) and cooled to  0 °C. 
LiBH
4
 (358 mg, 16.5 mmol) was added portionwise over a period of 15 minutes and 
the mixture was alowed to warm to ambient temperature over 16 h. The reaction was 
cooled to 0 °C and quenched by dropwise addition of H
2
O and was then acidified to 
pH 3 with 0.5 M aqueous HCL. The product was extracted with EtOAc (3 x 20 mL), 
and the  organic  phase  washed  with  brine,  dried (MgSO
4
), rotary evaporated and 
chromatographed (CH
2
Cl
2
:EtOAc 5/1), to give the desired product as a colourless oil, 
(2.41 g, 94%); Rf (CH
2
Cl
2
/EtOAc) (10/1);  0.26; α
D
 =  23.8 ° (c  = 13.4 mg/mL, 
CH
3
Cl); δ
H
 (400 MHz, CDCl
3
); 7.29 (d, J = 8.4, 2H), 7.19 (d, J = 8.4, 2H), 4.83-4.80 
(m, 2H), 4.17-4.15 (m, 1H), 3.81-3.78 (m, 2H), 2.32-2.24 (m, 1H), 2.08-1.97 (m, 1H), 
1.87-1.78 (m,  1H),  1.68-1.63 (m,  1H),  1.22 (s,  9H); δ
C
 (100  MHz,  CDCl
3
); 157.2, 
142.8, 132.3, 128.5, 126.9, 80.6, 67.5, 62.8, 61.6, 34.3, 28.1, 27.1; m/z [TOF MS ES+] 
found 312.1336 [M + H
+
], C
16
H
23
ClNO
3
 requires 312.1366; IR (neat) νmax =: 3450-
3300 (br), 2977, 1690, 1665, 1491, 1390, 1158, 1089, 1013, 820; 
 
 
 
(2R,5S)-tert-butyl 2-(4-chlorophenyl)-5-(E)-3-methoxy-3-oxoprop-1-
enyl)pyrolidine-1-carboxylate (270) 
 
 
 
 
 
 
Oxalyl chloride (598 µL, 7.10 mmol) in CH
2
Cl
2
 (60 mL, 0.1 M solution) was cooled to 
-78 ºC and  DMSO (1.37 mL, 19.3  mmol)  was added  dropwise  over  5  min.  The 
reaction was stired for  20 min, then a solution alcohol 269 (2.00 g, 6.43 mmol) in 
CH
2
Cl
2
 (5  mL)  was added  over  5  min.  The reaction was stired for an additional  45 
N
Boc
Cl
OH
N
Boc
Cl
CO
2
Me
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min and then Et
3
N (3.60 mL, 25.7 mmol) was added in one portion. The reaction was 
warmed to ambient temperature and stired for  2 h.  Folowing this,  Carboxymethyl 
phosphonium  ylide (2.79  g,  8.35  mmol)  was added in  one  portion and the reaction 
stired  overnight at room temperature.  The solvent  was then removed  via rotary 
evaporation and Et
2
O (100 mL) added to the residue. The ether was decanted and the 
solid washed with Et
2
O (2 x 50 mL). The combined organics were rotary evaporated 
and the residue chromatographed (CH
2
Cl
2
:EtOAc 15/1) to give the desired product as 
a light yelow oil, (1.84 g, 78%) ‘over two steps’; Rf (CH
2
Cl
2
/EtOAc) (10/1); 0.65; α
D
 
= 25.9 ° (c = 16.2 mg/mL, CH
3
Cl); δ
H
 (400 MHz, CDCl
3
); 7.31 (d, J = 8.3, 2H), 7.19 
(d, J = 8.3,  2H),  7.01 (m,  1H),  6.05 (m,  1H),  4.90-4.78 (m,  1H),  4.61-4.55 (m,  1H), 
3.78 (s, 3H), 2.34-2.25 (m, 1H), 2.18-2.09 (m, 1H), 1.91-1.78 (m, 2H), 1.35 (s, 9H); δ
C
 
(100 MHz, CDCl
3
); 166.9, 154.8, 148.7, 132.4, 128.5, 127.2, 121.3, 80.3, 62.5, 59.6, 
51.7,  34.5,  33.7,  30.3,  28.2; m/z [CI+] found 383.1746 [M  +  NH
4
+
], C
19
H
28
ClN
2
O
4 
requires 383.1738; IR (neat) ν
max
; 2983, 1723, 1691, 1364, 1271, 1149, 1090, 728; 
 
 
 
methyl 3-(2S,5R)-5-(4-chlorophenyl)pyrolidin-2-yl)propanoate hydrochloride salt 
(271) 
 
 
 
 
 
 
i. Alkene 270 (1.50 g, 4.11 mmol) in EtOH (3 mL) was added to a suspension of 10% 
Pd/C (430 mg,  0.41  mmol) in  EtOH (5 mL)  which  had  been activated  by  bubbling 
hydrogen through the solution for  10  min.  The reaction  was stired under an 
atmosphere of hydrogen for 4 h, the flask was then purged with nitrogen, filtered and 
rotary evaporated to give the desired product as a white crystaline solid, used directly 
in the next step; Rf (CH
2
Cl
2
/EtOAc) (5/1); 0.78; Mp (EtOH): 45-47 °C; δ
H
 (400 MHz, 
CDCl
3
); 7.32-7.29 (d, J = 8.2, 2H), 7.20-7.17 (d, J = 8.4, 2H), 4.89-4.64 (s, 1H), 4.05-
3.96 (s, 1H), 3.73 (s, 3H), 2.47 (t, J = 7.1, 2H), 2.34-2.26 (m, 2H), 2.09-1.99 (m, 1H), 
1.92-1.80 (m,  2H),  1.72-1.63 (m,  1H),  1.40-1.20 (brs,  9H); i. Crude carbamate 271i 
N
Boc
Cl
CO
2
Me
N
H.HCl
Cl
CO
2
Me
i.
i.
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was dissolved in CH
2
Cl
2 
(3 mL) and cooled to 0 ºC. 4 M HCl in dioxane (3 mL) was 
added dropwise and the mixture was alowed to warm to room temperature. After 1 h 
the reaction  was evaporated and the resulting residue taken  up in  Et
2
O (40  mL) and 
saturated aqueous  NaHCO
3 
(20  mL). The  product  was extracted  with  Et
2
O (3  x  30 
mL), the combined  organics  were  washed  with  H
2
O (15  mL),  brine,  dried (MgSO
4
), 
rotary evaporated and chromatographed (CH
2
Cl
2
:EtOAc  5/1) to  give the  desired 
product as a light  yelow  oil, (743  mg,  84%); Rf (CH
2
Cl
2
/EtOAc) (5/1);  0.13; α
D
 = 
55.5 ° (c = 14.4 mg/mL, CH
3
Cl); δ
H
 (400 MHz, CDCl
3
); 7.35 (d, J = 8.5, 2H), 7.29 (d, 
J = 8.5, 2H), 4.17 (t, J = 7.7, 1H), 3.71 (s, 3H), 3.31-3.24 (m, 1H), 2.46 (t, J = 7.5, 
2H),  2.19-2.11 (m, 1H),  2.11 (brs,  1H,  NH),  2.03-1.94 (m,  1H),  1.92-1.81 (m,  2H), 
1.69-1.59 (m,  1H),  1.57-1.49 (m,  1H); δ
C
 (100  MHz,  CDCl
3
);  174.3,  143.7,  132.3, 
128.3,  127.9,  61.8,  57.8,  51.6,  34.3,  31.9,  31.5,  30.9; m/z [TOF  MS  ES+] found 
268.1107 [M + H
+
], C
14
H
19
ClNO
2 
requires 268.1104; IR (neat) ν
max
; 2949, 1732, 1489, 
1252, 1169, 1087, 1013, 822; 
 
 
 
methyl-3-(2S,5R)-5-(4-chlorophenyl)-1-(2-methoxy-2-oxoethyl)pyrolidin-2-yl) 
propanoate (272) 
 
 
 
 
 
 
Amine 271 (200 mg, 0.75 mmol) and methylbromo acetate (92 µL, 0.97 mmol) were 
dissolved in DMF (2.5 mL). Cs
2
CO
3 
(365 mg, 1.12 mmol) was added and the ensuing 
mixture stired at room temperature for 16 h. The mixture was then diluted with H
2
O 
(10  mL) and extracted  with EtOAc (6  x  15  mL).  The separated  organics  were  dried 
(MgSO
4
)
, 
rotary evaporated and chromatographed (CH
2
Cl
2
:EtOAc  10/1) to  give the 
desired product as a colourless oil, (194 mg, 76%); Rf (CH
2
Cl
2
/EtOAc) (10/1); 0.81; 
α
D
 =  78.6 ° (c  =  14.5  mg/mL,  CH
3
Cl); δ
H
 (400  MHz,  CDCl
3
);  7.31-7.26 (m,  4H), 
4.15-4.10 (m, 1H), 3.70 (s, 3H), 3.64 (s, 3H), 3.47 (d, J = 17.4, 1H), 3.22 (d, J = 17.4, 
1H),  3.21-3.18 (m,  1H),  2.49 (ddd, J = 15.6,  9.4,  6.0,  1H),  2.38 (ddd, J = 15.8,  9.4, 
N
Cl
CO
2
Me
CO
2
Me
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6.3, 1H), 2.18-2.03 (m, 2H), 1.99-1.90 (m, 1H), 1.83-1.73 (m, 1H), 1.67-1.55 (m, 2H); 
δ
C
 (100 MHz, CDCl
3
); 174.3, 171.8, 142.5, 132.5, 128.6, 128.5, 66.7, 60.9, 51.6, 51.1, 
49.8,  34.7,  30.3,  29.8,  29.3; m/z [TOF  MS  ES+] found 340.1311 [M  +  H
+
], 
C
17
H
23
ClNO
4 
requires 340.1316; IR (neat) ν
max
; 2951, 1733, 1435, 1195, 1164, 1087, 
1013, 827; 
 
 
3-(2S,5R)-1-(carboxymethyl)-5-(4-chlorophenyl)pyrolidin-2-yl)propanoic acid (256) 
 
 
 
 
 
 
Diester 272 (150 mg, 0.44 mmol) was suspended in 1 M aqueous LiOH (1 mL) and 
THF (1 mL) and heated at 100 ºC for 16 h. The reaction was the evaporated to dryness 
and the residue taken up in H
2
O (15 mL) and Et
2
O (20 mL). The layers were separated 
and the aqueous extracted  with  Et
2
O (2  x  15  mL).  The aqueous layer  was then 
acidified to  pH  4 and re-extracted  with  Et
2
O (4  x  25  mL), the combined  organic 
extracts  were  dried (MgSO
4
), and rotary evaporated to  give the  desired  product as a 
pure white crystaline solid (65 mg, 47%); Mp (MeOH): 50-52 °C; α
D
 = 41.5 ° (c = 
10.1 mg/mL, MeOH); δ
H
 (400 MHz, MeOD
4
); 7.62 (d, J = 8.5, 2H), 7.49 (d, J = 8.5, 
2H), 4.75 (dd, J = 10.9, 6.8, 1H), 4.09 (d, J = 17.3, 1H), 3.98 (d, J = 17.3, 1H), 3.90 – 
3.82 (m, 1H), 2.63 – 2.45 (m, 4H), 2.40 – 2.26 (m, 2H), 2.12 – 2.02 (m, 2H); δ
C
 (100 
MHz, MeOD
4
); 178.7, 171.5, 139.8, 135.5, 134.4, 133.0, 76.2, 72.0, 54.9, 33.6, 32.9, 
30.8,  29.7;  m/z [TOF  MS  ES-] found 310.0836 [M - H
+
], C
15
H
17
ClNO
4 
requires 
310.0846; IR (neat) ν
max
; 3200-2700 (brs), 1717, 1496, 1405, 1196, 1091, 1014, 826; 
 
 
 
 
 
 
 
 
N
Cl
CO
2
H
CO
2
H
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(S)-5-(hydroxymethyl)pyrolidin-2-one (283) 
 
 
 
 
Ester 282 (2.0  g,  13.9  mmol)  was  dissolved in  EtOH (30  mL) and cooled to  0 °C. 
NaBH
4
 (739  mg,  19.5  mmol)  was added  portionwise  over  15  min and the resultant 
solution was warmed to room temperature and alowed to stir overnight. The reaction 
was quenched via the addition of neat acetic acid, and directly evaporated to dryness. 
The residue was  dissolved  on silica/CH
3
Cl and chromatographed (CH
3
Cl:MeOH 
(10/1) to give the desired product as a colourless oil, (1.50 g, 94%); α
D
 = -26.4 ° (c = 
13.2 mg/mL,  MeOH); Rf (CH
3
Cl/MeOH) (10/1);  0.22; δ
H
 (400  MHz, d
4
 MeOD); 
3.75-3.69 (m, 1H), 3.55 (dd, J = 11.2, 4.4, 1H), 3.45 (dd, J = 11.2, 5.6, 1H), 2.39-2.13 
(m, 3H), 1.90-1.82 (m, 1H); δ
C
 (100 MHz, d
4
 MeOD); 183.8, 68.5, 60.2, 33.6, 26.4; 
m/z [CI+] found 133.0982 [M + NH
4
+
], C
5
H
13
N
2
O
2 
requires, 133.0977; IR (neat) ν
max
; 
2942, 2865, 1694, 1461, 1117, 881, 641; 
 
 
(S)-(+)-Lysine methyl ester dihydrochloride (294)
2
 
 
 
 
 
 
(S)-lysine  monohydrochloride (15.00  g,  82.1  mmol)  was suspended in  2,2-
dimethoxypropane (80  mL) and  MeOH (160  mL).  Concentrated  HCl (30  mL)  was 
added and the  mixture  was  heated at reflux for  3  h.  The reaction  was the cooled to 
ambient temperature and stired  overnight.  The solvents  were removed  via rotary 
evaporation leaving a  white suspension.  The crystaline solid  was colected  by 
filtration and washed with a (5/1) mixture of Et
2
O/MeOH, to give the desired product 
as a  pure  white crystaline solid, (18.75  g,  98  %); Mp (Et
2
O);  209-211 °C; δ
H
 (400 
MHz, d
4
 MeOD); 4.10 (t, J = 6.5, 1H), 3.87 (s, 3H), 2.98 (t, J = 7.6, 2H), 2.08-1.89 
(m, 2H), 1.78-1.70 (m, 2H), 1.65-1.47 (m, 2H); δ
C
 (100 MHz, d
4
 MeOD); 169.7, 52.3, 
38.8, 29.6, 26.6, 21.7; (data matched literature); 
N
H
O
OH
ClH
.
H
2
N
OMe
O
NH
2.
HCl
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(S)-(+)-Di -N-(tert-butyloxycarbonyl)lysine methyl ester (295)
2
 
 
 
 
 
Ester 294 (10.00 g, 43.1 mmol) and NaHCO
3 
(21.68 g, 258.1 mmol) were suspended 
in MeOH (150 mL) and Boc
2
O (19.74 g, 90.4 mmol) was added portionwise over 10 
minutes. The mixture was stired briefly before being sonicated at 40 °C for 12 h. The 
solvents were removed via rotary evaporation and the resulting residue was taken up 
in  Et
2
O and filtered through celite.  The filtrate  was evaporated and the resulting  oil 
chromatographed (CH
2
Cl
2
:EtOAc:MeOH  10/1/1), to  give the  desired  product as a 
white crystaline solid, (13.31 g, 86%); Rf (CH
2
Cl
2
/EtOAc/MeOH) (10/1/1); 0.76; δ
H
 
(400 MHz, d
4
 MeOD); 4.08 (t, J = 5.8, 1H), 3.72 (s, 3H), 3.04 (t, J = 6.7, 2H), 1.83-
1.84 (m, 1H), 1.70-1.60 (m, 1H), 1.46 (s, 9H), 1.45 (s, 9H); m/z [TOF MS ES+] found 
383.2148 [M + Na
+
], C
17
H
32
N
2
NaO
6
 requires, 383.2158; (data matched literature); 
 
 
 
(S)-(+)-Di-N-(tert-butyloxycarbony1)adipamide methyl ester (296)
2
 
 
 
 
 
Ester 295 (14.00 g, 38.8 mmol) was dissolved in EtOAc (500 mL) bufered to pH 4.5 
with  potassium  hydrogen  phthalate.  The solution  was then added to a  vigorously 
stired solution  of sodium  metaperiodate (41.49  g,  194.0  mmol) and  RuCl
3
H
2
O (604 
mg, 2.91 mmol) in H
2
O (1.56 L). The biphasic system was stired at room temperature 
for 72 h. The EtOAc layer was separated and the aqueous extracted with EtOAc (5 x 
250  mL).  The combined  organics  were then filtered through a  plug  of celite and 
concentrated to  ~150  mL.  The  organics  were then  washed  with  1  M aqueous citric 
acid,  dried (MgSO
4
), rotary evaporated and chromatographed (Petrol:EtOAc  2/1), to 
give the desired product as a colourless oil, (12.23 g, 84%); Rf (Petrol/EtOAc) (1/1); 
0.51; δ
H
 (400  MHz, d
4
 MeOD);  4.15-4.12 (m, 1H),  3.74 (s,  3H),  2.54-2.43 (m,  2H), 
BocHN
OMe
O
NHBoc
BocHN
OMe
O
NHBocO
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1.84-1.62 (m, 4H), 1.52 (s, 9H), 1.47 (s, 9H); m/z [TOF MS ES+] found 397.1937 [M 
+ Na
+
], C
17
H
30
N
2
NaO
7 
requires, 397.1951; (data matched literature); 
 
 
(S)-(-)-Methyl-6-oxo-2-piperidinecarboxylate (297)
2
 
 
 
 
Ester 296 (12.00  g,  32.1  mmol)  was  dissolved in  neat  TFA (50  mL) and  CH
3
Cl (10 
mL). The resulting solution was heated at reflux overnight. The reaction was alowed 
to cool to ambient temperature and  was evaporated to  near  dryness.  The resulting 
residue was dissolved in CH
3
Cl (80 mL) and washed with saturated aqueous NaHCO
3
 
(40  mL),  H
2
O and  brine.  The separated  organics  were  dried (MgSO
4
),
 
rotary 
evaporated and chromatographed (CH
3
Cl:MeOH 90/10), to give the desired compound 
as a light yelow oil, (4.87 g, 96%); Rf (CH
3
Cl/MeOH) (90/10); 0.53; δ
H
 (400 MHz, d
4
 
MeOD); 4.19 (t, J = 5.9, 1H), 3.71 (s, 3H), 2.33 (t, J = 6.6, 2H), 2.16-2.08 (m, 1H), 
1.97-1.89 (m, 1H), 1.83-1.77 (m, 1H); δ
C
 (100 MHz, d
4
 MeOD); 173.2, 171.8, 56.4, 
54.1,  30.2,  24.9,  18.9; m/z [TOF  MS  ES+] found 158.0815 [M  +  H
+
], C
7
H
12
NO
3 
requires, 158.0817; (data matched literature); 
 
 
(S)-(+)-2-Hydroxymethyl-6-piperidinone (298)
2
 
 
 
 
Lactam 297 (4.38 g, 27.8 mmol) was dissolved in EtOH (150 mL) and cooled to 0 °C. 
NaBH
4
 (1.47  g,  39.1  mmol)  was added  portionwise  over  15  min and the resultant 
solution was warmed to room temperature and alowed to stir overnight. The reaction 
was quenched via the addition of neat acetic acid, and directly evaporated to dryness. 
The residue  was  dissolved  on silica/CH
3
Cl and chromatographed (CH
3
Cl:MeOH 
(20/1), to  give the  desired  product as a white crystaline solid, (3.27 g, 91%); α
D
 = 
20.9 ° (c = 10.3 mg/mL, CH
2
Cl
2
); Rf (CH
3
Cl /MeOH) (95/5); 0.28; δ
H
 (400 MHz, d
4
 
MeOD); 3.61-3.55 (m, 1H), 3.50-3.43 (m, 2H), 2.38-2.23 (m, 2H), 1.98-1.88 (m, 2H), 
N
H
O CO
2
Me
N
H
O
OH
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1.79-1.68 (m,  1H),  1.56-1.47 (m,  1H); δ
C
 (100  MHz, d
4
 MeOD);  173.9, 64.6,  54.2, 
30.7, 23.8, 18.7; m/z [TOF MS ES+] found 130.0865 [M + H
+
], C
6
H
12
NO
2
 requires, 
130.0868; (data matched literature); 
 
 
(S)-6-(Trisopropylsilyloxy)methyl)piperidin-2-one (299) 
 
 
 
Lactam 298 (2.30 g, 17.8 mmol) and imidazole (2.66 g, 39.2 mmol) were dissolved in 
DMF (15 mL). TIPS-Cl (8.39 mL, 39.2 mmol) was added dropwise and the resulting 
solution was stired at room temperature for 16 h. The mixture was then diluted with 
H
2
O and extracted  with  EtOAc (6  x  15  mL).  The separated  organics  were  dried 
(MgSO
4
), rotary evaporated and chromatographed (CH
2
Cl
2
:MeOH  20/1) to  give the 
desired product as a light yelow oil, (4.68 g, 91%); α
D
 = -126.1 ° (c = 10.7 mg/mL, 
CH
2
Cl
2
); Rf (CH
2
Cl
2
MeOH) (95/5); 0.38; δ
H
 (400 MHz, CDCl
3
); 3.76-3.66 (m, 1H), 
3.55-3.42 (m,  2H),  2.42 (ddd, J = 8.9,  4.3,  1.73,  1H),  2.29 (ddd, J = 11.2,  6.2,  4.9, 
1H), 1.93-1.68 (m, 3H), 1.34-1.25 (m, 1H), 1.06 (sept, J = 4.6, 3H), 1.06 (d, J = 4.6, 
18H); δ
C
 (100 MHz, CDCl
3
); 171.7, 67.4, 54.8, 31.6, 24.5, 19.8, 17.9, 11.8; m/z [TOF 
MS ES+] found 286.2196 [M + H
+
], C
15
H
32
NO
2
Si
 
requires, 286.2202; IR (neat) ν
max
; 
2892, 2733, 1681, 1422, 1231, 1127, 870, 691; 
 
 
S)-tert-butyl 2-oxo-6-(trisopropylsilyloxy)methyl)piperidine-1-carboxylate (300) 
 
 
 
 
 
Lactam 299 (2.60 g, 9.11 mmol) and DMAP (167 mg, 1.36 mmol) were dissolved in 
MeCN (5 mL) and cooled to 0 °C. Boc
2
O (2.58 g, 11.8 mmol) was added portionwise, 
and the mixture was alowed to stir overnight. The reaction was evaporated to dryness 
and chromatographed, (CH
2
Cl
2
:MeOH  50/1), to  give the  desired  product as a 
colourless  oil, (3.04  g,  87 %); α
D
 = -33.9 ° (c =  14.0 mg/mL,  MeOH); Rf 
N
H
O
OTIPS
N
Boc
O
OTIPS
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(CH
2
Cl
2
/MeOH) (50/1); 0.43; δ
H
 (400 MHz, CDCl
3
); 4.26-4.21 (m, 1H), 3.83-3.75 (m, 
2H),  2.51-2.47 (m,  2H),  2.16-2.09 (m,  1H),  2.05-1.96 (m,  1H),  1.91-1.83 (m,  1H), 
1.75-1.69 (m,  1H),  1.52 (s,  9H),  1,07 (sept, J = 4.4,  3H),  1.06 (d, J = 4.6,  18H); δ
C
 
(100 MHz, CDCl
3
); 172.1, 152.9, 82.7, 63.9, 56.2, 34.9, 27.9, 27.4, 24.4, 17.7, 11.8; 
m/z [TOF MS ES+] found 408.2539 [M + Na
+
], C
20
H
39
NNaO
4
Si requires, 408.2546; 
IR (neat) ν
max
; 2942, 2866, 1711, 1366, 1291, 1250, 1144, 881, 680; 
 
 
(S)-tert-butyl-6-(trifluoromethylsulfonyloxy)-2-(trisopropylsilyloxy)methyl)-3,4-
dihydropyridine-1(2H)-carboxylate (301) 
 
 
 
 
 
n-BuLi in hexanes (2.5 M; 567 µL, 1.42 mmol) was added dropwise with stiring to 
iso-Pr
2
NH (219 µL, 1.56 mmol) in THF (2 mL) at -78 °C. After 20 min, lactam 300 
(500 mg, 1.29 mmol) in THF (1 mL) was added dropwise with stiring at -78 °C. The 
resulting solution was warmed to -20° C over 30 minutes at which point TMEDA (449 
mg,  3.87  mmol)  was added in  one  portion.  The solution  was again cooled to -78° C 
and N-phenylbistriflimide (690 mg, 1.94 mmol) in THF (1 mL) was added dropwise. 
The ensuing  mixture  was alowed to stir at -78° C for  1  h  before  warming to room 
temperature for  1  h.  At  which  point the reaction  mixture  was  quenched  via the 
addition of saturated aqueous NH
4
Cl (5 mL) and extracted with Et
2
O (3 x 10 mL). The 
combined  organics  were  washed  with saturated aqueous  NaHCO
3
 (10  mL),  water, 
brine and  dried (MgSO
4
).  The filtrate  was rotary evaporated and chromatographed, 
(Petrol:Et
2
O 50/1-25/1) to give the desired product as a colourless oil (560 mg, 84%); 
α
D
 = -21.2 ° (c = 12.1 mg/mL, CH
3
Cl); Rf (Petrol/Et
2
O) (20/1); 0.36; δ
H
 (400 MHz, 
CDCl
3
); 5.27 (t, J = 3.8, 1H), 4.59-4.53 (m, 1H), 3.73 (dd, J = 9.9, 5.8, 1H), 3.66 (t, J 
= 9.9,  1H),  2.29-2.23 (m,  2H),  2.17-2.11 (m,  1H),  1.73-1.64 (m,  1H),  1.51 (s,  9H), 
1.09 (sept, J = 4.6, 3H), 1.07 (d, J = 4.6, 18H); δ
C
 (100 MHz, CDCl
3
); 152.4, 138.9, 
106.4,  82.9,  60.2,  55.2,  27.9,  21.6,  19.1,  17.9,  11.9; m/z [TOF  MS  ES+] found 
518.2224 [M + H
+
], C
21
H
39
F
3
NO
6
SSi
 
requires, 518.2219; IR (neat) ν
max
; 2944, 2867, 
1673, 1463, 1226, 1206, 1024, 881, 635; 
N
Boc
TfO
OTIPS
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(S)-tert-butyl-6-(4-methoxyphenyl)-2-(trisopropylsilyloxy)methyl)-3,4-
dihydropyridine-1(2H)-carboxylate (302) 
 
 
 
 
 
2-Napthylboronic acid (263 mg, 1.54 mmol), Pd(PPh
3
)
2
Cl
2
 (36 mg, 0.052 mmol), and 
Na
2
CO
3 
(163 mg, 1.54 mmol) were suspended in THF/H
2
O 3/1 (4 mL). After 5 min of 
stiring triflate 301 (530 mg, 1.03 mmol) was added and the mixture heated for 16 h at 
60 °C . The reaction mixture was cooled to ambient temperature, diluted with EtOAc 
(50 mL) and poured into water (35 mL). The aqueous phase was extracted with EtOAc 
(2 × 30 mL), combined organic extracts were washed with brine, dried (MgSO
4
) rotary 
evaporated, and chromatographed (Petrol:Et
2
O 50/1) to give the desired product as a 
colourless  oil, (315  mg,  62%); α
D
 = -50.7 ° (c  = 11.5 mg/mL,  MeOH); Rf 
(Petrol/Et
2
O) (20/1);  0.29; δ
H
 (400  MHz, CDCl
3
);  7.83-7.75 (m,  4H),  7.30 (dd, J = 
8.6, 1.7, 1H), 7.46-7.41 (m, 2H), 5.51 (t, J = 3.9, 1H), 4.78-4.73 (m, 1H), 3.97 (dd, J = 
9.8, 7.6, 1H), 3.76 (dd, J = 9.8, 7.4, 1H), 2.30-2.25 (m, 2H), 2.06-1.96 (m, 2H), 1.16 
(sept, J = 5.3, 3H), 1.12 (d, J = 4.3, 18H), 1.01 (s, 9H); δ
C
 (100 MHz, CDCl
3
); 153.9, 
139.0,  138.1,  133.4,  132.6,  127.8, 127.5,  127.2,  125.9,  125.3,  124.4,  123.4,  115.9, 
80.3, 61.3, 53.1, 27.7, 23.5, 20.6, 18.1, 12.0; m/z [TOF MS ES+] found 496.3248 [M 
+ H
+
], C
30
H
46
NO
3
Si
 
requires, 496.3247; IR (neat) ν
max
; 2940, 2864, 1697, 1365, 1166, 
1112, 1069, 813, 681; 
 
 
(S)-tert-butyl-2-(naphthalen-2-yl)-6-(trisopropylsilyloxy)methyl) 
piperidine-1-carboxylate (303) 
 
 
 
 
 
A solution  of alkene 302 (300  mg,  0.61  mmol) in  MeOH (1 mL)  was added to a 
suspension  of  10%  Pd/C (32 mg,  0.030  mmol) in  MeOH (2 mL)  which  had  been 
activated  by bubbling  hydrogen through the solution for  10  min.  The reaction  was 
stired under an atmosphere  of  hydrogen for  16 h, the flask  was then  purged  with 
N
Boc
OTIPS
N
Boc
OTIPS
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nitrogen, filtered and rotary evaporated to  give the  desired  product as a light yelow 
oil, (2:1 inseparable  mixture of  diastereomers), (171  mg,  57%); Rf (Petrol/Et
2
O) 
(20/1); 0.40; δ
H
 (400 MHz, CDCl
3
); Major Quoted; 7.84-7.78 (m, 3H), 7.66 (s, 1H), 
7.49-7.48 (m,  2H),  7.41 (dd, J = 8.6,  1.7,  1H),  5.21 (brs,  1H),  4.20-4.18 (brm,  1H), 
3.96 (dd, J = 9.1, 4.2, 1H), 3.83 (t, J = 9.1, 1H), 2.22-2.15 (m, 2H), 2.04-1.95 (m, 2H), 
1.49-1.40 (m,  2H),  1.36 (s,  9H),  1.13 (sept, J = 4.3,  3H),  1.11 (d, J = 4.5,  18H); δ
C
 
(100  MHz,  CDCl
3
); 155.9,  140.5,  133.6,  132.2,  127.9,  127.8,  127.3,125.9,  125.3, 
124.5, 123.9, 79.6, 64.4, 53.5, 52.5, 28.3, 21.2, 18.1, 17.8, 14.5, 12.0; m/z [TOF MS 
ES+] found 498.3408 [M + H
+
], C
30
H
48
NO
3
Si
 
requires, 498.3403; IR (neat) ν
max
; 2942, 
2865, 1684, 1461, 1364, 1100, 881, 731; 
 
 
(S)-tert-butyl 2-(hydroxymethyl)-6-(naphthalen-2-yl)piperidine-1-carboxylate (304) 
 
 
 
 
 
Carbamate 303 (170  mg,  0.34  mmol)  was  dissolved in  THF (1  mL) and cooled to  0 
°C.  TBAF (512 µL,  0.51  mmol)  was added  dropwise and the ensuing  mixture  was 
alowed to  warm to room temperature  over  3  h.  The reaction  was  quenched  via the 
addition of saturated aqueous NH
4
Cl (3 mL) and extracted with CH
2
Cl
2
 (3 x 10 mL). 
The combined organics were washed with saturated aqueous NaHCO
3
 (10 mL), H
2
O 
and brine, dried (MgSO
4
), rotary evaporated and chromatographed (CH
2
Cl
2
:Et
2
O 6/1) 
to  give the  desired  product as a colourless  oil, (2:1 inseparable  mixture  of 
diastereomers), (95  mg,  81%); Rf (CH
2
Cl
2
/Et
2
O) (3/1);  0.51; δ
H
 (400  MHz, CDCl
3
); 
Major  Quoted; 7.87-7.83 (m,  3H),  7.69 (brs,  1H),  7.51-7.48 (m,  2H),  7.43-7.41 (m, 
1H),  5.43-5.41 (m,  1H),  4.05 (brs,  1H,  OH),  3.87-3.82 (m,  2H),  2.48-2.43 (m,  2H), 
2.17-2.08 (m,  1H),  1.82-1.58 (m,  4H),  1.40 (s,  9H); δ
C
 (100  MHz,  CDCl
3
); 156.9, 
139.6,  132.2,  128.3,  127.8,  127.6,  126.2,  125.7,  124.5,  80.5,  66.0,  55.4,  52.3,  28.3, 
27.4, 24.9, 16.8; m/z [TOF MS ES+] found	  
	  
	  
	  
	  
	  
N
Boc
OH
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(S)-methyl 2-(tert-butoxycarbonylamino)-5-(4-methoxyphenyl)-5-oxopentanoate (314) 
 
 
 
 
 
Carbamate 262 (4.00 g, 16.4 mmol) was dissolved in THF (80 mL) and cooled to -50 
°C.  4-Methoxyphenyl  magnesium  bromide (0.5  M  THF) (37.0 mL,  18.8  mmol)  was 
added dropwise to the solution over 10 minutes. The ensuing mixture was alowed to 
warm to 0 °C over 2 h. The reaction was carefuly quenched with 1 M aqueous HCl 
(50  mL),  diluted  with  H
2
O (50  mL) and extracted  with  Et
2
O (5  x  50  mL).  The 
combined organics were washed with saturated aqueous NaHCO
3
 (40 mL), H
2
O and 
brine, dried (MgSO
4
), rotary evaporated and chromatographed (CH
2
Cl
2
/EtOAc) (15/1) 
to give the desired product as a white crystaline solid, (5.34 g, 93%); α
D
 = 11.2 ° (c = 
mg/mL,  CH
3
Cl); Mp (Et
2
O);  42-44 °C; Rf (CH
2
Cl
2
/EtOAc) (15/1); 0.61; δ
H
 (400 
MHz, CDCl
3
); 7.94 (d, J = 7.3, 2H), 6.94 (d, J = 8.8, 2H), 5.22 (d, J = 7.8, 1H, NH), 
4.39 (dd, J = 12.9, 7.8, 1H), 3.88 (s, 3H), 3.76 (s, 3H), 3.14-2.98 (m, 2H), 2.35-2.26 
(m, 1H), 2.11-2.06 (m, 1H), 1.43 (s, 9H); δ
C
 (100 MHz, CDCl
3
); 197.4, 172.9, 163.6, 
155.5, 130.3, 129.8, 113.7, 79.9, 55.5, 53.2, 52.4, 34.2, 28.3, 27.1; m/z [TOF MS ES+] 
found 374.1572  [M  +  Na
+
], C
18
H
25
NNaO
6
 requires  374.1580; IR (neat) ν
max
; 3335, 
1719, 1666, 1599, 1211, 1161, 1029, 832, 780; 
 
 
(2S,5R)-methyl 5-(4-methoxyphenyl)pyrolidine-2-carboxylate (316) 
 
 
 
 
 
i. Ketone 314 (5.30 g, 15.1 mmol) and TFA (12 mL, 156.1 mmol) were dissolved in 
CH
2
Cl
2
 (18  mL) and cooled to  0 °C.  The resulting  mixture  was alowed to  warm to 
room temperature over 2 h. The reaction was then diluted with CH
2
Cl
2
 (70 mL) and 
washed  with  H
2
O (10  x  20  mL). The  organics  were then  dried (MgSO
4
) and rotary 
evaporated to  give the crude imine intermediate,  which  was  used  without further 
purification; i.  The imine  was  dissolved in 
i
PrOH (1 mL) and was added to a 
O
NHBoc
CO
2
Me
MeO
O
NHBoc
CO
2
Me
N
CO
2
Me
N
H
CO
2
Me
i.
i.
MeO
MeO MeO
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suspension  of  5%  Pt/C (1.60 g,  1.51  mmol) in 
i
PrOH (15 mL)  which  had  been 
activated  by  bubbling  hydrogen through the solution for  10  min.  The reaction  was 
stired under an atmosphere of hydrogen (30 bar) for 24 h, the flask was then purged 
with  nitrogen, filtered, rotary evaporated and chromatographed (CH
2
Cl
2
:EtOAc  2/1), 
to  give the  desired  product as a colourless  oil and single  diastereoisomer, (2.87  g, 
81%) ‘over two steps’; α
D
 = 9.8 ° (c  =  mg/mL,  CH
3
Cl); Rf (CH
2
Cl
2
:EtOAc) (5/1); 
0.24; δ
H
 (400 MHz, CDCl
3
); 7.37 (d, J = 8.7, 2H), 6.89 (d, J = 8.7, 2H), 4.16 (dd, J = 
9.5, 5.8, 1H), 3.92 (dd, J = 8.9, 4.8, 1H), 3.81 (s, 3H), 3.79 (s, 3H), 2.25-2.08 (m, 3H), 
1.76-1.68 (m,  1H); δ
C
 (100  MHz,  CDCl
3
); 175.7,  158.8,  135.4,  127.9,  113.8,  63.1, 
59.9, 55.3, 52.1, 34.2, 30.6; m/z [TOF MS ES+] found 236.1282 [M + H
+
], C
13
H
18
NO
3
 
requires 236.1287; IR (neat) ν
max
; 2952, 1731, 1611, 1512, 1242, 1170, 1032, 828; 
 
 
(2S,5R)-1-tert-butyl 2-methyl 5-(4-methoxyphenyl)pyrolidine-1,2-dicarboxylate 
(317) 
 
 
 
 
 
Amine 316 (8.00 g, 34.0 mmol) and DMAP (623 mg, 5.09 mmol) were dissolved in 
MeCN (60 mL) and cooled to 0 °C. Boc
2
O (11.31 g, 51.0 mmol) was added and the 
ensuing  mixture  was alowed to  warm to room temperature  over  3  h.  The reaction 
mixture  was rotary evaporated and  directly chromatographed (Neat  CH
2
Cl
2
), to  give 
the  desired  product as a  yelow  oil, (1.77  g, 87%); α
D
 = 13.8 ° (c  = 10.1 mg/mL, 
CH
3
Cl); Rf (CH
2
Cl
2
/Et
2
O) (15/1); 0.61; δ
H
 (400 MHz, d
6
 DMSO 353K); 7.41 (d, J = 
8.3, 2H), 6.86 (d, J = 8.2, 2H), 4.76 (brs, 1H), 4.34 (dd, J = 7.9, 6.4, 1H), 3.74 (s, 3H), 
3.72 (s, 3H), 2.30-2.24 (m, 1H), 2.19 (ddt, J = 14.7, 8.0, 6.6, 1H), 1.93-1.86 (m, 1H), 
1.80-1.74 (m, 1H), 1.23 (s, 9H); δ
C
 (100 MHz, d
6
 DMSO 353K); 172.7, 157.7, 152.9, 
135.6, 126.7, 113.1, 78.6, 61.1, 59.8, 54.7, 51.2, 34.1, 27.8, 27.4; m/z [TOF MS ES+] 
found 358.1628 [M  +  Na
+
], C
18
H
25
NNaO
5
 requires  358.1630; IR (neat) ν
max
;  2975, 
1749, 1690, 1513, 1389, 1244, 1153, 832, 753; 
 
 
N
Boc
CO
2
Me
MeO
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(2S,5R)-tert-butyl 2-(hydroxymethyl)-5-(4-methoxyphenyl)pyrolidine-1-carboxylate 
(318) 
 
 
 
 
 
Carbamate 317 (10.72 g, 32.0 mmol) was dissolved in THF (80 mL) and cooled to 0 
°C. Lithium borohydride (1.51 g, 70.4 mmol) was added and the resulting mixture was 
alowed to warm to room temperature over 16 h. The reaction was then quenched via 
the addition of 1 M aqueous HCl (250 mL), diluted with Et
2
O (300 mL) and H
2
O (100 
mL) and the organics were separated. The product was further extracted Et
2
O (3 x 70 
mL), and the combined organics  were  washed  with saturated aqueous  NaHCO
3
 (25 
mL),  H
2
O, and  brine.  The  organic  phase  was then  dried (MgSO
4
), rotary evaporated 
and chromatographed (CH
2
Cl
2
;Et
2
O 15/1), to give the desired product as a colourless 
oil, (7.91 g, 80%); α
D
 = 16.2 ° (c = 17.2 mg/mL, CH
3
Cl); Rf (CH
2
Cl
2
/Et
2
O) (15/1); 
0.41; δ
H
 (400  MHz,  CDCl
3
); 7.18 (d, J = 8.6,  2H),  6.87 (d, J = 8.6,  2H),  4.97 (brs, 
1H), 4.82 (t, J = 6.7, 1H), 4.25-4.09 (m, 1H), 3.88-3.75 (m, 2H), 3.87 (s, 3H), 2.29-
2.21 (m, 1H), 2.07-1.98 (m, 1H), 1.91-1.79 (m, 1H), 1.75-1.61 (m, 1H), 1.24 (s, 9H); 
δ
C
 (100 MHz, CDCl
3
); 158.4, 157.4, 136.2, 126.7, 113.6, 80.6, 67.7, 62.8, 61.6, 55.3, 
34.3, 28.1, 27.2; m/z [TOF MS ES+] found 308.1864 [M + H
+
], C
17
H
26
NO
4
 requires 
308.1862; IR (neat) ν
max
; 2974, 1662, 1512, 1392, 1244, 1161, 1035, 908, 728; 
 
 
 
 
 
 
 
 
 
 
 
N
Boc
OH
MeO
	   278	  
(2R,5S)-tert-butyl-2-(4-methoxyphenyl)-5-(tosyloxymethyl)pyrolidine-1-carboxylate 
(319) 
 
 
 
 
 
 
 
 
 
Alcohol 318 (3.50 g, 11.2 mmol) was dissolved in CH
2
Cl
2
 (30 mL) and cooled to 0 °C. 
Triethylamine (10.9 mL, 78.4 mmol) and DMAP (273 mg, 2.24) were added and the 
ensuing mixture was alowed to stir for 30 min. 4-Toluenesulphonyl chloride (3.26 g, 
17.1 mmol) was added portionwise over 30 min, and the reaction was alowed to warm 
to ambient temperature over 4 h. The reaction was then quenched via the addition of 1 
M aqueous  HCl (25  mL),  diluted  with  CH
2
Cl
2
 (70  mL) and  H
2
O (50  mL) and the 
organics were separated. The product was further extracted CH
2
Cl
2
 (4 x 40 mL), and 
the combined organics were washed with saturated aqueous NaHCO
3
 (40 mL), H
2
O, 
and  brine.  The  organic  phase  was then  dried (MgSO
4
), rotary evaporated and 
chromatographed (CH
2
Cl
2
;Et
2
O 15/1) to give the desired product as a pure yelow oil, 
(4.94 g, 96%); α
D
 = 15.7 ° (c = 12.3 mg/mL, CH
3
Cl); Rf (CH
2
Cl
2
/Et
2
O) (15/1); 0.71; 
δ
H
 (400 MHz, CDCl
3
); 7.84 (d, J = 8.1, 2H), 7.37 (d, J = 8.1, 2H), 7.12 (d, J = 11.2, 
2H), 6.83 (d, J = 8.7, 2H), 4.77-4.61 (brm 1H), 4.32 (brs, 2H), 4.14 (brs, 1H), 3.81 (s, 
3H), 2.47 (s, 3H), 2.21 (dt, J = 12.0, 5.0, 1H), 2.04-1.91 (m, 3H), 1.25 (s, 9H); δ
C
 (100 
MHz,  CDCl
3
); 158.4,  144.9,  135.9,  129.9,  127.9,  127.6,  126/7.  115/9,  113.6,  79.7, 
70.3, 62.2, 57.3, 55.3, 34.5, 30.5, 28.1, 21.6; m/z [TOF MS ES+] found 484.1768 [M 
+  Na
+
], C
24
H
31
NNaO
6
S requires  484.1770; IR (neat) ν
max
;  2973,  1686,  1512,  1362, 
1244, 1173, 1096, 964, 813; 
 
 
 
 
 
 
N
Boc
O
MeO
S
O
O
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(2S,5R)-tert-butyl 2-(azidomethyl)-5-(4-methoxyphenyl)pyrolidine-1-carboxylate 
(320) 
 
 
 
 
 
 
Tosylate 319 (4.65  g,  10.1  mmol) and sodium azide (1.44  g,  22.1  mmol)  were 
dissolved in  DMF (15  mL) and  heated to  60 °C for  6  h.  The reaction  was cooled to 
ambient temperature,  diluted  with  H
2
O (50  mL) and extracted  with  EtOAc (6  x  25 
mL).  The combined  organics  were  dried (MgSO
4
), rotary evaporated and 
chromatographed (CH
2
Cl
2
;Et
2
O 30/1) to give the desired product as a light yelow oil, 
(3.31 g, 94%); Rf (CH
2
Cl
2
/Et
2
O) (15/1); 0.77; α
D
 = 15.1 ° (c = 15.4 mg/mL, CH
3
Cl); 
δ
H
 (400 MHz, CDCl
3
); 7.19 (d, J = 8,7, 1H), 6.88 (d, J = 8.7, 1H), 4.74 (brs, 1H), 4.11 
(m, 1H), 3.82 (s, 3H), 3.82-3.75 (m, 2H), 3.49 (brs, 1H), 2.37-2.24 (m, 1H), 2.11-2.05 
(m, 1H), 1.96-1.87 (m, 2H), 1.46-1.25 (brs, 9H); δ
C
 (100 MHz, CDCl
3
); 158.4, 135.2, 
129.6,  127.1,  113.6,  79.9,  62.4,  58.2,  55.3,  53.9,  41.9,  34.3,  28.3; m/z [CI+] found 
333.1932 [M
+
], C
17
H
25
N
4
O
3
 requires 333.1927; IR (neat) νmax =: 2974, 2098, 1686, 
1512, 1384, 1365, 1244, 1155, 909; 
 
 
(2S,5R)-tert-butyl 2-(aminomethyl)-5-(4-methoxyphenyl)pyrolidine-1-carboxylate 
(321) 
 
 
 
 
 
 
A solution azide 320 (2.50 g, 7.52 mmol) in EtOH (5 mL) was added to a suspension 
of  10%  Pd/C (790 mg,  0.75  mmol) in  EtOH (10 mL)  which  had  been activated  by 
bubbling hydrogen through the solution for 10 min. The reaction was stired under an 
atmosphere of hydrogen for 16 h, the flask was then purged with nitrogen, filtered and 
rotary evaporated to give the desired amine as a pure colourless oil, (2.16 g, 94%); Rf 
(CH
2
Cl
2
/MeOH) (20/1); 0.19; α
D
 = 13.0 ° (c = 15.3 mg/mL, CH
3
Cl); δ
H
 (400 MHz, 
N
Boc
N
3
MeO
N
Boc
NH
2
MeO
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CDCl
3
);  7.12 (d, J = 8.4,  1H),  6.86 (d, J = 8.7,  1H),  5.50 (brs,  2H,  NH
2
),  4.79 (m, 
1H), 4.12 (m, 1H), 3.81 (s, 3H), 3.21 (m, 2H), 2.29-2.20 (m, 1H), 2.15-2.10 (m, 1H), 
1.90-1.75 (m,  2H),  1.23 (s,  9H); δ
C
 (100  MHz,  CDCl
3
); 158.5,  135.7,  126.7,  113.7, 
80.9, 62.9, 59.2, 55.3, 45.8, 33.9, 28.6, 28.1; m/z [TOF MS ES+] found 307.2010 [M
 
+ 
H
+
], C
17
H
27
N
2
O
3 
requires 307.2022; IR (neat) ν
max
; 2973,  1678,  1512,  1388,  1244, 
1166, 1034, 909, 726; 
 
 
 
(2S,5R)-tert-butyl-2-(chloromethylsulfonamido)methyl)-5-(4-
methoxyphenyl)pyrolidine-1-carboxylate (323) 
 
 
 
 
 
 
Amine 321 (2.10 g, 6.86 mmol), pyridine (1.21 mL, 15.1 mmol) and DMAP (83 mg, 
0.69  mmol)  were  dissolved in  CH
2
Cl
2
 (25  mL) and cooled to  0 °C. 
Chloromethanesulphonyl chloride (804 µL,  8.91  mmol)  was added  dropwise and the 
ensuing mixture was warmed to room temperature over 6 h. The reaction was diluted 
with CH
2
Cl
2 
(40  mL) and the solution  washed  with  1  M aqueous  HCl (15  mL), 
saturated aqueous NaHCO
3
 (25 mL), H
2
O and brine. The organic phase was separated, 
dried (MgSO
4
), rotary evaporated and chromatographed (CH
2
Cl
2
:Et
2
O  25/1) to  give 
the  desired  product as a light  yelow  oil, (2.18  g,  76%);  Rf (CH
2
Cl
2
/Et
2
O) (15/1); 
0.54; α
D
 = 17.7 ° (c = 16.9 mg/mL, CH
3
Cl); δ
H
 (400 MHz, CDCl
3
); 7.17 (d, J = 8.7, 
2H), 6.89 (d, J = 8.6, 2H), 4.80-4.77 (m, 1H), 4.57 (d, J = 2.5, 2H), 4.27-4.21 (m, 1H), 
3.83 (s, 3H), 3.46-3.43 (m, 2H), 2.23-2.25 (m, 1H), 2.19-2.09 (m, 1H), 1.95-1.86 (m, 
1H),  1.79-1.72 (m,  1H),  1.23 (s,  9H); δ
C
 (100  MHz,  CDCl
3
); 158.6,  135.6,  126.7, 
113.8, 81.0, 63.0, 58.4, 55.3, 55.2, 50.0, 34.4, 28.6, 28.1; m/z [TOF MS ES+] found 
441.1233 [M  +  Na
+
], C
18
H
27
ClN
2
NaO
5
S requires 441.1227; IR (neat) ν
max
;  2973, 
1664, 1512, 1392, 1243, 1156, 1032, 829, 724; 
 
 
N
Boc
HN
MeO
S
Cl
O
O
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(2S,5R)-tert-butyl-2-(N-(tert-butoxycarbonyl)-1-chloromethylsulfonamido)methyl)-5-
(4-methoxyphenyl)pyrolidine-1-carboxylate (324) 
 
 
 
 
 
 
Sulphonamide 323 (710 mg, 1.70 mmol), DMAP (21 mg, 0.18 mmol) and Boc
2
O (482 
mg, 2.21 mmol) were dissolved in CH
2
Cl
2 
(2 mL). The reaction was stired for 2 h at 
ambient temperature, rotary evaporated and chromatographed (CH
2
Cl
2
:Et
2
O  30/1) to 
give the desired product as a white crystaline solid, (703 mg, 80%); Rf (CH
2
Cl
2
/Et
2
O) 
(30/1); 0.59; Mp (Et
2
O):  32-34 °C; α
D
 = 24.1 ° (c  =  12.4  mg/mL,  CH
3
Cl); δ
H
 (400 
MHz,  CDCl
3
);  7.19 (d, J = 8.7,  2H),  6.86 (d, J = 8.7,  2H),  5.00-4.92 (m,  2H),  4.65 
(brs, 1H), 4.40-4.37 (m, 1H), 4.23 (dd, J = 14.1, 5.6, 1H), 3.87-3.79 (m, 1H), 3.80 (s, 
3H), 2.29-2.21 (m, 1H), 1.99-1.90 (m, 3H), 1.56 (s, 9H), 1.40-1.22 (brs, 9H); δ
C
 (100 
MHz,  CDCl
3
); 158.4,  151.1,  136.1,  126.9,  113.6,  86.4,  85.7,  63.1,  56.6,  55.3,  53.5, 
50.1,  34.6,  28.2,  27.9,  27.6; m/z [TOF  MS  ES+] found 541.1740 [M  +  Na
+
], 
C
23
H
35
ClNaN
2
O
7
S
 
requires 541.1751; IR (neat) νmax  =: 2982,  1730,  1689,  1513, 
1364, 1243, 1137, 828; 
	  
	  
	  
(2S,5S)-tert-butyl 2-(4-methoxyphenyl)-5-(vinylsulfonamidomethyl) 
pyrolidine-1-carboxylate (327) 
 
 
 
 
 
 
Amine 321 (310 mg, 1.01 mmol) and chloroethane sulphonyl chloride (127 µL, 1.21 
mmol) were dissolved in CH
2
Cl
2 
(5 mL) and cooled to 0 °C. Triethylamine (130 µL, 
1.01  mmol)  was added  dropwise and the reaction  was alowed to  warm to ambient 
temperature  over  1  h.  Triethylamine (130 µL,  1.01  mmol)  was added again and the 
white precipitate disappeared. The solution was stired for 2 h, rotary evaporated and 
directly chromatographed (CH
2
Cl
2
:Et
2
O  15/1) to  give the  desired  product as a 
N
Boc
BocN
MeO
S
Cl
O
O
MeO
N
Boc
HN
S
O
O
	   282	  
colourless oil, (289 mg, 72%); Rf (CH
2
Cl
2
/Et
2
O) (15/1); 0.33; α
D
 = 16.5 ° (c = 15.7 
mg/mL, CH
3
Cl); δ
H
 (400 MHz, CDCl
3
); 7.14 (d, J = 8.5, 2H), 6.87 (d, J = 8.7, 2H), 
6.57 (dd, J = 16.6, 9.9, 1H), 6.26 (d, J = 17.1, 1H), 5.95 (d, J = 9.8, 1H), 4.74 (m, 1H), 
4.20-4.14 (m, 1H), 3.81 (s, 3H), 3.36-3.26 (m, 1H), 3.22-3.19 (m, 1H), 2.31-2.23 (m, 
1H), 2.14-2.04 (m, 1H), 1.92-1.85 (m, 1H), 1.77-1.73 (m, 1H), 1.22 (s, 9H); δ
C
 (100 
MHz,  CDCl
3
); 158.5,  136.1,  135.7,  126.8,  126.1,  113.7,  80.8,  62.9,  58.2,  55.3,  48.8, 
34.5,  28.6,  28.1; m/z [CI+] found 397.1797 [M  +  H
+
], C
19
H
29
N
2
O
5
S requires 
397.1797; IR (neat) ν
max
; 1665, 1512, 1391, 1366, 1244, 1149, 1033, 909, 727; 
 
 
 
(2S,5S)-tert-butyl-2-(N-(tert-butoxycarbonyl)vinylsulfonamido)methyl)-5-(4-
methoxyphenyl) 
pyrolidine-1-carboxylate (328) 
 
 
 
 
 
 
Vinyl sulfone 327 (300 mg, 0.78 mmol) and DMAP (9 mg, 0.07 mmol) were dissolved 
in MeCN (2 mL) and cooled to 0 °C. Boc
2
O (300 mg, 1.37 mmol) was added and the 
mixture  was alowed to stir  overnight.  The reaction  was evaporated to  dryness and 
chromatographed, (CH
2
Cl
2
:Et
2
O 15/1), to  give the  desired  product as a white foam 
solid, (312  mg,  81%); Rf (CH
2
Cl
2
/Et
2
O) (15/1);  0.65; Mp (EtOH); 28-30 °C; α
D
 = 
18.7 ° (c = 14.0 mg/mL, CH
3
Cl); δ
H
 (400 MHz, CDCl
3
); 7.22 (d, J = 8.7, 2H), 6.94 
(dd, J = 16.7, 9.9, 1H), 6.87 (d, J = 8.7, 2H), 6.41 (d, J = 16.6, 1H), 6.04 (d, J = 9.9, 
1H), 4.77-4.66 (brm, 1H), 4.41 (brm, 1H), 4.21-4.18 (brm, 1H), 3.82 (s, 3H), 3.81-3.79 
(brm, 1H), 2.28-2.20 (m, 1H), 1.96-1.90 (m, 3H), 1.55 (s, 9H), 1.31-1.20 (brs, 9H); δ
C
 
(100 MHz, CDCl
3
); 158.3, 155.2, 151.4, 136.3, 128.8, 127.9, 127.0, 113.5, 84.7, 83.9, 
63.3, 57.5, 55.3, 48.6, 34.1, 28.8, 28.1, 27.9; m/z [TOF MS ES+] found 497.2321 [M 
+  H
+
], C
24
H
36
N
2
O
7
S requires  497.2321; IR (neat) νmax  =: 2974,  1727,  1690,  1513, 
1352, 1231, 1134, 952, 658; 
 
 
MeO
N
Boc
BocN
S
O
O
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4-bromo-4'-methoxybiphenyl (331) 
 
 
 
 
Alcohol 330 (4.86  g,  19.5  mmol) and iodomethane (1.58 mL,  25.3 mmol) were 
combined  with acetone (30 mL).  K
2
CO
3
 (3.23  mg,  23.4 mmol) was added and the 
mixture  heated at 60 °C for  16  h. The reaction  was evaporated to dryness and the 
residue  directly chromatographed (Petrol:Et
2
O 30/1) to  give the  desired  product as a 
light brown crystaline solid, (4.31 g, 84%); Rf (Petrol/Et
2
O) (50/1); 0.42; Mp (Et
2
O); 
81-83 °C; δ
H
 (400 MHz, CDCl
3
); 7.56 (d, J = 7.2, 2H), 7.52 (d, J = 7.5, 2H), 7.45 (d, J 
= 7.2, 2H), 7.01 (d, J = 7.3, 2H), 3.89 (s, 3H); δ
C
 (100 MHz, CDCl
3
); 159.4, 139.8, 
132.5,  131.8,  128.3,  127.9,  120.8,  114.4,  55.4; m/z [TOF  MS  ES+] found 261.9985 
[M
+
], C
13
H
11
BrO requires 261.9993; IR (neat) ν
max
;  1603,  1523,  1479, 1288,  1036, 
807; 
 
 
(S)-methyl-2-(tert-butoxycarbonylamino)-5-(4'-methoxybiphenyl-4-yl)-5-
oxopentanoate (334) 
 
 
 
 
 
 
 
Aryl bromide 331 (6.50 g, 24.9 mmol) was dissolved in THF (35 mL) and cooled to -
78 °C.  n-BuLi in  hexanes (2.5  M;  9.96  mL,  24.9  mmol)  was added and the ensuing 
mixture stired for  1  h at -78 °C.  Lactam 262 (5.26  g,  21.6  mmol)  was  dissolved in 
THF (40  mL) and cooled to -78 °C.  The aryl lithium  was then cannulated into the 
aldehyde solution over 15 min, and the mixture stired for 2 h at -78 °C. The reaction 
was  quenched  via the addition  of  1  M aqueous  HCl (15  mL) and  diluted  with  Et
2
O 
(150  mL).  The  product  was extracted  with  Et
2
O (3  x  50  mL) and the combined 
organics  washed  with  H
2
O (50  mL), brine,  dried (MgSO
4
), rotary evaporated and 
chromatographed (CH
2
Cl
2
:EtOAc  15/1) to  give the  desired  product as a  white 
MeO
Br
MeO
O
CO
2
Me
NHBoc
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crystaline solid: Rf (CH
2
Cl
2
/EtOAc) (10/1); 0.63; Mp (EtOH): 88-90 °C; α
D
 = 8.7 ° 
(c = 11.4 mg/mL, CH
3
Cl); δ
H
 (400 MHz, CDCl
3
); 8.02 (d, J = 8.4, 2H), 7.66 (d, J = 
8.4, 1H), 7.60 (d, J = 8.8, 2H), 7.02 (d, J = 8.8, 2H), 5.22 (brs, 1H, NH), 4.44-4.41 (m, 
1H), 3.89 (s, 3H), 3.79 (s, 3H), 3.22-3.05 (m, 2H), 2.40-2.31 (m, 1H), 2.16-2.09 (m, 
1H),  1.45 (s,  9H); δ
C
 (100  MHz,  CDCl
3
); 198.4,  172.9,  159.9,  155.5,  145.6,  134.8, 
132.2,  128.7,  128.4,  126.6,  114.4,  80.0,  55.4,  53.2,  52.4,  34.5,  28.3,  27.1; m/z [TOF 
MS ES+] found 450.1892 [M + Na
+
], C
24
H
29
NNaO
6
 requires 450.1893; IR (neat) ν
max
; 
3368, 2953, 1748, 1684, 1511, 1366, 1252, 1152, 997, 822; 
 
 
 
(2S,5S)-methyl 5-(4'-methoxybiphenyl-4-yl)pyrolidine-2-carboxylate (335) 
 
 
 
 
 
 
 
 
i. Ketone 334 (1.50 g, 3.51 mmol) and TFA (2.61 mL, 35.1 mmol) were dissolved in 
CH
2
Cl
2
 (3  mL) and cooled to  0 °C.  The resulting  mixture  was alowed to  warm to 
room temperature over 2 h. The reaction was then diluted with CH
2
Cl
2
 (70 mL) and 
washed  with  H
2
O (10  x  20  mL).  The  organics  were then  dried (MgSO
4
) and rotary 
evaporated to  give the crude imine intermediate,  which  was  used  without further 
purification; i.  The imine  was  dissolved in EtOAc (2 mL) and was added to a 
suspension  of  5%  Pt/C (1.60 g,  1.51  mmol) in 
i
PrOH (10 mL)  which  had  been 
activated  by bubbling  hydrogen through the solution for  10  min.  The reaction  was 
stired under an atmosphere  of  hydrogen for  16 h, the flask  was then  purged  with 
nitrogen, filtered, rotary evaporated and chromatographed (Petrol:EtOAc 5/1), to give 
the desired product as a white crystaline solid, (612 mg, 56%) ‘over two steps’; Mp 
(Et
2
O):  38-40 °C;  Rf (CH
2
Cl
2
/EtOAc) (1/1); 0.13; α
D
 = 11.2 ° (c  =  12.5  mg/mL, 
CH
3
Cl); δ
H
 (400  MHz,  CDCl
3
);  7.56-7.51 (m,  6H),  7.01-6.99 (d, J = 8.7,  2H),  4.27 
(dd, J = 9.1, 5.7, 1H), 3.99 (dd, J = 8.5, 5.0, 1H), 3.88 (s, 3H), 3.81 (s, 3H), 2.38 (brs, 
1H, NH), 2.29-2.14 (m, 3H), 1.81-1.77 (m, 1H); δ
C
 (100 MHz, CDCl
3
); 175.7, 159.1, 
MeO
O
CO
2
Me
NHBoc
N
H
CO
2
Me
MeO
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141.9, 139.8, 133.5, 128.1, 127.2, 126.8, 114.2, 63.3, 60.1, 55.4, 52.2, 34.3, 30.6; m/z 
[TOF  MS  ES+] found 312.1594 [M  +  H
+
], C
19
H
22
NO
3 
requires  312.1600; IR (neat) 
ν
max
; 2952, 1736, 1606, 1498, 1248, 1181, 1034, 811; 
 
 
 
(2S,5S)-5-(4'-methoxybiphenyl-4-yl)pyrolidin-2-yl)methanol (329) 
 
 
 
 
 
 
 
Ester 335 (400  mg,  1.29  mmol)  was  dissolved in  EtOH (5  mL) and cooled to  0 °C. 
NaBH
4 
(74  mg,  1.95  mmol)  was added.  The ensuing  mixture  was stired at room 
temperature overnight and then quenched via the addition of glacial acetic acid (500 
µL), rotary evaporated and chromatographed (CH
3
Cl:MeOH 10/1) to give the desired 
product as a light yelow crystaline solid, (213 mg, 58%); Rf (CH
2
Cl
2
/MeOH) (10/1); 
0.21; α
D
 = 13.4 ° (c = 11.6 mg/mL, CH
3
Cl); δ
H
 (400 MHz, CDCl
3
); 7.67 (d, J = 8.3, 
2H), 7.59 (d, J = 8.3, 2H), 7.57 (d, J = 8.7, 2H), 7.01 (d, J = 8.7, 2H), 4.77-4.64 (brs, 
1H, NH), 3.84 (s, 3H), 3.75 (dd, J = 6.7, 3.9, 1H), 3.70-3.66 (m, 2H), 3.61-3.58 (m, 
1H),  2.48-1.73 (brm,  4H); δ
C
 (100  MHz,  CDCl
3
);  159.7,  141.7,  132.5,  132.3,  127.9, 
127.6,  126.6,  113.9,  71.0,  60.6,  54.3,  42.3,  29.4,  25.2;  m/z [TOF  MS  ES+] found 
284.1654 [M + H
+
], C
18
H
22
NO
2 
requires 284.1651; IR (neat) ν
max
; 2952, 1601, 1498, 
1316, 1222, 1165, 1051, 867, 795; 
	  
	  
	  
(S)-dimethyl 2-(bis(tert-butoxycarbonyl)amino)pentanedioate (341)
3
 
 
 
 
 
 
L-Glutamic acid  dimethyl ester  hydrochloride (8.50  g,  40.2  mmol) and  Et
3
N (33.35 
mL,  241.6  mmol)  were  dissolved in  MeOH (100  mL) and cooled to  0 °C.  Boc
2
O 
N
H
MeO
OH
MeO
2
C CO
2
Me
NBoc
2
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(10.51 g, 48.2 mmol) was added in one portion. The resulting mixture was alowed to 
warm to room temperature over a period of 3 hours, at which point the mono-protected 
boc amine  was fuly formed (
1
H  NMR).  The  mixture  was concentrated and the 
resulting residue suspended in  Et
2
O (150  mL).  The  organics were  washed  with 
saturated aqueous NaHCO
3
 (35 mL), H
2
O, brine, dried (MgSO
4
) and rotary evaporated 
to give the desired mono-boc protected amine, which was used directly in the second 
protection;  Carbamate 341i,  DMAP (982  mg,  8.04  mmol) and  Boc
2
O (10.51  g, 48.2 
mmol) were dissolved in MeCN (50 mL) and the mixture was stired for 30 min at 0 
°C before being warmed to room temperature and stired for 6 hours. The mixture was 
concentrated and the resulting residue suspended in Et
2
O (150 mL). The organics were 
washed with saturated aqueous NaHCO
3
 (35 mL), H
2
O, brine, dried (MgSO
4
), rotary 
evaporated and chromatographed (CH
2
Cl
2
:Et
2
O 15/1), to give the desired product as a 
colourless oil, (13.04  g,  87%); Rf (CH
2
Cl
2
/EtOAc) (20/1);  0.71; δ
H
 (400  MHz, 
CDCl
3
); 4.95 (dd, J = 9.6,  4.8,  1H),  3.73 (s,  3H),  3.68 (s,  3H),  2.54-2.39 (m,  3H), 
2.24-2.15 (m,  1H),  1.50 (s,  18H); δ
C
 (100  MHz,  CDCl
3
); 173.1,  172.6,  155.3,  79.9, 
52.8,  52.3,  51.7,  30.0,  28.2,  27.2; m/z [TOF  MS  ES+] found 398.1786 [M  +  H
+
], 
C
17
H
29
NNaO
8
 requires 398.1791; (data matched literature); 
 
 
(S)-methyl 2-(bis(tert-butoxycarbonyl)amino)-5-oxopentanoate (342)
3
 
 
 
 
 
To a solution of ester 341 (10.00 g, 26.6 mmol) in Et
2
O (150 mL) at -78 °C, DIBAL in 
hexanes (1.0 M; 31.9 mL, 31.9 mmol) was slowly added. The reaction was stired for 
2 h and  was  quenched at -78 °C via the addition  of saturated aqueous sodium 
potassium tartrate (60  mL).  The resulting  mixture was warmed to room temperature 
and stired for 1 h. The layers were separated and the aqueous layer was extracted with 
Et
2
O (4 x 50 mL). The combined organics were dried (MgSO
4
), rotary evaporated and 
chromatographed (CH
2
Cl
2
:EtOAc 40/1) to give the desired product as a colourless oil, 
(6.98 g,  76%); Rf (CH
2
Cl
2
/EtOAc) (40/1); 0.56; δ
H
 (400  MHz,  CDCl
3
);  9.77 (t, J = 
2.3,  1H),  4.87 (dd, J = 9.4,  5.1,  1H),  3.71 (s,  3H),  2.62-2.57 (m,  1H),  2.55-2.47 (m, 
2H),  2.18-2.12 (m ,1H),  1.50 (s,  9H),  1.49 (s, 9H); δ
C
 (100  MHz,  CDCl
3
);  200.5, 
CO
2
Me
NBoc
2
O
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170.5, 151.9, 83.0, 57.4, 51.9, 40.7, 27.9, 23.0; m/z [TOF MS ES+] found 346.1863 
[M + H
+
], C
16
H
28
NO
7
 requires 346.1866; (data matched literature); 
 
 
(S)-methyl 2-(bis(tert-butoxycarbonyl)amino)-5-hydroxy-5-(naphthalen-2-
yl)pentanoate (343) 
 
 
 
 
 
1-Iodonapthalene (2.12 mL, 14.9 mmol) was dissolved in Et
2
O (10 mL) and cooled to 
0 °C. Isopropylmagnesium chloride in THF (2.0 M; 7.45 mL, 14.9 mmol) was added 
and the ensuing mixture stired for 2 h at 0 °C. Aldehyde 342 (3.50 g, 10.1 mmol) was 
dissolved in  Et
2
O (10  mL) and cooled to -78 °C.  The  Grignard  was then cannulated 
into the aldehyde solution over 15 min, and the mixture stired for 2 h at -78 °C. The 
reaction was quenched via the addition of 1 M aqueous HCl (10 mL) and diluted with 
Et
2
O (40  mL).  The  product  was extracted  with  Et
2
O (3  x  30  mL) and the combined 
organics  washed  with  H
2
O (30  mL),  brine,  dried (MgSO
4
), rotary evaporated and 
chromatographed (CH
2
Cl
2
/EtOAc 10/1) to give the desired product as a colourless oil, 
(4.71 g, 98%); Rf (CH
2
Cl
2
/EtOAc) (40/1); 0.17; δ
H
 (400 MHz, CDCl
3
); 8.12 (dd, J = 
7.1, 2.5, 1H), 7.90-7.78 (m, 2H), 7.70-7.64 (m, 1H), 7.53-7.46 (m, 3H), 5.57-5.48 (m, 
1H), 5.01-4.96 (m, 1H), 3.72 (s, 3H), 2.44-2.35 (m, 2H), 2.09-1.97 (m, 2H), 1.46 (s, 
9H); δ
C
 (100  MHz,  CDCl
3
); 171.5,  152.2,  140.1,  133.9, 130.4,  128.8,  128.0,  126.0, 
125.5, 125.4, 123.2, 122.9, 83.2, 71.2, 58.1, 52.2, 34.5, 27.9, 26.8; m/z [TOF MS ES+] 
found 496.2326  [M  +  Na
+
], C
26
H
35
NO
7
Na requires 496.2311; IR (neat) ν
max
; 2921, 
1736, 1696, 1366, 1251, 1232, 1138, 1115, 778; 
 
 
 
 
 
 
 
CO
2
Me
OH
NBoc
2
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(S)-methyl 2-(bis(tert-butoxycarbonyl)amino)-5-(naphthalen-2-yl)-5-oxopentanoate 
(344) 
 
 
 
 
 
 
Alcohol 343 (4.60 g, 9.72 mmol) was dissolved in CH
2
Cl
2 
(30 mL) and cooled to 0 °C. 
Pyridinium chlorochromate (2.51 g, 11.7 mmol) was added portionwise over 15 min 
and the reaction  warmed to room temperature  over  3  h.  The reaction  was filtered, 
rotary evaporated and chromatographed (CH
2
Cl
2
/EtOAc  50/1) to  give the  desired 
product as a light yelow oil, (3.02 g, 66%); α
D
 = 52.2 ° (c = 14.1 mg/mL, CH
3
Cl); Rf 
(CH
2
Cl
2
/EtOAc) (30/1); 0.60; δ
H
 (400 MHz, CDCl
3
); 8.66 (d, J = 8.6, 1H), 8.01 (d, J 
= 8.2, 1H), 7.91 (dd, J = 9.7, 3.6, 2H), 7.63-7.49 (m, 3H), 5.10 (dd, J = 9.3, 5.4, 1H), 
3.77 (s, 3H), 3.30-3.24 (m, 1H), 3.15-3.09 (m, 1H), 2.75-2.68 (m, 1H), 2.38-2.33 (m, 
1H),  1.48 (s,  18H); δ
C
 (100  MHz,  CDCl
3
); 202.9,  171.1,  152.1,  135.7,  133.9,  132.7, 
130.2, 128.3, 127.9, 127.6, 126.4, 126.0, 124.3, 83.3, 57.5, 52.2, 38.6, 27.8, 24.7; m/z 
[TOF  MS  ES+] found 494.2153 [M  +  Na
+
], C
26
H
33
NO
7
Na requires 494.2155; IR 
(neat) νmax =: 2899, 1752, 1691, 1421, 1366, 1231, 1127, 1011, 989, 813; 
 
 
(2S,5R)-methyl 5-(naphthalen-2-yl)pyrolidine-2-carboxylate (345) 
 
 
 
 
 
 
i. Ketone 344 (2.60 g, 5.52 mmol) and TFA (4.11 mL, 55.2 mmol) were dissolved in 
CH
2
Cl
2
 (15  mL) and cooled to  0 °C.  The resulting  mixture  was alowed to  warm to 
room temperature over 2 h. The reaction was then diluted with CH
2
Cl
2
 (70 mL) and 
washed  with  H
2
O (10  x  20  mL).  The  organics  were then  dried (MgSO
4
) and rotary 
evaporated to  give the crude imine intermediate,  which  was  used  without further 
purification; i.  The imine  was  dissolved in 
i
PrOH (1 mL) and was added to a 
suspension of 5% Pt/C (1.60 g, 1.51 mmol) in 
i
PrOH/EtOAc (1/1) (15 mL) which had 
CO
2
Me
NBoc
2
O
CO
2
Me
NBoc
2
O
N
CO
2
Me
N
H
CO
2
Me
i.
i.
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been activated  by  bubbling  hydrogen through the solution for  10  min.  The reaction 
was stired under an atmosphere of hydrogen for 16 h, the flask was then purged with 
nitrogen, filtered, rotary evaporated and chromatographed (CH
2
Cl
2
:EtOAc  50/1), to 
give the desired product as a light yelow oil and single diastereoisomer, (420 mg, 31 
%); Rf (CH
2
Cl
2
/Et
2
O) (50/1); 0.27; α
D
 =  45.0 ° (c  = 12.0 mg/mL,  CH
3
Cl); δ
H
 (400 
MHz, CDCl
3
); 8.20 (d, J = 8.3, 1H), 7.89 (dd, J = 4.5, 2.7, 2H), 7.79 (d, J = 8.2, 1H), 
7.58-7.49 (m, 3H), 5.04 (m, 1H), 4.09 (dd, J = 8.3, 6.5, 1H), 3.83 (s, 3H), 2.46-2.37 
(m, 2H), 2.35-2.26 (m, 1H), 2.23-2.10 (m, 1H), 1.93 (m, 1H); δ
C
 (100 MHz, CDCl
3
); 
175.4, 139.3, 133.8, 131.4, 128.8, 127.5, 125.9, 125.6, 125.4, 123.5, 122.7, 60.0, 58.9, 
52.1, 32.9, 29.9; m/z [TOF MS ES+] found 256.1329 [M + H
+
], C
16
H
18
NO
2 
requires 
256.1338; IR (neat) νmax =: 2949 (w), 1731 (s), 1596 (m), 1509 (m), 1435 (m), 1201 
(s), 1115 (m), 799 (s), 777 (s); 
 
 
 
(2S,5R)-5-(naphthalen-2-yl)pyrolidin-2-yl)methanol (336) 
 
 
 
 
 
Ester 345 (50  mg,  0.20  mmol)  was  dissolved in  EtOH (1  mL) and cooled to  0 °C. 
NaBH
4 
(16  mg,  0.43  mmol)  was added.  The ensuing  mixture  was stired at room 
temperature overnight and then quenched via the addition of glacial acetic acid (100 
µL), rotary evaporated and chromatographed (CH
3
Cl:MeOH 10/1) to give the desired 
product as a light orange crystaline solid, (31 mg, 70%); Mp (EtOH): 51-53 °C; α
D
 = 
37.0 ° (c = 11.7 mg/mL, CH
3
Cl); δ
H
 (400 MHz, CDCl
3
); 8.09 (d, J = 8.1, 1H), 7.88-
7.85 (m, 1H), 7.80 (d, J = 8.3, 1H), 7.76 (d, J = 8.1, 1H), 7.54-7.42 (m, 4H), 6.65 (brs, 
2H,  het-H), 5.22-5.18 (m,  1H),  3.62-3.56 (m,  3H),  2.44-2.39 (m,  1H),  2.14-1.97 (m, 
3H),  1.77 (s,  3H); δ
C
 (100  MHz,  CDCl
3
);  177.7,  133.8,  131.0,  128.9,  128.5,  127.1, 
126.6,  125.9,  125.4,  123.3,  122.8,  62.1,  60.7,  58.4,  32.3,  26.6,  23.1; m/z [TOF  MS 
ES+] found 228.1385 [M  +  H
+
], C
15
H
18
NO
 
requires 228.1388; IR (neat) ν
max
;  2929, 
2864, 1536, 1399, 1092, 1049, 803, 777; 
	  
N
H
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(2S,5S)-tert-butyl-2-(N-(tert-butoxycarbonyl)-2-(S)-1-(S)-2,2-dimethyl-1,3-
dioxolan-4-yl)-2- methoxymethoxyamino)ethylsulfonamido)methyl)-5-(4-
methoxyphenyl)pyrolidine-1-carboxylate (356) 
 
 
 
 
 
 
 
 
Amine 355 (40  mg,  0.20  mmol) and  vinyl sulfone 328 (50  mg,  0.10  mmol)  were 
dissolved in 
i
PrOH (200 µL) and heated at 85 °C for 16 h. The mixture was alowed to 
cool to ambient temperature, rotary evaporated and  directly chromatographed 
(CH
2
Cl
2
:MeOH 50/1) to give the desired product as a light orange oil, (67 mg, 95%); 
Rf (CH
2
Cl
2
/MeOH) (20/1); 0.43; α
D
 = 17.1 ° (c = 14.0 mg/mL, CH
3
Cl); δ
H
 (400 MHz, 
CDCl
3
); 7.21 (d, J = 8.7, 2H), 6.86 (d, J = 8.7, 2H), 4.67-4.63 (m, 2H), 4.41-4.38 (m, 
1H), 4.20-4.13 (m, 1H), 4.08-4.02 (m, 2H), 3.92-3.87 (m, 1H), 3.80 (s, 3H), 3.77-3.72 
(m, 2H), 3.70-3.55 (m, 4H), 3.38 (s, 3H), 3.32-3.26 (m, 1H), 3.10-3.04 (m, 1H), 2.78-
2.73 (m, 1H), 2.29-2.18 (m, 1H), 1.95-1.89 (m, 3H), 1.75 (brs, 1H), 1.55 (s, 9H), 1.41 
(s, 3H), 1.34 (s, 3H), 1.20 (s, 9H); δ
C
 (100 MHz, CDCl
3
); 158.3, 155.3, 151.6, 127.0, 
126.7,  113.6,  108.9,  96.7,  84.7,  75.7,  67.1,  65.8,  59.8,  57.5,  55.4,  54.9,  48.8,  41.9, 
28.2,  28.0,  27.2,  26.7,  25.2; m/z [TOF  MS  ES+] found 702.3612 [M  +  H
+
], 
C
33
H
56
N
3
O
11
S requires 702.3636; IR (neat) ν
max
; 2961, 1726, 1689, 1513, 1349, 1136, 
1038, 909, 727; 
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N-((2S,5S)-5-(4-methoxyphenyl)pyrolidin-2-yl)methyl)-2-(2S,3S)-1,3,4-
trihydroxybutan-2-ylamino)ethanesulfonamide (351) 
 
 
 
 
 
 
 
 
Carbamate 356 (65 mg, 0.09 mmol) was dissolved in CH
2
Cl
2
 (2 mL) and cooled to 0 
°C. 4 M HCl in dioxane (2 mL) was added dropwise and the mixture was alowed to 
warm to room temperature.  After  3  h the reaction  was evaporated and the resulting 
residue triturated chromatographed (CH
3
Cl:MeOH  10/1) to  give the  product as an 
orange solid.  Trituration  of the solid  with  Et
2
O  gave the  desired  product as a cream 
crystaline solid, (18 mg, 42%); Rf (CH
3
Cl/MeOH) (10/1); 0.03; Mp (MeOH) = 29-31 
°C; α
D
 = 10.2 ° (c = 15.6 mg/mL, MeOH); δ
H
 (400 MHz, CDCl
3
); 7.47 (d, J = 8.7, 
2H),  7.00 (d, J = 8.7,  2H),  4.57 (dd, J = 10.4,  6.9,  1H),  3.83 (s,  3H),  3.82-3.76 (m, 
3H), 3.71-3.63 (m, 4H), 3.47-3.45 (m, 2H), 3.41-3.38 (m, 2H), 3.31-3.19 (m, 2H), 2.87 
(q, J = 5.4, 1H), 2.45-2.19 (m, 3H), 2.03-1.95 (m, 1H); δ
C
 (100 MHz, CDCl
3
); 161.7, 
130.0,  128.9,  115.4,  71.9,  64.9,  64.6,  62.3,  61.4,  60.7,  55.8,  51.9,  45.5,  42.9,  31.1, 
28.1; m/z [TOF MS ES+] found 418.2020 [M + H
+
], C
18
H
32
N
3
O
6
S requires 418.2012; 
IR (neat) ν
max
; 3300-2900 (br), 2931, 1612, 1517, 1310, 1250, 1139, 1023, 830; 
 
 
(S,E)-methyl 3-(2,2-dimethyl-1,3-dioxolan-4-yl)acrylate, (S,Z)-methyl 3-(2,2-
dimethyl-1,3-dioxolan-4-yl)acrylate (363)
4
 
 
 
 
 
 
R-(-)-2,2-dimethyl-1,3-dioxolane-4-methanol (2.5 g, 18.9 mmol) was oxidised using a 
Swern  protocol.  Oxalyl chloride (1.76  mL,  20.8  mmol) in CH
2
Cl
2
 (150  mL,  0.1  M 
solution) was cooled to -78 ºC and DMSO (3.2 mL, 45.3 mmol) was added dropwise 
over  5  min.  The reaction was stired for  20 min, then a of solution alcohol 362 in 
MeO
N
H.HCl
HN
S
O
O
HN
OH
HO
HO
O
O
CO
2
Me
O
O
CO
2
Me
O
O
OH
i. Swern Ox
i. Witig Oleﬁnation
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CH
2
Cl
2
 (5  mL)  was added  over  5  min.  The reaction was stired for an additional  45 
min and then Et
3
N (15.0 mL, 192.0 mmol) was added in one portion. The reaction was 
warmed to ambient temperature and stired for  2 h.  Folowing this,  Carboxymethyl 
phosphonium  ylide (8.21  g,  24.5  mmol)  was added in  one  portion and the reaction 
stired  overnight at room temperature.  The solvent  was then removed  via rotary 
evaporation and Et
2
O (100 mL) added to the residue. The ether was decanted and the 
solid washed with Et
2
O (2 x 50 mL). The combined organics were rotary evaporated 
and the residue chromatographed (Petrol:EtOAc 5/1) to give the desired products as a 
(2:1)  mixture  of trans/cis isomers, colourless  oil, (3.34  g, 93%) ‘over two steps’; Rf 
(Petrol/EtOAc) (3/1); 0.66; Trans: δ
H
 (400 MHz, CDCl
3
); 6.89 (dd, J = 15.6, 5.4, 1H), 
6.10 (d, J = 15.6, 1H), 4.65 (dd, J = 12.6, 6.1, 1H), 4.19 (t, J = 7.3, 1H), 3.74 (s, 3H), 
3.68 (t, J = 7.6, 1H), 1.44 (s, 3H), 1.41 (s, 3H); δ
C
 (100 MHz, CDCl
3
); 166.0, 149.5, 
120.3,  109.7,  73.5,  69.3,  51.5,  26.5,  25.4; Cis: δ
H
 (400  MHz, CDCl
3
);  6.36 (dd, J = 
11.7, 6.7, 1H), 5.85 (d, J = 11.7, 1H), 5.51-5.46 (m, 1H), 4.38 (t, J = 8.2, 1H), 3.72 (s, 
3H),  3.61 (t, J = 8.2,  1H),  1.45 (s,  3H),  1.39 (s,  3H); δ
C
 (100  MHz,  CDCl
3
); 166.4, 
145.0, 121.9, 110.2, 74.9, 68.8, 51.7, 26.4, 25.7; m/z [CI+] found 187.0973 [M + H
+
], 
C
9
H
15
O
4 
requires, 187.0970; IR (neat) ν
max
; 2988, 1721, 1663, 1259, 1171, 1057, 1030, 
976, 843; (data matched literature); 
	  
	  
	  
(S,E)-3-(2,2-dimethyl-1,3-dioxolan-4-yl)prop-2-en-1-ol , (S,Z)-3-(2,2-dimethyl-1,3-
dioxolan-4-yl)prop-2-en-1-ol (364)
4
 
 
 
 
 
 
To a solution of esters 363 (3.15 g, 16.6 mmol) in THF (60 mL) at -78 °C, DIBAL in 
hexanes (1.0 M; 38.2 mL, 38.2 mmol) was slowly added. The reaction was stired for 
2 h and  was  quenched at -78 °C via the addition  of saturated aqueous sodium 
potassium tartrate (60  mL).  The resulting  mixture was warmed to room temperature 
and stired overnight. The layers were separated and the aqueous layer was extracted 
with CH
2
Cl
2
 (4  x  50  mL).  The combined organics were dried (MgSO
4
), rotary 
evaporated and chromatographed (CH
2
Cl
2
:Et
2
O 3/1) to give the desired products as a 
O
O
O
O
OH
OH
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(2:1)  mixture  of trans/cis isomers, (2.33  g,  89%); Rf (CH
2
Cl
2
/Et
2
O) (3/1);  0.31; 
Trans: δ
H
 (400  MHz, CDCl
3
);  5.89-5.75 (m,  1H),  5.57-5.52 (m,  1H),  4.88-4.83 (m, 
1H), 4.31-4.18 (brm, 2H), 4.10 (dd, J = 6.0, 1.9, 1H), 3.55, (t, J = 8.0, 1H), 2.32-2.30 
(m, 1H), 1.42 (s, 3H), 1.39 (s, 3H); δ
C
 (100 MHz, CDCl
3
); 133.2,  129.9,  109.5,  71.9, 
69.5, 58.5, 26.7, 25.9; Cis: δ
H
 (400 MHz, CDCl
3
); 5.95 (dt, J = 15.0, 4.7, 1H), 5.71 
(ddd, J = 15.5, 7.4, 1.6, 1H), 4.53 (q, J = 7.3, 1H), 4.16-4.14 (m, 2H), 4.09 (dd, J = 
6.2, 1.9, 1H), 3.59 (t, J = 7.9, 1H), 2.12-2.09 (m, 1H), 1.42 (s, 3H), 1.38 (s, 3H); δ
C
 
(100 MHz, CDCl
3
); 133.5, 128.4, 109.4, 76.5, 69.4, 62.5, 26.7, 25.9; m/z [CI+] found 
159.1024 [M  +  H
+
], C
8
H
15
O
3 
requires, 159.1021; IR (neat) ν
max
;  2986,  1371,  1213, 
1155, 1053, 1024, 855, 792; (data matched literature); 
	  
	  
	  
	  
(2R,3S)-3-(R)-2,2-dimethyl-1,3-dioxolan-4-yl)oxiran-2-yl)methanol (365)
4
 
 
 
 
 
(100 mg) of 4A powdered, activated molecular sieves were suspended in CH
2
Cl
2
 (25 
mL).  The suspension  was cooled to -20 °C, (-)-Diethyl  D-tartrate (2.08  mL,  12.1 
mmol) and Ti(O
i
Pr)
4
 (2.98 mL, 10.1 mmol) were added sequentialy with stiring. The 
reaction mixture was continuously stired at -20 °C as TBHP in decane (5.5 M; 3.67 
mL, 20.2 mmol) was added and the ensuing mixture was alowed to stir for 30 min. 
Alcohols 364 (1.60 g, 10.1 mmol) dissolved in CH
2
Cl
2 
(3 mL) were added dropwise 
maintaining the temperature between -20 and -15 °C. The reaction was stired at -20 
°C for 4 h and then quenched via the addition of 1 M aqueous tartaric acid (10 mL). 
The mixture was warmed to ambient temperature over 15 min and further diluted with 
CH
2
Cl
2 
(30 mL). The organic phase was separated and washed with saturated aqueous 
Na
2
S
2
O
3 
(10 mL), H
2
O and brine. The colected organics were dried (MgSO
4
), rotary 
evaporated and chromatographed (CH
2
Cl
2
:Et
2
O  4/1) to  give the  desired  product as a 
colourless  oil, (867  mg,  74%); α
D
 =  62.7 ° (c  =  17.2  mg/mL,  CH
3
Cl); Rf 
(CH
2
Cl
2
/Et
2
O) (1/1); 0.34; δ
H
 (400 MHz, CDCl
3
); 4.18-4.08 (m, 2H), 3.98-3.95 (brm, 
1H), 3.90-3.85 (m, 1H), 3.70-3.68 (brm, 1H), 3.16-3.12 (brm, 2H), 2.13 (brs, 1H), 1.44 
(s, 3H), 1.38 (s, 3H); δ
C
 (100 MHz, CDCl
3
); 110.1, 75.3, 66.0, 60.8, 57.1, 55.0, 26.5, 
O
O
OH
O
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25.2; m/z [TOF MS ES+] found 175.0964 [M + H
+
], C
8
H
15
O
4
 requires, 175.0970; IR 
(neat) ν
max
;  3424 (br),  1375,  1252,  1214,  1056,  910,  842,  728; (data  matched 
literature); 
 
 
 
(2S,3S)-2-(R)-2,2-dimethyl-1,3-dioxolan-4-yl)tetrahydrofuran-3-ol (366)
4
 
 
 
 
 
 
 
(500  mg)  of  4A  powdered, activated  molecular sieves and  NaHMDS (4.73  g,  25.8 
mmol) were transfered to a flask under an inert atmosphere in a glovebox. The flask 
was removed from the  glovebox and  DMSO (25  mL)  was added.  The resulting 
suspension  was alowed to stir at ambient temperature for  30  min. 
Trimethylsulphoxonium iodide (5.29  g,  25.8  mmol)  was added  portionwise  over  30 
min and the milky white suspension was alowed to stir for a further 30 min. Epoxy 
alcohol 365 (450 mg, 2.58 mmol) was dissolved in DMSO (2 mL) and added dropwise 
to the suspension, the ensuing mixture was then heated at 90 °C for 48 h. The reaction 
was carefuly quenched with saturated aqueous NH
4
Cl (10 mL), diluted with H
2
O (10 
mL) and extracted with EtOAc (3 x 30 mL). The combined organics were washed with 
saturated aqueous NaHCO
3
 (10 mL), H
2
O and brine, dried (MgSO
4
), rotary evaporated 
and chromatographed (CH
2
Cl
2
:EtOAc 5/1) to give the desired product as a colourless 
oil, (211 mg, 43 %); Rf (CH
2
Cl
2
/EtOAc) (2/1); 0.16; α
D
 = 29.3 ° (c = 11.6 mg/mL, 
CH
3
Cl); δ
H
 (400 MHz, CDCl
3
); 4.30-4.25 (m, 1H), 4.17 (td, J = 6.9, 5.1, 1H), 4.07-
3.95 (m, 3H), 3.88 (dd, J = 8.2, 7.2, 1H), 3.74 (dd, J = 5.6, 3.7, 1H), 2.38 (brs, 1H, 
OH), 2.24-2.15 (m, 1H), 1.93-1.86 (m, 1H), 1.44 (s, 3H), 1.37 (s, 3H); δ
C
 (100 MHz, 
CDCl
3
); 109.6,  85.7,  76.3,  73.7,  67.4,  65.6,  35.6,  26.3,  25.4; m/z [TOF  MS  ES+] 
found 189.1129 [M + H
+
], C
9
H
17
O
4
 requires 189.1127; IR (neat) ν
max
; 3421 (br), 2983, 
1370, 1211, 1108, 1056, 845; (data matched literature); 
 
 
	  
	  
O
HO
O
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diethyl 3-(1,3-dioxoisoindolin-2-yl)propylphosphonate (373)
5
 
 
 
 
 
 
 
 
Pthalimide 372 (2.00 g, 6.15 mmol) was dissolved in triethylphosphite (6.74 mL, 39.3 
mmol) and heated at 160 °C for 4 h. The reaction was cooled to ambient temperature 
and the excess triethylphosphite removed via vacuum distilation (3 mmHg) at 60 °C 
to give the desired product as a light yelow oil, (1.94 g, 84%); δ
H
 (400 MHz, CDCl
3
); 
7.59 (m, 2H), 7.51 (m, 2H), 3.85 (q, J = 5.6, 4H), 3.51 (t, J = 6.6, 2H), 1.77-1.62 (m, 
2H),  1.59-1.51 (m,  2H),  1.08 (t, J  =  6.9,  6H); δ
C
 (100  MHz,  CDCl
3
); 167.6,  133.5, 
131.4,  122.6,  61.0,  37.6,  24.0,  15.5; 
31
P (121  MHz,  CDCl
3
);  33.2; (data  matched 
literature); 
 
 
diethyl 3-aminopropylphosphonate (374)
5
 
 
 
 
 
Phosphonate 373 (1.90 g, 5.84 mmol) was dissolved in EtOH (15 mL) and cooled to 0 
°C.  Hydrazine  hydrate (2.47  mL,  58.4  mmol)  was added  dropwise and the reaction 
was stired at room temperature for 16 h. The reaction was filtered to remove the white 
precipitate, the filtrate  was rotary evaporated and chromatographed (CH
3
Cl:MeOH 
20/1) to  give the  desired  product as a light  yelow  oil, (1.01  g,  87%);  Rf 
(CH
3
Cl/MeOH) (20/1);  0.07; δ
H
 (400  MHz,  CDCl
3
); 4.82 (brs,  2H,  NH
2
),  4.09-4.04 
(m, 4H), 2.88 (t, J = 6.1, 2H), 1.87-1.80 (m, 4H), 1.31-1.28 (t, J = 6.1, 6H); δ
C
 (100 
MHz, CDCl
3
); 61.7, 41.4, 24.4, 23.6, 16.4; δ
P
 (121 MHz, CDCl
3
); 31.7; m/z [TOF MS 
ES+] found 196.1100 [M  +  H
+
], C
7
H
19
NO
3
P requires  196.1103; (data  matched 
literature); 
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3-(2-(N-((2S,5S)-5-(4-hydroxyphenyl)pyrolidin-2-
yl)methyl)sulfamoyl)ethylamino)propylphosphonate diethyl ester (375) 
 
 
 
 
 
 
 
 
 
Amine 374 (25  mg,  0.13  mmol) and  vinyl sulfone 328 (50  mg,  0.10  mmol)  were 
dissolved in 
i
PrOH (300 µL) and heated at 85 °C for 16 h. The mixture was alowed to 
cool to ambient temperature, rotary evaporated and  directly chromatographed 
(CH
2
Cl
2
:MeOH 50/1) to give the desired product as a colourless oil, (65 mg, 94%); Rf 
(CH
2
Cl
2
/MeOH) (20/1); 0.20; α
D
 = 12.5 ° (c = 11.2 mg/mL, CH
3
Cl); δ
H
 (400 MHz, 
CDCl
3
); 7.21 (d, J = 8.3, 2H), 6.86 (d, J = 8.3, 2H), 4.69-4.65 (m, 1H), 4.41-4.38 (m, 
1H), 4.17-4.15 (m, 1H), 4.16-4.06 (m, 4H), 3.81 (s, 3H), 3.80-3.74 (brm, 2H), 3.58 (dt, 
J = 13.6, 6.3, 1H), 3.15-3.10 (m, 2H), 2.70 (t, J = 6.4, 2H), 2.25-2.19 (m, 1H), 1.95-
1.89 (m,  4H),  1.83-1.77 (m,  5H),  1.56 (s,  9H),  1.33 (t, J = 6.4,  6H),  1.30-1.17 (brs, 
9H); δ
C
 (100 MHz, CDCl
3
); 158.3, 151.6, 127.1, 113.6, 84.8, 61.5 (d), 55.3, 54.2, 49.4 
(d), 43.3, 28.2, 28.0, 27.4, 23.9, 22.8 (d), 22.6, 16.5, (d); δ
P
 (121 MHz, CDCl
3
); 32.1; 
m/z [TOF MS ES+] found 692.3349 [M + H
+
], C
31
H
55
N
3
O
10
PS requires 692.3346; IR 
(neat) ν
max
; 2980, 1725, 1691, 1517, 1347, 1243, 1134, 1025, 954, 727; 
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3-(2-(N-((2S,5S)-5-(4-hydroxyphenyl)pyrolidin-2-yl)methyl)sulfamoyl)ethylamino) 
propylphosphonic acid (376-OH)
 
 
 
 
 
 
 
 
 
 
Phosphonate 375 (48 mg, 0.07 mmol) was suspended in concentrated HCl (2 mL) and 
heated at  100 °C for  16  h.  The reaction  was alowed to cool to ambient temperature 
and the residue triturated with EtOAc/Et
2
O to give the desired product as a 4/1 mixture 
of  demethylated/methylated  phosphonates as  white crystaline solids, (27  mg,  89%); 
Mp (EtOH); 108-111 °C; α
D
 = -41.1 ° (c = 10.0 mg/mL, CH
3
Cl); δ
H
 (400 MHz, D
2
O) 
(Phenol Major); 7.40 (d, J = 8.6, 2H), 6.88 (d, J = 8.6, 2H), 4.73-4.64 (m, 1H), 3.95-
3.88 (m,  1H),  3.59-3.53 (m,  4H),  3.47-3.43 (m,  2H),  3.21-3.18 (m,  2H),  2.51-2.33 
(brm, 3H), 2.07-1.98 (m, 3H), 1.83-1.76 (m, 2H); δ
C
 (100 MHz, D
2
O); 159.6, 156.5, 
149.9,  129.3,  115.9,  66.6,  63.3,  60.3, 50.4,  48.7,  47.5,  43.1,  41.4,  28.1,  26.1, 20.0;  
m/z [TOF  MS  ES+] found 422.1515 [M  +  H
+
], C
16
H
29
N
3
O
6
PS requires 422.1515; 
Anisole Minor; m/z [TOF MS ES+] found 436.1671 [M + H
+
], C
17
H
31
N
3
O
6
PS requires 
436.1671; IR (neat) νmax  =: 3500-2500 (brs),  1519 (m),  1453 (m),  1321 (m),  1244 
(m), 1122 (s), 1034 (s), 909 (m), 832 (m); 
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(2S,4R)-tert-butyl 4-(benzyloxy)-2-(2-ethoxy-2-oxoethylamino)methyl) 
pyrolidine-1-carboxylate (383) 
 
 
 
 
 
Aldehyde 382 (1.00  g,  3.28  mmol) and  glycine ethyl ester  hydrochloride (685 mg, 
4.92 mmol) were suspended in THF (10 mL) containing disopropylethylamine (1.71 
mL,  9.84  mmol).  The resulting  mixture  was stired at room temperature for  30 
minutes.  Sodium triacetoxyborohydride (1.04  g,  4.92  mmol)  was then added and the 
reaction stired for a further 6 h. 1 M aqueous NaOH (10 mL) was added to quench the 
reaction.  The  product  was extracted  with  EtOAc (3  x  10  mL) and the combined 
organic extracts  were  washed  with  brine,  dried (MgSO
4
) rotary evaporated, and 
chromatographed  CH
2
Cl
2
:EtOAc  2/1) to  give the desired  product as a colourless  oil, 
(1.23 g, 97%); α
D
 = -20.2 ° (c = 10.0 mg/mL, CHCl
3
); Rf (CH
2
Cl
2
/EtOAc) (1/1); 0.28; 
δ
H
 (400 MHz, CDCl
3
); 7.37-7.26 (m, 5H), 4.50 (d, J = 8.3, 2H), 4.18 (q, J = 7.2, 2H), 
4.13 (brs, 1H), 4.07-4.00 (brm, 1H), 3.67 (d, J = 9.9, 1H), 3.40-3.36 (brs, 3H), 2.79-
2.75 (m, 2H), 2.16 (brs, 1H), 2.08 (brs, 1H), 1.69 (brs, 1H), 1.47 (s, 9H), 1.28 (t, J = 
7.2,  3H); δ
C
 (100  MHz, CDCl
3
);  172.4,  155.0,  138.1,  128.4,  127.7,  76.2,  70.9,  60.7, 
56.1, 52.8, 52.4, 52.3, 51.2, 36.5, 35.4, 28.5, 14.2; m/z [TOF MS ES+] found 393.2375 
[M + H
+
], C
21
H
33
N
2
O
5 
requires, 393.2389; IR (neat) νmax =: 2891, 2866, 1783, 1751, 
1712, 1451, 1384, 1263, 1137, 1100, 891, 743; 
 
 
 
 
 
 
 
 
 
 
 
N
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(2S,4R)-tert-butyl 4-(benzyloxy)-2-((2-ethoxy-2-oxoethyl)(sulfamoyl)amino)methyl) 
pyrolidine-1-carboxylate (384) 
 
 
 
 
 
 
Ester 383 (1.20 g, 3.05 mmol) and disopropylethylamine (637 µL, 3.66 mmol) were 
dissolved in  CH
2
Cl
2 
(10  mL) and cooled to  0 °C.  Freshly  prepared sulfamoyl 
chloride
REF
 (1.39 mL, 18.3 mmol) was added dropwise and the ensuing mixture was 
stired at room temperature until the solution became transparent, ~ 3 h. The mixture 
was then  diluted  with  CH
2
Cl
2
 (40  mL) and the  organic  phase  washed  with  0.5  M 
aqueous  HCl (20  mL),  H
2
O and  brine.  The separated  organics  were  dried (MgSO
4
),
 
rotary evaporated and chromatographed (CH
2
Cl
2
:EtOAc  5/1), to  give the  desired 
product as a colourless oil, (977 mg, 68%); α
D
 = -4.5 ° (c = 12.0 mg/mL, CHCl
3
); Rf 
(CH
2
Cl
2
/EtOAc) (1/1); 0.74; δ
H
 (400 MHz, CDCl
3
); 7.38-7.30 (m, 5H), 5.24 (brs, 1H, 
NH), 5.15 (brs, 1H, NH), 4.52 (dd, J = 12.3, 9.5, 2H), 4.22 (q, J = 6.6, 2H), 4.22-4.02 
(m, 4H), 3.70 (d, J = 10.9, 1H), 3.47-3.29 (brm, 3H), 2.31-2.28 (brm, 1H), 2.22-2.09 
(brm,  1H),  1.48 (s,  9H),  1.30 (t, J = 7.1,  1H); δ
C
 (100  MHz, CDCl
3
);  171.3,  155.0, 
137.9,  128.5,  127.8,  79.9,  76.3,  75.8,  71.0,  61.9,  55.0,  52.1,  51.1,  50.4,  35.8,  34.6, 
28.4, 14.0; m/z [TOF MS ES+] found 494.1920 [M + H
+
], C
21
H
33
N
3
NaO
7
S
 
requires, 
494.1937; IR (neat) ν
max
; 2912, 2701, 1773, 1732, 1692, 1510, 1396, 1154, 1063, 909, 
862; 
 
 
(377) 
 
 
 
 
 
i.  Sulfamoyl ester 384 (800  mg,  1.69  mmol)  was  dissolved in  MeOH (35  mL) and 
cooled to 0 °C. Freshly prepared sodium methoxide (119 mg, 2.21 mmol) in MeOH (2 
N
Boc
BnO
N
CO
2
EtS
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2
O
O
N
Boc
BnO
N
H
N
S
O
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2
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mL)  was added and the ensuing  mixture  was alowed to  warm to room temperature 
over 16 h. The reaction was quenched via the addition of 1 M aqueous HCl (10 mL) 
and the mixture was evaporated to dryness. The resulting residue was then suspended 
in CH
2
Cl
2
 (40 mL) and the organic phase washed with 0.5 M aqueous HCl (20 mL), 
H
2
O and  brine.  The separated  organics  were  dried (MgSO
4
),
 
rotary evaporated and 
chromatographed (CH
2
Cl
2
:EtOAc:MeOH:FA 5/5/1/0.1), to give the desired product as 
a  white crystaline solid, (425  mg,  60%); Rf (CH
2
Cl
2
/EtOAc/MeOH/FA) (5/5/1/0.1); 
0.23; m/z [TOF  MS  ES+] found 326.1160 [M - boc  + H
+
], C
14
H
20
N
3
O
4
S
 
requires, 
326.1175; i. A solution  of sulphur  hydantoin 385 (330  mg,  0.78  mmol) in  EtOH (1 
mL) was added to a suspension of 10% Pd/C (41 mg, 0.038 mmol) in EtOH (5 mL) 
which had been activated by bubbling hydrogen through the solution for 10 min. The 
reaction  was stired under an atmosphere  of  hydrogen for  16 h, the flask  was then 
purged  with  nitrogen, filtered and rotary evaporated to  give the  desired  deprotected 
alcohol, (249  mg,  97%) that  was  used  directly  without  purification; ii.  Sulphur 
hydantoin 385i (20 mg, 0.06 mmol) was suspended in CH
2
Cl
2
 (200 µL) and cooled to 
0 °C.  Neat trifluoroacetic acid (100 µL) was added  dropwise and the  mixture  was 
alowed to  warm to room temperature.  After  1  h the reaction  was evaporated to 
dryness and the resulting residue triturated with Et
2
O
 
and EtOH. Repeated trituration 
and filtration gave the desired product as a white crystaline solid, (16 mg, 80%); α
D
 = 
19.6 ° (c = 6.1 mg/mL, DMSO); Mp (EtOH): 187-189 °C; δ
H
 (400 MHz, d
6
 DMSO); 
9.36 (s, 1H, NH), 8.54 (s, 1H, NH), 5.39 (s, 1H, OH), 4.40 (brs, 1H), 3.82 (brm, 1H), 
3.62 (d, J = 13.2, 1H), 3.53 (d, J = 13.4, 1H), 3.48-3.41 (m, 1H), 3.23 (dd, J = 13.7, 
9.5, 1H), 3.12 (dd, J = 13.7, 4.6, 1H), 3.03-2.98 (m, 1H), 2.02 (dd, J = 13.4, 6.2, 1H), 
1.73 (ddd, J = 13.3, 11.0, 4.3, 1H); δ
C
 (100 MHz, d
6
 DMSO); 171.8, 68.4, 58.3, 57.2, 
52.7, 47.7, 37.7; m/z [TOF MS ES+] found 236.0722 [M + H
+
], C
7
H
14
N
3
O
4
S requires 
236.0705; IR (neat) ν
max
; 3203, 1657, 1630, 1332, 1257, 1136, 1051, 996, 863; 
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(2S,4R)-1-tert-Butyl 2-methyl 4-(methoxymethoxy)pyrolidine-1,2-dicarboxylate 
(388) 
 
	  
	  
	  
	  
	  
Protected proline derivative (2.00 g, 8.15 mmol) was dissolved in CH
2
Cl
2
 (35 mL) and 
cooled to 0 °C. Disopropylethylamine (5.78 mL, 32.6 mmol) was added folowed by 
MOM-Cl (2.47 mL, 32.6 mmol). The ensuing mixture was alowed to warm to room 
temperature and stired for 24 hours. The mixture was diluted with CH
2
Cl
2
 (10 mL), 
and the  organic  phase  washed  with saturated aqueous NaHCO
3 
(15  mL),  H
2
O and 
brine.  The separated  organics  were  dried (MgSO
4
), rotary evaporated and 
chromatographed (CH
2
Cl
2
:EtOAc 3/1) to give the desired product as a colourless oil, 
(2.21  g,  94%); α
D
 = -12.9 ° (c  =  10.0  mg/mL, CH
2
Cl
2
); Rf (CH
2
Cl
2
/EtOAc) (1/1); 
0.48; δ
H
 (400  MHz, d
6
 DMSO  373K);  4.62 (d, J = 6.7,  1H),  4.60 (d, J = 6.6,  1H), 
4.28-4.22 (m, 2H), 3.67 (s, 3H), 3.52 (dd, J = 11.2, 4.8, 1H), 3.45-3.42 (m, 1H), 3.28 
(s, 3H), 2.30 (ddd, J = 8.7, 3.9, 1.2, 1H), 2.04 (m, 1H), 1.38 (s, 9H); δ
C
 (100 MHz, d
6
 
DMSO  373K);  172.1,  152.7,  94.6,  78.7,  73.9,  57.1,  54.3,  51.5,  51.0,  35.5,  27.5; m/z 
[TOF  MS  ES+] found 312.1413  [M  +  Na
+
], C
13
H
23
NNaO
6
 requires  312.1423; IR 
(neat) ν
max
; 1748, 1698, 1393, 1149, 1028, 917; 
 
 
(2S,4R)-tert-Butyl 2-(hydroxymethyl)-4-(methoxymethoxy)pyrolidine-1-carboxylate 
(389) 
 
 
 
 
 
Ester 388 (1.50  g,  5.18  mmol)  was  dissolved in  THF (25  mL) and cooled to  0 °C. 
LiBH
4
 (225 mg, 10.3 mmol) was added portionwise over a period of 15 minutes and 
the mixture was alowed to warm to ambient temperature over 16 h. The reaction was 
N
Boc
MOMO
CO
2
Me
N
Boc
MOMO
OH
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cooled to 0 °C and quenched by dropwise addition of H
2
O and was then acidified to 
pH 3 with 0.5 M aqueous HCL. The product was extracted with EtOAc (3 x 20 mL), 
and the  organic  phase  washed  with  brine,  dried (MgSO
4
), rotary evaporated and 
chromatographed (CH
2
Cl
2
:EtOAc 1/1), to give the desired product as a colourless oil, 
(1.32  g,  98%); α
D
 = -22.9 ° (c  =  10.0  mg/mL, CH
2
Cl
2
); Rf (CH
2
Cl
2
/EtOAc) (1/1); 
0.19; δ
H
 (400 MHz, d
6
 DMSO 373K); 4.60 (d, J = 6.6, 1H), 4.58 (d, J = 6.6, 1H), 4.31 
(t, J = 5.5, 1H), 4.25-4.20 (m, 1H), 3.84-3.79 (m, 1H), 3.52-3.40 (m, 3H), 3.34 (dd, J 
= 11.2,  5.2,  1H),  3.27 (s,  3H),  2.08-1.94 (m,  2H),  1.42 (s,  9H); δ
C
 (100  MHz, d
6
 
DMSO  373K);  153.5,  94.6,  77.9,  74.2,  62.1,  57.0,  54.2,  51.9,  34.1,  27.7;  m/z [TOF 
MS  ES+] found 262.1658 [M  +  H
+
], C
12
H
24
NO
5
 requires  262.1654; IR (neat) ν
max
; 
2937, 1692, 1393, 1150, 1029, 917;  
 
 
(2S,4R)-tert-Butyl 2-formyl-4-(methoxymethoxy)pyrolidine-1-carboxylate (390) 
 
 
 
	  
	  
Oxalyl chloride (472 µL, 5.47 mmol) was dissolved in CH
2
Cl
2
 (8 mL) and cooled to -
78 °C. DMSO (776 µL, 10.93 mmol) was added dropwise over a period of 15 minutes. 
The resulting  mixture  was alowed to stir for  30  minutes, after  which  prolinol 389 
(1.30 g, 4.97 mmol) was added dropwise as a solution in CH
2
Cl
2
 (2 mL). The ensuing 
mixture was alowed to stir at -78 °C for 1 hour before the addition of Et
3
N (1.66 mL, 
11.90 mmol). After the addition the mixture was alowed to warm to room temperature 
and stired for a further hour. The mixture was then diluted with CH
2
Cl
2
 (40 mL) and 
the  organic  phase  washed  with  0.5  M aqueous  HCl (20  mL),  H
2
O and  brine.  The 
separated  organics  were  dried (MgSO
4
),
 
rotary evaporated and chromatographed 
(CH
2
Cl
2
:EtOAc 5/1), to give the desired product as a colourless oil, (1.15 g, 89%); α
D
 
= -22.3 ° (c = 10.0 mg/mL, CH
2
Cl
2
); Rf (CH
2
Cl
2
/EtOAc) (3/1); 0.53; δ
H
 (400 MHz, d
6
 
DMSO 373K); 9.44 (d, J = 2.9, 1H), 4.63 (d, J = 6.6, 1H), 4.61 (d, J = 6.6, 1H), 4.26-
4.22 (m, 1H), 4.14 (td, J = 8.2, 2.9, 1H), 3.49 (d, J = 3.6, 2H), 3.29 (s, 3H), 2.95 (brs, 
1H), 2.18-2.12 (brm, 1H), 2.07-2.00 (brm, 1H), 1.40 (s, 9H); δ
C
 (100 MHz, d
6
 DMSO 
373K); 199.3, 94.6, 79.1, 73.9, 62.8, 54.3, 51.9, 32.4, 27.5; m/z [TOF MS ES+] found 
N
Boc
MOMO
O
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260.1500 [M + H
+
], C
12
H
22
NO
5
 requires 260.1498; IR (neat) ν
max
; 1736, 1689, 1392, 
1150, 1112, 1027, 916; 
 
 
(2S,4R)-tert-Butyl-2-(R)-3-ethoxy-2,2-difluoro-1-hydroxy-3-oxopropyl)-4-
(methoxymethoxy)pyrolidine-1-carboxylate Major & (2S,4R)-tert-Butyl 2-(S)-3-
ethoxy-2,2-difluoro-1-hydroxy-3-oxopropyl)-4-(methoxymethoxy)pyrolidine-1-
carboxylate Minor (392) 
 
 
	  
	  
	  
	  
	  
Iodine pelets (44 mg, 0.18 mmol) and Zinc dust (251 mg, 3.85 mmol) were suspended 
in  Et
2
O (1  mL) and stired at room temperature for  1  hour.  Aldehyde 390 (200  mg, 
0.77  mmol) and ethyl  bromodifluoroacetate (328  mg,  1.62  mmol)  were added 
sequentialy dropwise in THF (2 mL). The resulting mixture was then heated at 50 °C 
for 6 h. The mixture was cooled to ambient temperature and diluted with Et
2
O (10 mL) 
and 1 M aqueous HCl (2 mL). The organic phase was washed with saturated aqueous 
Na
2
S
2
O
3
 (5  mL),  H
2
O and  brine.  The separated  organics  were  dried (MgSO
4
),
 
rotary 
evaporated and chromatographed (CH
2
Cl
2
:EtOAc 4/1) to give the desired product as a 
mixture of diastereoisomers; Major - Light yelow oil, (105 mg, 36%); α
D
 = -10.5 ° (c 
= 10.0 mg/mL, CH
2
Cl
2
); Rf (CH
2
Cl
2
/EtOAc) (6/1); 0.52; δ
H
 (400 MHz, CDCl
3
); 4.77-
4.51 (brm, 2H), 4.66 (s, 2H), 4.37 (q, J = 6.6, 2H), 4.32-4.26 (brm, 2H), 3.71-3.68 (m, 
1H), 3.38 (s, 3H), 3.30-3.24 (m, 1H), 2.43-2.29 (brm, 1H), 2.23-2.09 (brm, 1H), 1.50 
(s,  9H),  1.38 (t, J = 6.6,  3H); δ
C
 (100  MHz, CDCl
3
);  158.7,  95.4,  80.7,  75.1,  70.9, 
63.1, 57.5, 55.6, 53.2, 52.3, 33.4, 32.0, 28.4, 13.9, (
*
2 qn not visible);
 
m/z [TOF MS 
ES+] found 384.1828 [M + H
+
], C
16
H
28
F
2
NO
7 
requires 384.1834; IR (neat) ν
max
; 1761, 
1669, 1394, 1368, 1089, 1032, 918; Minor - Light yelow oil, (35 mg, 12%); α
D
 = -
19.9 ° (c =  10.0  mg/mL, CH
2
Cl
2
); Rf (CH
2
Cl
2
/EtOAc) (6/1);  0.30; δ
H
 (400  MHz, 
CDCl
3
); 6.35 (brs, 1H), 4.68 (d, J = 7.1, 1H), 4.66 (d, J = 7.1, 1H), 4.41-4.35 (m, 1H), 
4.38 (q, J = 7.0, 2H), 4.22 (brs, 1H), 4.00-3.92 (m, 1H), 3.79 (dd, J = 12.2, 3.1, 1H), 
3.39 (s, 3H), 3.35 (dd, J = 12.2, 4.0, 1H), 2.35-2.30 (m, 1H), 2.05-2.02 (m, 1H), 1.48 
Boc
N
OMOM
OH
O
EtO
F
F
Boc
N
OMOM
OH
O
EtO
F
F
Major Minor
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(s,  9H),  1.38 (t, J = 7.0,  3H); δ
C
 (100  MHz, CDCl
3
);  158.9,  95.4,  81.8,  76.0,  74.6, 
62.9, 56.8, 55.5, 52.8, 34.8, 28.3, 13.9, (
*
2 qn not visible);
 
m/z [TOF MS ES+] found 
384.1819 [M + H
+
], C
16
H
28
F
2
NO
7 
requires 384.1834; IR (neat) ν
max
; 1776, 1759, 1652, 
1368, 1152, 1093, 825;  
	  
	  
 
(3R)-2,2-difluoro-3-hydroxy-3-(2S)-4-hydroxypyrolidin-2-yl)propanoic acid (387) 
 
 
 
 
 
 
 
i. Ester 392 (170 mg, 0.44 mmol) was suspended in a mixture of 1N aqueous LiOH (5 
mL), THF (3 mL) and heated at 100 °C for 16 h. The reaction was the evaporated to 
dryness and the residue taken up in H
2
O (15 mL) and Et
2
O (20 mL). The layers were 
separated and the aqueous extracted  with  Et
2
O (2  x  15  mL).  The aqueous layer  was 
then acidified to pH 4 and re-extracted with Et
2
O (4 x 25 mL), the combined organic 
extracts  were  dried (MgSO
4
), and rotary evaporated to  give the intermediate acid as 
light orange oil; i. Acid 387i (65 mg, 0.18 mmol) was dissolved in CH
2
Cl
2
 (2 mL) and 
cooled to 0 °C. 4 M HCl in dioxane (2 mL) was added dropwise and the mixture was 
alowed to warm to room temperature. After 1 h the reaction was evaporated and the 
resulting residue triturated  with MeCN
 
and  H
2
O.  Repeated trituration and filtration 
gave the desired product as a light brown solid, (23 mg, 21% “two steps”); α
D
 = -18.7 
° (c = 11.3 mg/mL, EtOH); Mp (EtOH): 136-139 °C; δ
H
 (400 MHz, D
2
O); 4.48-4.47 
(m, 1H), 4.21 (ddd, J = 10.6, 7.9, 2.7, 1H), 4.03 (ddd, J = 9.4, 6.3, 2.4, 1H), 3.24 (dd, 
J = 12.7, 3.6, 1H), 3.15-3.12 (m, 1H), 2.08 (dd, J = 13.9, 6.4, 1H), 1.98-1.90 (m, 1H); 
δ
C
 (100  MHz, D
2
O);  166.4,  114.7,  68.8,  67.8,  56.5,  53.4,  36.2; m/z [TOF  MS  ES+] 
found 212.0728 [M + H
+
], C
7
H
12
F
2
NO
4 
requires, 212.0734; IR (neat) ν
max
; 3100-2700 
(br), 1709, 1635, 1422, 1410, 1321, 1109, 1064, 990; 
 
	  
	  
	  
Boc
N
OMOM
OH
O
EtO
F
F
H.HCl
N
OH
OH
O
HO
F
F
i. LiOH H
2
O/THF
i. 4N HCl
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(2S,5S)-tert-butyl-2-(N-(tert-butoxycarbonyl)-2-(4-(tetrahydrofuran-2-
yl)methyl)piperazin-1-yl)ethylsulfonamido)methyl)-5-(4-methoxyphenyl)pyrolidine-
1-carboxylate (400) 
 
 
 
 
 
 
 
 
 
 
Amine 350 (34  mg,  0.20  mmol) and  vinyl sulfone 328 (50  mg,  0.10  mmol)  were 
dissolved in 
i
PrOH (200 µL) and heated at 85 °C for 16 h. The mixture was alowed to 
cool to ambient temperature, rotary evaporated and  directly chromatographed 
(CH
2
Cl
2
:MeOH 50/1) to give the desired product as a light yelow oil, (47 mg, 87%); 
Rf (CH
2
Cl
2
/MeOH) (20/1); 0.33; α
D
 = 8.6 ° (c = 11.6 mg/mL, CH
3
Cl); δ
H
 (400 MHz, 
CDCl
3
); 7.20 (d, J =  8.7,  2H),  6.86 (d, J =  8.7,  2H),  4.78-4.64 (brm,  1H),  4.43-4.36 
(brm, 1H), 4.21-4.15 (brm, 1H), 4.07-4.00 (m, 1H), 3.92-3.86 (m, 1H), 3.81 (s, 3H), 
3.79-3.72 (m, 2H), 3.70-3.63 (m, 1H), 3.48-3.45 (m, 1H), 2.91-2.79 (m, 2H), 2.53 (brs, 
6H), 2.50-2.40 (m, 4H), 2.26-2.21 (m, 1H), 2.04-1.82 (m, 7H), 1.56 (s, 9H), 1.40-1.20 
(brs, 9H); δ
C
 (100 MHz, CDCl
3
); 158.3, 155.1, 151.8, 127.0, 113.6, 84.7, 76.6, 68.1, 
63.3,  55.3,  53.6,  52.8,  51.9,  50.9,  49.1,  30.3,  28.4,  28.0,  27.1,  25.4; m/z [TOF  MS 
ES+] found 667.3755 [M  +  H
+
], C
33
H
55
N
4
O
8
S requires 667.3741; IR (neat) νmax  =: 
2974, 2814, 1724, 1691, 1513, 1458, 1351, 1244, 1163, 1134;  
 
 
 
 
 
 
 
 
 
MeO
N
Boc
BocN
S
O
O
N
N
O
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N-((2S,5S)-5-(4-methoxyphenyl)pyrolidin-2-yl)methyl)-2-(4-(tetrahydrofuran-2-
yl)methyl)piperazin-1-yl)ethanesulfonamide trifluoroacetate salt (399) 
 
 
 
 
 
 
 
 
 
 
Carbamate 400 (47 mg, 0.07 mmol) was suspended in CH
2
Cl
2
 (500 µL) and cooled to 
0 °C.  Neat trifluoroacetic acid (27 µL,  0.33  mmol) was added  dropwise and the 
mixture  was alowed to  warm to room temperature.  After  1  h the reaction  was 
evaporated to dryness and the resulting residue chromatographed (CH
3
Cl:MeOH 10/1) 
to  give the  desired  product as  a white crystaline foam solid, (33 mg, 83%); Rf 
(CH
3
Cl/MeOH) (10/1);  0.11;  Mp (Et
2
O)  = 34-36 °C; α
D
 = 15.3 ° (c  = 14.3 mg/mL, 
CH
3
Cl); δ
H
 (400 MHz, CDCl
3
); 7.41 (d, J = 8.7, 2H), 6.97 (d, J = 8.7, 2H), 4.67 (dd, J 
= 10.9,  6.3,  1H),  4.17-4.12 (m,  1H),  3.94-3.84 (m,  2H),  3.80 (s,  3H),  3.78-3.73 (m, 
1H),  3.44-3.42 (m,  2H),  3.36-3.33 (m,  2H),  3.20-3.18 (m,  2H),  3.04-2.94 (brm,  4H), 
2.87-2.83 (m, 2H), 2.80-2.75 (m, 2H), 2.72-2.65 (brm, 4H), 2.43-2.34 (m, 2H), 2.29-
2.21 (m, 1H), 2.10-2.03 (m, 1H), 2.01-1.95 (m, 1H), 1.93-1.84 (m, 3H), 1.57-1.50 (m, 
1H); δ
C
 (100  MHz,  CDCl
3
); 161.9,  130.2,  128.1,  115.5,  75.9,  63.8,  69.3,  62.7,  61.1, 
55.8,  53.9,  52.6,  52.0,  49.7,  49.2,  45.1,  44.6,  31.9,  30.9,  29.2,  26.2; m/z [TOF  MS 
ES+] found 467.2698 [M + H
+
], C
23
H
39
N
4
O
4
S requires 467.2692; IR (neat) ν
max
; 2957, 
1672, 1519, 1440, 1330, 1178, 1127, 838, 722; 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
MeO
N
H.TFA
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O
O
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PROJECT-II LRH-1 – EXPERIMENTAL DETAILS 
 
 
tert-Butyl-4-(1H-imidazole-1-carbonyl)piperidine-1-carboxylate (53) 
 
 
 
 
 
 
1-(tert-butoxycarbonyl)-4-piperidinecarboxylic acid (750  mg,  3.27  mmol)  was 
dissolved in THF (8 mL) and cooled to 0 °C. CDI (582 mg, 3.60 mmol), was added 
portionwise  over  5  minutes, and the  mixture  was alowed to  warm to room 
temperature. After 2 hours, the mixture was diluted with Et
2
O (25 mL), and H
2
O (10 
mL). The organic layer was washed with H
2
O (2 x 10 mL) and brine (10 mL), dried 
(MgSO
4
), and rotary evaporated to  give the  desired  product as a  white crystaline 
solid, which was used in the next step without further purification; (764 mg, 84%); Rf 
(EtOAc/Hexanes) (1/1);  0.19; δ
H
 (400  MHz,  CH
3
Cl);  8.20 (s,  1H),  7.50 (t, J = 1.3, 
1H), 7.14 (m, 1H), 4.20 (brs, 2H), 3.11-3.06 (m, 1H), 2.96-2.90 (m, 2H), 1.94-1.84 (m, 
4H), 1.49 (s, 9H); δ
C
 (100 MHz, CH
3
Cl); 171.3, 154.5, 136.0, 131.3, 116.0, 80.0, 42.8, 
41.7, 28.4, 28.3; 
 
 
tert-Butyl-4-(7-hydroxy-2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl)piperidine-
1-carboxylate (55) 
 
 
 
 
 
 
n-BuLi in hexanes (2.5 M; 4.56 mL, 11.40 mmol) was added dropwise with stiring to 
disopropylethylamine (1.65  mL,  11.88  mmol) in  THF (18  mL) at -78 °C. After  20 
min,  keto-dioxinone (2.00  g,  10.88 mmol) in  THF (8 mL)  was added  dropwise  with 
stiring at -78 °C. After 40 min, Et
2
Zn in hexanes (1.0 M; 11.40 mL, 11.40 mmol) was 
added slowly, and after a further 20 min, imidazole 53 (1.52 g, 5.44 mmol) in THF (4 
N
Boc
O N
N
OO
HO
O
NBoc
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mL) was added and the mixture stired for 3 h, maintaining the temperature at -78 °C. 
The reaction was quenched with saturated aqueous NH
4
Cl (30 mL) and 1 M aqueous 
HCl (15 mL), and the aqueous layer  was acidified to  pH  2  using  1  M aqueous  HCl. 
The product was extracted twice with EtOAc (50 mL, 25 mL), the combined organic 
extracts  were  dried (MgSO
4
) and rotary evaporated to  give the crude acylation 
product, which  was  dissolved in  CH
2
Cl
2
 (30  mL). Et
3
N (6 mL)  was added, and the 
mixture was stired at 40 °C. After 24 h, saturated aqueous NH
4
Cl (40 mL) and EtOAc 
(80 mL) were added, and the aqueous layer was acidified to pH 2 using 1 M aqueous 
HCl. The layers  were separated, and the aqueous layer  was further extracted  with 
EtOAc (40  mL).  The combined  organic extracts  were  dried (MgSO
4
), rotary 
evaporated, and chromatographed (Petrol:EtOAc  5/1 to  1/1) to  give the desired 
product as a white crystaline solid, (1.53  g,  75%); Mp (Et
2
O):  138-140 °C; Rf 
(EtOAc/Hexanes) (2/1);  0.67; δ
H
 (400  MHz,  d
6
 Acetone);  9.49 (s,  1H),  6.63 (d, J = 
2.3, 1H), 6.33 (d, J = 2.4, 1H), 4.23-4.20 (m, 2H), 4.00 (t, J = 11.9, 3.1, 1H), 1.84-
1.81 (m, 2H), 1.67 (s, 6H), 1.57-1.43 (m, 4H), 1.47 (s, 9H); δ
C
 (100 MHz, d
6
 Acetone); 
163.7,  159.3,  159.1,  154.2,153.0,  109.4,  104.3,  103.6,  101.3,  78.5,  37.9,  32.6,  27.7, 
24.8; m/z [TOF MS ES+] found 400.1737 [M + H
+
], C
20
H
27
NNaO
6 
requires 400.1736; 
IR (neat) ν
max
; 3354 (m),  1689 (s),  1603 (s),  1424 (s),  1268 (s),  1210 (s),  1160 (s), 
1120 (s), 963 (m), 867 (m);  
 
tert-Butyl-4-(3,5-dihydroxy-2-(methoxycarbonyl)phenyl)piperidine-1-carboxylate (56) 
 
 
 
 
 
Compound 55 (35 mg, 0.09 mmol) and Cs
2
CO
3
 (66 mg, 0.20 mmol) were dissolved in 
MeOH (600 µL) and heated to 60 °C for 16 h. The reaction was evaporated to dryness 
and the residue  dissolved in  1  M aqueous  HCl (5  mL) and  EtOAc (10  mL).  The 
organic layer was separated and the aqueous extracted with EtOAc (3 x 10 mL), the 
combined organic extracts were washed with brine, dried (MgSO
4
) rotary evaporated, 
and chromatographed (Petrol:EtOAc 4/1 to 1/1) to give the desired product as a white 
CO
2
Me
OH
HO
NBoc
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crystaline solid, (22 mg, 70%); Mp (EtOAc): 141-143 °C; Rf (EtOAc/Hexanes) (1/1); 
0.59; δ
H
 (400  MHz,  d
6
 Acetone);  11.07 (s,  1H),  9.05 (s,  1H),  6.39 (d, J = 2.4,  1H), 
6.25 (d, J = 2.4, 1H), 4.20-4.18 (m, 2H), 3.94 (s, 3H), 3.51 (t, J = 11.8, 3.1, 1H), 1.80-
1.77 (m,  2H),  1.51-1.42 (m,  4H),  1.44 (s,  9H); δ
C
 (100  MHz,  d
6
 Acetone); 172.2, 
164.9, 163.2, 155.1, 151.6, 107.6, 105.9, 101.9, 52.4, 45.7, 40.6, 34.2, 29.8, 28.7; m/z 
[TOF  MS ES+] 252.1224 [M - Boc  + H
+
], C
13
H
18
NO
4 
requires 252.1236 IR (neat) 
ν
max
; 3200-2850 (br), 2932, 1651, 1602, 1437, 1312, 1239, 1155, 1101, 759; 
 
 
tert-Butyl-4-(7-methoxy-2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl)piperidine-
1-carboxylate (57i) 
 
 
 
 
 
Compound 55 (420  mg,  1.11  mmol) and iodomethane (208 µL,  3.33 mmol) were 
combined  with acetone (5 mL).  K
2
CO
3
 (307  mg,  2.22 mmol) was added and the 
mixture  heated at 60 °C for  16  h. The reaction  was evaporated to  dryness and the 
residue directly chromatographed (Petrol:EtOAc 1/1) to give the desired product as a 
white foam solid, (429 mg, 97 %); Mp (Et
2
O): 29-31 °C; Rf (EtOAc/Hexanes) (1/1); 
0.69; δ
H
 (400 MHz, CDCl
3
); 6.59 (d, J =2.5, 1H), 6.34 (d, J =2.5, 1H), 4.26 (brs, 2H), 
4.04 (t, J = 11.9, 3.1, 1H), 3.85 (s, 3H), 2.91 (brm, 2H), 1.88-1.85 (m, 2H), 1.72 (s, 
6H),  1.58-1.46 (m,  2H),  1.50 (s, 9H); δ
C
 (100  MHz,  CDCl
3
); 161.3,  156.2,  155.3, 
150.9,  148.9,  105.1,  100.8,  100.4,  95.2,  75.4,  51.6,  40.6,  33.9,  28.8,  24.6,  21.6; m/z 
[TOF  MS  ES+] found 414.1895 [M  +  Na
+
], C
21
H
29
NNaO
6 
requires  414.1893; IR 
(neat) ν
max
; 2974, 1723, 1687, 1610, 1576, 1427, 1270, 1154, 1032, 874; 
 
 
 
 
 
 
OO
MeO
O
NBoc
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7-Methoxy-2,2-dimethyl-5-(piperidin-4-yl)-4H-benzo[d][1,3]dioxin-4-one TFA salt 
(57) 
 
 
 
 
 
 
Compound 57i (400 mg, 1.03 mmol) was dissolved in CH
2
Cl
2
 (3 mL) and cooled to 0 
°C.  TFA (402 µL,  5.05  mmol)  was added  dropwise and the  mixture  was alowed to 
warm to room temperature.  After  1  h the reaction  was evaporated and the resulting 
residue triturated  with  CH
2
Cl
2 
and  Et
2
O.  Repeated trituration and filtration  gave the 
desired product as a white crystaline solid, (373 mg, 93%); Mp (Et
2
O): 158-161 °C; 
Rf (CH
2
Cl
2
/MeOH) (95/5); 0.11; δ
H
 (400 MHz, MeOD
4
); 6.66 (d, J = 2.4, 1H), 6.49 
(d, J = 2.4, 1H), 4.07 (t, J = 11.9, 3.0, 1H), 3.85 (s, 3H), 3.52-3.49 (m, 2H), 3.13 (td, 
J = 12.9,  2.9,  2H),  2.09-2.05 (m,  2H),  1.89 (qd, J = 13.4,  3.8,  2H),  1.69 (s,  6H); δ
C
 
(100 MHz, MeOD
4
); 164.5, 159.0, 158.1, 148.6, 107.5, 103.5, 102.1, 97.8, 53.4, 42.9, 
34.3, 27.5, 22.7, 22.3, 18.8; m/z [TOF MS ES+] found 292.1544 [M + H
+
], C
16
H
22
NO
4 
requires  292.1549; IR (neat) ν
max
;  2944,  2722,  1713,  1608,  1575,  1315,  1285,  1188, 
1161, 1039, 842; 
 
 
5-(1-Benzylpiperidin-4-yl)-7-methoxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 
(58) 
 
 
 
 
 
Compound 57 (60 mg, 0.21 mmol) and benzaldehyde (27 µL, 0.26 mmol) were added 
to  THF (1  mL) containing  1  drop  of  glacial acetic acid.  The resulting  mixture  was 
stired at room temperature for  30  minutes.  Sodium triacetoxyborohydride (88  mg, 
0.42  mmol)  was then added and the reaction stired for a further  6  h.  1  M aqueous 
NaOH (10  mL)  was added to  quench the reaction.  The  product  was extracted  with 
EtOAc (3 x 10 mL) and the combined organic extracts were washed with brine, dried 
OO
MeO
O
NH.TFA
OO
MeO
O
N
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(MgSO
4
) rotary evaporated, and chromatographed (CH
2
Cl
2
:MeOH  20/1) to  give the 
desired product as a, colourless oil, (52 mg, 65 %); Rf (CH
2
Cl
2
/MeOH) (95/5); 0.16; 
δ
H
 (400 MHz, CH
3
Cl); 6.66 (d, J = 2.5, 1H), 6.30 (d, J = 2.5, 1H), 3.92 (t, J = 10.6, 
5.1, 1H), 3.81 (s, 3H), 3.78 (s, 2H), 3.20 (d, J = 11.6, 2H), 2.41 (td, J =11.3, 4.1, 2H), 
1.97-1.88 (m,  4H),  1.68 (s,  6H); δ
C
 (100  MHz,  CH
3
Cl); 165.3,  160.2,  159.1,  152.4, 
135.1, 130.9, 130.1, 129.6, 128.5, 127.9, 127.8, 108.9, 104.7, 104.3, 99.5, 62.4, 55.6, 
53.5,  37.2,  31.7,  25.6; m/z [TOF  MS  ES+] found 382.2008 [M  +  H
+
], C
23
H
28
NO
4 
requires  382.2018; IR (neat) ν
max
;  2948,  1718,  1610,  1576,  1267,  1202,  1156,  908, 
727; 
 
 
Methyl 2-(1-benzylpiperidin-4-yl)-6-hydroxy-4-methoxybenzoate (59) 
 
 
 
 
 
Compound 58 (40 mg, 0.11 mmol) and Cs
2
CO
3
 (136 mg, 0.42 mmol) were dissolved 
in  MeOH (1.5  mL) and  heated to  60 °C for  16  h. The reaction  was evaporated to 
dryness and the residue  dissolved in  1  M aqueous  HCl (5  mL) and  EtOAc (10  mL). 
The organic layer was separated and the aqueous extracted with EtOAc (3 x 10 mL), 
the combined  organic extracts  were  washed  with  brine,  dried (MgSO
4
) rotary 
evaporated, and chromatographed (CH
2
Cl
2
/MeOH 50/1) to give the desired product as 
a white crystaline solid, (27 mg, 73 %); Mp (MeOH): 56-58 °C; Rf (CH
2
Cl
2
/MeOH) 
(20/1); 0.41; δ
H
 (400 MHz, MeOD
4
); 7.38-7.30 (m, 5H), 6.48 (d, J = 2.5, 1H), 6.36 (d, 
J = 2.5, 1H), 3.95 (s, 3H), 3.83 (s, 3H), 3.62 (s, 2H), 3.21 (t, J = 11.4, 3.6, 1H), 3.09 
(d, J  = 11.7,  2H),  2.19 (td, J  = 11.7,  2.4,  2H),  1.86-1.72 (m,  4H); δ
C
 (100  MHz, 
MeOD
4
);  171.1,  163.6,  162.1,  149.2,  136.6,  129.6,  128.1,  127.3,  107.3,  105.6,  98.6, 
63.1,  54.6,  54.1,  51.2,  39.4,  32.7; m/z [TOF  MS  ES+] found 356.1857 [M  +  H
+
], 
C
21
H
26
NO
4 
requires 356.1862; IR (neat) ν
max
;  2949,  2791,  1647,  1612,  1572,  1436, 
1318, 1255, 1203, 1154, 994; 
 
 
 
CO
2
Me
OH
MeO
N
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Ethyl 1-(3-chlorophenyl)piperidine-4-carboxylate (62) 
 
 
 
 
 
 
 
3-Chloroiodobenzene (1.02  mL,  8.27 mmol),  Pd
2
(dba)
3
 (291  mg,  0.32 mmol), rac-
BINAP (396  mg,  0.64 mmol), and  NaO
t
Bu (1.20 g,  12.7 mmol)  were suspended in 
toluene (12 mL). After 5 min of stiring ethyl isonipecotate (980 µL, 6.36 mmol) was 
added and the mixture heated for 16 h at 95 °C . The reaction mixture was cooled to 
ambient temperature, diluted with EtOAc (50 mL) and poured into water (35 mL). The 
aqueous  phase was extracted  with  EtOAc (2 ×  30 mL), combined  organic extracts 
were  washed  with  brine,  dried (MgSO
4
) rotary evaporated, and chromatographed 
(Petrol:EtOAc 10/1) to give the desired product as a light yelow oil, (1.32 g, 78%); Rf 
(Petrol/EtOAc) (10/1); 0.50; δ
H
 (400 MHz, CDCl
3
); 6.78 (d, J = 2.4, 1H), 6.69 (d, J = 
2.4, 1H), 4.34 (q, J = 7.1, 2H), 3.96 (s, 3H), 1.75 (s, 6H), 1.33 (t, J = 7.1, 3H); δ
C
 (100 
MHz, CDCl
3
); 174.7, 152.5, 134.9, 130.0, 119.1, 116.2, 114.5, 60.5, 48.7, 40.9, 27.8, 
14.3; m/z [TOF MS ES+] found 268.1103 [M + H
+
], C
14
H
19
ClNO
2
 requires 268.1104; 
IR (neat) ν
max
; 1726, 1592, 1484, 1311, 1250, 1167, 1097, 987, 935, 766, 681; 
 
 
 
1-(3-Chlorophenyl)piperidine-4-carboxylic acid (63) 
 
 
 
 
 
 
Ester 62 (600 mg, 2.24 mmol) was suspended in a mixture of 1N aqueous LiOH (12 
mL), THF (5 mL) and MeOH (3 mL) and heated at 100 °C for 16 h. The reaction was 
the evaporated to dryness and the residue taken up in H
2
O (15 mL) and Et
2
O (20 mL). 
The layers  were separated and the aqueous extracted  with  Et
2
O (2  x  15  mL).  The 
aqueous layer was then acidified to pH 4 and re-extracted with Et
2
O (4 x 25 mL), the 
N
Cl
CO
2
Et
N
Cl
CO
2
H
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combined  organic extracts  were  dried (MgSO
4
), and rotary evaporated to  give the 
desired acid as a  pure light yelow solid, (457  mg,  85%); Mp (Et
2
O): 79-81 °C; δ
H
 
(400 MHz, CDCl
3
); 7.13 (t, J = 8.2, 1H), 6.89 (s, 1H), 6.84 (d, J = 8.3, 1H), 6.74 (d, J 
= 8.1,  1H),  3.60 (d, J = 12.3,  2H),  3.27 (s,  1H),  2.76 (t, J = 11.9,  2H),  2.42 (t, J = 
10.6, 1H), 1.97 (d, J = 11.9, 3H), 1.74 (d, J = 11.2, 2H); δ
C
 (100 MHz, CDCl
3
); 156.6, 
138.4, 136.4, 133.7, 122.8, 119.9, 118.5, 52.5, 44.5, 31.7; m/z [TOF MS ES+] found 
238.0634 [M - H
+
], C
12
H
13
ClNO
2
 requires 238.0635; IR (neat) ν
max
; 3079-2557 (br), 
2824, 1692, 1590, 1487, 1306, 1100, 985, 932, 836, 749, 682; 
 
 
5-(1-(3-Chlorophenyl)piperidin-4-yl)-7-hydroxy-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one (66) 
 
 
 
 
 
 
 
n-BuLi in hexanes (2.5 M; 1.74 mL, 4.36 mmol) was added dropwise with stiring to 
disopropylethylamine (630 µL, 4.46 mmol) in THF (10 mL) at -78 °C. After 20 min, 
keto-dioxinone (381 mg, 2.07 mmol) in THF (4 mL) was added dropwise with stiring 
at -78 °C.  After  40  min,  Et
2
Zn in  hexanes (1.0  M; 4.36  mL,  4.36 mmol)  was added 
slowly, and after a further 20 min, imidazole 64 (300 mg, 1.04 mmol) in THF (4 mL) 
was added and the mixture stired for 3 h, maintaining the temperature at -78 °C. The 
reaction was quenched with saturated aqueous NH
4
Cl (15 mL) and 1 M aqueous HCl 
(10 mL), and the aqueous layer  was acidified to  pH  2  using  1  M aqueous  HCl.  The 
product  was extracted twice  with  EtOAc (50  mL,  25  mL), the combined  organic 
extracts  were  dried (MgSO
4
) and rotary evaporated to  give the crude acylation 
product, which  was  dissolved in  CH
2
Cl
2
 (20 mL),  Et
3
N (4 mL)  was added, and the 
mixture was stired at 40 °C. After 24 h, saturated aqueous NH
4
Cl (20 mL) and EtOAc 
(60 mL) were added, and the aqueous layer was acidified to pH 2 using 1 M aqueous 
HCl.  The layers  were separated, and the aqueous layer  was further extracted  with 
EtOAc (40  mL).  The combined  organic extracts  were  dried (MgSO
4
), rotary 
evaporated, and chromatographed (Petrol:EtOAc  4/1 to 2/1) to  give the desired 
HO
N
OO
O
Cl
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product as a white foam solid, (181 mg, 45%); Mp (Et
2
O): 42-44 °C; Rf (Petrol/EtOAc 
(1/1); 0.62; δ
H
 (400 MHz, d
6
 Acetone); 7.25 (t, J = 7.9, 1H), 7.04-6.99 (m, 2H), 6.82 
(m, 1H), 6.69 (d, J = 2.3, 1H), 6.36 (d, J = 2.3, 1H), 4.04 (t, J = 11.8, 1H), 3.90 (m, 
2H), 2.95 (m, 2H), 1.99-1.96 (m, 2H), 1.84-1.77 (m, 2H), 1,68 (s, 6H); δ
C
 (100 MHz, 
d
6
 Acetone);  163.8,  159.4,  159.2,  153.0,  134.4,  130.3,  118.4,  115.7,  114.6,  109.4, 
104.4, 103.7, 101.4, 49.8, 37.5, 32.2, 24.8; m/z [TOF MS ES+] found 388.1314 [M + 
H
+
], C
21
H
23
ClNO
4
 requires 388.1316; IR (neat) ν
max
; 3310,  2939,  1687,  1611,  1591, 
1482, 1387, 1267, 1166, 935, 683; 
 
 
 
Methyl 2-(1-(3-chlorophenyl)piperidin-4-yl)-4,6-dihydroxybenzoate (67) 
 
 
 
 
 
 
 
Isopropylidene ester 66 (96 mg, 0.25 mmol) and Cs
2
CO
3
 (242 mg, 0.74 mmol) were 
dissolved in MeOH (2 mL) and heated to 60 °C for 16 h. The reaction was evaporated 
to dryness and the residue dissolved in 1 M aqueous HCl (5 mL) and EtOAc (15 mL). 
The organic layer was separated and the aqueous extracted with EtOAc (3 x 10 mL), 
the combined  organic extracts  were  washed  with  brine,  dried (MgSO
4
) rotary 
evaporated, and chromatographed (Petrol:EtOAc  4/1 to  2/1) to  give the desired 
product as a white crystaline solid, (68  mg,  75%); Mp (Et
2
O): 157-159 °C;  Rf 
(Petrol/EtOAc (1/1); 0.69; δ
H
 (400 MHz, d
6
 Acetone); 11.15 (s, 1H, OH), 9.13 (s, 1H, 
OH), 7.22 (t, J = 8.1, 1H), 6.98 – 6.93 (m, 2H), 6.77 (dd, J = 7.8, 1.8, 1H), 6.46 (d, J 
= 2.4, 1H), 6.29 (d, J = 2.4, 1H), 3.97 (s, 3H), 3.91-3.88 (m, 2H), 3.54 (t, J =11.9, 
3.1, 1H), 2.87 (td, J = 12.3, 2.3, 2H), 1.95-1.92 (m, 2H), 1.75 (qd, J = 12.4, 3.8, 2H); 
δ
C
 (100 MHz,  d
6
 Acetone); 171.4,  164.1,  162.4,  153.0,  150.8,  134.4,  130.2,  118.0, 
115.3, 114.2, 106.7, 101.0, 51.6, 49.6 39.5, 33.1; m/z [TOF MS ES+] found 362.1157 
[M  +  H
+
], C
19
H
21
ClNO
4
 requires 362.1159; IR (neat) ν
max
; 3270,  2964,  2813,  1645, 
1590, 1435, 1317, 1277, 1202, 1101, 938; 
 
HO
N
CO
2
Me
OH
Cl
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7-Hydroxy-2,2-dimethyl-5-(piperidin-4-yl)-4H-benzo[d][1,3]dioxin-4-one 
hydrochloride (68) 
 
 
 
 
 
 
Isopropylidene ester 55 (500  mg,  1.35  mmol)  was  dissolved in  CH
2
Cl
2
 (5  mL) and 
cooled to 0 °C. 4 M HCl in dioxane (6 mL) was added dropwise and the mixture was 
alowed to warm to room temperature. After 1 h the reaction was evaporated and the 
resulting residue triturated  with  CH
2
Cl
2 
and  Et
2
O.  Repeated trituration and filtration 
gave the desired product as a light yelow solid, (398 mg, 94%); Mp (Et
2
O): 262-264 
°C; δ
H
 (400 MHz, d
6 
DMSO); 11.06 (s, 1H, OH), 9.08 (s, 2H, NH
2
), 6.55 (d, J = 2.2, 
1H), 6.34 (d, J = 2.1, 1H), 3.91 (t, J = 11.3, 3.4, 1H), 3.36-3.33 (m, 2H), 2.97-2.92 
(m,  2H),  1.89-1.76 (m,  4H),  1.62 (s,  6H); δ
C
 (100  MHz,  d
6 
DMSO); 169.6,  164.6, 
163.8,  156.3,  114.6,  109.7,  107.6,  106.7,  71.6,  48.9,  40.5,  33.9,  30.3; m/z [TOF  MS 
ES+] found 278.1392 [M + H
+
], C
15
H
20
NO
4
 requires 278.1392; IR (neat) ν
max
; 3200-
2500 (br), 1692, 1614, 1443, 1310, 1276, 1250, 1201, 1146, 1041; 
 
 
Methyl-2-(1-(5-chloro-1,3-dimethyl-1H-pyrazol-4-ylsulfonyl)piperidin-4-yl)-4,6 
dihydroxybenzoate (71) 
 
 
 
 
 
 
 
Hydrochloride salt 55 (80  mg,  0.26  mmol) and Et
3
N (107 µL,  0.77 mmol) were 
combined with CH
2
Cl
2
 (1 mL) and stired at room temperature. Heteroaryl sulphonyl 
chloride (71 mg, 0.31 mmol) was added and the ensuing mixture stired for 1 h. The 
reaction was quenched with MeOH (1 mL) and evaporated to dryness and the residue 
directly chromatographed (CH
2
Cl
2
:Et
2
O 50/1) to give the desired product as a impure 
white solid,  which  was  used  directly in the  next step.  Crude isopropylidene ester 70 
(111 mg, 0.25 mmol) and Cs
2
CO
3
 (360 mg, 1.10 mmol) were dissolved in MeOH (2 
HO
NH.HCl
OO
O
HO
N
S
O
O
N
N
Cl
OO
O
HO
NH.HCl
OO
O
HO
N
S
O
O
N
N
Cl
CO
2
Me
OH
i. i.
	   316	  
mL) and  heated to  60 °C for  16  h. The reaction  was evaporated to  dryness and the 
residue dissolved in 1 M aqueous HCl (5 mL) and EtOAc (15 mL). The organic layer 
was separated and the aqueous extracted  with  EtOAc (3  x  10  mL), the combined 
organic extracts  were  washed  with  brine,  dried (MgSO
4
) rotary evaporated, and 
chromatographed (Petrol:EtOAc  2/1 to  2/1) to  give the desired  product as a white 
crystaline solid, (61 mg, 51%); Mp (Et
2
O): 111-113 °C; Rf (EtOAc/Petrol (2/1); 0.50; 
δ
H
 (400 MHz, d
6 
Acetone); 10.93 (s, 1H, OH), 9.20 (s, 1H, OH), 6.45 (d, J = 2.4, 1H), 
6.30 (d, J = 2.4, 1H), 3.94-3.92 (m, 2H), 3.89, (s, 3H), 3.88 (s, 3H), 3.34-3.38 (m, 1H), 
2.67 (td, J = 12.1, 2.3, 2H), 2.39 (s, 3H), 1.96-1.93 (m, 2H), 1.72 (td, J = 12.4, 3.7, 
2H); δ
C
 (100 MHz, d
6 
Acetone); 171.9, 164.6, 163.2, 150.8, 149.2, 130.1, 113.5, 107.6, 
106.1, 102.5, 51.6, 46.5, 38.8, 36.2, 32.7, 13.4; m/z [TOF MS ES+] found 442.0845 
[M - H
+
], C
18
H
21
ClN
3
O
6
S requires 442.0840; IR (neat) ν
max
; 3375, 2953, 1652, 1435, 
1324, 1252, 1174, 1153, 1126, 923, 848, 807; 
 
 
7-Hydroxy-2,2-dimethyl-5-(1-(phenylsulfonyl)piperidin-4-yl)-4H-
benzo[d][1,3]dioxin-4-one (72) 
 
 
 
 
 
 
 
Hydrochloride salt 68 (80  mg,  0.26  mmol) and Et
3
N (107 µL,  0.77 mmol) were 
combined  with  CH
2
Cl
2
 (1  mL) and stired at room temperature.  Benzene sulphonyl 
chloride (40 µL, 0.31 mmol) was added and the ensuing mixture stired for 1 h. The 
reaction was quenched with MeOH (1 mL) and evaporated to dryness and the residue 
directly chromatographed (CH
2
Cl
2
:Et
2
O  50/1) to  give the desired  product as a white 
crystaline solid, (39  mg,  36%);  Mp (Et
2
O): 185-187 °C;  Rf (CH
2
Cl
2
/Et
2
O (30/1); 
0.56; δ
H
 (400 MHz, d
6 
DMSO); 10.76 (s, 1H, OH), 7.80-7.74 (m, 3H), 7.71-7.67 (m, 
2H), 6.50 (d, J = 2.2, 1H), 6.27 (d, J = 2.2, 1H), 3.83-3.80 (m, 2H), 3.59-3.54 (m, 1H), 
2.28-2.23 (m, 2H), 1.84-1.81 (m, 2H), 1.62-1.56 (m, 2H), 1.60 (s, 6H); δ
C
 (100 MHz, 
d
6 
DMSO); 164.5, 159.8, 159.0, 152.1, 135.7, 133.7, 129.9, 127.9, 109.9, 104.8, 102.9, 
101.7,  55.4,  47.3,  37.2,  31.8,  25.5; m/z [TOF  MS  ES+] found  416.1173 [M - H
+
], 
HO
N
OO
O
S
O
O
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C
21
H
22
NO
6
S requires 416.1168; IR (neat) ν
max
; 3386, 2922, 2852, 1673, 1613, 1590, 
1306, 1158, 1024, 936, 731;   
 
 
1-(Phenylsulfonyl)piperidine-2-carboxylic acid (76) 
 
 
 
 
 
Piperidine-2-carboxylic acid (1.00  g, 6.03  mmol) and  Na
2
CO
3 
(1.40  g,  13.2  mmol) 
were suspended in  H
2
O/dioxane (3/1) (16  mL) and stired at room temperature. 
Benzene sulphonyl chloride (926 µL, 7.24 mmol) was added dropwise and the ensuing 
mixture  was alowed to stir for  3  h. The reaction  was evaporated to  dryness and the 
residue dissolved in 1 M aqueous HCl (15 mL) and EtOAc (30 mL). The organic layer 
was separated and the aqueous extracted  with  EtOAc (3  x  10  mL), the combined 
organic extracts  were  washed  with  brine,  dried (MgSO
4
) and rotary evaporated to 
provide the product as a pure white crystaline solid crystaline solid, (1.27 g, 78%); 
Mp (Et
2
O): 65-68 °C; δ
H
 (400 MHz, CDCl
3
); 7.87-7.81 (m, 2H), 7.59-7.56 (m, 1H), 
7.52-7.48 (m, 2H), 4.81-4.79 (m, 1H), 3.80-3.77 (m, 1H), 3.23 (td, J = 10.6, 3.4, 1H), 
2.20-2.16 (m,  1H),  1.80-1.51 (m,  3H),  1.31-1.27 (m,  2H); δ
C
 (100  MHz,  CDCl
3
); 
175.9,  139.9,  132.6,  128.9,  127.1,  67.0,  54.8,  42.6,  27.5,  24.5,  m/z [TOF  MS  ES+] 
found 268.0642 [M - H
+
], C
12
H
14
NO
4
S requires 268.0644; IR (neat) ν
max
; 3551, 2939, 
1717, 1325, 1309, 1182, 1127, 1111, 1092, 958, 754; 
 
 
(1H-Imidazol-1-yl)(1-(phenylsulfonyl)piperidin-2-yl)methanone (77) 
 
 
 
 
 
 
Carboxylic acid 76 (900 mg, 3.34 mmol) was dissolved in THF (5 mL) and cooled to 0 
°C. CDI (596 mg, 3.67 mmol), was added portionwise over 5 minutes, and the mixture 
was alowed to warm to room temperature. After 2 hours, the mixture was diluted with 
N CO
2
H
S
O
O
N
N
O
N
S
O
O
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Et
2
O (25 mL), and H
2
O (10 mL). The organic layer was washed with H
2
O (2 x 10 mL) 
and brine (10 mL), dried (MgSO
4
), and rotary evaporated to give the desired product 
as a  white crystaline solid, which  was  used in the  next step  without further 
purification; (1.01  g,  95%); δ
H
 (400  MHz,  CDCl
3
); 8.19 (s,  1H),  7.74-7.72 (m,  2H), 
7.62-7.58 (m, 1H), 7.50-7.46 (m, 3H), 7.15-7.12 (m, 1H), 5.29 (t, J = 4.4, 1H), 3.84-
3.73 (m, 2H), 3.57-3.51 (m, 1H), 2.05-2.00 (m, 2H), 1.79-1.53 (m, 3H); δ
C
 (100 MHz, 
CDCl
3
); 167.8, 138.6, 136.3, 133.1, 131.4, 129.1, 127.1, 116.1, 54.2, 43.2, 27.6, 24.1, 
18.9; 
 
 
7-Hydroxy-2,2-dimethyl-5-(1-(phenylsulfonyl)piperidin-2-yl)-4H-
benzo[d][1,3]dioxin-4-one (79) 
 
 
 
 
 
 
 
 
 
n-BuLi in hexanes (2.5 M; 1.92 mL, 4.79 mmol) was added dropwise with stiring to 
disopropylethylamine (689 µL, 4.91 mmol) in THF (10 mL) at -78 °C. After 20 min, 
keto-dioxinone (420  mg,  2.28 mmol) in  THF (1.5 mL)  was added  dropwise  with 
stiring at -78 °C. After 40 min, Et
2
Zn in hexanes (1.0 M; 4.79 mL, 4.79 mmol) was 
added slowly, and after a further 20 min, imidazole 77 (363 mg, 1.14 mmol) in THF (2 
mL) was added and the mixture stired for 3 h, maintaining the temperature at -78 °C. 
The reaction was quenched with saturated aqueous NH
4
Cl (30 mL) and 1 M aqueous 
HCl (15 mL), and the aqueous layer  was acidified to  pH  2  using  1  M aqueous  HCl. 
The product was extracted twice with EtOAc (50 mL, 25 mL), the combined organic 
extracts  were  dried (MgSO
4
) and rotary evaporated to  give the crude acylation 
product, which  was  dissolved in  CH
2
Cl
2
 (15 mL),  Et
3
N (4 mL)  was added, and the 
mixture was stired at 40 °C. After 24 h, saturated aqueous NH
4
Cl (40 mL) and EtOAc 
(80 mL) were added, and the aqueous layer was acidified to pH 2 using 1 M aqueous 
HCl.  The layers  were separated, and the aqueous layer  was further extracted  with 
EtOAc (40  mL).  The combined  organic extracts  were  dried (MgSO
4
), rotary 
OO
HO
N
O
S
O
O
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evaporated, and chromatographed (Petrol:EtOAc  4/1 to  2/1) to  give the desired 
product as a light  yelow  oil, (370  mg,  79%); Rf (Petrol/EtOAc (1/1);  0.56; δ
H
 (400 
MHz, d
6
 Acetone); 9.58 (s, 1H, OH), 7.86-7.84 (m, 2H), 7.69-7.66 (m, 1H), 7.63-7.59 
(m, 2H), 6.79 (d, J = 2.4, 1H), 6.34 (d, J = 2.3, 1H), 6.19 (dd, J = 6.1, 4.6, 1H), 3.93-
3.8 (m, 1H), 3.55-3.48 (m, 1H), 2.95 (brs, 1H), 2.06 (dt, J = 4.4, 2.2, 1H), 1.85-1.76 
(m,  2H),  1.68 (s,  6H),  1.38-1.26 (m,  2H); δ
C
 (100  MHz,  d
6
 Acetone); 168.6,  164.5, 
155.4, 146.0, 137.7, 134.3, 132.1, 116.0, 111.7, 109.8, 106.7, 101.4, 59.2, 52.4, 35.7, 
29.4, 28.5, 23.6; m/z [TOF MS ES+] found 418.1321 [M + H
+
], C
21
H
24
NO
6
S requires 
418.1324; IR (neat) ν
max
; : 3231,  2946,  1674,  1615,  1583,  1333,  1288,  1268,  1158, 
1059, 735; 
 
 
Methyl 2,4-dihydroxy-6-(1-(phenylsulfonyl)piperidin-2-yl)benzoate (80) 
 
 
	  
	  
	  
	  
Isopropylidene ester	  79 (60 mg, 0.15 mmol) and Cs
2
CO
3
 (199 mg, 0.62 mmol) were 
dissolved in MeOH (2 mL) and heated to 60 °C for 16 h. The reaction was evaporated 
to dryness and the residue dissolved in 1 M aqueous HCl (5 mL) and EtOAc (10 mL). 
The organic layer was separated and the aqueous extracted with EtOAc (3 x 10 mL), 
the combined  organic extracts  were  washed  with  brine,  dried (MgSO
4
) rotary 
evaporated, and chromatographed (Petrol:EtOAc  3/1 to  1/1) to  give the desired 
product as a white crystaline solid, (42 mg, 72%); Rf (Petrol/EtOAc (1/1); 0.50; Mp 
(Et
2
O):  32-35 °C; δ
H
 (400  MHz,  d
6
 Acetone); 11.21 (s,  1H,  OH),  9.21 (s,  1H,  OH), 
7.87-7.85 (m, 2H), 7.70-7.60 (m, 3H), 6.61 (d, J = 2.1, 1H), 6.29 (d, J = 2.2, 1H), 5.91 
(m, 1H), 3.97 (s, 3H), 3.97-3.91 (m, 1H), 3.51-3.44 (m, 1H), 1.75-1.57 (m, 3H), 1.35-
1.22 (m,  3H); δ
C
 (100  MHz,  d
6
 Acetone);  170.9,  164.9,  162.2,  147.6,  140.9,  132.5, 
129.1,  126.9,  108.6,  102.9,  101.4,  54.9,  51.8,  42.8,  31.1,  23.4,  18.3;  m/z [TOF  MS 
ES+] found 392.1165 [M + H
+
], C
19
H
22
NO
6
S requires 392.1168; IR (neat) ν
max
; 3300-
2800 (br), 1648, 1613, 1445, 1435, 1319, 1254, 1110, 1092, 929; 
 
CO
2
Me
OH
HO
N
S
O
O
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tert-Butyl-4-(7-(benzyloxy)-2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-
yl)piperidine-1-carboxylate (81) 
 
 
 
 
 
 
Isopropylidene ester 81 (420  mg,  1.11  mmol) and benzyl  bromide (181 µL,  1.67 
mmol) were combined with acetone (4 mL). K
2
CO
3
 (230 mg, 1.67 mmol) was added 
and the mixture heated at 60 °C for 2 h. The reaction was evaporated to dryness and 
the residue directly chromatographed (Petrol:EtOAc 4/1) to give the desired product as 
a white crystaline solid, (505 mg, 97 %); Mp (EtOAc): 136-138 °C; Rf (Petrol/EtOAc 
(1/1); 0.76; δ
H
 (400 MHz, CDCl
3
); 7.44-7.36 (m, 5H), 6.66 (d, J = 2.4, 1H), 6.41 (d, J 
= 2.4,  1H),  5.08 (s,  2H),  4.24 (brs,  2H),  4.04 (t, J = 11.9,  3.0,  1H),  2.90 (brs,  2H), 
1.87-1.84 (m,  2H),  1.71 (s,  6H),  1.55-1.46 (m,  2H),  1.49 (s,  9H); δ
C
 (100  MHz, 
CDCl
3
);  164.3,  160.0,  159.2,  154.9,  152.9,  135.7,  128.8,  128.4,  127.6,  109.7,  104.8, 
104.5, 99.9, 79.3, 70.3, 37.9, 32.8, 28.5, 25.6; m/z [TOF MS ES+] found 468.2378 [M 
+  H
+
], C
27
H
34
NO
6
 requires 468.2386; IR (neat) ν
max
; 2975,  1729,  1681,  1611,  1428, 
1270, 1160, 1117, 1031, 964, 841, 762; 
 
 
7-(Benzyloxy)-2,2-dimethyl-5-(piperidin-4-yl)-4H-benzo[d][1,3]dioxin-4-one 
hydrochloride (82) 
 
 
 
 
 
Ester 81 (470 mg, 1.01 mmol) was dissolved in CH
2
Cl
2
 (5 mL) and cooled to 0 °C. 4 
M HCl in dioxane (8 mL) was added dropwise and the mixture was alowed to warm 
to room temperature. After 1 h the reaction was evaporated and the resulting residue 
triturated  with  CH
2
Cl
2 
and  Et
2
O.  Repeated trituration and filtration  gave the  desired 
product as a white crystaline solid, (389 mg, 96 %); Mp (Et
2
O): 157-159 °C; δ
H
 (400 
MHz, d
6
 DMSO); 9.31 (brm, 2H, NH
2
), 7.48-7.34 (m, 5H), 6.67 (s, 2H), 5.19 (s, 2H), 
OO
BnO
NBoc
O
OO
BnO
NH.HCl
O
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4.00-3.93 (m, 1H), 3.37-3.33 (m, 2H), 2.96-2.94 (m, 2H), 1.97-1.89 (m, 4H), 1.65 (s, 
6H); δ
C
 (100 MHz, d
6
 DMSO); 164.6, 159.7, 159.2, 151.3, 136.4, 129.0, 128.7, 128.6, 
110.1,  105.3,  104.3,  100.8,  70.4,  44.1,  35.8,  29.1,  25.5; m/z [TOF  MS  ES+] found 
368.1861 [M + H
+
], C
22
H
26
NO
4
 requires 368.1862; IR (neat) ν
max
; 2928, 2705, 1716, 
1608, 1575, 1305, 1265, 1218, 1164, 1029, 736; 
 
 
7-(Benzyloxy)-2,2-dimethyl-5-(1-(phenylsulfonyl)piperidin-4-yl)-4H-
benzo[d][1,3]dioxin-4-one (83) 
 
 
 
 
 
 
 
 
Hydrochloride salt 82 (60  mg,  0.15  mmol) and K
2
CO
3
 (62 mg,  0.45 mmol) were 
combined  with acetone (1  mL) and stired at room temperature.  Benzene sulphonyl 
chloride (28 µL, 0.22 mmol) was added and the ensuing mixture stired overnight. The 
reaction  was evaporated to  dryness and the residue  directly chromatographed 
(Petrol:EtOAc 3/1 to 1/1) to give the desired product as a white crystaline solid, (64 
mg, 85 %); Mp (Et
2
O): 112-114 °C; δ
H
 (400 MHz, CDCl
3
); 7.80-7.78 (m, 2H), 7.64-
7.60 (m, 1H), 7.58-7.54 (m, 2H), 7.43-7.36 (m, 5H), 6.64 (d, J = 2.4, 1H), 6.40 (d, J = 
2.4, 1H), 5.08 (s, 2H), 3.96-3.93 (m, 1H),  3.76 (t, J = 12.0, 3.1, 1H), 2.43 (td, J = 
11.9,  2.1,  2H),  1.94-1.91 (m,  2H),  1.79-1.67 (m,  3H),  1.72 (s,  6H); δ
C
 (100  MHz, 
CDCl
3
); 164.4,  160.1,  159.2,  151.8,  136.0,  135.6,  132.8,  129.1,  128.8,  128.5,  127.7, 
127.6,  109.6,  104.8,  104.4,  100.3,  70.4,  46.9,  37.1,  32.1,  25.5;  m/z [TOF  MS  ES+] 
found 508.1785 [M + H
+
], C
28
H
30
NO
6
S requires 508.1794; IR (neat) ν
max
; 2838, 1719, 
1612, 1572, 1285, 1168, 1096, 1034, 930, 730; 
 
 
 
 
 
 
BnO
N
S
O
O
OO
O
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Methyl 4-(benzyloxy)-2-hydroxy-6-(1-(phenylsulfonyl)piperidin-4-yl)benzoate (84) 
 
 
 
 
 
 
 
Isopropylidene ester 84 (40 mg, 0.079 mmol) and Cs
2
CO
3
 (76 mg, 0.24 mmol) were 
dissolved in MeOH (1 mL) and heated to 60 °C for 16 h. The reaction was evaporated 
to dryness and the residue dissolved in 1 M aqueous HCl (5 mL) and EtOAc (10 mL). 
The organic layer was separated and the aqueous extracted with EtOAc (3 x 10 mL), 
the combined  organic extracts  were  washed  with  brine,  dried (MgSO
4
) rotary 
evaporated, and chromatographed (Petrol:EtOAc  3/1 to  1/1) to  give the desired 
product as a white crystaline solid, (32 mg, 84 %); Rf (Petrol/EtOAc (3/1); 0.33; Mp 
(Et
2
O): 114-116 °C; δ
H
 (400 MHz, d
6
 Acetone); 10.89 (s, 1H, OH), 7.87-7.84 (m, 2H), 
7.77-7.73 (m, 1H), 7.71-7.67 (m, 2H), 7.53-7.51 (m, 2H), 7.45-7.42 (m, 2H), 7.39-7.35 
(m, 1H), 6.59 (d, J = 2.5, 1H), 6.47 (d, J = 2.5, 1H), 5.21 (s, 2H), 3.95-3.92 (m, 2H), 
3.84 (s,  3H),  3.29 (t, J =11.9,  3.3,  1H),  2.45 (td, J = 12.0,  2.3,  2H),  1.92-1.89 (m, 
2H),  1.76 (qd, J = 12.5,  3.9,  2H); δ
C
 (100  MHz,  d
6
 Acetone);  170.7,  163.2,  163.1, 
149.3, 136.9, 136.8, 132.7, 129.2, 128.5, 127.9, 127.7, 127.6, 106.6, 100.3, 69.7, 51.7, 
46.9, 38.9, 32.5; m/z [TOF MS ES+] found 482.1630 [M + H
+
], C
26
H
28
NO
6
S requires 
482.1637; IR (neat) ν
max
; 1653, 1613, 1581, 1321, 1305, 1245, 1165, 1092, 931, 829, 
739, 729; 
 
 
 
 
 
 
 
 
 
 
CO
2
Me
OH
O
N
S
O
O
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7-(Benzyloxy)-5-(1-(3-chlorobenzoyl)piperidin-4-yl)-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one (86) 
 
 
 
 
 
 
 
 
Hydrochloride salt 82 (100  mg,  0.25  mmol) and K
2
CO
3
 (102  mg,  0.74 mmol) were 
combined  with acetone (1  mL) and stired at room temperature.  3-chlorobenzoyl 
chloride (47 µL, 0.38 mmol) was added and the ensuing mixture stired overnight. The 
reaction  was evaporated to  dryness and the residue  directly chromatographed 
(Petrol:EtOAc 3/1 to 1/1) to give the desired product as a white crystaline solid, (113 
mg, 90 %); Mp (Et
2
O): 132-134 °C; δ
H
 (400 MHz, CDCl
3
); 7.43-7.40 (m, 5H), 7.37-
7.33 (m, 2H), 7.31-7.28 (m, 2H), 6.66 9d, J = 2.4, 1H), 6.42 (d, J = 2.4, 1H), 5.08 (s, 
2H), 4.88-4.85 (m, 1H), 4.19 (dt, J = 11.9, 3.0, 1H), 3.81-3.78 (m, 1H), 3.24 (t, J = 
10.9, 1H), 2.94 (t, J = 10.4, 1H), 2.01-1.98 (m, 1H), 1.88-1.86 (m, 1H), 1.70 (s, 6H), 
1.67-1.43 (m,  3H); δ
C
 (100  MHz,  CDCl
3
);  168.8,  164.4,  160.1,  159.3,  151.8,  137.9, 
135.6,  134.5,  129.9,  129.7,  128.8,  128.5,  127.6,  127.1,  125.0,  109.8,  104.9,  104.4, 
100.2,  70.4,  48.5,  43.0,  37.9,  33.6,  32.3,  25.7,  25.5; m/z [TOF  MS  ES+] found 
506.1726 [M  + H
+
], C
29
H
29
ClNO
5
 requires 506.1734; IR (neat) ν
max
; 2953,  1720, 
1610, 1576, 1439, 1389, 1282, 1163, 1033, 740; 
 
 
 
 
 
 
 
 
 
 
 
OO
BnO
N
O
O
Cl
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Methyl 2-(1-(3-chlorobenzoyl)piperidin-4-yl)-4,6-dihydroxybenzoate (87) 
 
 
 
 
 
 
 
A solution of isopropylidene ester 86 (100 mg, 0.19 mmol) in methanol/EtOAc (5/1) 
(1 mL) was added to a suspension of 10% Pd/C (21 mg, 0.19 mmol) in methanol (2 
mL) which had been activated by bubbling hydrogen through the solution for 10 min. 
The reaction was stired under an atmosphere of hydrogen for 12 h, the flask was then 
purged with nitrogen, filtered, rotary evaporated to obtain the intermediate phenol as a 
colourless crystaline solid; Phenol 86i (60 mg, 0.14 mmol) and Cs
2
CO
3
 (140 mg, 0.44 
mmol)  were  dissolved in  MeOH (1 mL) and  heated to  60 °C for  16  h. The reaction 
was evaporated to dryness and the residue dissolved in 1 M aqueous HCl (5 mL) and 
EtOAc (10  mL).  The  organic layer  was separated and the aqueous extracted  with 
EtOAc (3  x  10  mL), the combined  organic extracts  were  washed  with  brine,  dried 
(MgSO
4
) rotary evaporated, and chromatographed (Petrol:EtOAc  3/1 to  1/1) to  give 
the desired product as a white crystaline solid, (31 mg, 55%); Rf (Petrol/EtOAc (1/1); 
0.26; Mp (Acetone): 138-140 °C; δ
H
 (400 MHz, d
6
 DMSO); 9.86 (s, 1H, OH), 9.65 (s, 
1H, OH), 7.56-7.39 (m, 4H), 6.23 (d, J = 1.9, 1H), 6.21 (d, J = 1.9, 1H), 4.60 (brm 
1H), 3.76 (s, 3H), 3.63 (brm, 1H), 3.08 (brm, 1H), 2.78 (t, J = 11.7, 2H), 1.77-1.62 (m, 
2H), 1.57-1.36 (m, 2H); δ
C
 (100 MHz, d
6
 DMSO); 169.5, 160.2, 157.3, 146.1, 136.9, 
129.8,  128.9,  127.2,  111.9,  105.0,  101.1,  52.2,  39.8,  33.4,  33.1;  m/z [TOF  MS  ES+] 
found 390.1104 [M + H
+
], C
20
H
21
ClNO
5
 requires 390.1108; IR (neat) ν
max
; 3200-2850 
(br), 1592, 1567, 1451, 1432, 1310, 1268, 1218, 1159, 822; 
 
 
 
 
 
 
 
 
OO
BnO
N
O
O
Cl
OO
HO
N
O
O
Cl
CO
2
Me
OH
HO
N
O
Cl
i. i.
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Methyl 2,4,6-trihydroxybenzoate (98)
6
 
 
 
 
2,4,6-trihydroxybenzoic acid (5.00 g, 29.4 mmol) and dimethylsulfate (3.06 mL, 32.3 
mmol) were combined with acetone (150 mL). K
2
CO
3
 (4.06 g, 29.4 mmol) was added 
and the mixture stired for 24 h at ambient temperature. The reaction was evaporated 
to dryness and the resulting solid was dissolved in EtOAc (100 mL) and washed with 
cold 1 M aqueous HCl (25 mL), saturated aqueous NaHCO
3
, and brine. The organic 
layer was dried and concentrated to give the desired product as an off white crystaline 
solid, (4.86 g, 90%); Mp (MeOH): 176-179 °C; δ
H
 (400 MHz, CH
3
Cl); 5.88 (s, 2H), 
3.98 (s, 3H); (data matched literature); 
 
 
Methyl 2-hydroxy-4,6-bis(methoxymethoxy)benzoate (99) 
 
 
 
 
Compound 98 (500 mg, 2.71 mmol) and disopropylethylamine (1.44 mL, 8,15 mmol) 
were  dissolved in  CH
2
Cl
2
 and cooled to  0 °C.  MOM-Cl (619 µL,  8.15  mmol)  was 
added dropwise and the ensuing mixture was stired at room temperature for 24 h. The 
reaction was then diluted with H
2
O (15 mL) and extracted with EtOAc (3 x 15 mL), 
combined organic extracts were washed with saturated aqueous NaHCO
3
, brine, dried 
(MgSO
4
) rotary evaporated, and chromatographed (Petrol:Et
2
O 4/1 to 2/1) to give the 
desired product as a colourless oil, (361 mg, 49%); Rf (Hexanes/EtOAc) (1/1); 0.54; 
δ
H
 (400 MHz, CDCl
3
); 11.81 (s, 1H, OH), 6.35 (d, J = 2.3, 1H), 6.28 (d, J =2.3, 1H), 
5.21 (s,  2H),  5.19 (s,  2H),  3.95 (s,  3H),  3.54 (s,  3H),  3.49 (s,  3H); δ
C
 (100  MHz, 
CDCl
3
); 171.4, 165.2, 162.7, 159.6, 98.4, 97.3, 95.9, 94.8, 93.7, 56.5, 56.3, 52.2; m/z 
[TOF MS ES+] found 273.0973 [M + H
+
], C
12
H
17
O
7 
requires 273.0974; IR (neat) ν
max
; 
1650, 1611, 1578, 1435, 1320, 1262, 1144, 1054, 1016, 919; 
 
 
OMOM
MOMO OH
CO
2
Me
OH
HO OH
CO
2
Me
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Methyl 2,4-bis(methoxymethoxy)-6-(trifluoromethylsulfonyloxy)benzoate (100) 
 
 
 
 
Phenol 99 (1.25 g, 4.59 mmol) and pyridine (3.68 mL) were dissolved in CH
2
Cl
2 
(20 
mL) and cooled to  0 °C.  Tf
2
O (967 µL,  5.73  mmol)  was added  dropwise and the 
ensuing mixture was stired at room temperature for 4 h. The reaction was diluted with 
H
2
O (15 mL), and extracted with CH
2
Cl
2
 (3 x 25 mL), combined organic extracts were 
washed  with  brine,  dried (MgSO
4
) rotary evaporated, and chromatographed 
(Petrol:Et
2
O  3/1) to  give the desired  product as a colourless  oil, (1.11  g,  60%);  Rf 
(Hexanes/EtOAc) (1/1); 0.40; δ
H
 (400 MHz, CDCl
3
); 6.91 (d, J = 2.2, 1H), 6.69 (d, J 
= 2.0, 1H), 5.22 (s, 2H), 5.19 (s, 2H), 3.93 (s, 3H), 3.51 (s, 3H), 3.49 (s, 3H); δ
C
 (100 
MHz,  CDCl
3
); 163.3,  159.7,  157.2,  147.7,  120.1,  116.9,  111.8,  103.5,  103.1,  95.2, 
94.6,  56.6,  56.4,  52.5; m/z [TOF  MS  ES+] found 427.0287 [M  +  Na
+
], 
C
13
H
15
F
3
NaO
9
S
 
requires  427.0287; IR (neat) ν
max
; 1731,  1619,  1424,  1208,  1138, 
1008, 809, 762; 
 
 
tert-Butyl 4-(3-chlorophenyl)piperazine-1-carboxylate (102) 
 
 
 
 
 
 
3-Chloroiodobenzene (1.30  mL,  10.5  mmol),  Pd
2
(dba)
3
 (769  mg,  0.84  mmol), rac-
BINAP (784  mg,  1.26  mmol), and  NaO
t
Bu (1.99  g,  20.9  mmol)  were suspended in 
toluene (10  mL).  After  5  min  of stiring  1-Boc-piperazine (2.34  g,  12.5  mmol)  was 
added and the mixture heated for 16 h at 95 °C . The reaction mixture was cooled to 
ambient temperature, diluted with EtOAc (30 mL) and poured into water (20 mL). The 
aqueous  phase was extracted  with  EtOAc (4 ×  25 mL), combined  organic extracts 
were  washed  with  brine,  dried (MgSO
4
) rotary evaporated, and chromatographed 
(Petrol:Et
2
O 5/1 to 1/1) to give the desired product as a yelow crystaline solid, (3.01 
g, 97%); Mp (Et
2
O): 57-59 °C; Rf (Hexanes/Et
2
O) (1/1); 0.61; δ
H
 (400 MHz, CH
3
Cl); 
OMOM
MOMO OTf
CO
2
Me
N
Boc
N
Cl
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7.19 (t, J = 8.1, 1H), 6.89 (t, J = 2.1, 1H), 6.85 (dd, J = 7.7, 1.7, 1H), 6.80 (dd, J = 
8.3, 2.4, 1H), 3.59 (m, 4H), 3.15 (m, 4H), 1.50 (s, 9H); δ
C
 (100 MHz, CH
3
Cl); 154.7, 
152.3, 135.0, 130.1, 119.8, 116.3, 114.4, 80.0, 48.9, 28.4; m/z [TOF MS ES+] found 
297.1370 [M  +  H
+
], C
15
H
22
ClN
2
O
2 
requires 297.1370; IR (neat) ν
max
;  2981,  1678, 
1592, 1422, 1236, 1158, 1122, 933, 761, 679; 
 
 
1-(3-Chlorophenyl)piperazine trifluoroacetate salt (103) 
 
 
 
 
Compound 102 (3.01 g, 10.2 mmol) was dissolved in CH
2
Cl
2
 (15 mL) and cooled to 0 
°C. TFA (7.96 mL, 101.9 mmol) was added dropwise and the mixture was alowed to 
warm to room temperature.  After  1  h the reaction  was evaporated and the resulting 
residue triturated  with  CH
2
Cl
2 
and  Et
2
O.  Repeated trituration and filtration  gave the 
desired product as a white crystaline solid, (2.70 g, 90%); Mp (Et
2
O): 59-61 °C; δ
H
 
(400 MHz, CH
3
Cl); 9.90 (s, 1H), 7.23 (t, J = 8.1, 1H), 6.98-6.92 (m, 1H), 6.91 (t, J = 
2.1,  1H),  6.81 (dd, J = 8.3,  1.9,  1H),  3.45-3.43 (m,  4H),  3.35-3.33 (m,  4H); δ
C
 (100 
MHz,  CH
3
Cl); 151.1,  135.2,  130.4,  121.5,  117.2,  115.1,  46.5,  43.2; m/z [TOF  MS 
ES+] found 197.0844 [M + H
+
], C
10
H
14
ClN
2 
requires 197.0846; IR (neat) ν
max
; 2984, 
2714, 2499, 1693, 1672, 1595, 1203, 1173, 1122, 836, 723; 
 
 
1-(3-Chlorophenyl)-4-(3,5-dimethoxyphenyl)piperazine (105) 
 
 
 
 
 
 
3-bromodimethoxybenzene (91  mg,  0.49 mmol),  Pd
2
(dba)
3
 (22.4  mg,  0.023 mmol), 
rac-BINAP (30 mg, 0.049 mmol), and NaO
t
Bu (116 mg, 1.23 mmol) were suspended 
N
H.TFA
N
Cl
OMe
MeO N
N Cl
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in toluene (1.5 mL). After 5 min of stiring TFA salt 103 (130 mg, 0.44 mmol) was 
added and the mixture heated for 16 h at 95 °C . The reaction mixture was cooled to 
ambient temperature, diluted with EtOAc (10 mL) and poured into water (15 mL). The 
aqueous  phase was extracted  with  EtOAc (2 ×  10 mL), combined  organic extracts 
were  washed  with  brine,  dried (MgSO
4
) rotary evaporated, and chromatographed 
(Petrol:EtOAc  10/1 to  5/1) to  give the desired  product as a light  yelow crystaline 
solid, (127 mg, 87%); Mp (Et
2
O): 58-60 °C; Rf (Hexanes/EtOAc) (5/1); 0.57; δ
H
 (400 
MHz, CH
3
Cl); 7.21 (t, J = 8.1, 1H), 6.95 (t, J = 2.1, 1H), 6.88-6.82 (m, 2H), 6.17 (d, J 
= 2.0,  2H),  6.09 (t, J = 2.1,  1H),  3.82 (s,  3H),  3.36 (s,  8H); δ
C
 (100  MHz,  CH
3
Cl); 
161.6, 153.1, 152.2, 135.0, 130.1, 119.6, 116.0, 114.1, 95.4, 91.9, 55.3, 49.2, 48.8; m/z 
[TOF MS ES+] found 333.1371 [M + H
+
], C
18
H
22
ClN
2
O
2 
requires 333.1370; IR (neat) 
ν
max
; 2838, 1581, 1481, 1437, 1201, 1158, 1037, 940, 770, 814, 677; 
 
 
5-(4-(3-Chlorophenyl)piperazin-1-yl)benzene-1,3-diol (106) 
 
 
 
 
 
 
 
Compound 105 (20 mg, 0.060 mmol) was dissolved in CH
2
Cl
2 
and cooled to -78 °C. 
BBr
3
 (1.0  M in  CH
2
Cl
2
) (240 µL,  0.24  mmol)  was added  dropwise and the ensuing 
mixture alowed to  warm to room temperature  over  4  h.  The reaction  was  quenched 
MeOH (2  mL), evaporated to  dryness and the residue  directly chromatographed 
(CH
2
Cl
2
:Et
2
O 4/1) to give the desired product as an of white crystaline solid, (11 mg, 
60%); Mp (Et
2
O): 175-177 °C; Rf (CH
2
Cl
2
:Et
2
O) (2/1); 0.63; δ
H
 (400 MHz, CH
3
Cl); 
7.22 (t, J = 8.1, 1H), 7.00 (t, J = 2.2, 1H), 6.93 (dd, J = 8.2, 2.4, 1H), 6.83 (dd, J = 
7.8, 1.8, 1H), 6.02 (d, J = 2.1, 1H), 5.89 (t, J = 2.1, 1H), 3.31-3.29 (m, 4H), 3.25-3.23 
(m, 4H); δ
C
 (100 MHz, CH
3
Cl); 158.7, 153.2, 152.6, 134.6, 129.9, 119.0, 115.5, 114.1, 
95.3, 94.8, 49.2, 48.6; m/z [TOF MS ES+] found 305.1057 [M + H
+
], C
16
H
18
ClN
2
O
2 
requires 305.1057; IR (neat) ν
max
; 3324, 2831, 1591, 1482, 1234, 1191, 1005, 935, 828 
770; 
 
OH
HO N
N Cl
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1-(4-Bromo-3,5-dimethoxyphenyl)-4-(3-chlorophenyl)piperazine (107) 
 
 
 
 
 
 
Compound 105 (600 mg, 1.80 mmol) was dissolved in CH
2
Cl
2 
(20 mL) and cooled to -
78 °C.  NBS (334  mg,  1.89  mmol)  was added  portionwise  over  5  minutes, and the 
ensuing mixture was alowed to stir for 1 hour. The reaction was then evaporated to 
dryness and the residue directly chromatographed (Petrol:Et
2
O 3/1) to give the desired 
product as a white crystaline solid, (457  mg,  62%); Mp (Et
2
O): 86-88 °C; Rf 
(Petrol/Et
2
O) (1/1); 0.53; δ
H
 (400 MHz, CH
3
Cl); 7.22 (t, J = 8.1, 1H), 6.94 (t, J = 2.2, 
1H), 6.87 (td, J = 8.4, 2.0, 2H), 6.22 (s, 2H), 3.92 (s, 6H), 3.36 (s, 8H); δ
C
 (100 MHz, 
CH
3
Cl); 157.5, 152.1, 151.9, 135.1, 130.2, 119.8, 116.1, 114.2, 94.1, 91.9, 56.4, 49.5, 
48.8;  m/z [TOF  MS  ES+] found 411.0455 [M  +  H
+
], C
18
H
21
BrClN
2
O
2 
requires 
411.0475; IR (neat) ν
max
; 2836, 1575, 1445, 1249, 1208, 1115, 993, 948, 785, 631; 
 
 
 
1-(2-Bromo-3,5-dimethoxyphenyl)-4-(3-chlorophenyl)piperazine (108i) 
 
 
 
 
 
 
Compound 105 (600 mg, 1.80 mmol) was dissolved in CH
2
Cl
2 
(20 mL) and cooled to -
78 °C.  NBS (334  mg,  1.89  mmol)  was added  portionwise  over  5  minutes, and the 
ensuing mixture was alowed to stir for 1 hour. The reaction was then evaporated to 
dryness and the residue directly chromatographed (Petrol:Et
2
O 3/1) to give the desired 
product as a white  gummy solid, (228  mg,  31%); Mp (Et
2
O): 29-31 °C; Rf 
(Petrol/Et
2
O) (1/1);  0.59; δ
H
 (400  MHz,  CH
3
Cl); 7.22 (t, J = 8.1,  1H),  6.97 (t, J = 
1.97, 1H), 6.88-6.85 (m, 2H), 6.35 (d, J = 2.7, 1H), 6.32 (d, J = 2.7, 1H), 3.92 (s, 3H), 
3.86 (s,  3H),  3.42-3.39 (m,  4H),  3.22-3.20 (m,  4H); δ
C
 (100  MHz,  CH
3
Cl); 160.3, 
157.6, 152.4, 134.9, 130.1, 119.5, 115.9, 114.1, 99.0, 94.5, 56.4, 55.5, 51.5, 48.8; m/z 
OMe
MeO N
N Cl
Br
OMe
MeO N
N Cl
Br
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[TOF  MS  ES+] found 411.0474 [M  +  H
+
], C
18
H
21
BrClN
2
O
2 
requires 411.0475; IR 
(neat) ν
max
; 2833, 1581, 1449, 1435, 1224, 1200, 1122, 1025, 986; 
 
 
 
tert-Butyl 4-(3,5-dimethoxyphenyl)piperazine-1-carboxylate (109) 
 
 
 
 
 
3-Bromodimethoxybenzene (4.20 g, 19.3 mmol), Pd
2
(dba)
3
 (530 mg, 0.58 mmol), rac-
BINAP (721  mg,  1.16 mmol), and  NaO
t
Bu (4.08 g,  43.0 mmol)  were suspended in 
toluene (25 mL).  After  5  min  of stiring 1-boc-piperazine (4.00 g,  21.5 mmol)  was 
added and the mixture heated for 16 h at 95 °C . The reaction mixture was cooled to 
ambient temperature,  diluted  with EtOAc (150  mL) and  poured into  water (75 mL). 
The aqueous phase was extracted with EtOAc (2 × 40 mL), combined organic extracts 
were  washed  with  brine,  dried (MgSO
4
) rotary evaporated, and chromatographed 
(Petrol:Et
2
O 1/1) to give the desired product as a yelow crystaline solid, (4.53 g, 73 
%); Mp (Et
2
O): 68-71 °C; Rf (Petrol/Et
2
O) (1/1); 0.47; δ
H
 (400 MHz, CDCl
3
); 6.12 (d, 
J = 2.1, 2H), 6.07 (t, J = 2.1, 1H), 3.80 (s, 6H), 3.60-3.58 (m, 4H), 3.17-3.14 (m, 4H), 
1.51 (s, 9H); δ
C
 (100 MHz, CDCl
3
); 161.5, 154.7, 153.2, 95.2, 92.1, 79.9, 55.3, 49.4, 
43.6,  28.4; m/z [TOF  MS  ES+] found 323.1974 [M  +  H
+
], C
17
H
27
N
2
O
4 
requires 
323.1971; IR (neat) ν
max
; 1687, 1587, 1428, 1201, 1148, 1122, 1063, 995, 977, 813; 
 
 
tert-Butyl 4-(4-bromo-3,5-dimethoxyphenyl)piperazine-1-carboxylate (110i) 
 
 
 
 
Compound 109 (5.31 g, 16.4 mmol) was dissolved in CH
2
Cl
2 
(100 mL) and cooled to -
78 °C.  NBS (3.07  g,  17.3  mmol)  was added  portionwise  over  15  minutes, and the 
ensuing mixture was alowed to stir for 1 hour. The reaction was then evaporated to 
dryness and the residue directly chromatographed (Petrol:EtOAc 5/1 to 3/1) to give the 
OMe
MeO N
NBoc
OMe
MeO N
NBoc
Br
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desired product as a white crystaline solid, (4.46 g, 68%); Mp (Et
2
O): 120-122 °C; Rf 
(Petrol/Et
2
O) (1/1); 0.41; δ
H
 (400 MHz, CDCl
3
); 6.17 (s, 2H), 3.89 (s, 6H), 3.63-3.60 
(m, 4H), 3.18-3.15 (m, 4H), 1.51 (s, 9H); δ
C
 (100 MHz, CDCl
3
); 157.4, 154.6, 152.2, 
94.3, 91.9, 80.0, 56.3, 49.6, 43.2, 28.4; m/z [TOF MS ES+] found 401.1071 [M + H
+
], 
C
17
H
26
BrN
2
O
4 
requires 401.1076; IR (neat) ν
max
; 1682, 1578, 1400, 1367, 1250, 1215, 
1202, 1162, 1093, 989;  
 
 
tert-Butyl 4-(2-bromo-3,5-dimethoxyphenyl)piperazine-1-carboxylate (110i) 
 
 
 
 
 
Compound 109 (5.31 g, 16.4 mmol) was dissolved in CH
2
Cl
2 
(100 mL) and cooled to -
78 °C.  NBS (3.07  g,  17.3  mmol)  was added  portionwise  over  15  minutes, and the 
ensuing mixture was alowed to stir for 1 hour. The reaction was then evaporated to 
dryness and the residue directly chromatographed (Petrol:EtOAc 5/1 to 3/1) to give the 
desired product as a white foam, (1.90 g, 28%); Mp (Et
2
O): 32-35 °C; Rf (Petrol/Et
2
O) 
(1/1); 0.63; δ
H
 (400 MHz, CDCl
3
); 6.29 (d, J = 2.6, 1H), 6.27 (d, J = 2.6, 1H), 3.90 (s, 
3H), 3.82 (s, 3H), 3.64-3.62 (m, 4H), 3.01-2.98 (m, 4H), 1.51 (s, 9H); δ
C
 (100 MHz, 
CDCl
3
); 160.2, 157.8, 154.7, 152.4, 99.0, 94.5, 79.8, 56.4, 55.5, 51.7, 43.9, 28.5; m/z 
[TOF MS ES+] found 401.1086 [M + H
+
], C
17
H
26
BrN
2
O
4 
requires 401.1076; IR (neat) 
ν
max
; 1682, 1578, 1400, 1367, 1202, 1124, 1094, 990, 634; 
 
 
tert-Butyl-4-(3,5-dimethoxy-2-(methoxycarbonyl)phenyl)piperazine-1-carboxylate 
(111) 
 
 
 
 
 
n-BuLi in hexanes (2.5 M; 1.92 mL, 4.82 mmol) was added dropwise with stiring to 
aryl bromide 110i (1.04 g, 2.60 mmol) in THF (10 mL) at -78 °C. The mixture was 
alowed to stir for  45  min and  Mander’s reagent (400 µL,  5.04  mmol)  was added. 
OMe
MeO N
NBoc
Br
OMe
MeO N
NBoc
CO
2
Me
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After 2 h the reaction was warmed to room temperature and quenched with saturated 
aqueous  NH
4
Cl (20  mL). The  product  was extracted  with  EtOAc (3  x  30  mL), the 
combined organic extracts were washed with brine, dried (MgSO
4
), rotary evaporated, 
and chromatographed (Petrol:EtOAc 3/1) to give the desired product as a light yelow 
oil, (741 mg, 75 %); Rf (Petrol/EtOAc) (1/1); 0.63; δ
H
 (400 MHz, CDCl
3
); 6.21 (d, J = 
2.1, 1H), 6.20 (d, J = 2.1, 1H), 3.86 (s, 3H), 3.79 (s, 3H), 3.78 (s, 3H), 3.49-3.46 (m, 
4H),  2.93-2.91 (m,  4H),  1.46 (s,  9H); δ
C
 (100  MHz,  CDCl
3
);  168.4,  162.0,  158.2, 
154.7, 152.5, 112.8, 97.9, 93.7, 79.7, 55.9, 55.3, 52.5, 52.2, 43.5, 28.4; m/z [TOF MS 
ES+] found 381.2023 [M + H
+
], C
19
H
29
N
2
O
6 
requires 381.2026; IR (neat) ν
max
; 1710, 
1689, 1600, 1583, 1418, 1247, 1215, 1200. 1125, 1098, 1049; 
 
 
 
Methyl 2,4-dimethoxy-6-(piperazin-1-yl)benzoate hydrochloride (112) 
 
 
 
 
 
Ester 111 (255 mg, 0.55 mmol) was dissolved in CH
2
Cl
2
 (5 mL) and cooled to 0 °C. 4 
M HCl in dioxane (8 mL) was added dropwise and the mixture was alowed to warm 
to room temperature. After 1 h the reaction was evaporated and the resulting residue 
triturated  with  CH
2
Cl
2 
and  Et
2
O.  Repeated trituration and filtration  gave the  desired 
product as a light  yelow solid, (201  mg,  92 %); Mp (Et
2
O): 211-213 °C; δ
H
 (400 
MHz, d
6
 DMSO); 9.37 (s, 2H), 6.50 (s, 1H), 3.80 (s, 3H), 3.79 (s, 3H), 3.60 (s, 3H), 
3.12-3.08 (m, 8H), 2.86 (t, J = 11.2, 2.5, 1H), 2.02-1.93 (m, 2H), 1.75-1.65 (m, 3H), 
1.46-1.43 (m, 2H), 1.29-1.17 (m, 3H); δ
C
 (100 MHz, d
6
 DMSO); 167.7, 160.3, 155.9, 
148.5,  123.6,  117.5,  100.5,  62.7,  55.8,  52.2,  49.1,  43.2,  35.5,  29.9,  26.8,  25.7; m/z 
[TOF MS ES+] found 363.2283 [M + H
+
], C
20
H
31
N
2
O
4
 requires 363.2284; IR (neat) 
ν
max
; 2928, 2698, 2474, 1729, 1592, 1449, 1272, 1173, 1155, 1092, 1025, 966; 
 
 
 
OMe
CO
2
Me
MeO N
NH.HCl
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tert-Butyl-4-(4-(cyclohex-2-enyl)-3,5-dimethoxyphenyl)piperazine-1-carboxylate 
(122) 
 
 
 
 
 
 
n-BuLi in hexanes (2.5 M; 4.53 mL, 11.3 mmol) was added dropwise with stiring to 
aryl  bromide 110i (4.12  g,  10.3  mmol) in  THF (15  mL) at  0 °C.  After  30  min the 
resulting aryl lithium was transfered via cannulation to a suspension of CuI (980 mg, 
5.15 mmol) in THF (3 mL). After 1 h, DMSO (10 mL) was added and the resulting 
mixture transfered via cannulation to a solution of 3-bromocyclohexene (600 µL, 5.15 
mmol) in  DMSO/THF (1/1) (14  mL) at  0 °C.  The reaction  was alowed to  warm to 
room temperature and stired  overnight. The reaction  was  quenched  by addition  of 
saturated aqueous  NH
4
Cl (20  mL). The  product  was extracted  with  EtOAc (3  x  30 
mL), the combined  organic extracts  were washed  with  brine, dried (MgSO
4
), rotary 
evaporated, and chromatographed (Petrol:Et
2
O  2/1) to  give the desired  product as a 
white crystaline solid,  (1.77 g, 86%)*; Rf (Petrol/EtOAc) (1/1); 0.42; δ
H
 (400 MHz, 
CDCl
3
); 6.15 (s, 2H), 5.68-5.63 (m, 1H), 5.57-5.55 (m, 1H), 3.96-3.90 (m, 1H), 3.78 
(s, 6H), 3.61-3.57 (m, 4H), 3.15-3.13 (m, 4H), 2.15-2.00 (m, 2H), 1.96-1.84 (m, 2H), 
1.74-1.66 (m,  2H),  1.50 (s,  9H); m/z [TOF  MS  ES+] found  403.2599 [M  +  H
+
], 
C
23
H
35
N
2
O
4
 requires  403.2597; *Contaminated  with 109 and trace  unidentified  by-
products. 
 
 
 
tert-Butyl-4-(4-cyclohexyl-3,5-dimethoxyphenyl)piperazine-1-carboxylate (123) 
 
 
 
 
A solution of alkene 122 (2.26 g, 5.62 mmol) in methanol/EtOAc (5/1) (12 mL) was 
added to a suspension of 10% Pd/C (500 mg, 0.46 mmol) in methanol (5 mL) which 
had been activated by bubbling hydrogen through the solution for 10 min. The reaction 
OMe
MeO N
NBoc
OMe
MeO N
NBoc
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was stired under an atmosphere of hydrogen for 3 h, the flask was then purged with 
nitrogen, filtered, rotary evaporated, and chromatographed (Petrol:Et
2
O  2/1) to  give 
the desired product as a colourless oil,  (2.08 g, 92%)*; Rf (Petrol/EtOAc) (1/1); 0.42; 
δ
H
 (400  MHz,  CDCl
3
); 6.16 (s,  2H),  3.81 (s,  6H),  3.62-3.59 (m,  4H),  3.15-3.13 (m, 
4H), 3.14-3.11 (m, 1H), 2.06-1.97 (m, 2H), 1.84-1.70 (m, 4H), 1.51 (s, 9H), 1.42-1.29 
(m,  4H); m/z [TOF  MS  ES+] found  405.2744 [M  +  H
+
], C
23
H
37
N
2
O
4
 requires 
405.2753; IR (neat) ν
max
; 2921, 2856, 1688, 1604, 1422, 1247, 1152, 1137, 1084, 993, 
809; *Contaminated with 109 and trace unidentified by-products. 
 
 
 
tert-Butyl-4-(2-bromo-4-cyclohexyl-3,5-dimethoxyphenyl)piperazine-1-carboxylate 
(124) 
 
 
 
 
 
 
Compound 123 (2.20 g, 5.44 mmol) was dissolved in CH
2
Cl
2 
(30 mL) and cooled to -
78 °C.  NBS (1.46  g,  7.61  mmol)  was added  portionwise  over  15  minutes, and the 
ensuing mixture was alowed to stir for 3 hour. The reaction was then evaporated to 
dryness and the residue directly chromatographed (Petrol:Et
2
O 3/1 to 2/1) to give the 
desired product as a white crystaline solid, (1.77 mg, 67%); Mp (Et
2
O): 95-97 °C; Rf 
(Petrol/Et
2
O (1/1);  0.71; δ
H
 (400  MHz,  CDCl
3
); 6.40 (s,  1H),  3.80 (s,  3H),  3.78 (s, 
3H), 3.63-3.61 (m, 4H), 3.06 (t, J = 12.2, 3.2, 1H), 2.99-2.97 (m, 4H), 2.02 (td, J = 
12.4, 2.9, 2H), 1.81 (d, J = 12.8, 2H), 1.73 (d, J = 11.5, 1H), 1.57 (d, J = 13.0, 2H), 
1.49 (s,  9H),  1.42-1.25 (m,  3H); δ
C
 (100 MHz,  CDCl
3
); 159.0,  156.2,  154.9,  149.5, 
125.8, 106.8, 101.0, 79.9, 61.5, 55.5, 51.8, 44.5, 43.4, 37.2, 30.6, 28.5, 27.4, 26.2; m/z 
[TOF MS ES+] found 483.1844 [M + H
+
], C
23
H
36
BrN
2
O
4
 requires 483.1858; IR (neat) 
ν
max
; 2925, 2849, 1687, 1570, 1449, 1426, 1291, 1275, 1236, 1191, 1042, 944; 
 
 
 
OMe
Br
MeO N
NBoc
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tert-Butyl-4-(4-cyclohexyl-3,5-dimethoxy-2-(methoxycarbonyl)phenyl)piperazine-1-
carboxylate (125) 
 
 
 
 
 
n-BuLi in hexanes (2.5 M; 1.76 mL, 4.41 mmol) was added dropwise with stiring to 
aryl  bromide 124 (1.77  g,  3.67  mmol) in  THF (15  mL) at -78 °C.  The  mixture  was 
alowed to stir for  45  min and  Mander’s reagent (377 µL,  4.77  mmol)  was added. 
After 2 h the reaction was warmed to room temperature and quenched with saturated 
aqueous  NH
4
Cl (20  mL). The product  was extracted  with  EtOAc (3  x  30  mL), the 
combined organic extracts were washed with brine, dried (MgSO
4
), rotary evaporated, 
and chromatographed (Petrol:Et
2
O  3/1) to  give the desired  product as a white foam 
solid, (619 mg, 36%); Mp (Et
2
O): 35-37 °C; Rf (Petrol/Et
2
O (1/1); 0.56; δ
H
 (400 MHz, 
CDCl
3
); 6.39 (s, 1H), 3.89 (s, 3H), 3.81 (s, 3H), 3.75 (s, 3H), 3.51-3.49 (m, 4H), 3.01-
2.97 (m, 1H), 2.96-2.94 (m, 4H), 2.08-1.98 (m, 2H), 1.81-1.71 (m, 3H), 1.58-1.55 (m, 
2H),  1.49 (s,  9H),  1.41-1.25 (m,  3H); δ
C
 (100  MHz,  CDCl
3
);  168.8,  160.8,  156.1, 
154.8, 149.4, 124.7, 118.4, 100.0, 79.7, 63.1, 55.4, 52.6, 52.2, 45.3, 44.2, 36.2, 30.4, 
28.4, 27.4, 26.2; m/z [TOF MS ES+] found 463.2800 [M + H
+
], C
25
H
39
N
2
O
6
 requires 
463.2808; IR (neat) ν
max
; 2932,  1720,  1677, 1427,  1246,  1163,  1148,  1128,  1112, 
1096, 999, 972; 
 
 
Methyl 2,4-dimethoxy-6-(piperazin-1-yl)benzoate hydrochloride (126) 
 
 
 
 
 
Ester 125 (255 mg, 0.55 mmol) was dissolved in CH
2
Cl
2
 (5 mL) and cooled to 0 °C. 4 
M HCl in dioxane (8 mL) was added dropwise and the mixture was alowed to warm 
to room temperature. After 1 h the reaction was evaporated and the resulting residue 
triturated  with  CH
2
Cl
2 
and  Et
2
O.  Repeated trituration and filtration  gave the  desired 
product as a light  yelow solid, (201  mg,  92 %); Mp (Et
2
O): 211-213 °C; δ
H
 (400 
OMe
CO
2
Me
MeO N
NBoc
OMe
CO
2
Me
MeO N
NH.HCl
	   336	  
MHz, d
6
 DMSO); 9.37 (s, 2H), 6.50 (s, 1H), 3.80 (s, 3H), 3.79 (s, 3H), 3.60 (s, 3H), 
3.12-3.08 (m, 8H), 2.86 (t, J = 11.2, 2.5, 1H), 2.02-1.93 (m, 2H), 1.75-1.65 (m, 3H), 
1.46-1.43 (m, 2H), 1.29-1.17 (m, 3H); δ
C
 (100 MHz, d
6
 DMSO); 167.7, 160.3, 155.9, 
148.5,  123.6,  117.5,  100.5,  62.7,  55.8,  52.2,  49.1,  43.2,  35.5,  29.9,  26.8,  25.7; m/z 
[TOF MS ES+] found 363.2283 [M + H
+
], C
20
H
31
N
2
O
4
 requires 363.2284; IR (neat) 
ν
max
; 2928, 2698, 2474, 1729, 1592, 1449, 1272, 1173, 1155, 1092, 1025, 966; 
 
 
Methyl-2-(4-(5-chloro-1,3-dimethyl-1H-pyrazol-4-ylsulfonyl)piperazin-1-yl)-4,6-
dimethoxybenzoate (127) 
 
 
 
 
 
 
Hydrochloride salt 112 (60  mg,  0.21  mmol) and K
2
CO
3
 (88  mg,  0.64 mmol) were 
combined with acetone (1 mL) and stired at room temperature. Heteroaryl sulphonyl 
chloride (73 µL, 0.32 mmol) was added and the ensuing mixture stired overnight. The 
reaction  was evaporated to  dryness and the residue  directly chromatographed 
(CH
2
Cl
2
:Et
2
O 25/1) to give the desired product as a white crystaline solid, (77 mg, 77 
%);  Mp (Et
2
O):  123-125 °C; Rf (CH
2
Cl
2
/Et
2
O (10/1);  0.36; δ
H
 (400  MHz,  CDCl
3
); 
6.25 (d, J = 2.0, 1H), 6.24 (d, J = 2.0, 1H), 3.85 (s, 3H), 3.81 (s, 3H), 3.80 (s, 3H), 
3.79 (s,  3H),  3.23-3.20 (m,  4H),  3.08-3.06 (m,  4H),  2.41 (s,  3H); δ
C
 (100  MHz, 
CDCl
3
); 168.3, 162.1, 158.3, 151.6, 149.2, 129.9, 112.8, 112.3, 98.2, 94.2, 55.9, 55.5, 
52.3,  52.0,  46.1,  36.7,  14.2; m/z [TOF  MS  ES+] found  473.1263 [M  +  H
+
], 
C
19
H
26
ClN
4
O
6
S requires 473.1262; IR (neat) ν
max
; 1719,  1603,  1577,  1346,  1269, 
1182, 1128, 1102, 1038, 936, 729, 643; 
 
 
 
 
 
 
 
OMe
CO
2
Me
MeO N
N
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N
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Methyl 2,4-dimethoxy-6-(4-(phenylsulfonyl)piperazin-1-yl)benzoate (128) 
 
 
 
 
 
 
 
Hydrochloride salt 112 (60  mg,  0.21  mmol) and K
2
CO
3
 (88  mg,  0.64 mmol) were 
combined  with acetone (1  mL) and stired at room temperature.  Benzene sulphonyl 
chloride (41 µL, 0.32 mmol) was added and the ensuing mixture stired overnight. The 
reaction  was evaporated to  dryness and the residue  directly chromatographed 
(CH
2
Cl
2
:Et
2
O 25/1) to give the desired product as a white crystaline solid, (65 mg, 73 
%);  Mp (Et
2
O):  134-146 °C;  Rf (CH
2
Cl
2
/Et
2
O (10/1);  0.67; δ
H
 (400  MHz,  CDCl
3
); 
7.79-7.77 (m, 2H), 7.66-7.62 (m, 1H), 7.59-7.55 (m, 2H), 6.24 (d, J = 2.0, 1H), 6.23 
(d, J = 2.0, 1H), 3.80 (s, 3H), 3.78 (s, 3H), 3.72 (s, 3H), 3.11-3.06 (m, 8H); δ
C
 (100 
MHz,  CDCl
3
);  168.3,  162.1,  158.2,  151.8,  135.7,  132.9,  129.1,  127.7,  112.9,  98.2, 
94.2,  5.9,55.4,  52.2,  52.0,  46.5; m/z [TOF  MS  ES+] found 421.1429 [M  +  H
+
], 
C
20
H
25
N
2
O
6
S requires 421.1433; IR (neat) ν
max
; 2856, 1716, 1586, 1454, 1342, 1269, 
1128, 1101, 1036, 929, 742; 
 
 
Methyl 2-(4-(3-chlorophenyl)piperazin-1-yl)-4,6-dimethoxybenzoate (129) 
 
 
 
 
 
 
 
3-Chlorobromobenzene (66 µL, 0.57 mmol), Pd(OAc)
2
 (6.0 mg, 0.028 mmol), SPhos 
(18.0 mg, 0.045 mmol), and Cs
2
CO
3
 (364 mg, 1.12 mmol) were suspended in toluene 
(1 mL). After 5 min of stiring HCl salt 112 (80 mg, 0.28 mmol) was added and the 
mixture  heated for  16  h at  95 °C . The reaction  mixture  was cooled to ambient 
temperature,  diluted  with  CH
2
Cl
2
 (10  mL) and filtered through a  plug  of celite.  The 
filtrate  was rotary evaporated, and chromatographed (CH
2
Cl
2
:Et
2
O  25/1) to  give the 
desired product as a colourless crystaline solid, (71 mg, 65%); Mp (Et
2
O): 84-86 °C; 
OMe
CO
2
Me
MeO N
N
S
O
O
OMe
CO
2
Me
MeO N
N Cl
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Rf (CH
2
Cl
2
/Et
2
O (10/1); 0.67; δ
H
 (400 MHz, CDCl
3
); 7.20 (t, J = 8.1, 1H), 6.93 (t, J = 
2.1, 1H), 6.86-6.82 (m, 2H), 6.31 (d, J = 2.1, 1H), 6.26 (d, J = 2.1, 1H), 3.90 (s, 3H), 
3.85 (s,  3H),  3.84 (s,  3H),  3.29-3.27 (m,  4H),  3.18-3.15 (m,  4H); δ
C
 (100  MHz, 
CDCl
3
); 168.5,  162.1,  158.3,  152.4,  152.3,  134.9,  130.1,  119.4,  115.8,  113.9,  112.7, 
97.9, 93.6, 55.9, 55.4, 52.4, 52.3, 49.2; m/z [TOF MS ES+] found 391.1421 [M + H
+
], 
C
20
H
24
ClN
2
O
4
 requires 391.1425; IR (neat) ν
max
; 2824, 1713, 1581, 1430, 1270, 1224, 
1166, 1147, 1126 1097, 936,776; 
 
 
Methyl-6-(4-(5-chloro-1,3-dimethyl-1H-pyrazol-4-ylsulfonyl)piperazin-1-yl)-3-
cyclohexyl-2,4-dimethoxybenzoate (130) 
 
 
 
 
 
 
 
Hydrochloride salt 126 (50  mg,  0.15  mmol) and K
2
CO
3
 (48  mg,  0.35 mmol) were 
combined with acetone (1 mL) and stired at room temperature. Heteroaryl sulphonyl 
chloride (37 mg, 0.16 mmol) was added and the ensuing mixture stired overnight. The 
reaction was evaporated to  dryness and the residue  directly chromatographed 
(CH
2
Cl
2
:Et
2
O  20/1) to  give the desired  product as a colourless crystaline solid, (70 
mg,  99  %);  Mp (EtOAc): 40-42 °C;  Rf (CH
2
Cl
2
/Et
2
O (20/1);  0.38; δ
H
 (400  MHz, 
CDCl
3
); 6.40 (s, 1H), 3.86 (s, 3H), 3.83 (s, 3H), 3.80 (s, 3H), 3.72 (s, 3H), 3.22 (m, 
4H), 3.08 (m, 4H), 2.96 (t, J = 12.1, 8.9, 1H), 2.42 (s, 3H), 2.05-1.98 (m, 3H), 1.80-
1.70 (m,  2H),  1.56-1.53 (m,  2H),  1.39-1.27 (m,  3H); δ
C
 (100  MHz,  CDCl
3
); 168.6, 
160.9,  156.1,  149.3,  148.7,  129.9,  125.9,  118.5,  112.4,  100.2,  63.1,  55.4,  52.3,  52.1, 
46.2, 36.7, 36.2, 30.3, 27.3, 26.2, 14.2; m/z [TOF MS ES+] found 555.2035 [M + H
+
], 
C
25
H
36
ClN
4
O
6
S requires 555.2044; IR (neat) ν
max
; 2928,  1727,  1599,  1444,  1267, 
1184, 1130, 1120, 1029, 929, 734; 
 
 
 
OMe
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2
Me
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Methyl-6-(4-(3-chlorophenyl)piperazin-1-yl)-3-cyclohexyl-2,4-dimethoxybenzoate 
(131) 
 
 
 
 
 
 
3-Chloroiodobenzene (32 µL,  0.27 mmol),  Pd(OAc)
2
 (3.0  mg,  0.014 mmol), SPhos 
(9.0 mg, 0.022 mmol), and Cs
2
CO
3
 (179 mg, 0.55 mmol) were suspended in toluene 
(600 µL). After 5 min of stiring HCl salt 126 (55 mg, 0.14 mmol) was added and the 
mixture  heated for  16  h at  95 °C . The reaction  mixture  was cooled to ambient 
temperature,  diluted  with  CH
2
Cl
2
 (10  mL) and filtered through a  plug  of celite.  The 
filtrate  was rotary evaporated, and chromatographed (Petrol:Et
2
O  5/1) to  give the 
desired  product as a white  powder solid, (46 mg,  66%); Mp (Et
2
O): 80-82 °C;  Rf 
(Petrol/Et
2
O (5/1); 0.50; δ
H
 (400 MHz, d
6
 Acetone); 7.24 (t, J = 8.1, 1H), 6.98 (t, J = 
1.9, 1H), 6.95 (dd, J = 8.4, 2.2, 1H), 6.81 (dd, J = 7.8, 1.4, 1H), 6.66 (s, 1H), 3.89 (s, 
3H),  3.85 (s,  3H),  3.73 (s,  3H),  3.31-3.29 (m,  4H),  3.15-3.13 (m,  4H),  3.01 (t, J = 
12.2, 3.3, 1H), 2.17-2.12 (m, 2H), 1.82-1.71 (m, 3H), 1.57-1.54 (m, 2H), 1.42-1.36 (m, 
3H); δ
C
 (100  MHz,  d
6
 Acetone); 168.2,  160.7,  152.8,  149.7,  134.4,  130.2,  123.7, 
118.5,  115.1,  113.9,  100.3,  62.4,  55.0,  52.4,  51.4,  48.9,  36.1,  30.3,  27.2,  26.0; m/z 
[TOF MS ES+] found 473.2198 [M + H
+
], C
26
H
34
ClN
2
O
4
 requires 473.2207; IR (neat) 
ν
max
; 2921, 2852, 1725, 1592, 1568, 1445, 1266, 1234, 1159, 1117, 1089, 970; 
 
 
 
Methyl-3-cyclohexyl-2,4-dimethoxy-6-(4-(phenylsulfonyl)piperazin-1-yl)benzoate 
(132) 
 
 
 
 
 
 
Hydrochloride salt 126 (50  mg,  0.15  mmol) and K
2
CO
3
 (48  mg,  0.35 mmol) were 
combined  with acetone (1  mL) and stired at room temperature.  Benzene sulphonyl 
OMe
CO
2
Me
MeO N
N
S
O
O
OMe
CO
2
Me
MeO N
N Cl
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chloride (18 µL, 0.15 mmol) was added and the ensuing mixture stired overnight. The 
reaction  was evaporated to  dryness and the residue  directly chromatographed 
(CH
2
Cl
2
:Et
2
O  10/1) to  give the desired  product as a  white crystaline solid (43  mg, 
57%); Mp (EtOAc): 38-40 °C;  Rf (Petrol/Et
2
O (1/1);  0.31; δ
H
 (400  MHz,  CDCl
3
); 
7.78-7.77 (m, 2H), 7.64-7.61 (m, 1H), 7.58-7.55 (m, 2H), 6.37 (s, 1H), 3.79 (s, 3H), 
3.72 (s, 3H), 3.68 (s, 3H), 3.11-3.07 (m, 8H), 2.93 (t, J = 12.0, 2.3, 1H), 2.00 (qd, J = 
12.4,  2.8,  2H),  1.74-1.68 (m,  3H),  1.62-1.51 (m,  2H),  1.37-1.23 (m,  3H); δ
C
 (100 
MHz,  CDCl
3
); 168.6,  160.8,  156.0,  148.8,  135.8,  132.9,  129.0,  127.7,  121.4,  118.5, 
100.2, 63.1, 55.4, 52.2, 52.1, 46.5, 36.2, 30.2, 27.3, 26.1; m/z [TOF MS ES+] found 
503.2206 [M + H
+
], C
26
H
35
N
2
O
6
S requires 503.2216; IR (neat) ν
max
; 2928, 2842, 1717, 
1272, 1263, 1169, 1130, 1114, 1095, 973, 942, 737; 
 
 
 
5-(4-(3-Chlorophenyl)piperazin-1-yl)-2-cyclohexylbenzene-1,3-diol (133) 
 
 
 
 
 
Ester 131 (40 mg, 0.085 mmol) was dissolved in CH
2
Cl
2 
(1 mL) and cooled to -78 °C. 
BBr
3
 1.0  M in  CH
2
Cl
2 
(900 µL,  0.90 mmol)  was added dropwise, and the ensuing 
mixture  was alowed to  warm to room temperature  over  3  h.  The reaction  was 
quenched  with  MeOH (1  mL), rotary evaporated and  directly chromatographed 
(Petrol:EtOAc 5/1 to 1/1) to give the decarboxylated product as a colourless crystaline 
solid, (22  mg,  67%); Mp (Et
2
O): 121-123 °C; Rf (Petrol:EtOAc (3/1);  0.42; δ
H
 (400 
MHz, d
6 
Acetone); 7.81 (s, 2H, OH), 7.23 (t, J = 8.1, 1H), 6.98 (t, J = 2.1, 1H), 6.95 
(dd, J = 8.4,  1.8,  1H),  6.81 (dd, J = 7.7,  1.7,  1H),  6.07 (s,  2H),  3.34-3.31 (m,  4H), 
3.19-3.14 (m, 4H), 3.12 (dt, J = 12.2, 3.5, 1H), 2.20 (qd, J = 12.4, 2.9, 2H), 1.79-1.76 
(m, 2H), 1.70-1.67 (m, 1H), 1.56-1.53 (m, 2H), 1.39-1.27 (m, 3H); δ
C
 (100 MHz, d
6 
Acetone); 156.7,  152.7,  150.1,  134.4,  130.2,  118.6,  115.2,  114.0,  95.6,  49.0,  48.4, 
34.7, 30.3, 27.4, 26.2; m/z [TOF MS ES+] found 387.1834 [M + H
+
], C
22
H
28
ClN
2
O
2
 
requires 387.1839; IR (neat) ν
max
; 3324,  2800,  1585,  1466,  1322  1205,  1191,  1087, 
935, 839 798 
OH
HO N
N Cl
	   341	  
1-tert-Butyl 3-methyl 4-(phenylsulfonyl)piperazine-1,3-dicarboxylate (136) 
 
 
 
 
 
 
 
Carboxylic acid 135 (1.25 g, 3.37 mmol) and iodomethane (627 µL, 10.10 mmol) were 
combined  with acetone (15 mL). Cs
2
CO
3
 (2.19  g,  6.74 mmol) was added and the 
mixture  heated at 60 °C for  16  h. The reaction  was evaporated to  dryness and the 
residue directly chromatographed (CH
2
Cl
2
:Et
2
O 10/1) to give the desired product as a 
colourless crystaline solid, (891 mg, 69 %); Mp (Et
2
O): 79-81 °C; Rf (CH
2
Cl
2
/Et
2
O 
(10/1); 0.65; δ
H
 (400 MHz, CDCl
3
); 7.79-7.76 (m, 2H), 7.61-7.58 (m, 1H), 7.54-7.50 
(m, 2H), 4.61 (d, J = 3.5, 1H), 4.51 (brs, 1H), 3.71-3.68 (m, 1H), 3.49 (s, 3H), 3.42 
(brs, 1H), 3.14 (brs, 1H), 2.89 (brs, 1H), 1.40 (s, 9H); δ
C
 (100 MHz, CDCl
3
); 162.0, 
137.5,  132.8,  128.9,  127.2,  78.1,  54.5,  52.2,  41.7,  28.2; m/z [TOF  MS  ES+] found 
385.1432 [M + H
+
], C
17
H
25
N
2
O
6
S requires 385.1433; IR (neat) ν
max
; 2979, 1734, 1691, 
1287, 1220, 1164, 1124, 1102, 941, 916, 748; 
 
 
Methyl 1-(phenylsulfonyl)piperazine-2-carboxylate hydrochloride (137) 
 
 
 
 
 
 
Ester 136 (750 mg, 1.95 mmol) was dissolved in CH
2
Cl
2
 (5 mL) and cooled to 0 °C. 4 
M HCl in dioxane (8 mL) was added dropwise and the mixture was alowed to warm 
to room temperature. After 1 h the reaction was evaporated and the resulting residue 
triturated  with  CH
2
Cl
2 
and  Et
2
O.  Repeated trituration and filtration  gave the  desired 
product as a light orange crystaline solid, (578 mg, 93%); Mp (Et
2
O): 126-128 °C; δ
H
 
(400 MHz, CDCl
3
); 7.82-7.60 (brm, 5H), 4.87 (brm, 1H), 3.78 (s, 3H), 3.65-3.40 (brm, 
6H); δ
C
 (100 MHz, CDCl
3
); 168.1, 138.8, 133.5, 129.6, 127.7, 77.3, 72.3, 71.2, 61.7, 
43.0; m/z [TOF MS ES+] found 285.0908 [M + H
+
], C
12
H
17
N
2
O
4
S requires 285.0909; 
N
Boc
N
S
O
O
CO
2
Me
N
H.HCl
N
S
O
O
CO
2
Me
	   342	  
IR (neat) ν
max
; 3400-2600 (br), 1737, 1447, 1345, 1311, 1292, 1159, 1093, 1068, 949, 
737; 
 
 
Methyl-3-(3-chlorophenyl)-1-(phenylsulfonyl)-1,4,5,6-tetrahydropyrazine-2-
carboxylate (139) 
 
 
 
 
 
 
 
3-Chlorobromobenzene (275 µL, 2.34 mmol), Pd(OAc)
2
 (35 mg, 0.16 mmol), SPhos 
(102 mg, 0.25 mmol), and Cs
2
CO
3
 (1.52 g, 4.68 mmol) were suspended in toluene (4 
mL).  After  5  min  of stiring HCl salt 137 (500 mg,  1.56 mmol)  was added and the 
mixture  heated for  16  h at  95 °C . The reaction  mixture  was cooled to ambient 
temperature,  diluted  with CH
2
Cl
2
 (10  mL) and filtered through a  plug  of celite.  The 
filtrate  was rotary evaporated, and chromatographed (CH
2
Cl
2
:Et
2
O  50/1) to  give the 
desired product as a white crystaline solid, (256 mg, 42%); Mp (Et
2
O): 103-107 °C; 
Rf (CH
2
Cl
2
/Et
2
O (50/1);  0.57; δ
H
 (400  MHz,  CDCl
3
);  7.86 (s,  1H,  NH),  7.31 (t, J = 
8.1,  1H),  7.24-7.20 (m,  1H),  7.10 (t, J = 2.1,  1H),  7.06 (dd, J = 7.6,  1.9,  1H),  6.99 
(ddd, J = 8.3,  2.4,  0.7,  1H),  6.97 (d, J = 1.5,  1H),  6.98-6.94 (m,  1H),  6.87-6.85 (m, 
1H), 3.75 (s, 3H), 3.73-3.71 (m, 2H), 3.53-3.51 (m, 2H); δ
C
 (100 MHz, CDCl
3
); 165.4, 
150.3,  145.4,  135.4,  134.7,  130.5,  130.0,  129.6,  122.8,  121.8,  120.7,  118.7,  117.2, 
114.9,  111.1,  51.6,  48.9,  43.7; IR (neat) ν
max
;  2949,  1688,  1618,  1589,  1568,  1437, 
1251, 1232, 1144, 1005, 760; 
 
 
 
 
 
 
 
 
N
H
N
S
O
O
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2
Me
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tert-Butyl-3-(1H-imidazole-1-carbonyl)-4-(phenylsulfonyl)piperazine-1-carboxylate 
(141) 
 
 
 
 
 
 
Carboxylic acid 136 (1.17 g, 3.16 mmol) was dissolved in THF (4 mL) and cooled to 0 
°C. CDI (615 mg, 3.79 mmol), was added portionwise over 5 minutes, and the mixture 
was alowed to warm to room temperature. After 2 hours, the mixture was diluted with 
Et
2
O (25 mL), and H
2
O (10 mL). The organic layer was washed with H
2
O (2 x 10 mL) 
and brine (10 mL), dried (MgSO
4
), and rotary evaporated to give the desired product 
as a  white crystaline solid, which  was  used in the  next step  without further 
purification; (919 mg, 69%); δ
H
 (400 MHz, CDCl
3
); 7.93 (s, 1H), 7.70-7.68 (m, 2H), 
7.62-7.58 (m,  1H),  7.49-7.45 (m,  2H),  7.41-7.37 (m,  1H),  7.12 (m,  1H),  5,16 (t, J = 
2.9, 1H), 4.44-4.28 (m, 1H), 4.12-3.94 (m, 1H), 3,65-3.46 (m, 2H), 3.08-7.20 (m, 2H), 
1.35-1.16 (brs, 9H); δ
C
 (100 MHz, CDCl
3
); 165.8, 138.0, 135.9, 134.7, 133.4, 131.7, 
129.3, 127.1, 120.8, 115.8, 81.1, 57.1, 46.6, 42.5, 41.9, 28.2; 
 
 
 
tert-Butyl-3-(7-hydroxy-2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl)-4-
(phenylsulfonyl)piperazine-1-carboxylate (143) 
 
 
 
 
 
 
 
 
 
n-BuLi in hexanes (2.5 M; 3.64 mL, 9.15 mmol) was added dropwise with stiring to 
disopropylethylamine (1.31 mL, 9.34 mmol) in THF (10 mL) at -78 °C. After 20 min, 
keto-dioxinone (800 mg, 4.34 mmol) in THF (3 mL) was added dropwise with stiring 
at -78 °C.  After  40  min,  Et
2
Zn in  hexanes (1.0  M; 9.15  mL,  9.15 mmol)  was added 
N
Boc
N
N
O
N
S
O
O
OO
HO
N
NBoc
O
S
O
O
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slowly, and after a further 20 min, imidazole 141 (911 mg, 2.17 mmol) in THF (3 mL) 
was added and the mixture stired for 3 h, maintaining the temperature at -78 °C. The 
reaction was quenched with saturated aqueous NH
4
Cl (30 mL) and 1 M aqueous HCl 
(15 mL), and the aqueous layer  was acidified to  pH  2  using  1  M aqueous  HCl.  The 
product  was extracted twice  with  EtOAc (50  mL,  25  mL), the combined  organic 
extracts  were  dried (MgSO
4
) and rotary evaporated to  give the crude acylation 
product, which  was  dissolved in  CH
2
Cl
2
 (30 mL),  Et
3
N (6 mL)  was added, and the 
mixture was stired at 40 °C. After 24 h, saturated aqueous NH
4
Cl (40 mL) and EtOAc 
(80 mL) were added, and the aqueous layer was acidified to pH 2 using 1 M aqueous 
HCl.  The layers  were separated, and the aqueous layer  was further extracted  with 
EtOAc (40  mL).  The combined  organic extracts  were  dried (MgSO
4
), rotary 
evaporated, and chromatographed (Petrol:EtOAc  3/1 to  1/1) to  give the desired 
product as a white crystaline solid, (421  mg,  19%),  Mp (Et
2
O):  100-102 °C;  Rf 
(Petrol/EtOAc (1/1); 0.41; δ
H
 (500 MHz, 358K d
6 
DMSO); 10.56 (s, 1H, OH), 7.76-
7.74 (m, 2H), 7.69-7.66 (m, 1H), 7.61-7.58 (m, 2H), 6.71 (d, J = 2.2, 1H), 6.28 (d, J = 
2.3, 1H), 5.93 (t, J = 4.3, 1H), 3.74-3.64 (m, 3H), 3.61-3.56 (m, 1H), 3.45 (brm, 1H), 
3.13-3.07 (m,  1H),  1.67 (s,  3H),  1.66 (s,  3H),  1.20 (s,  9H); δ
C
 (100  MHz, 358K d
6 
DMSO); 163.6, 159.3, 158.3, 153.4, 146.9, 138.2, 132.7, 129.0, 126.5, 110.7, 104.5, 
101.5, 101.4, 78.7, 54.3, 45.1, 42.2, 41.0, 39.7, 27.4, 24.7; m/z [TOF MS ES+] found 
267.1595 [M  +  H
+
], C
15
H
23
O
4
 requires  267.1596; IR (neat) ν
max
; 3180,  1615,  1604, 
1417, 1353, 1307, 1240, 1149, 1131, 911, 735; 
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7-Hydroxy-2,2-dimethyl-5-(1-(phenylsulfonyl)piperazin-2-yl)-4H-
benzo[d][1,3]dioxin-4-one hydrochloride (144) 
 
 
 
 
 
 
 
 
 
Ester 143 (200 mg, 0.39 mmol) was dissolved in CH
2
Cl
2
 (3 mL) and cooled to 0 °C. 4 
M HCl in dioxane (2 mL) was added dropwise and the mixture was alowed to warm 
to room temperature. After 1 h the reaction was evaporated and the resulting residue 
triturated  with  CH
2
Cl
2 
and  Et
2
O.  Repeated trituration and filtration  gave the  desired 
product as a light  yelow powder solid, (191  mg,  93%); Mp (Et
2
O):  257-259 °C; δ
H
 
(400 MHz, MeOD
4
); 11.08 (s, 1H, OH), 9.29-9.18 (brs, 2H, NH
2
), 7.77-7.73 (m, 3H), 
7.66-7.59 (m, 2H), 6.64 (d, J = 1.7, 1H), 6.36 (d, J = 1.9, 1H), 6.16 (t, J = 5.4, 1H), 
3.97 (m,  2H),  3.45-3.40 (m,  3H),  3.21-3.14 (m,  1H),  1.74 (s,  6H); δ
C
 (100  MHz, 
MeOD
4
); 164.6, 160.8, 159.4, 143.2, 138.5, 133.4, 129.3, 127.1, 111.9, 105.5, 102.8, 
102.1,  51.5,  42.1,  40.3,  24.4,  24.1;  m/z [TOF  MS  ES+] found 419.1273 [M  + H
+
], 
C
20
H
23
N
2
O
6
S requires  419.1277; IR (neat) ν
max
; 3350-2600 (br),  1708,  1615,  1594, 
1297, 1272, 1129, 1093, 1046, 905, 733; 
 
 
5-(4-(3-Chlorophenyl)-1-(phenylsulfonyl)piperazin-2-yl)-7-hydroxy-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one (146) 
 
 
 
 
 
 
 
 
3-Chlorobromobenzene (31 µL, 0.26 mmol), Pd(OAc)
2
 (2.0 mg, 0.009 mmol), SPhos 
(7.0 mg, 0.018 mmol), and Cs
2
CO
3
 (228 mg, 0.70 mmol) were suspended in toluene 
OO
HO
N
NH.HCl
O
S
O
O
OO
HO
N
N
O
S
O
O
Cl
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(900 µL). After 5 min of stiring HCl salt 144 (80 mg, 0.18 mmol) was added and the 
mixture  heated for  16  h at  95 °C. The reaction  mixture  was cooled to ambient 
temperature,  diluted  with  CH
2
Cl
2
 (10  mL) and filtered through a  plug  of celite.  The 
filtrate  was rotary evaporated, and chromatographed (Et
2
O:Petrol  2/1) to  give the 
desired product as a yelow crystaline solid, (46 mg, 50%); Rf (Et
2
O:Petrol 2/1); 0.59; 
Mp (Et
2
O): 201-202 °C; δ
H
 (400 MHz, CDCl
3
); 7.88-7.86 (m, 2H), 7.46-7.43 (m, 1H), 
7.40-7.37 (m, 2H), 7.02-6.98 (m, 2H), 6.61 (dd, J = 7.7, 1.5, 1H), 6.38 (t, J = 2.0, 1H), 
6.24-6.19 (m, 1H), 6.18 (d, J = 1.8, 1H), 4.15-4.00 (m, 2H), 3.86 (dd, J = 14.4, 5.4, 
1H), 3.42-3.37 (m, 1H), 3.27 (dd, J = 14.4, 7.7, 1H), 3.06 (dq, J = 10.4, 6.4, 1H); δ
C
 
(100  MHz,  CDCl
3
); 164.8,  160.9,  159.9,  151.5,  148.9,  140.3,  135.3,  133.6,  130.9, 
129.9,  127.9,  117.8,  113.4,  112.1,  111.9,  105.9,  103.5,  103.1,  56.7,  49.2,  47.1,  42.6, 
25.7,  25.5; m/z [TOF  MS  ES+] found 529.1191 [M  + H
+
], C
26
H
26
ClN
2
O
6
S requires 
529.1200; IR (neat) ν
max
; 3417, 2921, 1693, 1613, 1583, 1286, 1269, 1243, 1160, 983, 
741; 
 
 
 
5-(4-(2-Chlorobenzyl)-1-(phenylsulfonyl)piperazin-2-yl)-7-(2-chlorobenzyloxy)-2,2-
dimethyl-4H-benzo[d][1,3]dioxin-4-one (147) 
 
 
 
 
 
 
 
 
 
Hydrochloride salt 144 (40  mg,  0.088  mmol) and K
2
CO
3
 (36  mg,  0.26 mmol) were 
combined  with acetone (500 µL) and stired at room temperature.  3-chlorobenzyl 
bromide (35 µL, 0.26 mmol) was added and heated to 60 °C for 16 h. The reaction was 
evaporated to dryness and the residue directly chromatographed (CH
2
Cl
2
:Et
2
O 10/1) to 
give the desired product as a colourless oil, (41 mg, 70%); Rf (Neat CH
2
Cl
2
); 0.33; δ
H
 
(400  MHz,  CDCl
3
);  7.84-7.81 (m,  2H),  7.60-7.44 (m,  4H),  7.37-7.26 (m,  4H),  7.15-
7.05 (m, 3H), 6.45 (d, J = 2.4, 1H), 6.26 (dd, J = 4.6, 2.3, 1H), 5.17 (s, 2H), 3.82 (dt, J 
= 13.1, 3.3, 1H), 3.67 (ddd, J = 13.5, 11.0, 3.6, 1H), 3.47 (s, 3H), 2.87-2.84 (m, 1H), 
OO
O
O
N
N
S
O
O
ClCl
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2.78-2.75 (m,  1H),  2.25-2.13 (m,  2H),  1.75 (s,  3H),  1.59 (s,  3H); δ
C
 (100  MHz, 
CDCl
3
);  163.4,  160.3,  158.9,  148.1,  140.1,  135.3,  134.2,  133.5,  132.7,  132.6,  130.2, 
129.5,  129.4,  129.3,  129.1,  128.9,  128.8,  128.7,  128.2,  127.2,  126.5,  112.1,  105.2, 
104.3, 100.8, 67.4, 62.8, 59.1, 58.1, 52.9, 52.2, 43.9, 25.6, 25.4; m/z [TOF MS ES+] 
found 667.1430 [M  + H
+
], C
34
H
33
Cl
2
N
2
O
6
S requires 667.1436; IR (neat) ν
max
; 2813, 
1716, 1610, 1577, 1442, 1272, 1159, 1103, 1035, 913, 751; 
 
 
Methyl-2-(4-(2-chlorobenzyl)-1-(phenylsulfonyl)piperazin-2-yl)-4-(2-
chlorobenzyloxy)-6-hydroxybenzoate (148) 
 
 
 
 
 
 
 
 
Isopropylidene ester 147 (40 mg, 0.06 mmol) and Cs
2
CO
3
 (78 mg, 0.24 mmol) were 
dissolved in MeOH (1 mL) and heated to 60 °C for 16 h. The reaction was evaporated 
to dryness and the residue dissolved in 1 M aqueous HCl (5 mL) and EtOAc (15 mL). 
The organic layer was separated and the aqueous extracted with EtOAc (3 x 10 mL), 
the combined  organic extracts  were  washed  with  brine,  dried (MgSO
4
) rotary 
evaporated, and chromatographed (CH
2
Cl
2
:Et
2
O 10/1) to give the desired product as a 
white crystaline solid, (31 mg, 81%); Mp (Et
2
O): 118-121 °C; Rf (CH
2
Cl
2
/Et
2
O 10/1); 
0.56; δ
H
 (400 MHz, d
6 
Acetone); 8.34 (s, 1H, OH), 7.62-7.59 (m, 2H), 7.50-7.42 (m, 
11H), 6.80 (brs, 1H), 6.51 (brs, 1H), 5.93 (brs, 1H), 5.19-5.16 (m, 2H), 4.57 (brs, 2H), 
4.22-4.20 (m, 1H), 3.98-3.96 (brs, 1H), 3.96 (s, 3H), 3.56 (m, 4H); δ
C
 (100 MHz, d
6 
Acetone); 164.8, 163.1, 135.8, 135.2, 134.5, 133.8, 133.7, 132.1, 130.6, 130.5, 130.1, 
129.6, 128.4, 128.2, 127.9, 112.4, 102.3, 67.8, 56.3, 55.7, 53.5, 50.7, 45.0; m/z [TOF 
MS  ES+] found 641.1271 [M  + H
+
], C
32
H
31
Cl
2
N
2
O
6
S requires 641.1280; IR (neat) 
ν
max
; 3504, 2413, 1646, 1334, 1258, 1229, 1169, 1155, 1038, 755, 743, 733;  
 
 
 
 
CO
2
Me
OH
O
N
N
S
O
O
Cl Cl
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N-methyl-N-phenyl-1H-imidazole-1-carboxamide (150)
 
 
 
 
 
 
N-methylaniline (990 µL, 9.34 mmol) and CDI (1.65 g, 10.2 mmol) were dissolved in 
THF (15  mL) and  heated at reflux for  16  h.  The reaction  was cooled to ambient 
temperature and diluted with Et
2
O (20 mL), and H
2
O (10 mL). The organic layer was 
washed  with  H
2
O (2  x  10  mL) and  brine (10  mL),  dried (MgSO
4
), and rotary 
evaporated and chromatographed (EtOAc:CH
2
Cl
2
 1/1) to give the desired product as a 
white crystaline solid, (1.10  g,  59  %); Mp (EtOAc):  60-62 °C;  Rf (CH
2
Cl
2
/EtOAc 
(1/1); 0.38; δ
H
 (400 MHz, CDCl
3
); 7.58 (s, 1H), 7.41-7.37 (m, 2H), 7.34-7.30 (m, 1H), 
7.14-7.12 (m,  2H),  6.86 (s,  1H),  6.82 (s,  1H),  3.50 (s,  3H); δ
C
 (100  MHz,  CDCl
3
); 
150.3, 142.9, 137.7, 130.3, 128.9, 128.1, 125.9, 118.4, 40.1; (data matched literature) 
 
 
 
 
4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-N-methyl-3-oxo-N-phenylbutanamide 
(151) 
 
 
 
 
 
n-BuLi in hexanes (2.5 M; 4.56 mL, 11.40 mmol) was added dropwise with stiring to 
disopropylethylamine (1.65 mL,  11.68  mmol) in  THF (12  mL) at -78 °C. After  20 
min,  keto-dioxinone (1.00  g,  5.43 mmol) in  THF (3 mL)  was added  dropwise  with 
stiring at -78 °C. After 40 min, Et
2
Zn in hexanes (1.0 M; 11.40 mL, 11.40 mmol) was 
added slowly, and after a further 20 min, imidazole 150 (546 mg, 2.73 mmol) in THF 
(4 mL) was added and the mixture stired for 3 h, maintaining the temperature at -78 
°C. The reaction  was  quenched  with saturated aqueous  NH
4
Cl (15  mL) and  1  M 
aqueous HCl (10 mL), and the aqueous layer was acidified to pH 2 using 1 M aqueous 
HCl.  The  product  was extracted twice  with  EtOAc (50  mL, 25  mL), the combined 
organic extracts  were  dried (MgSO
4
), rotary evaporated and chromatographed 
N
O O OO
O
N N
O
N
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(CH
2
Cl
2
:Et
2
O  100/0 to  5/1) to  give the desired  product as an  orange  oil, (637  mg, 
76%); Rf (CH
2
Cl
2
/Et
2
O (3/1); 0.50; δ
H
 (400 MHz, CDCl
3
); 7.54-7.50 (m, 2H), 7.45-
7.42 (m, 1H), 7.38-7.35 (m, 2H), 5.34 (s, 1H), 3.53-3.41 (brs, 2H), 3.30-3.26 (brs, 3H), 
3.14-3.00 (brs, 2H), 1.65-1.57 (brs, 6H); δ
C
 (100 MHz, CDCl
3
); 203.2, 171.5, 170.8, 
164.8, 149.0, 135.1, 133.3, 132.7, 111.7, 100.5, 53.9, 51.7, 41.5, 29.4, 29.2; m/z [TOF 
MS  ES+] found 318.1333 [M  +  H
+
],requires 318.1341; IR (neat) ν
max
; 1720,  1630, 
1593, 1495, 1374, 1271, 1252, 1120, 1013, 773; 
 
 
 
N-methoxy-N-methylfuran-2-carboxamide (159) 
 
 
 
N,O-dimethylhydroxylamine  hydrochloride (896 mg,  9.19  mmol) and  pyridine (1.54 
mL,  19.5  mmol) were  dissolved in  CH
2
Cl
2
 (25  mL) and cooled to  0 °C. 2-Furoryl 
chloride (679 µL, 7.66 mmol) was added dropwise and the ensuing mixture was stired 
for 1.5 h. The reaction was quenched with MeOH (5 mL), evaporated to dryness and 
the residue suspended in  CH
2
Cl
2 
(30  mL).  The  organic phase  was  washed  with 
saturated aqueous NaHCO
3 
(15 mL), brine, dried (MgSO
4
), and rotary evaporated, to 
give the desired  product as a  pure light  yelow  oil, (1.03  g,  87%); δ
H
 (400  MHz, 
CDCl
3
); 7.59 (d, J =1.7, 1H), 7.14 (d, J = 3.6, 1H), 6.50 (dd, J = 3.5, 1.7, 1H), 3.76 (s, 
3H), 3.34 (s, 3H); δ
C
 (100 MHz, CDCl
3
); 159.1, 145.7, 145.2, 117.4, 111.6, 61.3, 33.1; 
m/z [TOF MS ES+] found 156.0652 [M + H
+
], C
7
H
10
NO
3
 requires 156.0661; IR (neat) 
ν
max
; 1635, 1561, 1474, 1415, 1389, 1370, 1023, 976, 931, 886. 757; 
 
 
 
 
 
 
 
 
 
 
 
O
N
O
OMe
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5-(Furan-2-yl)-7-hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (161) 
 
 
 
 
 
n-BuLi in hexanes (2.5 M; 5.48 mL, 13.69 mmol) was added dropwise with stiring to 
disopropylethylamine (1.98  mL,  14.01  mmol) in  THF (15  mL) at -78 °C. After  20 
min,  keto-dioxinone (1.20  g,  6.52 mmol) in  THF (3 mL)  was added  dropwise  with 
stiring at -78 °C. After 40 min, Et
2
Zn in hexanes (1.0 M; 13.69 mL, 13.69 mmol) was 
added slowly, and after a further 20 min the solution was warmed to -30 °C, Weinreb 
amide 159 (505 mg, 3.26 mmol) in THF (2 mL) was added and the mixture stired for 
3  h. The reaction  was  quenched  with saturated aqueous  NH
4
Cl (30  mL) and  1  M 
aqueous HCl (15 mL), and the aqueous layer was acidified to pH 2 using 1 M aqueous 
HCl.  The  product  was extracted  with  EtOAc (2  x  40  mL), the combined  organic 
extracts  were  dried (MgSO
4
) and rotary evaporated to  give the crude acylation 
product, which  was  dissolved in  CH
2
Cl
2
 (30  mL). Et
3
N (5 mL)  was added, and the 
mixture was stired at 40 °C. After 24 h, saturated aqueous NH
4
Cl (20 mL) and EtOAc 
(60 mL) were added, and the aqueous layer was acidified to pH 2 using 1 M aqueous 
HCl.  The layers  were separated, and the aqueous layer  was further extracted  with 
EtOAc (40  mL).  The combined  organic extracts  were  dried (MgSO
4
), rotary 
evaporated, and chromatographed (Petrol:EtOAc 4/1) to give the desired product as a 
yelow crystaline solid, (640  mg,  75 %); Rf (Petrol/EtOAc) (1/1);  0.59;  Mp (Et
2
O): 
146-148 °C; δ
H
 (400 MHz, CDCl
3
); 7.67 (d, J = 1.4, 1H), 6.89 (d, J = 2.4, 1H), 6.87 
(d, J = 3.4 1H), 6.54 (dd, J = 3.4, 1.8 1H), 6.47 (d, J = 2.4, 1H); δ
C
 (100 MHz, CDCl
3
); 
168.5, 164.5, 163.2, 156.6, 148.1, 140.5, 117.1, 116.5, 115.8, 109.9, 107.7, 29.9; m/z 
[TOF MS ES+] found 261.0766 [M + H
+
], C
14
H
13
O
5
 requires 261.0763; IR (neat) ν
max
; 
3353 (br), 1697, 1604, 1577, 1313, 1273, 1206, 1175, 1160, 1056, 831; 
 
 
 
 
 
 
OO
HO
O
O
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5-(Furan-2-yl)-7-methoxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (162) 
 
 
 
 
 
Phenol 161 (600  mg,  2.30  mmol) and iodomethane (285 µL, 4.61 mmol) were 
combined  with acetone (12 mL).  K
2
CO
3
 (956  mg,  6.92 mmol) was added and the 
mixture  heated at 60 °C for  16  h. The reaction  was evaporated to  dryness and the 
residue directly chromatographed (Petrol:EtOAc 1/1) to give the desired product as a 
yelow oil, (607 mg, 96%); Rf (Petrol/EtOAc) (1/1); 0.78; δ
H
 (400 MHz, CDCl
3
); 7.54 
(d, J = 1.3, 1H), 6.92 (d, J = 2.6, 1H), 6.89 (d, J =3.3, 1H), 6.53 (dd, J = 3.4, 1.8, 1H), 
6.44 (d, J = 2.5, 1H), 3.89 (s, 3H), 1.79 (s, 6H); δ
C
 (100 MHz, CDCl
3
); 164.8, 159.2, 
159.1,  151.1,  142.9,  135.2,  111.6,  111.1,  111.0,  105.1,  103.9,  100.8,  55.8,  25.5; m/z 
[TOF  MS ES+] found 275.0904 [M  +  H
+
], C
15
H
15
O
5
 requires  275.0919; IR (neat) 
νmax; 1726, 1603, 1578, 1273, 1234, 1201, 1125, 1050, 1032, 825; 
 
 
Ethyl 2-(methoxy(methyl)amino)-2-oxoacetate (164) 
 
 
 
	  
	  
N,O-dimethylhydroxylamine  hydrochloride (1.72  g,  17.6  mmol) and  pyridine (2.82 
mL, 35.2 mmol) were dissolved in CH
2
Cl
2
 (25 mL) and cooled to 0 °C. Ethyl chloro-
oxoacetate (1.63  mL,  14.7  mmol)  was added  dropwise and the ensuing  mixture  was 
stired for  1.5  h.  The reaction  was  quenched  with  MeOH (5  mL), evaporated to 
dryness and the residue triturated with EtOAc/THF. The solids were discarded and the 
volatiles rotary evaporated to obtain the desired product as a pure colourless oil, (2.01 
g, 85%); δ
H
 (400 MHz, CDCl
3
); 4.36 (q, J = 7.3, 2H), 3.78 (s, 3H), 3.25 (s, 3H), 1.38 
(t, J = 7.3, 3H); δ
C
 (100 MHz, CDCl
3
); 162.4, 162.1, 62.3, 62.1, 31.4, 13.9; m/z [TOF 
MS  ES+] found  162.0758 [M  +  H
+
], C
6
H
12
NO
4 
requires  162.0766; IR (neat) ν
max
; 
2833, 1596, 1449, 1435, 1224, 1204, 1122, 1025, 845, 766; 
 
OO
MeO
O
O
EtO
O
N
O
OMe
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Ethyl 7-hydroxy-2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxine-5-carboxylate (166) 
 
 
 
 
 
 
n-BuLi in hexanes (2.5 M; 4.89 mL, 12.35 mmol) was added dropwise with stiring to 
disopropylethylamine (1.74  mL,  12.24  mmol) in  THF (12  mL) at -78 °C. After  20 
min,  keto-dioxinone (1.00  g,  5.43 mmol) in  THF (3 mL)  was added  dropwise  with 
stiring at -78 °C. After 40 min, Et
2
Zn in hexanes (1.0 M; 12.24 mL, 12.24 mmol) was 
added slowly, and after a further 20 min the solution was warmed to -30 °C, Weinreb 
amide 164 (437 mg, 2.72 mmol) in THF (3 mL) was added and the mixture stired for 
3  h. The reaction  was  quenched  with saturated aqueous  NH
4
Cl (30  mL) and  1  M 
aqueous HCl (15 mL), and the aqueous layer was acidified to pH 2 using 1 M aqueous 
HCl.  The  product  was extracted  with  EtOAc (2  x  40  mL), the combined  organic 
extracts  were  dried (MgSO
4
) and rotary evaporated to  give the crude acylation 
product, which  was  dissolved in  CH
2
Cl
2
 (15  mL). Et
3
N (3 mL)  was added, and the 
mixture was stired at 40 °C. After 24 h, saturated aqueous NH
4
Cl (20 mL) and EtOAc 
(60 mL) were added, and the aqueous layer was acidified to pH 2 using 1 M aqueous 
HCl.  The layers were separated, and the aqueous layer  was further extracted  with 
EtOAc (40  mL).  The combined  organic extracts  were  dried (MgSO
4
), rotary 
evaporated, and chromatographed (Petrol:EtOAc  5/1 to  3/1) to  give the desired 
product as a yelow crystaline solid, (881  mg,  61%);  Mp (Et
2
O):  109-111 °C; Rf 
(EtOAc/Hexanes) (1/1);  0.47; δ
H
 (400  MHz,  CDCl
3
);  9.97 (s,  1H,  OH),  6.68 (d, J = 
2.3,  1H),  6.54 (d, J = 2.4,  1H),  4.32 (q, J = 7.1,  2H),  1.73 (s,  6H),  1.32 (t, J = 7.1, 
3H); δ
C
 (100  MHz,  CDCl
3
);  168.9,  163.7,  160.1, 158.3,  137.2,  111.2,  106.5,  104.7, 
102.8,  62.7,  25.5,  13.8; m/z [TOF  MS  ES+] found 267.0859 [M  +  H
+
], C
13
H
15
O
6 
requires  267.0869; IR (neat) ν
max
; 3300-2900 (br),  3171,  1728,  1694,  1585,  1375, 
1299, 1237, 1197, 1057, 1032; 
 
 
 
 
 
OO
HO CO
2
Et
O
	   353	  
Ethyl 7-methoxy-2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxine-5-carboxylate (167) 
 
 
 
 
 
Phenol 166 (1.48  g,  5.58  mmol) and iodomethane (1.03 mL,  16.7 mmol) were 
combined  with acetone (25 mL).  K
2
CO
3
 (1.54  g,  11.2 mmol) was added and the 
mixture  heated at 60 °C for  16  h. The reaction  was evaporated to  dryness and the 
residue directly chromatographed (Petrol:EtOAc 6/1 to 4/1) to give the desired product 
as a light yelow oil, (1.01 g, 65%); Rf (Petrol/EtOAc) (1/1); 0.69; δ
H
 (400 MHz, d
6
 
Acetone); 6.78 (d, J = 2.4, 1H), 6.69 (d, J = 2.4, 1H), 4.34 (q, J = 7.1, 2H), 3.96 (s, 
3H),  1.75 (s,  6H),  1.33 (t, J  = 7.2,  3H); δ
C
 (100  MHz,  d
6
 Acetone); 167.0,  165.7, 
158.2,  157.9,  138.3,  109.8,  106.1,  102.1,  61.3,  55.9,  24.7,  13.3; m/z [TOF  MS  ES+] 
found 281.1022 [M  +  H
+
], C
14
H
17
O
6 
requires 281.1025; IR (neat) ν
max
; 1727,  1608, 
1583, 1371, 1284, 1242, 1186, 1162, 1050, 1036; 
 
 
 
6-(1-(Cyclohex-2-enyl)-2-oxopropyl)-2,2-dimethyl-1,3-dioxan-4-one (172) 
 
 
 
 
 
n-BuLi in hexanes (2.5 M; 1.79 mL, 4.48 mmol) was added dropwise with stiring to 
disopropylethylamine (659 µL, 4.69 mmol) in THF (8 mL) at -78 °C. After 20 min, 
keto-dioxinone (750 mg, 4.08 mmol) in THF (8 mL) was added dropwise with stiring 
at -78 °C. The mixture was then alowed to warm to 5 °C over 1.5 h. The solution was 
then re-cooled to -60 °C and Et
2
Zn in  hexanes (1.0  M; 4.48  mL,  4.48 mmol)  was 
added slowly, and after a further 20 min, 3-bromocyclohexene (703 µL, 6.12 mmol) in 
THF (1.5 mL) was added and the mixture stired for 3 h, maintaining the temperature 
at -20 °C. The reaction was quenched with saturated aqueous NH
4
Cl (30 mL) and 1 M 
aqueous HCl (15 mL), and the aqueous layer was acidified to pH 2 using 1 M aqueous 
HCl.  The  product  was extracted twice  with  EtOAc (50  mL,  25  mL), the combined 
organic extracts  were  dried (MgSO
4
), rotary evaporated and chromatographed 
OO
MeO CO
2
Et
O
O OO
O
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(Petrol:Et
2
O 1/1 to 1/2) to give the desired product as a bright yelow oil, (407 mg, 37 
%); Rf (Et
2
O/Petrol (2/1); 0.50; δ
H
 (400 MHz, CDCl
3
); (Mixture of diastereoisomers 
1/1); 5.82-5.76 (m, 1H), 5.52-5.49 (m, 1H), 5.43 (s, 1H), 3.19 (dd, J =15.3 10.1, 1H), 
2.89-2.86 (m, 1H), 2.24 (s, 3H), 1.80-1.76 (m, 2H), 1.78-1.55 (m, 2H), 1.71 (s, 6H), 
1.38-1.30 (m,  1H); δ
C
 (100  MHz,  CDCl
3
); 202.8,  166.3,  160.5,  130.2,  127.3,  106.9, 
96.5, 63.1, 34.5, 30.3, 27.2, 26.1, 25.2, 24.9, 20.8; m/z [TOF MS ES+] found 265.1440 
[M + H
+
], C
15
H
21
O
4
 requires 265.1440; IR (neat) ν
max
; 2932, 1719, 1624, 1389, 1374, 
1271, 1201, 1009, 901, 858; 
 
 
 
6-(1-Cyclohexyl-2-oxopropyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (173) 
 
 
 
 
 
 
A solution  of alkene 172 (362  mg,  1.37  mmol) in  methanol (1 mL)  was added to a 
suspension  of  10%  Pd/C (500 mg,  0.46  mmol) in  methanol (2 mL)  which  had  been 
activated  by  bubbling hydrogen through the solution for  10  min.  The reaction  was 
stired under an atmosphere  of  hydrogen for  3 h, the flask  was then  purged  with 
nitrogen, filtered, rotary evaporated, and chromatographed (Petrol:Et
2
O  2/1) to  give 
the desired product as a colourless oil, (341 mg, 93%); Rf (Et
2
O/Petrol (2/1); 0.53; δ
H
 
(400 MHz, CDCl
3
); (Mixture of diastereoisomers 1/1); 5.39 (s, 1H), 3.06 (d, J = 10.1, 
1H), 2.22 (s, 3H), 2.10-2.00 (m, 1H), 1.78-1.64 (m, 4H), 1.70 (s, 6H), 1.35-1.24 (m, 
2H),  1.22-1.10 (m,  1H),  1.02-0.91 (m,  2H); δ
C
 (100  MHz,  CDCl
3
); 203.3, 166.7, 
160.5, 128.7, 106.8, 95.9, 64.6, 37.3, 31.3, 30.4, 30.2, 25.9, 24.9; m/z [TOF MS ES+] 
found 267.1602 [M  +  H
+
], C
15
H
23
O
4
 requires 267.1596; IR (neat) ν
max
; 2927,  2853, 
1724, 1625, 1390, 1273, 1202, 1009, 901; 
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A1 - Computational Appendix 
 
Molecular modeling simulations were caried out using the Maestro-software package 
from Schrödinger Inc, including Maestro 7.5.112, Glide 4.0, MacroModel 9.1, Prime, 
and  QikProp  v2.5.  The  unpublished crystal structure  of  Ape1/Ref-1, resolution  1.8 
angstroms  was  used as the in silico receptor target.  Made available courtesy  of the 
Freemont laboratory.  Prior to  molecular  modeling the  protein  was  prepped 
accordingly.  Al  water  molecules  were removed,  Mg
2+
 was left treated,  polar 
hydrogens remained, al  bond  orders  were assigned,  minimisation  was conducted 
RMSD 0.3 angstroms. His309 was manualy protonated and flipped out, reassigned to 
HIP309. 
Protein Minimisations; Force field OPLS 2005, solvent H2O, constant dielectric (1.0), 
charges from forcefield cutof, extended – VDW 8.0, electrostatic  20.0  H-Bond  4.0, 
method PRCG, convergence threshold 0.05. 
Receptor Grid Generation; 20 angstrom square grid was generated from the centre of 
selected residues,  Hip309,  Asp282,  Trp280,  Phe266,  Pro234,  Asn212,  Asp210, 
Leu179, Arg177 and Asn174. 
Ligand  Preparation; Generated  possible  pH states  7.0 -/+  2.0  using ioniser setings, 
desalt,  generate tautomers, retention  of specified chiralities.  To achieve the 
conformation with the lowest energy, which should be the conformation the molecule 
adopts under normal conditions 
Ligand Docking; HTVS, SP, XP setings, scaling of VDW radi, scaling factor 0.80, 
partial charge cutof 0.15. 
MMGBSA – Calculated ligand strain energies. 
‘Druglike’  Libraries  Screened; Courtesy  of  Emory  University,  Atlanta,  GA, 
Chembridge,  Asinex,  Zinc,  NCI, Indofine ICC,  Matrix  Scientific. Ligands contained 
within the libraries are designed with drug-like principles in mind, generaly applying 
lipinski’s rule. 
 
	   365	  
B1 – Biological Appendix
* 
 
According to the various conditions used in the literature we have examined activity of 
Ape1/Ref-1 over a brief range of pH and salt concentrations. This gained the optimal 
conditions for quantitative measurement of the cleavage of the DNA substrate. 
Optimal conditions; 
• 50 mM Tris pH = 8.0  
• 50 mM NaCl  
• 10 mM MgCl
2
 
• 1 mM EDTA  
• 1 mM DTT  
• 0.1 mg/ml BSA, t = 25 oC (al assays)  
Compounds were diluted in DMSO and used always as (100x) solutions for DMSO to 
get final 5 µM, 10 µM and 50 µM concentrations in the reaction of final volume 100 µl 
1  µl  of “inhibitor”  was incubated  with enzyme for five  minutes  before addition  of 
substrate (25  oC).  Al fluorescence  measurements  were recorded  on a  Perkin  Elmer 
Fluorimeter.  
Control  measurements;  Various controls  of  Ape1/Ref-1  were conducted in  order to 
confirm  validity  of the assay. No enzyme  =  no activity. No  MgCl
2
 =  no activity.  
Positive controls were conducted with several lesions used for BER assays showing no 
activity besides AP activity (litle activity in case of Thymine-glycol and 5-OH Uracil 
is being investigated). 
Relative concentrations -  
*Al information provided by Dr. Jan Silhan.  
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Enzymes and Fluorescent Substrates – (Wilson Conditions) 
Recombinant human APE1 and E. coli EndoIV were purified as previously described. 
Deoxyoligonucleotides containing a tetrahydrofuran (THF)  AP site analog, 
carboxytetramethyl rhodamine (TAMRA),  or  Black  Hole  Quencher-2 (BHQ-2), as 
appropriate and were purchased from Biosearch Technologies, Inc., (Novato, CA).  
To create double-stranded DNA substrates, equal volumes of 200 mM solutions of the 
respective strands in reaction bufer were mixed and incubated at 95 °C for 5 min. The 
annealing mixture was alowed to cool gradualy to room temperature. Annealing and 
assay experiments were performed in the folowing bufer:  
50 mM Tris pH 7.5, 25 mM NaCl, 2 mM MgCl
2
, 1 mM DTT, 0.01% Tween-20. 
 
Enzymatic Conditions – Neamati 
 
Enzymatic  Assays. To  determine the extent  of abasic residue cleavage  by  APE1, 
ExoII, and  EndoIV,  or integration  by  HIV-1 integrase, recombinant  APE1  was  pre-
incubated at a final concentration of 0.05 nM with the potential inhibitors in reaction 
bufer (50 mM NaCl, 1 mM HEPES, pH 7.5, 50 µM EDTA, 50 µM dithiothreitol, 10% 
glycerol (w/v),  7.5  mM  MnCl
2
,  0.1  mg/mL  bovine serum albumin,  10  mM  2-
mercaptoethanol,  10%  DMSO, and 25mM MOPS, pH7.2) at 30°Cfor10min.Then, 
200nM of the  5′-end 
32P-labeled
 
linear  oligonucleotide substrate  was added, and 
incubation  was continued for an additional  10  minutes.  Reactions  were  quenched  by 
the addition of an equal volume (16 µL) of loading dye (98% deionized formamide, 10 
mM EDTA, 0.025% xylene cyanol, and 0.025% bromophenol blue). An aliquot (5 µL) 
was electrophoresed on a denaturing 20% polyacrylamide gel (0.09 M tris-borate pH 
8.3,  2  mM  EDTA,  20% acrylamide,  8  M  urea).  The  gels  were  dried, exposed in a 
PhosphorImager cassete, analyzed  using a  Typhoon  8610  Variable  Mode Imager 
(Amersham  Biosciences), and  quantitated  using ImageQuant  5.2.  The  percent 
inhibition (% I)  was calculated  using the folowing equation: (% I) = 100×[1-(D-
C)/(N-C)] where C, N, and D are the fractions of 26-mer substrate converted to 13-mer 
incision  products (or integration  products) for  DNA alone,  DNA  plus enzyme, and 
enzyme  plus  drug, respectively.  The IC50  values  were  determined  by  ploting the 
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logarithm of drug concentration against percent inhibition of enzymatic activity. 
 
Truncated Ape1/Ref Composition 
        10         20         30         40         50         60  
EAAGEGPALY EDPPDQKTSP SGKPATLKIC SWNVDGLRAW IKKKGLDWVK EEAPDILCLQ  
        70         80         90        100        110        120  
ETKCSENKLP AELQELPGLS HQYWSAPSDK EGYSGVGLLS RQCPLKVSYG IGDEEHDQEG  
       130        140        150        160        170        180  
RVIVAEFDSF VLVTAYVPNA GRGLVRLEYR QRWDEAFRKF LKGLASRKPL VLCGDLNVAH  
       190        200        210        220        230        240  
EEIDLRNPKG NKKNAGFTPQ ERQGFGELLQ AVPLADSFRH LYPNTPYAYT FWTYMMNARS  
       250        260        270        280  
KNVGWRLDYF LLSHSLLPAL CDSKIRSKAL GSDHCPITLY LAL  
Number of amino acids: 283 
 
Molecular weight: 31759.1 
 
Theoretical pI: 6.69 
 
Ala (A)  22   7.8% 
Arg (R)  15   5.3% 
Asn (N)  10   3.5% 
Asp (D)  16   5.7% 
Cys (C)   7   2.5% 
Gln (Q)  10   3.5% 
Glu (E)  20   7.1% 
Gly (G)  22   7.8% 
His (H)   6   2.1% 
Ile (I)   8   2.8% 
Leu (L)  36  12.7% 
Lys (K)  20   7.1% 
Met (M)   2   0.7% 
Phe (F)   9   3.2% 
Pro (P)  19   6.7% 
Ser (S)  19   6.7% 
Thr (T)   9   3.2% 
Trp (W)   7   2.5% 
Tyr (Y)  12   4.2% 
Val (V)  14   4.9% 
Pyl (O)   0   0.0% 
Sec (U)   0   0.0% 
 
Total number of negatively charged residues (Asp + Glu): 36 
Total number of positively charged residues (Arg + Lys): 35 
 
Formula: C
1429
H
2213
N
387
O
416
S
9
 
Total number of atoms: 4454 
 
λ = 280nm 
Ext. coefficient    56755 
Abs 0.1% (=1 g/l)   1.787, assuming ALL Cys residues appear as half 
cystines 
 
Ext. coefficient    56380 
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Abs 0.1% (=1 g/l)   1.775, assuming NO Cys residues appear as half 
cystines 
 
Ful Length hApe1/Ref1 Composition 
        10         20         30         40         50         60  
PKRGKKGAVA EDGDELRTEP EAKKSKTAAK KNDKEAAGEG PALYEDPPDQ KTSPSGKPAT  
 
        70         80         90        100        110        120  
LKICSWNVDG LRAWIKKKGL DWVKEEAPDI LCLQETKCSE NKLPAELQEL PGLSHQYWSA  
 
       130        140        150        160        170        180  
PSDKEGYSGV GLLSRQCPLK VSYGIGDEEH DQEGRVIVAE FDSFVLVTAY VPNAGRGLVR  
 
       190        200        210        220        230        240  
LEYRQRWDEA FRKFLKGLAS RKPLVLCGDL NVAHEEIDLR NPKGNKKNAG FTPQERQGFG  
 
       250        260        270        280        290        300  
ELLQAVPLAD SFRHLYPNTP YAYTFWTYMM NARSKNVGWR LDYFLLSHSL LPALCDSKIR  
 
       310  
SKALGSDHCP ITLYLAL  
 
 
Number of amino acids: 317 
 
Molecular weight: 35423.3 
 
Theoretical pI: 8.42 
 
Ext. coefficient    56755 
Abs 0.1% (=1 g/l)   1.602, assuming all pairs of Cys residues form 
cystines 
 
 
Ext. coefficient    56380 
Abs 0.1% (=1 g/l)   1.592, assuming all Cys residues are reduced 
	  
 
